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Abstract 
 
A key impediment to successful cancer therapy with adenoviral vectors is the inefficient 
transduction of malignant tissue in vivo. Compounding this problem is the lack of 
cancer-specific targets, coupled with a shortage of corresponding high efficiency 
ligands, permitting selective retargeting. The epithelial specific integrin ανβ6 represents 
an attractive target for directed therapy since generally it is not expressed on normal 
epithelium, but is upregulated in numerous carcinomas where it plays a role in tumour 
progression. We previously have characterised a high affinity, ανβ6-selective peptide 
(A20FMDV2), derived from VP1 of Foot and Mouth Disease Virus. In an attempt to 
subvert the tropism of Ad5 to ανβ6, A20FMDV2 was incorporated genetically into the 
HI loop of the Ad5 fibre protein to generate Ad5-EGFPA20. Furthermore, the native 
CAR-binding and putative FIX/C4BP-binding capacity of Ad5-EGFPA20 was ablated to 
generate Ad5-477dlTAYTA20. In vitro, these A20-retargeted vectors displayed up to 50-
fold increases in CAR-independent transduction, and up to 480-fold increased 
cytotoxicity on a panel of ανβ6-positive human carcinoma lines compared with Ad5-
EGFPWT.  
 
In vivo, both Ad5-EGFPA20 and Ad5-477dlTAYTA20 improved tumour targeting (~2-
fold/3-fold) following systemic delivery in immunodeficient mice, when compared with 
Ad5-EGFPWT. Furthermore, ~5-fold fewer Ad5-EGFPA20/Ad5-477dlTAYTA20 genomes 
were detected in the liver, which correlated with reduced serum transaminase levels 
and minimal E1A expression. Warfarin pre-treatment, to deplete coagulation factors, 
did not improve tumour uptake significantly with either virus, but did further reduce liver 
sequestration and hepatic toxicity. The unexpected reduction in liver tropism and 
toxicity we observed was supported by similar results obtained in immunocompetent 
mice. Furthermore, in immunocompetent mice, Ad5-EGFPWT induced dramatic 
elevations in serum cytokines/chemokines in addition to inducing acute 
thrombocytopenia. These effects were attenuated substantially in Ad5-EGFPA20/Ad5-
477dlTAYTA20 treated cohorts. In summary, we have found that in vivo retargeting Ad5 
to ανβ6 in a murine model results in improved tumour delivery, limited 
hepatotropism/toxicity and a reduced induction of anti-viral innate immune responses.  
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CHAPTER 1.  Introduction 
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Section.1.1 Introduction 
 
Cancer is the second leading cause of death worldwide, and is estimated at 
approximately ~22% of all deaths in the UK (Bray et al., 2002). The global burden of 
cancer has remained largely unchanged for the past three decades despite significant 
advances in diagnosis, reductive surgery and therapeutic intervention. Furthermore, 
conventional chemo- and radiotherapies remain ineffective in treating tumour 
metastases, fail to prolong survival following late diagnosis, and are associated with 
adverse side effects. Therefore, it is clear that innovative approaches to treatment are 
required. Virotherapy or viral gene therapy of cancer represents such a strategy.  
 
Viruses are obligate intracellular parasites, which have evolved to behave as biological 
delivery vehicles, capable of self-amplification and lateral propagation. The potential for 
exploiting these intrinsic properties make viruses a natural choice of vector for gene 
therapy applications, including the therapy of cancer. In recent years, increased 
knowledge of the pathogenesis of cancer, and the molecular networks underlying 
malignant transformation, has prompted the development of rationally designed 
therapeutics, accelerating the manipulation of viruses for therapeutic effect.  
 
The exploitation of viruses for the treatment of cancer is not a novel concept, in fact, 
several reports of spontaneous tumour regression during/following an acute viral 
infection, have been documented over the past century (Bierman et al., 1953; Bluming 
& Ziegler, 1971; Pasquinucci, 1971; Pelner et al., 1958; Taqi et al., 1981; Taylor, 1953; 
Zygiert, 1971). These observations led to the initiation of a clinical trial at the National 
Cancer Institute during the 1950s, using a Human Adenovirus Type-5 (Ad5) for the 
treatment of cancer (Huebner et al., 1956). Although the trial was largely unsuccessful, 
with tumour progression following initially promising regression, it did serve to highlight 
the relative safety, and lack of significant toxicity associated with Ad5 in vivo. However, 
the use of Ad5 in clinical trials has been associated previously with adverse effects and 
severe outcome. In 1998, the field suffered substantial negative publicity following the 
death of 18 year old Jesse Gelsinger, a patient enrolled in a trial using adenovirus to 
deliver a corrective gene for an ornithine transcarbamylase (OTC) deficiency. His death 
was attributed to a massive inflammatory response; a cytokine cascade induced by 
widespread systemic dissemination of the virus, which resulted in respiratory distress, 
coagulopathy and multi organ failure (Raper et al., 2003). Consequently, this tragic 
event has highlighted the importance of designing vectors which display reduced 
immunogenicity and toxicity in vivo.  
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The ultimate goal of virotherapy is to generate a non-toxic, self-localising and self-
amplifying agent, which is capable of selectively eradicating malignant tissue. The 
modification of adenoviral tropism determinants represents a strategy for achieving 
selective delivery. Modifications to structural proteins aim to confer a new or expanded 
tropism, permitting vectors to be customised for a broad range of targeting applications. 
Native receptor detargeting when used in combination with retargeting strategies, can 
restrict delivery, and minimise non-specific sequestration at off target locations. 
However, it is becoming increasingly clear that achieving this is not as simple as 
originally envisaged, and several major challenges remain to be addressed before 
virotherapy can fulfil its promise. One such challenge is the distinct lack of cancer 
specific markers which would be suitable for selective retargeting of Ad5 to tumours in 
vivo. Compounding this is the lack of high efficiency targeting ligands capable of 
interacting with those identified markers to facilitate high efficiency retargeting to 
tumours, and to disseminated metastases.  
 
The epithelial specific integrin, ανβ6, is not normally expressed on normal adult 
epithelia but is upregulated significantly during epithelial remodelling events, which 
include wound healing, embryogenesis and carcinogenesis (Breuss et al., 1995). It is 
overexpressed in a broad range of carcinomas, and has been independently identified 
as a prognostic indicator in breast, lung, ovarian, cervical and colorectal carcinomas 
(Ahmed et al., 2002b; Bates et al., 2005; Elayadi et al., 2007; Hazelbag et al., 2007). 
Additionally, work in our laboratory has identified that >90% oral squamous cell 
(OSCC) carcinomas express ανβ6 to high levels, and that its expression is associated 
with invasion and metastasis in vivo (Nystrom et al., 2006; Thomas et al., 2001a; 
Thomas et al., 2001b; Van Aarsen et al., 2008). Therefore, the restricted expression 
profile of ανβ6 in vivo, coupled with its cell surface localisation, make it a very 
accessible and attractive cancer-specific target. Moreover, we already possess a 
suitable high-affinity targeting ligand capable of selective delivery to ανβ6, which has 
been characterised extensively both in vitro and in vivo. This ligand was initially 
identified by extensive functional analysis of a panel of linear peptides, which were 
rationally selected from known ανβ6 ligands (DiCara et al., 2007). A candidate peptide, 
A20FMDV2, derived from Foot and Mouth Disease Virus, was chosen for its very high 
affinity and specificity for ανβ6. The resolution of the crystal structure of the Ad5 knob 
domain by X-ray crystallography identified the HI loop region as being suitable for 
heterologous peptide incorporation (Xia et al., 1994). Thus, the focus of this study was 
to genetically incorporate the targeting ligand, A20FMDV2, into the HI loop of the Ad5 
fibre in an attempt to redirect the tropism of Ad5 to ανβ6.  
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Section.1.2 Molecular Genetics of Adenoviruses 
 
Adenoviruses (Ad) are dsDNA viruses which were first isolated from human adenoid 
lymphoid tissue in 1953 (Hilleman & Werner, 1954; Rowe et al., 1953). Clinical 
symptoms of adenoviral infection include acute respiratory infection, epidemic 
conjunctivitis and infantile gastroenteritis (Grandien et al., 1987; Louie et al., 2008; 
Yolken et al., 1982). The family Adenoviridae consists of five genera, most importantly 
the genus Mastadenovirus and genus Aviadenovirus, which infect mammals and birds 
respectively. There are 52 different serotypes of human adenoviruses, divided into 
subgroups A-G, which can be distinguished on the basis of their serological cross-
reactivity, haemagglutinating properties and phylogenetic sequence similarity 
(Crawford-Miksza & Schnurr, 1996; Fauquet et al., 2005; Rosen, 1960).  Additionally, 
the grouping correlates with their oncogenic potential and ability to form tumours in 
rodents, a characteristic which is associated with abortive infection. Subgroup C 
contains serotypes Ad2 and Ad5, which have been studied extensively, and have no 
oncogenic potential in humans. Therefore, these serotypes are used widely in 
experimental gene therapy applications.  
 
Section.1.2.1 Adenoviral Structure 
 
Adenoviruses are non-enveloped, icosahedral virions which contain a linear, 
monopartite, dsDNA genome approximately 36kbp in size (Figure.1.1). Adenovirus 
contains at least 13 structural proteins, assigned with a numbering order from II-X, 
including; IIIa, Mu, TP, IVa2, a protease which is putatively associated with interior of 
the icosahedron vertices, and L1-52K, which has been proposed to act as a scaffolding 
protein during viral assembly (Christensen et al., 2008; Hasson et al., 1992; Hasson et 
al., 1989; Russell, 2009; Silvestry et al., 2009). A nucleoprotein core complex 
surrounds the genome. This complex consists of a core-penton bridging protein (V), 
histone-like protein (VII), Mu protein and a Terminal Protein (TP), which is covalently 
attached to the 5’ region of the genome (Rekosh et al., 1977; Robinson et al., 1973). 
Together, adenoviral structural proteins are responsible for stabilisation of the genome 
and the encapsidation of the nucleoprotein core complex. 
 
The icosahedral capsid structure is composed of seven polypeptides; the trimeric 
hexon (II), which is complexed with three minor hexon polyproteins (VI, VIII and IX) 
which provide stabilisation, the penton (III) and penton associated protein (IIIa) which 
bridge the hexon-penton, and the receptor binding fibre (IV) protein (Everitt et al., 1975; 
Everitt et al., 1973). The fibre protein (IV) is composed of three domains; the tail at the 
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N-terminus, the rod-like shaft and the globular knob domain at the C-terminus. The 
fibre shaft is comprised of a 15 amino acid polylysine motif (KKTK), repeated 22 times 
in Ad5 (Chroboczek et al., 1995; van Raaij et al., 1999). The fibre exists as a 
glycosylated homotrimer, non-covalently complexed to the pentameric penton base 
protein (III) at the N-terminus (Mautner & Pereira, 1971). This complex is also known 
as the penton capsomere. These trimeric complexes are embedded at the 12 vertices 
of the icosahedron structure, extending as protrusions on the external viral surface (van 
Oostrum & Burnett, 1985; Xia et al., 1994). 
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Section.1.2.2 Adenoviral Entry 
 
The classical two-step Ad5 entry pathway in epithelial cells is initiated by a docking 
process in which the distal knob of the fibre binds to target cells via the 46kDa, 
transmembrane Coxsackie and Adenovirus Receptor, CAR (Bergelson et al., 1997; 
Bergelson et al., 1998; Kirby et al., 2000; Roelvink et al., 1998; Roelvink et al., 1999; 
Santis et al., 1999; Tomko et al., 1997). CAR, a member of the immunoglobulin 
Figure.1.1 Adenovirus Structure. Schematic representation of the major and minor structural proteins of 
adenovirus and the nucleoprotein core with terminal protein (TP) covalently attached at each end of the 
dsDNA genome. Figure adapted from (Russell, 2000; 2009).         
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superfamily has two extracellular Ig-like domains (D1 and D2) and functions as a tight 
junction protein forming homodimeric adhesions between polarised epithelial cells and 
the cardiac intercalated disc (Cohen et al., 2001; Shaw et al., 2004; van Raaij et al., 
2000). Additionally, in associaton with tight junction protein Zona Occludens (ZO-1), it 
can function as a barrier to the paracellular movement of macromolecules and ions 
(Cohen et al., 2001). Importantly, the localisation of CAR means that it is not initially 
accessible as a receptor for viral entry, unless membrane integrity is compromised. 
Therefore, it may seem paradoxical for a virus to utilise an occluded receptor for 
primary attachment. However, Ad5 appears to have exploited the location of CAR to 
facilitate maximal spread, as progeny virions have been shown to be released from the 
basolateral surface of infected cells (Cohen et al., 2001; Walters et al., 2002). This 
phenomenon and its role in viral release and spread, is discussed further detail in 
Section.1.2.6. 
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Base
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Figure.1.2 Classical Two-Step Entry Pathway of Adenovirus. (1) Adenovirus attachment is mediated 
by the distal knob domain of the fibre. The flexible fibre binds to the 46kDa transmembrane protein, the 
Coxsackie and Adenovirus Receptor, CAR. (2) The RGD motif in the penton base of the Ad particle 
triggers internalisation via ανβ3/ανβ5 integrins. Partial disassembly of the capsid is induced by 
acidification of the endosome following clathrin-mediated endocytosis. Endosomal escape is modulated 
through the action of protein VI, after which the nucleocapsid core is translocated to the nucleus along the 
microtubule network. Further capsid dissociation permits the viral DNA to enter the nucleus for 
subsequent transcription and replication. Figure adapted from (Horwood et al., 2002). 
 24
Fibre-CAR binding is followed by the interaction  of an Arg-Gly-Asp (RGD) motif in the 
penton base to ανβ3/ανβ5 integrins, which subsequently triggers viral internalisation 
(Wickham et al., 1993). It is thought that the Ad5 penton-integrin interaction results in 
integrin clustering which activates signalling pathways, such as phosphoinositide-3-OH 
kinase (PI3K), p38 MAPK and ERK1/2, inducing downstream effects resulting in the 
polymerisation and reorganisation of actin filaments (Bhat & Fan, 2002; Li et al., 1998a; 
Li et al., 1998b; Shayakhmetov et al., 2005a; Suomalainen et al., 2001; Tibbles et al., 
2002). Recent data have also shown that Ad5 binding to CAR leads to the activation of 
ERK1/2 (p44/42 MAPK) which promotes the dimerisation and clustering of CAR, in 
addition to increasing the activation status of -β1 and -β3 integrins (Farmer et al., 
2009). Viral internalisation is mediated via clathrin-mediated endocytosis (Meier et al., 
2002; Wang et al., 1998), followed by partial capsid disassembly upon acidification of 
the endosome (Greber et al., 1993). Endosomal escape is modulated by the lytic action 
of protein VI, after which the nucleocapsid is translocated to the perinuclear envelope 
along the microtubule network (Dales & Chardonnet, 1973; Suomalainen et al., 1999; 
Wiethoff et al., 2005). Transport to the nuclear pore complex involves the microtubule-
dependent motor, cytoplasmic dynein which permits Ad attachment to microtubules 
(Kelkar et al., 2004; Leopold et al., 2000). The capsid undergoes its final dissociation 
event at the nuclear pore complex (Greber et al., 1997), allowing the core DNA to 
extrude into the nucleus for subsequent transcription and replication (Figure.1.2). 
 
However, it is now clear that the process of infection by Ad5 is more complex than 
previously assumed, and it involves various receptors and co-receptors other than CAR 
and ανβ3/ανβ5 integrins. Heparan sulphate proteoglycans (HSPGs) have been shown 
to permit binding of Ad5 in the absence of CAR in A549 and CHO-K1 cells (Dechecchi 
et al., 2001; Dechecchi et al., 2000). The KKTK motif of the fibre shaft was once 
thought to be responsible for promoting infection through HSPGs (Dechecchi et al., 
2000; Smith et al., 2003b). However, it is now widely believed that the KKTK motif 
serves only to confer structural flexibility to the fibre (Nicklin et al., 2005; van Raaij et 
al., 1999). Alternatively, vascular cell adhesion molecule 1 (VCAM-1) or MHC class I 
have also been proposed to facilitate low affinity Ad5 interactions, although evidence 
which supports the latter interaction has been challenged (Chu et al., 2001; Davison et 
al., 1999; Hong et al., 1997; McDonald et al., 1999). Furthermore, additional integrins, 
ανβ1, α3β1, α5β1 and αMβ2 have also been shown to permit the internalisation of 
adenoviruses (Davison et al., 1997; Davison et al., 2001; Huang et al., 1996; Li et al., 
2001; Salone et al., 2003). 
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More recently, a number of “bridging interactions” have been identified which have 
particular relevance in vivo, especially following systemic delivery of Ad5 in mice 
(Figure.1.3). It has now been shown by several groups that direct interactions between 
the Ad5 capsid and vitamin K-dependent coagulation factors, including FX, FIX, FVII, 
Protein C, in addition to Complement 4-Binding protein (C4BP), can modulate viral 
entry through HSPGs or low-density lipoprotein receptor-related protein, LRP (Alba et 
al., 2009; Kalyuzhniy et al., 2008; Shayakhmetov et al., 2005b; Vigant et al., 2008; 
Waddington et al., 2008; Waddington et al., 2007). These interactions play a critical 
role in directing off-target hepatocyte transduction in vivo. Additionally, coagulation 
Figure.1.3 Ad5 Interactions with Blood Components In Vivo. (1) FIX/C4BP binding to the fibre knob 
mediates hepatocyte entry via HSPGs or LRP. Additionally, FIX/C4BP binding to the fiber directs Kupffer 
cell uptake by an unknown mechanism (Shayakhmetov et al., 2005b). (2) Opsonisation of Ad5 with natural 
IgM and/or complement directs Kupffer cell uptake through complement receptor-3 (CR3), Fc Receptor or 
through scavenging receptor SR-A (Haisma et al., 2009; Xu et al., 2008). (3) FX binding to Ad5 hexon 
promotes hepatocyte entry through HSPGs (Waddington et al., 2008). (4) Adenovirus binding to platelets 
enhances uptake by Kupffer cells (Stone et al., 2007b). (5) Ad5 binds to CAR on erythrocytes causing 
trapping of virus in the circulation. Figure adapted from (Prudencio et al., 2006).  
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factor “bridging” has been shown to be involved in the enhanced infection of various 
tumour cells both in vitro and in vivo (Coughlan et al., 2009; Gimenez-Alejandre et al., 
2008; Liu et al., 2009; Parker et al., 2007; Parker et al., 2006; Shayakhmetov et al., 
2005b). However, Ad5 also has been shown to interact with various other components 
within the circulation, such as natural IgM and complement, platelets and erythrocytes. 
Opsonisation of Ad5 by IgM and complement, or binding to platelets to promote the 
formation of Ad5-platelet-leukocyte aggregates, are mechanisms proposed to play a 
role in Kupffer cell scavenging (Stone et al., 2007b; Xu et al., 2008). Moreover, Ad5 
interactions with CAR-expressing erythrocytes in mice have been shown to preclude 
efficient tumour transduction in vivo by trapping virus in the circulation (Carlisle et al., 
2009).  
 
Section.1.2.3 Adenoviral Genome Organisation  
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The Adenoviral genome is complex and contains terminally redundant sequences with 
inverted terminal repeats (ITR), each with an identical origin of replication and a 
Figure.1.4 Overview of the Transcription Profile of Ad5. Early gene transcripts are shown in green, late 
transcripts in blue and gene products in red. The Virus Associated (VA) RNAs are in brown. Black arrows 
indicate the direction of transcription, purple arrows indicate promoter regions. Rightward (R) and Leftward 
(L) strands are transcribed by 5’-3’ directional reading. The genes have been mapped by superimposing 
an arbitrary scale of 100 map units. Abbreviations are as follows; MLP = Major Late Promoter, Pr = 
Protease (adenain), ADP = Adenovirus Death Protein, RID = Receptor Internalisation and Destruction, 
ORF = Open Reading Frame, UXP = U exon protein (Tollefson et al., 2007), DBP = DNA Binding Protein, 
TP = Terminal Protein and Pol = Polymerase. All gene products listed numerically can be found in Fig.1.1. 
Figure adapted from (Russell, 2000; Wold & Gooding, 1991). 
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terminal protein (TP) covalently attached at the 5’ end (Rekosh et al., 1977; Robinson 
et al., 1973). A terminal, cis-acting packaging signal, required for successful 
encapsidation of the Ad5 genome, is situated at the left end of the viral DNA (Grable & 
Hearing, 1992). Viral genome transcription is defined by two main transcription events, 
Early and Late. Viral mRNAs are transcribed by a cellular RNA polymerase II from five 
early transcription units (E1-E4), two delayed early units (IX and IVa2) and one late 
(L1-5) transcription unit (Figure.1.4). The viral genome also contains two virus-
associated genes (VA) which are transcribed by host RNA polymerase III. Adenoviral 
gene transcription can give rise to differential mRNA transcripts through the use of 
alternate polyadenylation sites or by the generation of multiple splice variants (Berget 
et al., 1977; Berget & Sharp, 1977; Chow et al., 1977).  
 
Section.1.2.4 Activation of Early Transcription  
 
Early proteins have a range of functions which include; subversion of the host cell cycle 
in order to facilitate optimal conditions for viral replication (E1A, E1B and E4 region), 
the synthesis of viral gene products essential for replication (E2 region) and immune 
evasion from innate anti-viral responses (E3 region). Prior to, and independently of viral 
replication, the Immediate Early (IE) E1A mRNA transcripts, 12S and 13S, are spliced 
and exported to the cytoplasm where they are translated and their corresponding 
proteins phosphorylated extensively (Mal et al., 1996; Whalen et al., 1997). These are 
then transported back to the nucleus where they are required as trans-acting 
transcriptional activators of downstream Early (E) genes, and as regulators of cell cycle 
(Berk, 1986a; b; Berk et al., 1979; Jones & Shenk, 1979).  
 
The conserved regions of E1A proteins (CR1-3) can activate transcription through their 
ability to interact with a range of cellular transcription factors and regulatory proteins 
(Branton & Rowe, 1985; Harlow et al., 1986; Yee & Branton, 1985). However, in 
addition to these functions, E1A proteins promote cell cycle progression, creating a 
cellular environment conducive for viral replication. The CR1 and CR2 domains within 
E1A (12S and 13S) can bind directly to members of the cellular retinoblastoma (pRb) 
tumour suppressor family (ie. pRb, p107 and p130) preventing them from forming 
complexes with the transcriptional activator, E2F (Bandara & La Thangue, 1991; Whyte 
et al., 1989). Dissociated, or free E2F, activates several genes associated with cell 
cycle progression.  
 
Innate cellular tumour suppressor mechanisms (p53) respond to the unscheduled 
induction of proliferation effected by E1A, by activating pro-apoptotic pathways 
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(Debbas & White, 1993; Lowe & Ruley, 1993). The virus therefore employs E1B 
proteins, E1B-55kDa and E1B-19kDa, to act synergistically with E1A and counteract 
the accumulation of pro-apoptotic p53. The adenoviral E1B-55kDa protein, in 
conjunction with E4-Orf6 and cellular ubiquitination proteins, antagonises the ability of 
p53 to induce apoptosis by inducing its degradation (Harada et al., 2002; Querido et 
al., 2001a; Querido et al., 1997; Querido et al., 2001b). E1B-19kDa functions similarly 
to cellular anti-apoptotic Bcl-2, binding both Bax and Bak and inhibiting the induction of 
apoptosis (Rao et al., 1992; White et al., 1991; White et al., 1992).  
 
Section.1.2.5 Adenoviral Replication and Transition to Late Gene Transcription  
 
As is the case with most DNA viruses, adenoviral replication takes place in the nucleus. 
Both strands of DNA, rightward (R) and leftward (L), are transcribed by 5’-3’ directional 
reading. The E2 proteins which facilitate viral replication include; the terminal protein 
(TP), a precursor of which primes synthesis of the viral genome, the DNA polymerase, 
which possesses an intrinsic 3’-5’ exonuclease activity, and finally the DNA-binding 
protein (DBP), which permits elongation. These proteins act in concert with various 
cellular factors, such as nuclear factors NFI/NFIII which provide stabilisation, 
enhancing viral DNA replication, and NFII which facilitates successful DNA elongation 
(Bosher et al., 1990; Chen et al., 1990; Mul et al., 1990; Nagata et al., 1983). The E4 
open reading frame (ORF) encodes two proteins, Orf3 and Orf6, which have also been 
shown to play a role in viral replication. These proteins use complementary functions to 
interfere with various facets of the cellular DNA repair response, including inhibition of 
concatemer formation and ubiqitination of the dsDNA break repair complex, Mre11 
(Evans & Hearing, 2003; 2005; Stracker et al., 2002). 
 
Once critical levels of E2 gene products accumulate, genome replication is initiated in 
two stages, displacement replication and single strand replication, also called Type I 
and Type II replication, respectively (Lechner & Kelly, 1977). Displacement replication 
occurs when synthesis is initiated at the ITR of either strand of DNA. Synthesis 
proceeds continuously to the end of the genome without lagging strand synthesis, 
displacing the complementary single strand (Figure.1.5). This results in a duplex of 
nascent dsDNA, plus the single displaced strand which is capable of panhandle 
formation, as a result of its self-complementary termini. In single strand replication, this 
panhandle structure is again primed by the terminal protein and replication is 
reinitiated, resulting in the formation of another duplex DNA genome (Lechner & Kelly, 
1977). 
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1. Type I Replication
2. Type II Replication
Panhandle formation
 
 
 
 
 
 
 
 
 
Concomitant with the onset of DNA replication, Late phase expression from the major 
late promoter (MLP) is activated by E1A, and transcripts are processed by differential 
poly (A) utilisation (L1-5), and post-transcriptional splicing to generate at least 18 
mRNAs. Host cell transcription factors, MAZ and Sp1, in concert with E1A, can activate 
transcription from the MLP, independently of viral replication (Parks & Shenk, 1997). 
Additionally, a product of the delayed early transcription unit, IVa2, has been shown to 
contribute to the induction of expression from the MLP (Lutz & Kedinger, 1996). 
Following the processing of late viral mRNAs, an E1B-55kDa/E4-Orf6 complex is 
Figure.1.5 Overview of the Adenoviral Replication Strategy (1) Type I replication, or displacement 
replication, is initiated at the ITR of the dsDNA genome. Replication is primed by the terminal protein and 
is continuous without lagging strand synthesis. In this process a DNA duplex is created from the template 
of one strand of DNA, whereas the remaining strand of DNA is displaced. (2) Type II replication is the 
strategy of replication used for the synthesis of duplex DNA from the displaced single strand. Single 
stranded DNA is circularised via the complementary ITR, resulting in a panhandle structure. This 
panhandle structure can once again be primed for replication by the terminal protein, resulting in duplex 
DNA. (Figure is adapted from www.pathmicro.med.sc.edu/mhunt/dna1.htm).   
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responsible for their nuclear export and cytoplasmic accumulation, where they are 
translated into the proteins required for assembly of progeny virions (Babiss et al., 
1985; Sarnow et al., 1984). This complex also prevents the translocation of host 
mRNAs to the cytoplasm, in addition to targeting host proteins, p53 and Mre11, for 
ubiqitin-mediated degradation (Cheng et al., 2007; Evans & Hearing, 2005). 
 
The accumulation of dsRNA within adenovirally infected cells triggers the induction of 
an antiviral state (Maran & Mathews, 1988). This IFN-induced response involves the 
activation of the Protein Kinase R (PKR) pathway, which is stimulated by the presence 
of dsRNA in the cytoplasm. Upon its activation, PKR autophosphorylates and then 
subsequently phosphorylates eukaryotic initiation factor 2α (eIF2α), inactivating it and 
resulting in the inhibition of cellular mRNA translation. The preferential and sustained 
translation of viral mRNAs can overcome this shutdown in protein synthesis by several 
means. Firstly, the activation of PKR is counteracted by the virally encoded VA genes, 
which bind PKR directly, regulating its autophosphorylation and function (Katze et al., 
1987). Additionally, the inactivation of another cellular initiation factor (eIF-4F) late after 
infection is exploited to ensure the preferential translation of viral mRNAs. This factor, 
eIF-4F, possesses an inherent helicase activity which is required for host mRNA 
translation. This function becomes redundant in the translation of viral mRNAs due to 
the presence of the identical 200nt tripartite leader sequence at their 5’ end, which 
permits ribosomal shunting from the 5’ cap to the start codon, without the requirement 
for helicase activity. Additionally, the L4-100K protein is also responsible for blocking 
the translation of host mRNAs and ensuring the preferential translation of viral mRNAs 
which contain the tri-partite leader sequence (Cuesta et al., 2000; 2004; Hayes et al., 
1990; Xi et al., 2004). Thus, efficient viral translation is successfully achieved through 
the co-ordinated action of these multiple viral gene products.  
 
Section.1.2.6 Virion Assembly and Release 
 
The late genes predominantly encode structural and scaffolding proteins, and virion 
assembly is initiated by the formation of an empty capsid, after which a viral DNA 
molecule enters mediated by the cis-acting packaging sequence (Hearing et al., 1987; 
Sundquist et al., 1973). Monomeric hexon proteins polymerise into trimeric capsomers, 
assisted by the L4-100K chaperone protein (Cepko & Sharp, 1982; Hong et al., 2005). 
Penton-fibre capsomers are joined following their independent assembly (Horwitz et al., 
1969). Structural proteins accumulate in the nucleus where they are incorporated into 
the virus capsid structure. Encapsidation of the genome is polar and is facilitated by the 
L1-52/55kDa protein, IVa2 and pVII (Ewing et al., 2007; Gustin & Imperiale, 1998; 
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Hasson et al., 1989; Perez-Romero et al., 2006; Tyler et al., 2007). The L3-encoded 
proteinase cleaves several structural precursors including; VI, VII, VIII and the TP, to 
generate mature derivatives which result in infectious particle formation. This 
proteinase activity is dependent on the presence of DNA, in addition to the formation of 
a heterodimer complex with the 11aa, C-terminal peptide from pVI (Ding et al., 1996; 
Honkavuori et al., 2004; Mangel et al., 1993).  
 
Virion release is facilitated by disruptions to the cytoskeleton induced by L3 proteinase, 
in addition to the action of an E3-encoded gene, the adenovirus death protein (ADP) 
which has a cytolytic effect of unknown mechanism. Recent evidence has uncovered 
an interaction between ADP and MAD2B, a mitotic checkpoint protein, which may 
contribute to cell death (Tollefson et al., 1996; Ying & Wold, 2003; Yun et al., 2005). 
Furthermore, Ad5 displays a unique means of exploiting CAR to promote efficient 
lateral spread. Ad5 fibre is produced in excess quantities during the viral lifecycle and it 
has been shown that fibre can competitively disrupt CAR:CAR homodimer formation 
(Walters et al., 2002), as a result of the superior affinity of the knob domain for CAR 
(Freimuth et al., 1999; van Raaij et al., 2000). In further support of this, crystallographic 
analyses revealed that the interface bridging the fibre knob:CAR interaction, overlaps 
with the CAR:CAR homodimeric interface (van Raaij et al., 2000). The dissociation 
constant (Kd) for binding of the Ad5 fibre domain to soluble CAR has been calculated 
by SPR to be ~14.8nM (Kirby et al., 2000). Interestingly, the affinity for CAR 
homodimer formation was determined to be ~16uM, almost 1000-fold lower than the 
affinity of the Ad5 fibre for CAR (van Raaij et al., 2000). Therefore, the fibre of Ad5 can 
serve to function in the spread of virion progeny to neighbouring cells, through the 
disruption of CAR-mediated tight junction adhesions.  
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Section.1.3 Oncolytic Adenoviruses; Transcriptional Retargeting 
Strategies 
 
Achieving tumour selectivity and maximising efficacy are major goals for viral therapy 
applications. Replication selective, oncolytic adenoviruses possess the capacity for 
restricted oncolysis. Transcriptional selectivity can be achieved by two means; genetic 
complementation, or through the use of tumour-specific promoters to drive viral 
replication. Complementation strategies are dependent on an existing understanding of 
the underlying interactions between viral and cellular molecular networks. These 
approaches are typified by the genetic modification or deletion of viral effectors whose 
functions are essential for productive infection in normal cells, but are redundant in 
tumour cells. Thus, the viral defect results in the attenuation of viral replication in 
normal cells, but this defect is compensated for in transformed tissue, allowing 
replication to progress unaffected. These effects can also be achieved by exploiting the 
state of transcriptional dysfunction within the tumour cell environment, by placing 
critical viral genes under the control of heterogenous tumour-specific promoter 
responsive elements. In theory, these conditionally replicating agents have the 
potential for expansive transgene expression as a result of their ability to self-amplify 
and propagate throughout the tumour. However, this often is limited by the numerous 
physical and biological barriers imposed by the cellular heterogeneity of the tumour, 
and by its micro-environment.  
 
Section.1.3.1 Complementation of Viral Genetic Defects 
 
The design of conditionally replicating adenoviruses (CRAds) exploits the fact that 
tumours frequently possess dysfunctional, or non-functional, pRb or p53 tumour 
suppressor proteins (Sherr & McCormick, 2002). The critical and synergistic role for 
E1A and E1B-55kDa, in the coercion and deregulation of these growth-regulatory 
networks, is therefore rendered dispensable in the neoplastic context. The first 
generation CRAd developed was ONYX-015 (dl1520), which featured a non-functional 
E1B-55kDa protein. It was thought initially that productive infection of ONYX-015 was 
only possible in p53 deficient cells (Bischoff et al., 1996). However, replication of E1B-
55K mutants in tumour cells is no longer thought to be due to p53 deficiency, and this 
property is now attributed to the unique ability of some tumour cells to compensate for 
the lack of E1B-55K-mediated late viral mRNA export (O'Shea et al., 2004). 
Subsequent approaches to generate tumour-selective CRAds, were achieved by the 
introduction of a 24 base pair deletion (Δ24) within a conserved region (CR2) of the 
E1A gene (Fueyo et al., 2000). This modification inhibits CR2-mediated binding to the 
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tumour suppressor, pRb (Whyte et al., 1989), effectively limiting the replicative capacity 
of the virus to pRb defective cell types (Jelsma et al., 1989; Moran et al., 1986; Whyte 
et al., 1989). 
 
Section.1.3.2 Placement of Tumour Selective Promoters 
 
CRAds have also been developed so that replicative function is under the control of 
tumour activated promoters, and therefore restricted to neoplastic cell conditions. The 
fundamental principle of this approach is the absolute requirement of E1A for 
replication, and effects are achieved by substitution of the endogenous viral E1A 
promoter with selective tumour-associated promoters upstream of, and driving E1A 
expression. Various tumour-associated promoter elements, suitable for such 
applications, have been described previously. These have included the use of promoter 
elements from E2F (Tsukuda et al., 2002), prostate-specific antigen promoter (Pang et 
al., 1997), telomerase (Hernandez-Alcoceba et al., 2000; Huang et al., 2003), the COX-
2 promoter (Bauerschmitz et al., 2006) and hypoxia inducible factor (HIF) responsive 
elements (Cho et al., 2004; Post & Van Meir, 2003). Additionally, these responsive 
elements can be combined with complementation mutations, such as Δ24, or with 
insulators to prevent leaky transcription, and further enhance selectivity (Cascallo et al., 
2007; Guse et al., 2009; Majem et al., 2006; Suzuki et al., 2001). 
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Section.1.4 Oncolytic Adenoviruses; Transductional Retargeting 
Strategies 
 
Applications which aim to treat metastatic disease favour the systemic delivery of Ad-
based therapeutic agents. This requires restrictions to viral tropism determinants, in 
order to achieve selective delivery to malignant tissue. These restrictions require 
retargeting modifications, in which the natural tropism is redirected to a cancer-specific 
marker, in addition to detargeting modifications, in which the native receptor 
interactions of the vector are ablated. Thus, efficient transductional retargeting has the 
potential to subvert viral infection to defined tissues. However, efficient delivery also 
requires the evasion of various components which constitute the circulatory system, in 
addition to overcoming the inherent biological and physical barriers within the tumour, 
once selective delivery has been achieved.  
 
The Coxsackie and Adenovirus Receptor (CAR) is the critical determinant of adenoviral 
tropism in vitro, therefore it has long been considered to determine tumour transduction 
in vivo. However, in recent years its relevance in directing the tropism and 
biodistribution of Ad5 following systemic delivery has become controversial, and is 
currently the subject of much scrutiny. Nonetheless, several studies have reported the 
low expression of CAR in carcinoma lines, tumour explants and pathological 
specimens (Anders et al., 2009; Jee et al., 2002; Matsumoto et al., 2005; Mikami et al., 
2001; Rauen et al., 2002; Sachs et al., 2002). Downregulation of CAR is thought to 
correlate with tumour progression and advanced disease states (Matsumoto et al., 
2005; Mikami et al., 2001; Vincent et al., 2009), and low level CAR expression may 
render tumour cells somewhat refractory to adenoviral infection in vivo, or at least 
impair intratumoural spread (Douglas et al., 2001; Li et al., 1999a; Li et al., 1999b).  
 
A further impediment to generating successfully retargeted Ads is the lack of cancer-
specific targets. This is in addition to the distinct lack of corresponding ligands which 
could permit high efficiency retargeting. The incorporation of many targeting entities is 
limited by the incompatibility between the inserted ligand and the Ad fibre at the level of 
intracellular trafficking, and post-translational modification (Belousova et al., 2008; 
Magnusson et al., 2002). However, with the aim of improving tumour delivery in vivo, 
various retargeting strategies have been described for adenoviruses which include; 
chemical conjugate strategies, based on the conjugation of an adapter molecule to 
crosslink the vector to a cellular target receptor, (ii) capsid protein substitution or 
“pseudotyping”, between divergent strains or species of viruses which exhibit 
differential tropisms, or (iii) the genetic incorporation of heterogenous binding ligands to 
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redirect the tropism (Figure.1.6). However, the vast majority of these current retargeting 
strategies are designed to broadly enhance the tropism of Ad5, and do not display 
inherent tumour selectivity.   
 
The off-target sequestration of Ad5 in the liver also remains a major obstacle to 
achieving high efficiency, tumour-specific delivery following systemic delivery. The 
redundancy of CAR in directing the innate hepatotropism of Ad5 has been 
demonstrated in recent years (Alemany & Curiel, 2001; Leissner et al., 2001; Martin et 
al., 2003; Mizuguchi et al., 2002; Nicol et al., 2004; Smith et al., 2002) and it is now 
known that various coagulation factors, FVII, FIX, Protein C, but predominantly FX, 
direct the accumulation of Ad5 in the liver (Alba et al., 2009; Kalyuzhniy et al., 2008; 
Parker et al., 2006; Waddington et al., 2008; Waddington et al., 2007). It is evident that 
high affinity, tumour-specific retargeting strategies should be combined not only with 
native receptor (CAR) detargeting, but with liver avoidance strategies, in order to permit 
maximal vector efficacy at the lowest possible dose (Glasgow et al., 2006). 
 
Section.1.4.1 Transductional Retargeting by Chemical Conjugation of Ligands 
 
Adapter based transductional retargeting is achieved by cross-linking extraneous 
targeting entities to the virus, either by covalent or non-covalent interactions (Mathis et 
al., 2005). Additionally, various conjugate-based strategies can be combined to create 
multi-component targeting systems (Barnett et al., 2002; Glasgow et al., 2006; Myhre 
et al., 2009). Adapters can consist of chemically conjugated Ab fragments, genetically 
fused variable fragments (scFv) or bispecific diabodies (scFv-scFv), and recombinant 
fusion proteins (Belousova et al., 2008; Miller et al., 1998; Myhre et al., 2009; 
Nettelbeck et al., 2001; Yoshioka et al., 2008). 
 
Bispecific “adenobodies” possess dual selectivity; firstly for the target receptor, and 
secondarily for the virus itself (Watkins et al., 1997). This can be exploited so that these 
bivalent moieties simultaneously bind native Ad receptor tropism determinants, and 
thus facilitate ablation of native tropism, whilst in conjunction redirecting the 
transductional capacity of the vector. Similarly, with this concept in mind, Ab-sCAR 
ectodomain fusion proteins have also been assessed and have demonstrated 
enhanced in vitro retargeting to CD40 and Epidermal Growth Factor (EGF) in a CAR-
independent manner (Dmitriev et al., 2000; Pereboev et al., 2002). Successful 
retargeting in vivo has also been achieved using each of these strategies. Reynolds 
and colleagues demonstrated enhanced targeting to lung tissue which overexpressed 
angiotensin-converting enzyme (ACE) using a bispecific anti-knob, anti-ACE diabody 
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(Reynolds et al., 2000). Additionally, efficient tumour targeting was achieved following 
intravenous delivery of Ad5 conjugated to a bifunctional sCAR-anti carcinoembryonic 
antigen (CEA) scFv fusion complex (Li et al., 2007). Both studies demonstrated 
efficient retargeting which was accompanied by dramatic reductions in liver 
transduction. More recently, Ad5 has been successfully retargeted to Human 
Epidermal Growth Factor (Her2) in vitro using non-immunoglobulin based Affibodies™, 
a novel form of artificial protein ligand (Belousova et al., 2008; Henning et al., 2002; 
Magnusson et al., 2007; Myhre et al., 2009). However, performance in vivo has not 
been assessed for these vectors. 
 
Applications for adapter-ligand based complexes currently are limited, as they do not 
meet the requirements for applications in human gene therapy, a result of their low 
yield, and often heterogenous viral populations. They do, however, provide valuable 
evidence that such retargeting strategies can enhance gene delivery in a CAR-
independent fashion, and perhaps further pharmacoanalysis and confirmation of 
complex stability may enhance their clinical status in the future (Glasgow et al., 2006). 
 
Section.1.4.2 Transductional Retargeting by Genetic Pseudotyping 
 
There are over 50 distinct human adenoviruses, all of which exhibit differential 
tropisms, mediated primarily by the interaction of the fibre protein with diverse cell 
surface receptors (Shayakhmetov et al., 2003). Genetic pseudotyping of adenoviruses 
therefore represents a logical and natural approach to transductional retargeting 
allowing the expansion, or subversion of viral tropism. The vectors most commonly 
used for gene therapy applications are subgroup C Adenoviruses (ie. Ad5 and Ad2), 
which use CAR as their primary receptor (Bergelson et al., 1997). The high fidelity of 
structural integrity, and the conserved homology of fibre tail domains amongst diverse 
Ad species, permits genetic engineering with minimal perturbations to the trimeric fibre 
(Barnett et al., 2002; Tarassishin et al., 2000). Whole fibre replacement strategies 
mostly focus on the substitution of the Ad5 fibre with fibres derived from subgroup B 
adenoviruses (ie. Ad3, Ad11 and Ad35) for which the primary receptor is CD46 
(Gaggar et al., 2003; Liu et al., 2009; Rea et al., 2001; Segerman et al., 2003; Stone et 
al., 2007a; Stone et al., 2007b). Pseudotyped vectors based on Ad5/3 have 
demonstrated enhanced gene transfer to a broad range of cell types (Kanerva et al., 
2002a; Ulasov et al., 2007; Von Seggern et al., 2000). Additionally, the overexpression 
of CD46 in many human cancers has prompted the investigation of Ad5/11 and 
Ad5/35-based vectors for potential tumour targeting applications (Liu et al., 2009; 
Shayakhmetov et al., 2002; Stone et al., 2007a; Stone et al., 2005). Vectors 
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pseudotyped with fibres from subgroup D adenoviruses (ie. Ad17, Ad19, Ad24, Ad30, 
Ad33, Ad37, Ad43 and Ad47) which can use sialic acid and/or αν integrins as 
receptors, often in addition to CAR, are also currently undergoing investigation for 
various applications (Arnberg et al., 2000a; Arnberg et al., 2000b; Chiu et al., 2001; 
Diaconu et al., 2009; Hsu et al., 2005; Parker et al., 2007; Roelvink et al., 1998; 
Waddington et al., 2007).   
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Novel xenotyping strategies involve the substitution of Ad5 knob proteins with those of 
non-human adenoviruses such as canine adenovirus (CAV-1 and CAV-2), and ovine 
atadenovirus type 7 (OAdV7), the prototype member of genus Atadenovirus 
(Nakayama et al., 2006; Stoff-Khalili et al., 2005). Additionally, a successful fibre 
Figure.1.6 Tranductional Retargeting by Adenoviral Fibre Modification (A) Schematic overview of the 
structure of the fibre protein. (B) Outline of fibre retargeting strategies from top, clockwise, genetic 
incorporation of targeting peptides into the HI-loop, combinatorial approaches whereby chemical 
conjugates are attached by cross-linking targeting molecules to the fibre surface, substitution of the 
knob/fibre with that of another serotype whilst additionally retaining the original fibre, genetic pseudotype 
switching of knob/fibre with that of another serotype, and the genetic incorporation of targeting peptides 
into the C-terminus of the knob domain. Figure adapted from (Curiel, 1999) 
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mosaic virus has been constructed by incorporating the trimeric σ1 spike protein from 
Reovirus into Ad5 (Tsuruta et al., 2005). This approach was made technically possible 
by the high degree of structural similarity between the receptor-binding determinants of 
these two distinct viral families. The generation of this mosaic virus resulted in CAR-
independent infectivity enhancement conferred by reoviral tropism determinants, 
junction adhesion molecule (JAM-1) and sialic acid (Barton et al., 2001; Chappell et al., 
1997). However, it is worth considering that genetic pseudotyping of tropism 
determinants has been shown to alter the intracellular trafficking of Ads, and can often 
result in reduced infectivity as a result of inefficient endosomal escape, retarded 
nuclear translocation or retention of virus in late endosomal or lysosomal 
compartments (Miyazawa et al., 2001; Miyazawa et al., 1999). This may impact their 
use for gene therapy applications. 
 
Section.1.4.3 Transductional Retargeting by Genetic Incorporation of Ligands 
 
The genetic incorporation of retargeting ligands results in one-component Ad vectors, 
which are capable of multiple rounds of amplification due to their inherent ability to self-
assemble and self-replicate (Mathis et al., 2005). However, the criteria which define the 
success of this approach are based predominantly on retention of the structural 
integrity of the fibre. Trimerisation of the fibre is a requisite for capsid assembly which 
cannot be compromised, and therefore insertions must not disrupt the innate molecular 
interactions required for adequate assembly (Campos et al., 2004; Krasnykh et al., 
2001). Additionally, the heterologous ligand must retain its targeting capacity without 
the necessity for any major cytosolic post-translational modifications. This is because 
of the nature of Ad5 fibre translation and virion assembly, both of which take place 
under non-reducing conditions, in the cytosol and nucleus, respectively.   
 
Several studies have highlighted a number of potential sites suitable for the 
incorporation of heterologous binding ligands. Capsid sites which can tolerate the 
insertion of large peptides include the C-terminus of the fibre, the HI loop of the fibre, 
the penton base, the hypervariable regions of hexon and the minor hexon protein, IX 
(Belousova et al., 2002; Campos et al., 2004; Dmitriev et al., 1998; Krasnykh et al., 
1998; Kurachi et al., 2007a; Le et al., 2004; Le et al., 2005; Meulenbroek et al., 2004). 
The distal carboxy terminus of the fibre protein was first used for the genetic 
incorporation of gastrin releasing peptide (Michael et al., 1995). Further studies 
followed suit with the incorporation of a heparan-binding polylysine motif (pK7), and an 
arginine-glycine-aspartic acid (RGD) motif, both of which were successful in enhancing 
the in vitro infection of a panel of CAR deficient cell lines (Wickham et al., 1996; 
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Wickham et al., 1997). However, attempts to incorporate peptides at this site are 
limited to the inclusion of up to 27aa, due to disruptions to the trimerising capacity of 
the fibre (Hong & Engler, 1996).  
 
The resolution of the crystal structure of the Ad5 knob domain by X-ray crystallography 
identified the HI loop region as a region suitable for peptide incorporation (Xia et al., 
1994). The rationale for this was that the loop was exposed on the surface of the fibre 
knob structure, had no involvement in the native tropism of Ad5, was innately flexible, 
and its length varied greatly between Ad serotypes. To date, the HI loop has been 
shown to tolerate insertions of up to 83aa, with minimal detrimental effects on structural 
integrity (Belousova et al., 2002). Insertions range from rationally selected motifs, such 
as RGD-4C or TAT peptide from HIV-1, to various candidate peptides screened using 
phage display, including ligands for human transferrin receptor, vascular endothelial 
cells, and peptides with enhanced homing to the kidney (Denby et al., 2007; Dmitriev et 
al., 1998; Kurachi et al., 2007b; Nicklin et al., 2001; Nicklin et al., 2004; Wickham et al., 
1997; Xia et al., 2000). Strategies featuring dual incorporation of peptides within the C-
terminus in conjunction with the HI loop also have demonstrated enhanced infectivity in 
both CAR- and CAR+ cell lines (Koizumi et al., 2003; Wu et al., 2002).  
 
Additionally, the identification of a number of hypervariable regions within the solvent-
exposed loops on the hexon surface highlighted the potential of this capsid protein as 
an alternative site for the genetic incorporation of peptides (Crawford-Miksza & 
Schnurr, 1996; Kalyuzhniy et al., 2008; Vigant et al., 2008). This is a particularly 
attractive approach as the Ad5 hexon has been shown to be one of the major antigenic 
determinants for neutralising antibody responses (Sumida et al., 2005). Therefore 
insertions within the HVRs may result in the occlusion of antigenic target sites, 
permitting escape from neutralisation, or alternatively, presentation of antigenic 
peptides at these sites could be exploited for vaccine based strategies (Crompton et 
al., 1994; McConnell et al., 2006). Additionally, the insertion of targeting ligands into the 
hexon could, in theory, impair binding of FX and therefore reduce hepatotropism of Ad5 
in vivo (Kalyuzhniy et al., 2008; Vigant et al., 2008). 
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Section.1.5 Oncolytic Adenoviruses; Transductional Detargeting 
Strategies 
 
It is now clear that factors other than direct receptor-mediated interactions, contribute 
to the in vivo biodistribution of systemically delivered Ads. This is supported by various 
studies which have demonstrated that ablating native Ad5 tropism determinants (CAR 
and/or αν- integrins) have little, or no effect on the tropism of Ad5 in vivo (Alemany & 
Curiel, 2001; Fechner et al., 1999; Leissner et al., 2001; Martin et al., 2003; Mizuguchi 
et al., 2002; Nicol et al., 2004; Smith et al., 2002). However, the importance of CAR-
binding ablating strategies has once again become a worthy consideration when 
contemplating the design of therapeutic Ads. This is based on recent research which 
has uncovered implications for Ad5-CAR interactions with erythrocytes in vitro and in 
vivo (Carlisle et al., 2009; Nicol et al., 2004; Seiradake et al., 2009). This finding has 
particular relevance for the translation of Ad-based treatments to the clinical setting.  
 
A prominent role for receptor-independent bridging interactions in mediating the in vivo 
tropism of Ad5 has been uncovered in recent years. The intravenous delivery of Ad5 is 
associated with acute hepatotoxicity which limits the therapeutic efficacy (Engler et al., 
2004; Lieber et al., 1997). The mechanism underlying its innate hepatotropism is now 
known to result from a direct interaction between the hexon and vitamin K-dependent 
coagulation factor, FX (Alba et al., 2009; Kalyuzhniy et al., 2008; Waddington et al., 
2008). This interaction permits engagement with HSPGs or low density lipoprotein 
receptor on the surface of hepatocytes, facilitating viral entry via an indirect bridging 
mechanism (Parker et al., 2006; Shayakhmetov et al., 2005b; Waddington et al., 2008; 
Waddington et al., 2007). Therefore, modifications which ablate or disrupt this FX-
hexon interaction would have utility in minimising sequestration at non-target sites, and 
would greatly improve the selectivity of delivery.   
 
Section.1.5.1 Transductional Detargeting by Ablation of Native Tropism  
 
Ablation of CAR-binding determinants was once considered an essential strategy for 
refining the broad tropism of Ad5 in vivo. This was based on the assumption that the 
classical, two-step entry pathway for Ad5, via CAR and ανβ3/ανβ5, was also relevant in 
vivo. However, subsequent studies highlighted the redundancy of CAR in directing the 
tropism of Ad5 following systemic delivery (Alemany & Curiel, 2001; Fechner et al., 
1999; Leissner et al., 2001; Martin et al., 2003; Mizuguchi et al., 2002; Nicol et al., 
2004; Smith et al., 2002). Although the tissue distribution of CAR in humans has not 
been well characterised, it has been shown to be expressed in cardiac/skeletal muscle, 
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and on the surface of human erythrocytes (Carlisle et al., 2009; Seiradake et al., 2009; 
Shaw et al., 2004). Furthermore, CAR mRNA has been detected in the heart, testis,  
small intestine, pancreas, prostate, liver, kidney and brain (Tomko et al., 1997; Zhang 
& Bergelson, 2005). Therefore, it is important to consider that the localisation of CAR in 
humans may impact the selectivity/toxicity of targeted delivery and serves to further 
highlight the necessity for developing CAR-independent retargeting strategies. 
 
Murine CAR displays high amino acid sequence homology to human CAR, with more 
than 90% homology within the cytoplasmic and extracellular domains (Bergelson et al., 
1998; Tomko et al., 1997). Expression of CAR in mice is most abundant in the liver, 
kidney, lung and in the heart, where it has been shown to regulate atrioventricular 
conduction, through associations with connexion-45, β-catenin and ZO-1 (Cohen et al., 
2001; Kallewaard et al., 2009; Lim et al., 2008; Lisewski et al., 2008; Shaw et al., 
2004). It has also been shown to play a role in murine develoment (Dorner et al., 2005; 
Hotta et al., 2003). Ad5 can agglutinate human, but not murine, erythrocytes via a 
CAR-binding interaction (Carlisle et al., 2009; Seiradake et al., 2009). In vivo this 
interaction was shown to impair the extravasation of Ad5 into tumour xenografts when 
using transgenic mice expressing CAR on the surface of their erythrocytes, or mice 
transplanted with washed human erythrocytes (Carlisle et al., 2009). This factor has 
particular relevance when choosing suitable animal models in which to study the 
effects of systemically delivered therapeutic Ads. Alternatively, the use of CAR-binding 
ablated vectors which are also unable to agglutinate human erythrocytes, could 
represent an alternative means to improve the translational relevance of in vivo studies 
which are performed in murine models. Furthermore, Ad5 binding to CAR has been 
identified as a key event leading to the activation of pro-inflammatory cytokine 
transcription in respiratory epithelial cells in vitro (Tamanini et al., 2006), and has been 
associated with the induction of cytokine transcription in vivo (Schoggins et al., 2005).  
 
The precise molecular determinants for CAR binding have been described previously 
(Kirby et al., 1999; 2000; Roelvink et al., 1999; Santis et al., 1999). The fibre of Ad5 
exists as a homotrimer, and the topological arrangement of the knob monomer is as an 
eight-stranded antiparallel β sandwich, with interspersing loop regions (Xia et al., 
1995). The loop regions vary from 8-55aa residues and are named AB, CD, DE, DG, 
GH, HI and IJ (see Appendix I). Residues, Ser408 and Pro409 in the AB loop, Tyr477 
in the DG loop and Leu485 in β-strand F, have been identified as the critical epitopes 
involved in a high affinity interaction with CAR (Kirby et al., 2000). Substitution 
mutations at these sites, S408E, P409A, Y477A and L485K, have been shown to 
effectively abolish the interaction with CAR (Kirby et al., 2000; Leissner et al., 2001). 
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Interestingly, CAR-binding mutations, S408E and P409A, have also been shown to 
prevent the agglutination of human and rat erythrocytes (Nicol et al., 2004).  
 
Following on from the original hypothesis that ablating the native receptor binding 
determinants of Ad5 would refine its broad tissue biodistribution, several studies 
reported the generation of vectors featuring a mutation in the penton RGD motif, or 
penton mutants which were combined with CAR-binding ablations (Einfeld et al., 2001; 
Koizumi et al., 2006; Mizuguchi et al., 2002; Nicol et al., 2004; Smith et al., 2003a). The 
latter modifications (CAR- and αν-binding ablation) were sufficient to reduce liver 
tropism to some extent following systemic delivery, although this remains controversial. 
However, efficient retargeting with these vectors has not been reported.  
 
Finally, the KKTK motif within the shaft of the Ad5 fibre has been proposed to promote 
direct binding to HSPGs, although this has never been verified experimentally 
(Dechecchi et al., 2001; Dechecchi et al., 2000). Hepatocytes express high levels of 
HSPGs (Lyon et al., 1994), thus it was thought that HSPG-mediated entry could 
contribute to the dramatic liver transduction observed following systemic delivery of 
Ad5. Subsequently, various studies described significant hepatocyte detargeting in 
mice, rats and non-human primates as a result of introducing fibre shaft mutations, 
KKTK to GAGA, which were in some cases accompanied by CAR-binding mutations 
(Bayo-Puxan et al., 2006; Kritz et al., 2007; Nicol et al., 2004; Smith et al., 2003a; 
Smith et al., 2003b). In contrast with this, when shaft-chimeric Ad5 viruses featuring 
long Ad31, or Ad41 shaft domains (lacking the KKTK motif) were generated, the liver 
accumulation, transduction and levels of pro-inflammatory cytokines produced were 
identical to Ad5 (Di Paolo et al., 2007). These data suggest that the KKTK motif itself is 
not responsible for a direct, receptor-mediated interaction with HSPGs. It now is 
believed that the shaft mutation confers rigidity/instability to the fibre, impairing the 
flexibility required for efficient receptor interactions (Nicklin et al., 2005; Wu et al., 
2003). Thus, the mechanism underlying the reduced liver tropism of these vectors is 
now thought to be due to the inefficient endocytosis, viral trafficking or endosomal 
escape of these vectors (Di Paolo et al., 2009b; Kritz et al., 2007). Furthermore, 
transduction cannot be rescued by ligand-directed retargeting; the incorporation of 
RGD-4C, or the endothelial targeting peptide QPEHSST, into the HI loop of the KKTK 
mutant vectors failed to demonstrate efficient retargeting (Bayo-Puxan et al., 2006; 
Kritz et al., 2007).  
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Section.1.5.2 Transductional Detargeting by Ablation of “Bridging” Interactions 
 
Recent research has demonstrated a fundamental role for serum/coagulation factors, 
C4BP, FVII, FIX, protein C and predominantly FX, in directing the hepatocyte 
transduction of Ad5 following systemic delivery (Alba et al., 2009; Kalyuzhniy et al., 
2008; Parker et al., 2006; Shayakhmetov et al., 2005b; Vigant et al., 2008; Waddington 
et al., 2008; Waddington et al., 2007). Surface Plasmon Resonance (SPR) analysis 
was used to confirm the direct interaction between the hypervariable regions (HRV) of 
the Ad5 hexon and the Gla domain of FX (Waddington et al., 2008). This interaction 
was further supported the ablation of hepatocyte transduction when using an Ad5 
vector in which the HRVs were switched for those of Ad48, a serotype D adenovirus 
which fails to bind FX and does not display hepatocyte transduction in vivo 
(Waddington et al., 2008). Additionally, other studies have shown that the insertion of 
various peptides into hexon hypervariable region -5 (HRV5) of Ad5 also lead to 
reductions in liver transgene expression (Kalyuzhniy et al., 2008; Vigant et al., 2008).  
 
The critical domains and epitopes responsible for the hexon-FX interaction have 
recently been mapped to hexon HRV-5 and HRV-7 (Alba et al., 2009). Again, switching 
HRV5 or HRV7 with the corresponding domains derived from a non-FX interacting 
serotype Ad26, impaired FX binding both in vitro and in vivo, although the HRV5 
substitution was shown to prevent adequate virion assembly. Cryo-electron microscopy 
and structural modelling were used to predict putative interacting residues between the 
Ad5 hexon and FX. Several key residues mapping to HRV5 (T270P and E271G) and 
HRV7 (I421G, T423N, E424S, L426Y and E451Q) were identified and subsequently 
mutated. A single amino acid residue, E451, was found to be conserved among FX-
binding Ad serotypes, but to be absent from non-binders. Accordingly, a point mutation 
at this site, E451Q, was sufficient to ablate FX-mediated infectivity enhancement in 
vitro and in vivo.  
 
Additionally, Shayakhmetov and colleagues previously described an Ad5 mutant, 
Admut, featuring a set of mutations in the fibre knob domain which ablated binding to 
coagulation factors FIX/C4BP (Shayakhmetov et al., 2005b). The Y477A-dlTAYTFLAG 
modification was sufficient to reduce the hepatotropism of Ad5 in vivo. Furthermore, 
this construct displayed reduced hepatotoxicity and a failure to co-localise with Kupffer 
cells. However, a mechanism to explain this phenotype was never proposed and 
remains uncharacterised to date.  
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Alternative strategies which can be exploited to shield the Ad5 hexon from FX binding 
in vivo, involve coating the Ad5 particle in synthetic polymers, such as polyethylene 
glycol or the multivalent copolymer poly-[N-(2-hydroxypropyl) methacrylamide]. 
Originally, this approach was designed to permit efficient retargeting and impair native 
receptor utilisation whilst simultaneously allowing the evasion of neutralising antibody 
and innate inflammatory responses (Chillon et al., 1998; De Geest et al., 2005; Fisher 
et al., 2001; O'Riordan et al., 1999; Wortmann et al., 2008). However, more recently, 
these strategies have proven useful in reducing the liver tropism and hepatotoxicity 
associated with intravenous delivery of Ad5, in addition to demonstrating selective 
retargeting in vivo (Eto et al., 2008; Green et al., 2008; Kreppel et al., 2005; Morrison et 
al., 2008; Stevenson et al., 2007).  
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Section.1.6 Other Limitations of Adenoviral Gene Therapy 
 
Systemic delivery modalities are preferential for the treatment of many diseases, 
especially disseminated cancers. However, intravenous delivery of Ad5 in murine 
models is dose limiting, and is characterised by significant liver accumulation and 
hepatocyte transduction, which can result in acute toxicity and the induction of potent 
anti-viral immune effectors (Engler et al., 2004; Lieber et al., 1997). Viral capsid 
proteins also possess distinct antigenic determinants capable of eliciting cellular and 
humoral immune responses (Gahery-Segard et al., 1998; Gahery-Segard et al., 1997; 
Onion et al., 2007; Roberts et al., 2006; Sumida et al., 2005; Willcox & Mautner, 1976; 
Youil et al., 2002). Furthermore, pre-existing immunity and high Ad5 seroprevalance in 
humans represent major challenges to successful therapeutic interventions (Parker et 
al., 2009; Sprangers et al., 2003; Stallwood et al., 2000; Sumida et al., 2005).  
 
It is clear that a multitude of factors encountered in the circulation impede the delivery 
of Ad5 to target tissues in vivo. However, once successful tumour-selective delivery 
has been achieved, further challenges remain. Both the innate and adaptive immune 
responses contribute significantly to the clearance of virus from the tumour, resulting in 
limited efficacy. Furthermore, current in vivo models for studying the anti-tumoural 
efficacy of Ad5-based vectors do not accurately reflect the clinical scenario in patients, 
in that they are immunodeficient, naïve of pre-existing immunity and are non-
permissive for viral replication. However, the widespread use of immunocompetent 
animal models (ie. Syrian hamsters or Cotton rats) which are permissive, or semi-
permissive for Ad5 replication, is limited by the shortage of suitable reagents, the 
unavailability of multiple syngeneic tumour cell lines, in addition to the distinct lack of 
transgenic models which display genetic homogeneity (Thomas et al., 2006b; Toth et 
al., 2007). Additionally, the inherent physical and biological barriers imposed by the 
heterogenous nature of solid tumours also impedes adequate viral replication, lysis, 
intra-tumoural spread, transgene expression and, therefore, the potency of oncolytic 
strategies.  
 
Section.1.6.1 The Innate Immune Response 
 
Systemic delivery of Ads induces acute inflammation, which is characterised by the 
activation of multiple innate immune effectors. In mice, the innate response to Ad5 is 
biphasic (Lieber et al., 1997; Liu & Muruve, 2003; Liu et al., 2003). The first phase, 
induced independently of viral gene expression, peaks between 1 and 6hrs post-
infection and is followed by a secondary peak 5 to 7 days post-infection, when the 
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response is directed primarily against transgene expression (Lieber et al., 1997; Liu & 
Muruve, 2003; Liu et al., 2003). Recent evidence has implicated receptor binding 
determinants (CAR/integrins) in the potent activation of cytokines and chemokines (Di 
Paolo et al., 2009a; Liu et al., 2003; Schoggins et al., 2005; Shayakhmetov et al., 
2004b; Tamanini et al., 2006; Tibbles et al., 2002). These interactions can induce 
various signal transduction pathways including p38 mitogen activated kinase (MAPK), 
p44/42 MAPK (ERK1/2), PI3K and NF-κB. However, uptake by non-parenchymal cells 
in the liver, mediated via scavenging receptors (ie. SR-A), or through bridging 
interactions with platelets or coagulation factors, also contributes to the induction of 
innate responses (Di Paolo et al., 2009b; Haisma et al., 2009; Shayakhmetov et al., 
2005b; Shayakhmetov et al., 2004b; Stone et al., 2007b). Recently, an Ad5 interaction 
with the integrin subunit -β3, has been shown to promote the activation of IL-1α in 
splenic marginal zone macrophages in vivo (Di Paolo et al., 2009a).  
 
It is clear that macrophages and dendritic cells play a significant role in the recognition, 
clearance and subsequent inflammation associated with Ad5 in vivo (Di Paolo et al., 
2009a; Fejer et al., 2008; Koizumi et al., 2007). Pre-treatment of animals with 
clodronate liposomes has been shown to limit vector-related toxicity, and selective 
depletion of Kupffer cells using gadolinium chloride (GdCl3) has been shown to reduce 
hepatotoxicity through preventing serum TNF-α elevation (Kuzmin et al., 1997; Lieber 
et al., 1997). TNF-α plays a pivotal role in the clearance of adenoviral vectors (Elkon et 
al., 1997), and E1A expression can sensitise hepatocytes to TNF-α mediated cell killing 
(Engler et al., 2004). Additionally, much of the hepatic toxicity induced has also been 
attributed to neutrophil recruitment following the rapid release of macrophage 
inflammatory protein-2 (MIP-2) from activated Kupffer cells (Muruve et al., 1999). It was 
shown in two independent studies that hepatic injury induced by systemic delivery of 
Ad5 could be prevented either by pre-treatment with anti-MIP-2 antibodies, or by 
studying the effects of vector-related toxicity in IL-1 receptor knockout mice (Muruve et 
al., 1999; Shayakhmetov et al., 2005c). These findings were complemented by the fact 
that MIP-2 expression is dependent on intact IL-1 signalling and activation 
(Shayakhmetov et al., 2005c).   
 
More recently it has been shown that vectors which have reduced accumulation in the 
spleen, display attenuated hepatic injury despite extensive hepatocyte transduction 
(Koizumi et al., 2007). The phenotype of Ad5-pK7, a HSPG retargeted vector, has 
been attributed to diminished IL-6 signalling, as a direct result of limited uptake by 
splenic dendritic cells. These data highlight the importance of developing vectors which 
evade both splenic sequestration and Kupffer cell activation; although it is clear that 
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multiple mechanisms contribute to the toxicity of Ad5 in vivo. Further studies are 
warranted in order to determine the precise molecular interactions and cellular effectors 
involved in these processes.  
 
Section.1.6.2 Translational Relevance of Pre-Clinical In Vivo Studies 
 
A significant proportion of the data regarding the in vivo biodistribution, toxicity and 
efficacy of adenoviral vectors refer to studies performed in small animal models, 
namely mice. Undoubtedly, these studies have led to increased knowledge in the field 
and have influenced the future direction of Ad-based therapeutic strategies. However, 
the translational relevance of many of these findings remains unclear. Several major 
issues which limit the translational potential of adenoviral vectors, especially when 
attempting to achieve targeted delivery following systemic delivery, currently exist. 
Species variations in innate immune responses, permissiveness for viral replication, 
differences in hepatic micro-anatomy, differential interactions with blood cell 
populations and with native receptors, in addition to the presence of neutralising 
immunity (discussed below) all contribute the the broad spectrum of Ad responses 
observed in pre-clincal animal models. These differences are outlined in Table.1. 
 
The liver is the major site for accumulation of Ad5 following systemic delivery in murine 
models. The fenestrae of the sinusoidal endothelial cells in the livers of mice are 
relatively large (~140nm) and easily accomodate the smaller Ad5 particle (~100nm). 
This permits rapid access to hepatocytes and to the space of Disse (Lievens et al., 
2004). Conversely, the smaller endothelial fenestrae (~107nm) in humans may be 
more restrictive to Ad delivery (Wisse et al., 2008). The distinct hepatotropism of Ad5 in 
murine models is mediated through an interaction between the Ad5 hexon and 
coagulation factor FX (Kalyuzhniy et al., 2008; Waddington et al., 2008). However, the 
role of this interaction in determining liver transduction in humans, or in fact other small 
animal models, has not been well characterised. Murine and human FX display high 
amino acid sequence homology, and both bind to Ad5 with high affinity (Kalyuzhniy et 
al., 2008). Evidence supporting the relevance of this functional interaction has been 
demonstrated in vivo using human FX to rescue hepatocyte transduction in 
warfarinised mice. Whether or not this interaction plays a dominant role in limiting 
efficacy, or inducing toxicity in humans, remains to be determined. However, it is well 
established that the coagulation cascade is intrinsically linked with cancer and 
importantly, elevations in FX are frequently detected in patients with solid tumours 
(Falanga, 2005; Ferrigno et al., 2001; Iversen et al., 2002). Therefore, it is worth 
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considering that the Ad5-FX interaction may well be relevant in human patients 
undergoing oncolytic therapy. 
 
Transient liver toxicities and transaminitis are commonly reported side effects in human 
clinical trials with Ad5-based vectors (see Table.1). Dose-limiting hepatotoxicity is a 
characteristic effect of systemic Ad5 administration in murine models. However, acute 
liver toxicity is also observed in non-human primates, rats and hamsters (Brunetti-Pierri 
et al., 2004; Lichtenstein et al., 2009; Nicol et al., 2004). Additionally, it appears that a 
similar repertoire of inflammatory cytokines is induced by intravascular delivery of Ad5 
in multiple species. Serum elevations of IL-6, TNF-α, IFN-γ and IL-12 have been most 
frequently reported in humans, non-human primates and mice (see Table.1). Systemic 
activation of IL-6, TNF-α, IFN-γ and IL-12 in mice can pre-dispose to lethal septic shock 
in response to bacterial LPS or endotoxin (Starnes et al., 1992; Wysocka et al., 1995). 
Interestingly, septic shock in pediatric patients in response natural adenovirus infection 
has also been associated with dramatic elevations in IL-6 and TNF-α (Mistchenko et 
al., 1994).  
 
Although transient thrombocytopenia or leukopenia appears to be a common effect 
induced by Ad5 in humans, non-human primates and mice, there are vast differences 
in the interactions of Ad5 with other blood cell populations. Anemia and erythroid 
asplasia have been reported in humans and more recently, hamsters, although it is 
worth considering that the former may be related to regular phlebotomy during the 
course of the clinical trial. Alternatively, these effects may be related to the ability of 
Ad5 to agglutinate CAR-expressing erythrocytes, an interaction which has now been 
confirmed using rat and human, but not murine erythrocytes (Carlisle et al., 2009; Nicol 
et al., 2004). Furthermore, in non-human primate models it appears that the spleen is 
more efficiently transduced than in murine models (Schnell et al., 2001; Smith et al., 
2003a). This may be a reflection of differences in hepatic micro-anatomy, which could 
lead to increased bioavailability for the spleen. In support of this, increased blood 
persistence was also been reported in non-human primates (Smith et al., 2003a). 
Interestingly, data from human clinical trials has shown that input virus is cleared within 
6hrs of intravascular delivery (Reid et al., 2001). This is in stark contrast with clearance 
rates in mice, in which Ad5 has a half-life of less than 2 minutes following intravenous 
delivery (Alemany et al., 2000b). Nonetheless, it is clear that a great deal of work 
needs to be done in order to successfully correlate pre-clincial studies with outcome in 
humans and it is necessary that we adopt a pragmatic attitude when assigning 
relevance to data obtained from selected animal models.  
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(Atencio et al., 2006; Au et al., 2007; Reid et al., 2002)
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Section.1.6.3 Immunogenicity and Pre-Existing Immunity 
 
The use of immunocompetent animal models in which to study oncolytic Ad-mediated 
effects has greater translational relevance to the clinical setting. However, this is 
complicated when studying human cancers in murine models, as human xenografts 
must be grown using immunodeficient mice. Therefore, these models fail to adequately 
assess the in vivo safety profile of oncolytic Ads, and do not factor in the effects of an 
adaptive immune response, or the existence of neutralising antibodies. Ad5 does not 
replicate productively in murine cells due to host range restrictions (Duncan et al., 
1978; Ginsberg et al., 1991). However, a limited number of Ad5-permissive lines have 
now been identified which are suitable for developing syngeneic, immunocompetent 
murine models (Ganly et al., 2000; Guo et al., 2006; Hallden et al., 2003; Wang et al., 
2003).  
 
Recently, immunocompetent Syrian hamster models have proven useful in assessing 
the effects of oncolytic adenoviruses in vivo (Bortolanza et al., 2007; Bortolanza et al., 
2009; Gros et al., 2008; Spencer et al., 2009; Thomas et al., 2006b). Furthermore, the 
role of pre-existing immunity and the effects of transient immunosuppression on anti-
tumoural efficacy have recently been comparatively assessed (Dhar et al., 2009). 
Interestingly, pre-existing immunity to Ad5 did not impair the efficacy of an oncolytic 
Ad5 which was administered intratumourally, and in fact prevented the toxicity induced 
by vector leakage and dissemination from the tumour to other organs. Analyses of the 
toxicity and biodistribution of Ad5-based vectors in Syrian hamsters are also currently 
ongoing (Lichtenstein et al., 2009; Ying et al., 2009). Paralleling the findings in murine 
models, replicating Ad5-based vectors also display dramatic liver sequestration and 
hepatotoxicity in hamsters following systemic delivery. Although a direct role for 
coagulation factors was not demonstrated in these studies, it is possible that FX-
dependent hepatocyte transduction may also contribute to the accumulation of Ad5 in 
these models.  
 
The increased interest in utilising immunocompetent murine or Syrian hamster models 
has prompted careful considerations when developing vectors. This is due to several 
reports that the retention of the E3 region of Ad5 is critical in maintaining the longevity 
of viral transgene expression, and therefore the therapeutic efficacy (Bortolanza et al., 
2009; Wang et al., 2003). The E3 region produces viral proteins which function as 
immunomodulatory agents, counteracting various facets of the innate and adaptive 
immune response to Ad5 (Bennett et al., 1999; Carmody et al., 2006; Cox et al., 1991; 
Lichtenstein et al., 2004; Tollefson et al., 2001). In particular, deletions within the E3B 
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region (10.4/14.5kDa-RID and 14.7kDa) have resulted in accelerated vector clearance 
from the tumours of immunocompetent mice, which correlated with increased 
macrophage infiltration and cytokine production (Wang et al., 2003). Interestingly, 
deletion of E3-gp19kDa led to increased replication and anti-tumoural efficacy in an 
immunocompetent murine model, however the opposite effect was found in an 
immunocompetent hamster model (Bortolanza et al., 2009; Wang et al., 2003). 
 
Section.1.6.4 Tumour Microenvironment 
 
The heterogenous cellular milieu which constitutes a solid tumour represents a major 
challenge for the effective spread and lytic effect of oncolytic Ads. Solid tumour masses 
are composed of neoplastic cells, stromal fibroblasts, myofibroblasts, endothelial cells 
and immune cells, all of which interact with various components of the extracellular 
matrix (ECM) to affect migration, proliferation and invasion (Wernert, 1997).  
 
The diffusion of therapeutic agents into the tumour following systemic delivery is 
enhanced by vascular permeability, a feature which is reportedly found in solid tumours 
(Hashizume et al., 2000; Yuan et al., 1995). However, poorly distributed vasculature 
within the tumour mass can impede the uniform distribution and subsequent spread of 
therapeutic agents. Furthermore, the dysregulation of blood vessel formation or vessel 
architecture, in addition to the absence of functional lymphatics, contribute to the 
development of a necrotic and hypoxic microenvironment. The presence of expansive 
necrotic regions within the tumour mass negates the therapeutic efficacy of oncolytic 
Ads, which require living cells for replication and progeny production. Furthermore, the 
physical nature of the tumour stroma and ECM impose barrier-like restrictions on the 
dissemination of virus throughout the tumour. Additionally, the sequestration of input 
vector by fibroblasts within the ECM can also limit viral production and spread, as it is 
well established that productive adenoviral replication is dramatically impaired in 
fibroblasts (Bazan-Peregrino et al., 2008; Gonzalez et al., 2006). Thus, various Ad-
based vector engineering strategies have been employed in an attempt to overcome 
some of these restrictions.  
 
Angiogenesis is critical for the progression and dissemination of tumours, however 
under normal conditions in adults the process is strictly regulated (Folkman, 1971; 
1995). Therefore, targeting angiogenesis represents a means to retard tumour growth 
and metastasis, and induce widespread tumour necrosis. Adenoviral vectors can be 
retargeted efficiently to vascular endothelial cells (Nettelbeck et al., 2001; Nicklin & 
Baker, 2008; Nicklin et al., 2001; Nicklin et al., 2004; Nicklin et al., 2000; Reynolds et 
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al., 2000; Shinozaki et al., 2006; Trepel et al., 2000; Work et al., 2004a; Work et al., 
2004b), where they can be programmed to deliver anti-angiogenic factors or express 
cytotoxic/proapoptotic agents under the control of endothelial-specific promoter 
elements (Feldman et al., 2000; Greenberger et al., 2004; Regulier et al., 2001; Song 
et al., 2005; Varda-Bloom et al., 2001).  
 
Furthermore, the induction of hypoxia as a result of inadequate tumour vasculature is 
one of the hallmarks of solid cancers (Brown & Giaccia, 1998; Pouyssegur et al., 
2006). Again, this can be exploited for therapeutic effect by designing oncolytic Ads 
which feature hypoxia-inducible gene/cytotoxic transgene expression (Huang et al., 
2005; Post et al., 2007; Post & Van Meir, 2003). However, these strategies should also 
be combined with strategies to enhance the intra-tumoural spread and potency of Ad-
based therapies. Recently, dramatic improvements in efficacy have been achieved 
when delivering oncolytic Ads which exhibit an enhanced release phenotype; through 
the overexpression of the Adenoviral Death Protein (E3-ADP) or through the viroporin-
like activity of a truncated, mutant E3-gp19K protein, expressed by AdT1 (Doronin et 
al., 2003; Gros et al., 2008). Interestingly, the AdT1 mutant also displayed enhanced 
release from cancer-associated fibroblasts. Novel Ad-engineering strategies to 
enhance potency include the incorporation of fusogenic proteins to induce syncytia 
formation, or enzymatic transgenes which digest/depolymerise components of the 
extracellular matrix, therefore enhancing viral spread throughout the tumour (Ganesh et 
al., 2007; Guedan et al., 2008). Alternatively, such agents have also demonstrated 
efficacy following co-administration with virus (Ganesh et al., 2008).  
 
Other approaches to improving the spread and potency of therapeutic Ads, aim to 
suppress or subvert the immune response directed towards the virus. Several studies 
have reported prolonged transgene expression, in addition to successful repetitive 
administration, when using immunosuppressive treatment regimes (Bouvet et al., 1998; 
Jooss et al., 1996; Smith et al., 1996). Furthermore, a recent study using an 
immunocompetent Syrian hamster model, demonstrated enhanced anti-tumoural 
efficacy following transient immunosuppression with cyclophosphamide (Thomas et al., 
2008). In contrast, other studies aim to exploit Ad vectors for immunotherapy 
applications, by using them to express chemoattractants such as granulocyte-
macrophage colony-stimulating factor (GM-CSF), to actively recruit immune effectors to 
the tumour, or stimulate adaptive anti-tumoural immune responses (Lei et al., 2009).  
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Section.1.7 Integrins and the Role of ανβ6 in Cancer 
 
Integrins are a diverse family of cell surface adhesion molecules with a range of cell-
cell, cell-extracellular matrix (ECM) and signal transduction functions (Figure.1.7). 
Structurally, integrins are obligate heterodimers composed of two distinct non-
covalently associated α (alpha) and β (beta) subunits. There exist approximately 25 
characterised, ligand-distinct combinations generated from 18 α and 8 β subunits, with 
further variants created by differential splicing and post-translational modifications. 
Integrins are transmembrane proteins with a large extracellular domain and short non-
catalytic cytoplasmic domain, with the exception of -β4 which has a relatively large 
cytoplasmic region (Kajiji et al., 1989). Integrins play an essential role in regulating 
signalling pathways responsible for cytoskeleton reorganisation during adhesion and 
migration, and their signals promote cell survival and proliferation (Guo & Giancotti, 
2004).  
 
Ligand
Plasma Membrane
Extracellular Matrix
Cytoplasm
BA
 
 
 
 
 
 
 
Figure.1.7 The Integrin Superfamily, Structure and Signalling (A) Heterodimeric integrins can be 
classified into several subfamilies based on ligand specificity. The different subunits show selectivity in 
their binding partners; for example the αν subunit can pair with multiple β subunits, however the β6 subunit 
can only bind with αν subunits. (B) Integrins are composed of α and β transmembrane subunits with a 
short cytoplasmic tail (except β4) and an extended extracellular domain. The short cytoplasmic domains of 
both α and β subunits interact with downstream intracellular effector proteins, activating several signalling 
pathways, with roles in proliferation, cell survival and migration. Both figures have been taken from 
Thomas et al., 2006a. 
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Their indirect interactions with microfilament-scaffolding domains are mediated by 
regulating phosphorylating kinases, such as focal adhesion kinase (FAK) and Src 
kinase family members, which activate downstream effector substrates. Integrin 
binding ligands include fibronectin, vitronectin, collagen, laminin and tenascin-C and 
interactions are often characterised by the recognition of RGD (Arg-Gly-Asp) motifs in 
their binding domains. 
 
The epithelial-specific integrin ανβ6 remains undetectable on normal adult tissue, but is 
upregulated by inflammation, tumourigenesis and epithelial re-establishment following 
wound healing (Breuss et al., 1995; Haapasalmi et al., 1996). Overexpression of ανβ6 
is also found in a range of fibrotic conditions including kidney and biliary duct disease 
(Trevillian et al., 2004; Wang et al., 2007). Additionally, ανβ6 has been shown to play a 
role in maintaining immunological homeostasis in murine lung, and dysregulated 
expression of the integrin can lead to pulmonary fibrosis or Acute Lung Injury (Ganter 
et al., 2008; Horan et al., 2008; Munger et al., 1999; Puthawala et al., 2008). In the 
neoplastic context, expression of ανβ6 integrin is restricted to carcinomas, and has 
been reported in pre-malignant oral epithelial dysplasias (Hamidi et al., 2000), oral and 
dermal carcinomas, as well as carcinomas of the lung, pancreas, stomach, and ovary 
(Table.2). Additionally, ανβ6 recently has been independently identified as a strong 
prognostic indicator in ovarian, lung, colorectal, cervical and breast cancer (Ahmed et 
al., 2002b; Bates et al., 2005; Elayadi et al., 2007; Hazelbag et al., 2007). The cell 
surface localisation of ανβ6, coupled with its prognostic associations in a broad range 
of human carcinomas highlight its importance as a novel molecular target. However, 
the expression of ανβ6 in a range of underlying inflammatory or fibrotic conditions in 
humans warrants consideration when designing therapeutic delivery strategies targeted 
specifically to ανβ6, as this may impact the success of treatment regimes. 
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Kawashima et al., 2003                 38                      84           IHC, RT-PCR     94% ανβ6+ carcinomas had LN metastases 
Van Aarsen et al., 2008               100                      64                 IHC               Absent/minimal expression in normal tissue
Van Aarsen et al., 2008                 49                      84                 IHC               SCC, not normal tissue was ανβ6+ 
ReferenceCarcinoma Number of carcinomas
% Positive
tumours CommentEvidence
TABLE 2. Expression of ανβ6 in Human Carcinomasa
Impola et al., 2004 11                    100                  ISH               Expression maintained in LN metastases        
Nystrom et al., 2006                      20                      85                  IHC              <30% oral dysplasia were also ανβ6+ 
Regezi et al., 2002 40                    100                  IHC               Peri-tumoral dysplasia was also ανβ6+ 
Hamidi et al., 2000 5                      80                  IHC               41% OL, Peri-tumoral dysplasia ανβ6+ 
Jones et al., 1997 17                    100                  IHC               Absent expression in normal oral mucosa 
Breuss et al.,1995 30                      90                  ISH               Absent expression in normal oral mucosa
Oral SCCOral 
HNSCC
Skin 
Yang  et al., 2008                        358                      34                TMA               71% expression in liver metastases
Colon Van Aarsen et al., 2008                 60                      12                 IHC
Bates et al., 2005                        488                      47                  IHC               ανβ6 expression maintained in metastases
Stomach
Eosphagus Van Aarsen et al., 2008                56                      68                  IHC               Absent/minimal expression in normal tissue
Pancreas
Van Aarsen et al., 2008               107                     57                  IHC
Sipos et al., 2004                          34                    100                  IHC               Expressed in well differentiated tumours
Lung
Van Aarsen et al., 2008                54                      35                  IHC
Smythe  et al., 1995                      51                     50                   IHC           ανβ6 determined to be a prognostic marker
Elayadi  et al., 2007                    289                      54                 TMA              ανβ6+ correlated with poor prognosis
Breast
Van Aarsen et al., 2008               145                     43                  IHC
Arihiro et al., 2000                         90                     18               IHC, WB           No Grade 1 tumours ανβ6+ 
Ovarian
Van Aarsen et al., 2008                52                      33                  IHC
Ahmed et al., 2002 b                     45                   100                  IHC                ανβ6+ expression correlated with grade
Kidney
Liver Van Aarsen et al., 2008                 59                     <2                  IHC
Van Aarsen et al., 2008               103                     21                  IHC
a Abbreviations are as follows; SCC = Squamous Cell Carcinoma, HNSCC = Head and Neck SCC, BCC = Basal Cell Carcinoma, IHC =
Immunohistochemistry, ISH = In situ hybridisation, LN = lymph node, OL = Oral leukoplakia, TMA = Tissue microarray, RT-PCR = Reverse
Transcriptase polymerase chain reaction, WB = Western blot. Table updated from Thomas et al., 2006a.
Cervical Hazelbag et al., 2007                    85                     58                   IHC               ανβ6+ correlated with poor prognosis
Marsh et al., 2008                         13                       77                 IHC               Morphoeic BCC ανβ6+ 
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Section.1.7.1 Ligand Binding to ανβ6 
 
Ligand binding to ανβ6 is strongly preferential for RGD tripeptide motifs which are 
followed by +1 and +4 leucine residues. The DLXXL motif was first identified by phage 
display as the key epitope which conferred strong ανβ6 binding, with minimal 
interaction with other ανβ3/ανβ5 integrins (Kraft et al., 1999). This was further 
substantiated by DLXXL peptide inhibition studies on FMDV infection following the 
confirmation that natural FMDV infection is mediated by ανβ6 (Burman et al., 2006; 
DiCara et al., 2008; Jackson et al., 2000). Previous work in our laboratory selected a 
panel of sequence overlapping peptides, all containing the RGDLXXL motif, from 
known ανβ6 ligands (Table.3), which included latency associated peptide (LAP) of 
TGF-β1 and TGF-β3 (Annes et al., 2002; Munger et al., 1999), the VP1 structural 
protein of FMDV, Coxsackiesvirus A9 (Heikkila et al., 2009; Williams et al., 2004) and 
fibronectin (Weinacker et al., 1994). 
TABLE 3. Ligands for ανβ6a
Ligand Type of Protein Reference
a Abbreviations are as follows; ECM = Extracellular matrix, LAP = Latency associated
peptide, TGF-β = Transforming growth factor, FMDV = Foot and Mouth Disease Virus, CAV
= Coxsackies virus.
Fibronectin
Tenascin-C
Vitronectin
ECM
ECM
ECM
LAP of TGF-β1
LAP of TGF-β3
FMDV
CAV-9
Cytokine
Cytokine
Virus Capsid Protein
Virus Capsid Protein
Busk et al., 1992
Prieto et al., 1993
Huang et al., 1998
Munger et al., 1999
Annes et al., 2002
Jackson et al., 2000
Williams et al., 2004
 
Linear peptides were synthesised (CR-UK Peptide Synthesis Laboratory) and 
assessed for their ability to competitively inhibit ανβ6-dependent adhesion. A candidate 
peptide, derived from the viral surface protein, VP1, of Foot and Mouth Disease Virus 
(FMDV), was selected for its high affinity and specificity for ανβ6. Using nuclear 
magnetic resonance (NMR) analysis it was determined that the efficacy of the peptide 
was dependent on the inclusion of the DLXXL motif in an extended carboxy α-helical 
structure, with the RGD motif situated at the apex of a hairpin loop domain (DiCara et 
al., 2007). Saturation Transfer Difference NMR identified that the highly conserved 
+1/+4 Leucine or Isoleucine residues, presented adjacently on the surface of the loop, 
bind closely to the ανβ6 surface (DiCara et al., 2007). The critical function conferred by 
the formation of this post-RGD, α-helical domain was confirmed by substitution of two 
L-valine residues for D-valine isoforms. This effectively resulted in the disruption of the 
helix, without compromising the sequence or overall molecular charge, abrogating 
binding to the integrin and therefore confirming the importance of the structural 
conformation of this potential ανβ6 antagonist.  
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ReferenceFunction Cell TypeComment
TABLE 4. Functions of ανβ6a
Oral SCC
Promotion of 
Migration 
and Invasion
a Abbreviations are as follows; TGF-β = Transforming Growth Factor-β, HS-1 = Haematopoietic lineage cell-specific protein-1, TNF-α = Tumour
Necrosis Factor-α, MMP = Matrix metalloprotease, uPA = urokinase plasminogen activator , LAP = Latency associated peptide, EMT = Epithelial
mesenchymal transition, SCC = Squamous Cell Carcinoma, OSCC = Oral SCC.
Activation 
of TGF-β
ανβ6 binds and activates latent TGF-β1, activation 
dependent upon interaction of ανβ6 with actin 
cytoskeleton but independent of proteolytic cleavage 
of the peptide
Colon carcinoma cells, 
Keratinocytes Munger et al., 1999
ανβ6-mediated TGF-β1 activation can be induced by 
“inside-out” signalling to the Protease-Activated 
Receptor-1 (PAR1) via RhoA and Rho kinase
Murine lung epithelial 
cells Jenkins et al., 2006
ανβ6 promotes TGF-β-dependent EMT, risk factor for 
early stage disease Colon carcinoma cells Bates et al., 2005
ανβ6 binds and activates TGF-β3 Colon carcinoma cells Annes et al., 2002
Promotion of 
Proliferation and 
Generation of 
Survival Signals
Downregulation of  ανβ5 through upregulation of  
ανβ6 may protect SCCs from anoikis by activation of 
an Akt survival signal
OSCC Janes & Watt, 2004
ανβ6 promotes proliferation through 11 amino acids in 
the C-terminus of the  -β6 subunit Colon carcinoma cells Annes et al., 2002
Identification of the EKXKVDL motif in the C-terminus 
of the  -β6 subunit required for proliferation in 3D-
cultures
Colon carcinoma cells Dixit et al., 1996
ανβ6-dependent activation of TGF-β1 promotes 
invasion through inducing the trans-differentiation of 
fibroblasts into myofibroblasts
HS1-Associated protein (HAX-1) regulates migration 
and invasion via clathrin-mediated endocytosis of 
ανβ6
ανβ6 promotes  invasion through upregulation of 
MMP-3
Promotion of migration over fibronectin, vitronectin 
and LAP
Upregulation of uPA
OSCC
OSCC, 
Murine keratinocytes
Ovarian carcinoma
Li et al., 2003
Ramos et al., 2002
Thomas et al., 2002
Huang et al., 1998
Ahmed et al., 2002b
Marsh et al., 2008OSCC
TNF-α-dependent upregulation of ανβ6 associated 
with increased migration and upregulation of MMP-9
Murine keratinocytes Scott et al., 2004
Thomas et al., 2001a, bOSCC
ανβ6 promotes invasion through upregulation of 
MMP-9
Ramsay et al., 2007OSCC
 
(Arihiro et al., 2000; Dixit et al., 1996; Hamidi et al., 2000; Impola et al., 2004; Janes & Watt, 2004; Jenkins et al., 
2006; Jones et al., 1997; Kawashima et al., 2003; Li et al., 2003; Ramos et al., 2002; Regezi et al., 2002; Scott et 
al., 2004; Smythe et al., 1995; Yang et al., 2008) 
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Section.1.7.2 ανβ6 Promotes Invasion and Migration 
 
The integrin ανβ6 binds to the arginine-glycine-aspartic acid (RGD) motif in its ligands 
which include fibronectin, tenascin-C, vitronectin and the latency-associated peptide 
(LAP) of TGF-β1 and TGF-β3 (Table.3). Several studies have demonstrated that ανβ6 
can promote keratinocyte migration towards fibronectin and vitronectin, in addition to 
independently upregulating matrix metalloproteinase -9 (MMP-9) expression (Huang et 
al., 1998; Thomas et al., 2001c). In order for tumour cells to invade and metastasise, 
they are required to efficiently degrade and traverse the basement membrane, a dense 
network composed of Type IV collagen, laminins, fibronectin and HSPGs (Yurchenco 
et al., 2004). It has been shown that ανβ6 integrin initiates an invasive phenotype 
through the enhanced proteolytic activity of collagenases MMP-9, and, to a lesser 
extent, MMP-2 (Thomas et al., 2001a; Thomas et al., 2001c). The regulation of MMP-9 
expression by ανβ6 has been shown to be modulated through an interaction between 
the C-terminal cytoplasmic tail of the -β6 subunit and ERK, a member of the Mitogen 
Activated Protein Kinase family (Ahmed et al., 2002a; Gu et al., 2002; Morgan et al., 
2004; Niu et al., 2002). Additionally, clathrin-mediated endocytosis of ανβ6 has been 
shown to be necessary for carcinoma cell motility and invasion in vitro (Ramsay et al., 
2007). Thus, the functional roles of ανβ6 in growth, progression and migration, 
doubtlessly underlie its associations with progressive and invasive malignant 
phenotypes. An outline of ανβ6 functions is presented in Table.4.  
 
Section.1.7.3 ανβ6 Activates Latent TGF-β 
 
The pleiotropic cytokine, Transforming Growth Factor-β (TGF-β), regulates many 
biological events, including cell growth, apoptosis and inflammation (Massague et al., 
1992; McCartney-Francis & Wahl, 1994; Taipale et al., 1998; Wahl, 1992). 
Dysregulation of TGF-β expression and activation is associated with a number of 
pathological conditions including cancer, autoimmune disease, fibrosis and viral 
infection (Ma et al., 2003; Morris et al., 2003; Munger et al., 1999; Prime et al., 2004a; 
Prime et al., 2004b; Schultz-Cherry & Hinshaw, 1996; Sharma & Ziyadeh, 1994). 
During carcinogenesis, TGF-β is thought to exert its effects in a biphasic manner; 
initially acting as a tumour suppressor, but later stimulating tumour progression 
(Akhurst & Balmain, 1999; Akhurst & Derynck, 2001; Derynck et al., 2001).  
 
TGF-β is synthesised as an inactive complex, non-covalently associated with is 
Latency Associated Peptide (LAP). The latent complex is secreted and deposited in the 
extracellular matrix (ECM), where it can be activated when required by cleavage, or 
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through conformational changes induced upon ligand binding (Munger et al., 1999). 
TGF-β1 and TGF-β3, but not TGF-β2, are activated by binding of ανβ6 to LAP (Annes 
et al., 2002; Munger et al., 1999). Additionally, TGF-β itself has been shown to 
stimulate de novo expression of ανβ6 in keratinocytes (Zambruno et al., 1995). 
Furthermore, tumour necrosis factor-α (TNF-α) has also been implicated in the 
upregulation of ανβ6 and MMP-9 (Scott et al., 2004). Interestingly, both TGF-β and 
TNF-α have been proposed to co-ordinate the induction of ανβ6 through upregulation 
of the Ets-1 transcription factor (Bates et al., 2005). However, the precise factors which 
determine the transcriptional upregulation of ανβ6, currently remain unclear.  
 
Section.1.7.4 Strategies to Target ανβ6  
 
The high level cell surface expression of ανβ6 on malignant tissue relative to normal 
adult tissue, in addition to its roles in invasion and metastasis, make it an attractive 
target for targeted therapeutics and in vivo imaging applications. Indeed several 
strategies have now been evaluated, for the selective targeting and imaging of ανβ6 
positive neoplasms. Successful in vivo imaging of ανβ6+ tumours using radiolabelled 
A20FMDV2 peptide, or radiolabelling combined with PEGylation, has previously been 
demonstrated (Hausner et al., 2009a; Hausner et al., 2007; Hausner et al., 2009b). In 
an independent study, Li and colleagues assessed the in vivo tumour targeting 
capacity of an alternative RGDLXXL-containing ανβ6-targeting peptide, H2009.1 
(Elayadi et al., 2007; Li et al., 2009). This peptide, synthesised as a tetrameric peptide 
linked to PEG, displayed a ανβ6 binding affinity in the picomolar range (Li et al., 2009). 
Furthermore, this group have successfully conjugated doxorubicin to H2009.1 and 
demonstrated enhanced ανβ6-specific cytotoxicity in vitro (Guan et al., 2008).  
 
Alternative strategies include the use of small molecule inhibitors or function blocking 
antibodies to inhibit ανβ6-dependent migration and invasion (Van Aarsen et al., 2008; 
Weinreb et al., 2004; Xue et al., 2001). However, the large size of monoclonal 
antibodies can often preclude efficient penetration into the tumour (Colcher et al., 
1998). Additionally, their immunogenicity can also limit their therapeutic utility. More 
recently, a humanised recombinant scFv antibody to ανβ6 was engineered using the 
A20FMDV2 peptide, although to date this has only been characterised in vitro 
(Kogelberg et al., 2008). Furthermore, Pameijer and colleagues have described the 
conversion of an ανβ6-specific peptide, identified by phage display, to a chimeric 
antigen receptor displayed on T-cells (Pameijer et al., 2007). Subsequently, these 
ανβ6-directed cytotoxic T-lymphocytes were capable of enhanced killing of ανβ6-
expressing primary ovarian carcinoma lines.  
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Retargeting viral vectors represents another strategy to achieve in vivo efficacy or non-
invasive imaging. Adenoviruses are one of the best studied viral families for gene 
therapy applications. To date, adenovirus vectors have been retargeted efficiently 
through the genetic incorporation of various peptide ligands into the capsid (Dmitriev et 
al., 1998; Kurachi et al., 2007a; Wickham et al., 1997). Following the elucidation of the 
crystal structure of Ad5, the HI loop of the fibre protein was identified as a suitable 
locale for the genetic incorporation of active targeting modalities (Krasnykh et al., 1998; 
Xia et al., 1994). Therefore, we hypothesised that the insertion of the 20mer peptide 
A20FMDV2 at this site would permit the retention of its critical structural configuration, 
within the confines of the HI loop. Success of this strategy would initially confer an 
expanded viral tropism facilitating enhanced Ad5 transduction to ανβ6-positive cells in 
vitro and, potentially, in vivo. Furthermore, following the characterisation of retargeting, 
we planned to ablate native tropism determinants in order to refine the selectivity of 
infection.   
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Section.1.8 Aims of this Thesis 
 
General Aim 
To generate a recombinant Ad5 vector featuring the previously identified A20FMDV2 
peptide in the HI loop of the fibre knob domain. This vector was designated with the 
nomenclature Ad5-EGFPA20 to distinguish from the unmodified vector Ad5-EGFPWT 
featuring a wildtype fibre protein. Subsequent aims were to test the in vitro and in vivo 
characteristics of Ad5-EGFPA20 and to demonstrate successful retargeting to ανβ6 
integrin. 
 
Objectives 
 
• To generate a replication competent Ad5 vector featuring EGFP under the 
control of the endogenous E3 promoter in place of E3-6.7K/gp19K (Ad5-
EGFPWT).  
• To genetically engineer the A20FMDV2 peptide into the HI loop of Ad5-EGFPWT 
to generate Ad5-EGFPA20.  
• To screen and select a panel of ανβ6-expressing human carcinoma cell lines 
with varying levels of CAR expression, for subsequent in vitro and in vivo 
characterisation of virus constructs.  
 
In Vitro Characterisation of Virus Constructs 
 
• To demonstrate successful expansion of Ad5 tropism to ανβ6, and to confirm 
that this was mediated through the insertion of A20FMDV2. 
• Once efficient retargeting was demonstrated in vitro, the subsequent aims were 
to combine retargeting to ανβ6 with ablation mutations to Ad5 native receptor 
binding determinants (CAR), and further characterise these constructs.  
• Furthermore, these CAR-binding ablated constructs were to be combined with 
putative blood factor binding ablating mutations (477dlTAYT), in an effort to 
generate a vector retargeted to ανβ6, but detargeted from liver sequestration 
following systemic delivery. These constructs were again further characterised 
in vitro.  
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In Vivo Characterisation of Virus Constructs Following Local Delivery in Mice 
• To assess the efficacy of Ad5-EGFPWT or Ad5-EGFPA20, using the 
SKOV3ip1 intraperitoneal model of ovarian carcinoma.  
• To assess the anti-tumoural efficacy of Ad5-EGFPWT or Ad5-EGFPA20 
administered intratumourally.  
• To demonstrate efficient non-invasive in vivo fluorescence imaging of viral 
replication by detection of EGFP expression.  
 
In Vivo Characterisation of Virus Constructs Following Systemic Delivery in Mice 
 
• To demonstrate superior in vivo tumour targeting with Ad5-EGFPA20 compared 
with Ad5-EGFPWT, following systemic delivery. 
• To investigate and compare the effects of CAR-binding ablation, and putative 
blood factor binding ablation mutations on the hepatotropism and toxicity of an 
A20-modified vector Ad5-477dlTAYTA20, following systemic delivery.  
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Section.2.1 Reagents and Basic Cell Culture Techniques 
 
2.1.1 Cell lines and Growth Media. All human carcinoma cell lines used in this study, 
along with their growth requirements, are listed alphabetically in Table.5. A list of 
transfected lines used, or generated in this study, can be found in Table.6. Dulbecco’s 
Modification of Eagle’s Medium (DMEM), α-MEM, Ham’s F12, Roswell Park Memorial 
Institute (RPMI) and isotonic Phosphate Buffered Saline (PBS) were supplied by 
Cancer Research UK (CR-UK) Media Services (South Mimms, Herts). All culture 
medium contained 100IU penicillin and 100μg/ml streptomycin. Keratinocyte Growth 
Media (KGM) was made using α-MEM containing 10% foetal calf serum (Globepharm, 
Surrey) supplemented with 2.5μg/L amphotericin B (Gibco BRL), 1.8 x 10-4M adenine, 
5μg/ml insulin, 1.6 x 10-10 M cholera toxin, 0.5μg/ml hydrocortisone and 10ng/ml 
epidermal growth factor (Sigma). Oral squamous cell carcinoma line SCC25, was 
grown in 1:1 DMEM:Ham’s F12 supplemented with 2.5mM L-glutamine adjusted to 
contain 15mM HEPES and 1.2g/L sodium bicarbonate with 400ng/ml hydrocortisone. 
Unless otherwise stated, growth medium consisted of DMEM supplemented with 10% 
Foetal Calf Serum (FCS; Biowest, Nuaille, France). Cell lines used for the amplification 
and titration of adenoviruses were HEK293 and JH293, respectively. CAR-binding 
ablated, ανβ6-retargeted, mutant Ads were amplified using -β6 transfected lines, 
HEK293-β6 or A549-β6, and were titrated on JH293-β6. Medium used for culture of -β6 
transfected cell lines was supplemented additionally with 5μg/ml puromycin 
dihydrochloride (Sigma, UK).  
 
2.1.2 Maintenance, growth and passage of cell lines. Cells were grown at 37°C in a 
humidified atmosphere of 5-8% (v/v) carbon dioxide/air, and maintained as adherent 
monolayers on tissue culture plastic (Falcon, distributed by VWR). Cells were sub-
cultured approximately twice weekly by incubation with 33% (v/v) trypsin/PBS (CR-UK 
Media Services), followed by neutralisation of the trypsin with growth medium and 
distribution of a single-cell suspension to fresh tissue culture flasks with fresh growth 
medium. Cells required for frozen stocks were counted prior to being pelleted by 
centrifugation following trypsin neutralisation. Cells were resuspended in growth 
medium supplemented with 10% dimethyl sulphoxide (DMSO; BDH, distributed by 
VWR UK) to a final concentration of 2x106 cells/ml after which they were transferred to 
2ml cryovials (Falcon) and stored overnight in insulated polystyrene boxes (Eprak, 
Scotlab, Scotland) at -80°C. The vials were then transferred to liquid nitrogen for long-
term storage. Vials were subsequently defrosted on ice and the cells washed once in 
warm growth medium before plating. All cells were tested routinely for mycoplasma by 
scientific officers in the Department of Molecular Oncology and Imaging. 
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SiHa DMEM   Cervical SCC ATCC: HTB-35
JH293 DMEMClonal expansion of HEK293 CR-UK Cell Services
Pharyngeal CarcinomaDetroit 562 KGM ATCC: CCL-138
a Human cell lines used in this study are listed alphabetically. All cells were grown in media supplemented with 10% Foetal
Calf Serum (FCS). Full details of growth requirements can be found in Section.2.1. Abbreviations are as follows; SCC =
Squamous cell carcinoma, DMEM = Dulbecco’s Modification of Eagle’s Medium, KGM = Keratinocyte Growth Medium,
RPMI = Roswell Park Memorial Institute media, CR-UK = Cancer Research UK Cell Services, ECACC = European
Collection of Cell Culture, ATCC = American Type Culture Collection (catalogue numbers listed), QMUL = Queen Mary
University of London, ICO = Institut Català d’Oncologia, KI = Karmanos Institute. †MCF10CA1a is abbreviated throughout
this study as CA1a. * Selected lines were grown with 5% FCS.
TABLE 5. Human Cell Lines Used in this Studya
Cell Name         Cell Type Medium                        Source
A549 DMEM 
BT-20
MCF10CA1a†
CAOV3
HEK293
H400
BICR56
SKOV-3
SKOV3ip1
SCC25
HSC-3
KGM
DMEM
KGM
RPMI
DMEM   
DMEM   
Breast Adenocarcinoma
Ovarian Adenocarcinoma
Lung Adenocarcinoma
ATCC: HTB-19
CR-UK Cell Services
Tongue SCC
Ovarian Carcinoma
Tongue SCC
Colorectal Carcinoma
Oral SCC
Human Embryonic Kidney
Tongue SCC
Ovarian Adenocarcinoma
NP-9*
NP-18*
DLD-1*
TR126 RPMI   Tongue SCC
TR138 RPMI   Laryngeal SCC
KGM ECACC: 06031002
Breast AdenocarcinomaCA1 DMEM
Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
α-MEM
DMEM
DMEM
DMEM:Ham’s F12
RPMI Dr. R Alemany, ICO
BICR6 Hypopharynx SCC KGM ECACC: 05070501
DMEMBreast Adenocarcinoma
ATCC: CRL-1573
Dr. R Alemany, ICO
Dr. R Alemany, ICO
CR-UK Cell Services
CR-UK Cell Services
Dr. S Statner, KI
ATCC: HTB-75
Dr. J. Price, MD Anderson
ATCC: HTB-77
Dr. S Prime, Uni. of Bristol
Dr. I McKenzie, QMUL
RIKEN Cell Bank, Japan
ATCC: CRL-1628
 
 
2.1.3 Generation of Stable -β6 Expressing Cell Lines. A number of -β6 expressing 
cell lines were generated by retroviral cDNA transduction (Table.6), using a strategy 
described previously (Morgenstern & Land, 1990; Thomas et al., 2001b). Briefly, the 
amphotropic retroviral packaging cell line, AM12-β6, was grown to ~50% confluency. 
The following day culture medium was removed, and replaced with a smaller volume in 
order to concentrate the virus. Additionally, the target cell population was seeded to 
reach ~50% confluency the next day. Retrovirus-containing supernatant was removed 
from the AM12-β6 cells, 4mg/ml Polybrene hexadimethrine bromide (Sigma, UK) 
added, and the suspension filtered through a 0.45μm sterile filter. Growth medium was 
removed from the target cell population, and was replaced with the retrovirus-
containing suspension. The following day, cells were washed and medium was 
replaced with fresh, puromycin-containing medium. Selection in puromycin was carried 
out for ~10 days, washing and re-feeding every 2-3 days to remove dead cells. 
Resistant cells expressing -β6 were amplified sufficiently before they were screened for 
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-β6 surface expression by flow cytometry (see Section.2.1.5). When required, high β6-
expressing cell populations were obtained by Fluorescence Associated Cell sorting 
(see Section.2.1.6).  
 
Cell Name           Parental Cell Type Medium            Source/Reference
a Transfected cell lines used in this study are listed alphabetically. All lines transfected with -β6 cDNA were selected, and
grown in media supplemented with 5µg/ml puromycin. Abbreviations are as follows; SCC = Squamous cell carcinoma,
DMEM = Dulbecco’s Modification of Eagle’s Medium, KGM = Keratinocyte Growth Medium, RPMI = Roswell Park Memorial
Institute media, KCL = Kings College London.
TABLE 6. Transfected Cell Lines Used in this Studya
HEK293-β6 Human Embryonic Kidney
DMEM
A549-β6 DMEM
CHO-β6
DX3puro
CHO-CAR
SKOV3ip1-β6
RPMI
DMEM
DMEM
Chinese Hamster Ovary-K1
Lung Adenocarcinoma
DiCara et al., 2007
Ovarian Carcinoma
Chinese Hamster Ovary
Human Melanoma DX-3
JH293-β6
DMEM DiCara et al., 2007A375puro
A375-β6
C1
DX3-β6 RPMIHuman Melanoma DX-3
Human Embryonic Kidney
VB6 KGM
Human Tongue SCC H357
Dr. G Santis, KCL
Derived from C1 (above)
DMEM Thomas et al., 2001bAM12-β6
Generated in this study
Generated in this study
Generated in this study
Generated in this study
Generated in this study
Thomas et al., 2001b 
KGM Thomas et al., 2001b 
DMEM
DMEM
Hausner et al., 2007
Hausner et al., 2007
Melanoma A375 (ATCC; CRL-1619)
DMEM
NIH 3T3 Murine Fibroblasts
Melanoma A375 (ATCC; CRL-1619)
 
 
2.1.4 Antibodies. All antibodies used in this study are listed in Table.7. Antibodies 
used for flow cytometry were as follows; rat monoclonal anti-ανβ6, 53A.2 (generated in-
house), mouse anti-ανβ3 antibody LM609 (Chemicon) or 23C6 (Santa Cruz, USA), 
mouse anti-ανβ5 antibody P1F6 (Chemicon) and mouse anti-CAR antibody RmcB (a 
kind gift from Dr. Yaohe Wang, CR-UK). Matched isotype controls were rat IgG2a 
(Abcam) for 53A.2 and mouse IgG1 (Dako) for all other antibodies. All primary 
antibodies were used at a final concentration of 10μg/ml. Fluorescently labelled 
secondary antibodies used were donkey anti-rat, or goat anti-mouse AlexaFluor488 
conjugates (Molecular Probes, UK). Antibodies used in function inhibition assays 
included anti-ανβ6 6.3G9 (generously provided by S. Violette, BiogenIdec, USA), anti-
ανβ6 53A.2, anti-ανβ3, anti-ανβ5, as described above, in addition to anti-ανβ8, 14E5 (a 
kind gift from Dr. S. Nishimura, UCSF) and pan αν inhibitor, L230 (ATCC, hybridoma). 
Antibodies used for immunostaining procedures were as follows; polyclonal rabbit anti-
E1A, 13S-5 (Santa Cruz, USA), was used to detect Ad5 E1A in frozen liver tissue and 
the fluorescently labelled secondary antibody used was goat anti-rabbit Alexafluor488 
(Molecular Probes, UK). Staining for E1A in paraffin-embedded tissue sections was 
carried out by Pathology Services (Institute of Cancer), using the OmniMap™ kit with 
mouse anti-Adenovirus [M58] (GeneTex, AutogenBioclear), a rabbit anti-mouse IgG1 
Fc linker (Epitomics, USA) and a secondary anti-rabbit HRP-conjugate (Ventana, 
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Roche Diagnostics). Detection of ανβ6 integrin in human xenograft tissue was 
performed using mouse anti-ανβ6 antibody, 6.2G2 (provided by S. Violette, 
BiogenIdec, USA). Endogenous avidin/biotin or murine IgG activity was blocked using 
the Avidin/Biotin blocking kit or the MOM kit (both Vector Laboratories, USA). 
Biotinylated MOM anti-mouse IgG was detected with an avidin/biotin-HRP conjugate, 
using the Elite ABC kit (Vector Laboratories, USA).   
 
Santa Cruz Antibodies
Chemicon, Millipore
Secondary Ab Host/Iso.       Antigen           Application   Source                                   Reference
a Antibodies used in this study are listed alphabetically, or numerically. Abbreviations are as follows; Ab = antibody, Iso = Isotype, Ms = mouse, Rt
= rat, Rb = rabbit, CAR = coxsackie and adenovirus receptor, FB = Function blocking, FC = Flow cytometry, IHC-P = Immunohistochemistry
paraffin, IHC-Fr = Immunohistochemistry frozen, HRP = Horseradish peroxidase. *Isotype controls were as follows; Mouse IgG2a (Abcam), Mouse
IgG1 (Dako), Rat IgG2a (Abcam) and Rabbit IgG (Santa Cruz, USA). †Antibody was provided as part of the OmniMap™ detector kit with linkoid™
(Ventana). ‡Antibody was provided as part of the Elite ABC kit (Vector Laboratories).
TABLE 7. Antibodies Used in this Studya
6.2G2
14E5
6.3G9
L230
AlexaFluor488
Primary Ab Host/Iso.* Antigen           Application   Source                                    Reference
53A.2
LM609
M58
M78
P1F6
RmcB
Ms (IgG1)
Ms (IgG1) 
Ms (IgG1)
Ms (IgG1)
Rt (IgG2a)
Ms (IgG1)
Ms (IgG2a)
Rb (IgG)
Ms (IgG1)
Ms (IgG1)
ανβ6 
ανβ8
ανβ6 
αν subunit
ανβ6 
ανβ3 
Adenovirus
Ad2/5 E1A
ανβ5 
CAR
IHC-P
FB, FC
FB, IHC-P
FN, FC
FB, FC
FB, FC
IHC-P
IHC-Fr
FB, FC
FB, FC
Dr. S Violette, BiogenIdec
Dr. S Nishimura, UCSF
Dr. S Violette, BiogenIdec
ATCC: HB-8448
CR-UK Antibody Services
GeneTex, AutogenBio
Chemicon, Millipore
CR-UK Antibody Services
10D5 Ms (IgG2a) ανβ6 FB, FC Chemicon, Millipore, 
Donkey Rat IgG FC Invitrogen
AlexaFluor488 Goat Mouse IgG FC Invitrogen
AlexaFluor488 Goat Rabbit IgG IHC-Fr Invitrogen
HRP† Goat Rabbit IgG IHC-P Ventana, Roche Diag.
Avidin/Biotin HRP‡ Goat Rabbit IgG IHC-P Vector Laboratories
23C6 Ms (IgG1) ανβ3 FC Santa Cruz Antibodies
Cascallo et al., 2007
Coughlan et al., 2009
Weinreb et al., 2004
Kogelberg et al., 2008
Weinreb et al., 2004
Weinacker et al., 1996
Coughlan et al., 2009
Wang et al., 2003
Coughlan et al., 2009
Bergelson et al., 1997
DiCara et al., 2008
Jackson et al., 1997
N/A
N/A
N/A
N/A
N/A
 
 
2.1.5 Flow Cytometry for Surface Receptors. Detection of surface receptors by flow 
cytometry was carried out as follows; triplicate samples of 1x105 cells in 50μl serum 
free medium was added to 50μl of antibody at a final concentration of 10μg/ml. Primary 
antibody incubations were carried out on ice for 45mins after which samples were 
washed twice in 2ml serum free medium, centrifuging each time at 1200rpm for 3mins. 
Samples were incubated on ice in the dark for 30mins with the relevant, AlexaFluor488 
fluorescently labelled secondary antibody (final dilution of 1:125). Controls included 
both unstained cells and isotype matched controls, incubated under the same 
conditions. Labelled cells were scanned on an LSR1 flow cytometer (Becton-Dickinson, 
CA, USA) acquiring 1x104 gated events, and results analysed using CellQuestPro 
software. Statistics were collected using single parameter histograms (FL1-H). 
However, dead cells were excluded by propidium iodide staining (FL3-H) when 
required. Flow cytometry was also used to determine the ability of the modified 
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adenoviral KnobA20 protein to bind to ανβ6 on BT-20 cells, and to inhibit ανβ6-specific, 
53A.2 antibody binding (see Section.2.5.3). Furthermore, viral infectivity and 
competition EGFP gene transfer assays were also quantified by acquisition of EGFP 
fluorescence in FL1-H (see Section.2.8.2).  
 
2.1.6 Fluorescence Activated Cell Sorting (FACS). High -β6 expressing, transfected 
cells were sorted by Fluorescence Activated Cell Sorting (FACS) on a MoFlo FACS 
machine (Beckman Coulter) using Summit v4.0 software. Sorting was performed at the 
FACS laboratory, CR-UK London Research Institute, by Sukhveer Purewal and 
Carolyn Koh. Target cell lines were pre-screened on an LSR1 flow cytometer (Becton-
Dickinson, CA, USA) to determine the percentage of the population which were -β6 
positive. The cell number selected for FACS sorting differed from cell line to cell line, 
but was dependent on the % of positive cells determined by pre-screening, and the 
desired number of output, FACS-sorted cells. The amount of primary antibody was 
doubled for every 10-fold increase in cell number. A standard dilution of 1:60 is used 
for 53A.2 when staining ~2x105 cells, and so a 1:30 dilution was sufficient for 2x106 
cells, and scaled up accordingly. Cells in 500μl volumes were incubated with an equal 
volume of diluted primary antibody for 45mins on ice. Samples were washed twice in 
serum free medium, centrifuging at 1200rpm for 3mins each time. The amount of 
secondary antibody, donkey anti-rat AlexaFluor488, was also doubled for each 10-fold 
increase in cell number (final dilution 1:62.5). Samples were maintained on ice for 
30mins in the dark, washed twice in serum-free medium, centrifuged and resuspended 
in a final volume of 2ml serum-free DMEM. Unstained and secondary only control 
samples (in 50μl volumes) were used for setting up parameters on the FACS. Cell 
suspensions were filtered through a 70μm nylon cell strainer (Becton-Dickinson, USA). 
Viable cells were identified by DAPI [4’,6-diamidino-2-phenylindole] staining, and single 
cells were selected on the basis of forward and side light scatter characteristics and 
pulse width. A sample of the sorted population was run on an LSR1 flow cytometer 
(Becton-Dickinson, CA, USA) immediately following sorting to confirm expression 
levels. Selected populations were amplified for several weeks and frozen stocks 
generated.  
 
2.1.7 Quantification of Serum Cytokines/Chemokines Using a Cytometric Bead 
Assay. Serum was separated from whole blood using Sarstedt CB300 capillary tubes 
with clot activator (Sarstedt, Germany). Serum levels of IL-6, RANTES, IFN-γ, TNF-α 
and IL-12(p70) were quantified using a multiplex cytometric bead assay 
(FlowCytomix™, Bender MedSystems GmbH, Austria). Lyophilised standards for each 
cytokine/chemokine to be analysed, were centrifuged briefly and reconstituted with 1X 
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Assay Buffer (PBS and 10% BSA). Two separate standard curves, in the range 0-
20,000pg/ml, were prepared by diluting each cytokine stock 1:20, followed by a 3-fold 
serial dilution. A 1:20 cytometric bead mixture was made up to the required volume 
using 1X Assay Buffer (25μl per reaction). A 1:20 biotin-conjugate mixture was also 
made up to the required volume using 1X Assay Buffer (50μl per reaction). A 
preparation of Streptavadin-Phycoerythrin (PE) was prepared according to the 
manufacturer’s instructions.  
 
A 96-well filter plate was equilibrated using 50μl of 1X Assay Buffer, and medium 
aspirated using a vacuum Filtration Manifold (Millipore, UK). The bottom of the plate 
was blotted dry, and 25μl of each standard or serum sample added to the relevant 
wells. The pre-prepared cytometric bead mixture was added (25μl) to all wells, 
including the blank wells. 50μl of the Biotin-Conjugate mixture was added to all wells, 
the plate covered with adhesive film and aluminium foil, and incubated at room 
temperature (18-25˚C) for 2hrs on a microplate shaker at 500rpm. Following 
incubation, the adhesive film was removed and wells emptied using the vacuum 
filtration manifold. Wells were washed twice with 100μl Assay Buffer (1X), medium 
removed as before, and excess liquid removed from the base of the plate. Streptavidin-
PE solution (50μl) was added to all wells, the plate covered with adhesive film and 
incubated at room temperature for 1hr on a microplate shaker at 500rpm. Following 
incubation, wells were emptied and washed twice as before. 200μl Assay Buffer (1X) 
was added to each well and mixed thoroughly by repeated aspiration and ejection. 
Samples were transferred to flow cytometry tubes (Becton-Dickinson, CA, USA), and 
made up to a final volume of 500μl. Analysis was performed following acquisition on an 
LSR1 flow cytometer (Becton-Dickinson, CA, USA). Cytometer set up was established 
using a detailed protocol provided with the kit (FlowCytomix™, BenderMedSystems 
GmbH, Austria). Calculations and analysis of results were performed using 
FlowCytomix Pro 2.2 Software, as directed by the manufacturer. When necessary, 
CellQuestPro acquisition files were filtered to eliminate debris using FCS Filter v1.0.4 
Software (Soft Flow, Hungary).  
 
2.1.8 Bacterial strains, Yeast strains, Medium and Growth Conditions. Bacterial 
strains used in this study included chemically competent Escherichia coli (E.coli) 
DH10B (generated in-house), electrocompetent ElectroMAX™DH10B™ (Invitrogen™), 
One Shot™ Top10-F (Invitrogen™) and SG13009-pREP4 (Qiagen®). Bacterial strains 
were cultivated at 37°C in either Luria-Bertani (LB) broth [1% (w/v) tryptone, 0.5% (w/v) 
yeast extract and 1% (w/v) sodium chloride] or plated onto LB supplemented with 1.5% 
(w/v) agar. Medium was enriched with relevant antibiotics as required [ampicillin (Amp), 
 71
kanamycin (Kan) or chloramphenicol (Chl) at concentrations of 100μg/ml, 25μg/ml and 
25μg/ml respectively].  
 
Yeast strain, Saccharomyces cerevisiae YPH857 (ATCC 76628): genotype MATalpha 
ura3-52 lys2-801 ade2-101 trp1-Δ63 his3-Δ200 leu2Δ1, was grown at 30°C in YPD 
broth [2% (w/v) peptone-Y, 1% (w/v) yeast extract and 2% (w/v) dextrose] or plated 
onto YPD supplemented with 1.7% (w/v) agar. YPH857 harbouring the Ad5-containing 
plasmid pMB20 (generously provided by Richard Iggo, UK), were grown in synthetic 
defined dropout medium, -HIS [0.17% (w/v) yeast nitrogen base, 0.5% (w/v) 
ammonium sulphate and 2% (w/v) dextrose] or plated onto -HIS supplemented with 
1.7% (w/v) agar. Intermediate recombination derivatives (ie. pMB20 incorporating the 
URA3 integrating shuttle vector) were grown in synthetic dropout media -HIS -URA 
[0.17% (w/v) yeast nitrogen base, 0.5% (w/v) ammonium sulphate and 2% (w/v) 
dextrose] or plated onto medium supplemented with 1.7% (w/v) agar. All bacterial 
medium was supplied by Clare Hall Media Production Services (CR-UK) and yeast 
medium supplied commercially by Q.Biogene. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section.2.2 Recombinant DNA and Cloning Techniques 
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Standard restriction enzymes, T4 DNA Ligase and Antarctic Phosphatase were 
supplied by New England Biolabs®Inc and reactions carried out as recommended by the 
manufacturer. Methylation sensitive, modifying enzyme DpnI was supplied by 
Promega. Standard Polymerase Chain Reaction (PCR) reactions were optimised with 
Opti-Prime™ PCR Optimisation Kit (Stratagene) using Taq DNA polymerase (Roche). 
Mutagenic PCR, or strategies using Splicing by Overlap Extension (SOEing) PCR, 
were carried out using high fidelity Platinum® Pfx DNA polymerase (Invitrogen). All 
PCR primers and sequencing primers used were supplied by Sigma-Genosys (Table.8 
and Table.9, respectively).  
 
2.2.1 Restriction Digestions. Restriction enzyme digestions were set up in 20µl 
volumes. Samples were digested with 1.0U/μg DNA with the required restriction 
enzyme(s) in 1X buffer supplied by manufacturer, as directed. 1X Bovine Serum 
Albumin (BSA) was added when required.  
 
2.2.2 Antarctic Phosphatase Treatment. Digested backbone DNA (1µg) was 
modified by incubation with 1U Antarctic Phosphatase (New England Biolabs) in 1X 
buffer. Reactions were set up in 20μl reaction volumes and incubated at 37°C for 
15mins (for 5’ overhangs or blunt end digestions), or for 1hr (for 3’ overhangs) before 
further incubation for 5mins at 65°C to denature the modifying enzyme. Reactions were 
allowed to cool to room temperature before setting up ligation reactions. The molarities 
of the linearised backbone and desired insertion were calculated from the formula 
below, and ligation ratios were adjusted to 2:1, 3:1 or 4:1 for insert:dephosphorylated 
backbone (50ng). 
 
Picomole Ends per Microgram of Double-Stranded Linear DNA  
 
 
 
2.2.3 Ligations. Reactions were set up in 25μl volumes using 1μl T4 DNA Ligase, 1X 
T4 Ligase buffer and differential ratios of backbone to insert (described above). 
Controls included unmodified backbone-no insert, dephosphorylated backbone-no 
insert and no backbone-insert only. Standard ligation reactions were incubated 
overnight at 16°C in a PTC-200 Peltier Thermal Cycler (MJ Research), prior to 
transformation into competent E.coli bacteria.  
2.2.4 Standard PCR. PCR reactions were set up in 50µl volumes containing; 100-
200ng of template DNA, forward and reverse primers at 0.5-1μM each, 1mM dNTPs, 
(2 x 106)/(650 x Number of bases of plasmid)  = pmol ends/µg double-stranded 
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1X Opti-Prime™ buffer (Stratagene) and 1U Taq DNA polymerase (Roche). A control 
lacking DNA was run in parallel. PCR was performed in a PTC-200 Peltier Thermal 
Cycler (MJ Research) under the following conditions: denaturation at 94°C for 5mins 
followed by 28 cycles at 94°C for 45s, annealing at 58°C for 45s and elongation at 
72°C for 50s followed by a final extension step at 72°C for 10mins. PCR products were 
confirmed by gel electrophoresis analysis (Section.2.2.8.).  
 
2.2.5 Mutagenesis PCR. Site directed mutagenesis was carried out by mutagenic 
PCR using oligonucleotide primers encoding desired mutations and containing 
complementary flanking sequences. Reactions were set up in 50µl volumes containing; 
200ng of template DNA, forward and reverse primers at 1μM each, 1mM dNTPs, 1mM 
MgSO4, 1X Pfx buffer and 1U Pfx DNA polymerase (Invitrogen™). Control reactions 
lacking DNA polymerase were run in parallel. Mutagenic PCR was performed in a PTC-
200 Peltier Thermal Cycler (MJ Research) under the following conditions: denaturation 
at 94°C for 3mins followed by 20 cycles of 30s denaturing at 94°C, 30s annealing at 
60°C and 12mins elongation at 68°C, followed by a final extension step at 70°C for 
20mins. 15U of DpnI, a methylation sensitive restriction enzyme (Promega), was added 
after the PCR to digest the template DNA, leaving newly synthesised and unmethylated 
DNA intact. The digestion reaction was performed in buffer supplied by the 
manufacturer at 37˚C for 2hrs. DpnI modified DNA was transformed into DH10B E.coli 
and plasmid DNA extracted (QIAamp DNA mini kit, Qiagen). 
 
2.2.6 Gene Splicing by Overlap Extension (SOEing) PCR. Gene splicing by overlap 
extension is a PCR based system for generating recombinant or chimeric gene 
sequences, without the reliance on restriction sites (Horton, 1995; 1997; Horton et al., 
1990). A schematic overview of the strategy is presented in Fig.2.1. Firstly, fragments 
to be overlapped were amplified in separate reactions using primers which feature the 
desired modifications within the 5’ region (Step 1). These 5’ modified PCR fragments 
were purified using the QIAquick® Gel Extraction Kit 50 (Qiagen®) after which 5μl of 
each was added to a single PCR reaction carried out in the absence of primers (Step 
2). This step permits hybridisation of the complementary sequences within the primer-
introduced, 5’ regions. The resulting single PCR product was gel purified, as above, 
and 5μl subjected to a final round of PCR using forward and reverse primers designed 
to amplify the entire target sequence (Step 3).  
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PCR fragment A PCR fragment B
STEP 1
STEP 2
STEP 3
a-forward bmut-forward
amut-reverse b-reverse
a-forward
b-reverse
PCR fragments A+B
PCR fragment AB
DNA synthesis  5’→ 3’
PCR products A+B are 
mixed without primers
 
 
 
 
 
 
 
 
Reactions for Step 1 (PCR-A or PCR-B) were set up in 50µl volumes containing; 200ng 
of template DNA, primers (either a-forward and amut-reverse or bmut-forward and b-
reverse) at 1μM each, 1mM dNTPs, 0.5-1.0mM MgSO4, 1X Pfx buffer and 1U Pfx DNA 
polymerase (Invitrogen™). PCR was performed in a PTC-200 Peltier Thermal Cycler 
(MJ Research) under the following conditions; denaturation at 94°C for 3mins followed 
by 25 cycles of 1min denaturing at 94°C, 30s annealing at 60°C and 3mins elongation 
at 68°C, followed by a final extension step at 68°C for 10mins. Reactions for Step 2 
were set up in 25µl volumes containing; 5µl of each PCR product (ie. PCR-A + PCR-B), 
1mM dNTPs, 0.5-1.0mM MgSO4, 1X Pfx buffer and 1U Pfx DNA polymerase using 
identical conditions, with the exception of the number of cycles, which was reduced to 
15. For Step 3, 5μl of the PCR product obtained in Step 2 (PCR-AB) was added to the 
final PCR reaction (PCR-AB). The final amplification step was set up as described in 
Step.1, however primers used in this case were a-forward and b-reverse. In order to 
Figure.2.1 Schematic Overview of Splicing by Overlap Extension PCR (SOEing PCR). In Step 1 
separate PCR products, PCR A and PCR B, are amplified using primers designed to introduce a specific, 
mutant sequence into the region of DNA to be overlapped (amut-reverse and bmut-forward). In Step 2, 
PCR products generated in Step 1 (PCR A and PCR B) are added to a single PCR reaction, in the 
absence of primers. This reaction allows the hybridisation of their complementary mut regions, producing 
an overlapped fragment, PCR A+B. In the final reaction, Step 3, PCR A+B is amplified with primers, a-
forward and b-reverse, to generate the target sequence, PCR AB.  
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facilitate TA cloning into holding vector pcDNA3.1/V5-HIS©-TOPO® (Invitrogen™) the 
final product (PCR-AB) was incubated with an excess of dATPs at 72˚C for 10mins. 
Reactions were set up in 25μl volumes as follows; 14.5μl PCR-AB, 10mM dATP, 1X 
Buffer [10mM Tris-HCl pH8.8, 3.5mM MgCl2, 75mM KCl and 5nM EDTA]  and 1U Taq 
Polymerase. Plasmids were named accordingly (ie. pPCR-AB-TOPO), sequenced to 
verify the success of the strategy, and vectors used for various subcloning strategies 
when required. 
 
2.2.7 Quantitative Real Time PCR. Viral and total genomic DNA was obtained from 
virally infected cells, or murine tissue, using the QIAamp Blood mini kit or QIAamp DNA 
mini kit (both Qiagen, UK). 20ng of total DNA was subjected to fluorogenic TaqMan 
Real Time Quantitative PCR (qPCR) using the Applied Biosystems 7500 Real Time 
PCR system. TaqMan reactions were performed in triplicate, on two separate 
occasions, using primers for the hexon region of the genome, Forward: 5’-
AGCGCGCGAATAAACTGCT-3’ and Reverse: 5’-AGGAG ACCACTGCCATGTTGT-3’ 
(Sigma), and a probe from Applied Biosystems (Hexon Probe FAM-CCGCCG 
CTCCGTCCTGCA-MGB). Negative controls were run to ensure that no amplification 
occurred in the absence of DNA. Cycling conditions were as follows; 50˚C for 2mins, 
95˚C for 10mins, 95˚C for 15sec for 40 cycles followed by 60˚C for 1min. Total 
adenoviral genomes were calculated using a standard curve of 101-109 viral genomes 
(see Section.2.8.1), and data were analysed using Sequence Detection Software v1.3 
(Applied Biosystems). 
 
2.2.8 DNA Analysis by Gel Electrophoresis. Gel electrophoresis analysis was used 
to confirm successful cloning, ligation or PCR steps. 5-10µl of restriction digests or 
PCR products were run on a 1-2% (w/v) agarose gel [1-2g agarose in 1X Tris-Borate-
EDTA (TBE) buffer with 5µl ethidium bromide (EtBr) at 0.5µg/ml] for ~30mins @ 100V. 
Samples were run alongside a 1kb DNA ladder (Invitrogen™). Visualisation of the gel 
under UV light ensured that inserts were present or that PCR products were the 
expected size. Digested fragments, or PCR bands required for further cloning and 
ligation steps, were excised from the gel under UV light using a sterile blade and DNA 
purified using QIAquick® Gel Extraction Kit 50 (Qiagen®). 
 
2.2.9 Preparation of Chemically Competent E.coli. DH10B E.coli were made 
competent by CaCl2 treatment by standard method (Cohen et al., 1972). Briefly; a 
single colony was inoculated overnight in 10ml LB. 5ml of the overnight starter culture 
was added to 500ml LB, and bacteria grown with aeration for ~3hrs at 37˚C. Once 
bacteria had reached a mid-logarithmic phase of growth (OD600nm=0.4), cells were 
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pelleted by centrifugation at 4000rpm for 10mins at 4˚C. Supernatant was removed and 
cells resuspended in 10ml ice-cold 0.1M CaCl2. Cells were recovered by centrifugation 
at 4000rpm for 10mins at 4˚C. Supernatant was removed and the pellet resuspended in 
2ml ice-cold 0.1M CaCl2 with 20% (v/v) glycerol, for each 50ml of original culture. Cells 
were dispensed into 200μl aliquots and were stored for 12-24hrs at 4˚C, after which 
they were transferred to -80˚C for long term storage. SG13009 E.coli, suitable for 
recombinant protein expression, were made competent as follows; a single bacterial 
colony harbouring the KanR pREP4 which had been freshly grown overnight, was 
picked from an LB agar plate at 25μg/ml Kan, inoculated into 10ml LB/Kan and grown 
overnight at 37°C with aeration. The following morning, 1ml of the overnight culture 
was added to 100ml of pre-warmed selective medium and was incubated with aeration 
at 37°C until an optical density (OD) of 600nm was reached. The culture was chilled for 
5mins on ice and transferred to a sterile round-bottom centrifuge tube. Cells were 
pelleted by centrifugation at 4000g for 5mins at 4°C. Supernatant was discarded and 
cells resuspended gently in 30ml cold, sterile, TFB1 buffer pH5.8 [100mM RbCl, 50mM 
MnCl2, 30mM KAc, 10mM CaCl2 and 15% (v/v) glycerol] and held on ice for 90mins. 
Cells were collected by centrifugation at 4000g for 5mins at 4°C, after which the 
supernatant was discarded and cells resuspended in 4ml ice-cold, sterile, TFB2 buffer 
[10mM MOPS, 10mM RbCl, 75mM CaCl2 and 15% (v/v) glycerol]. Cells were aliquoted 
into 100μl volumes in sterile eppendorfs before being frozen at -80°C until required for 
transformation. 5μl of pQE30-based ligation reactions were used to transform, by heat 
shock, one aliquot of competent SG13009 cells, as recommended by the manufacturer 
(Qiagen®). Transformants were selected as before on LB/Kan, now supplemented 
additionally with Amp at 100μg/ml.  
 
2.2.10 Transformations. Chemically competent DH10B E.coli were transformed using 
5μl of standard ligation reactions. The same strain was used for transformation with 2μl 
DpnI digested, mutagenic shuttle vectors. Cells were held on ice for 10mins before 
addition of DNA (~50ng DNA in a volume of 10μl or less) and the cell-DNA suspension 
was incubated for a further 30mins on ice. Bacteria were subjected to heatshock at 
42˚C for 90secs and transferred immediately to ice for 2mins. Cells were resuscitated 
in 800μl SOC (Invitrogen) medium [2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10mM 
NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose], and cultures 
incubated for 45min at 37˚C with aeration. Approximately 200μl of culture was spread 
onto pre-warmed selective agar and plates incubated overnight at 37˚C. Plasmid DNA 
constructs resulting from ligation into pcDNA3.1/V5-HIS©-TOPO® (Invitrogen™) were 
used to transform one vial of One Shot™ Top10-F competent cells (Invitrogen™) as 
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recommended by the manufacturer, and transformants were selected on LB agar 
supplemented with 100µg/ml Amp. Competent SG13009 (pREP4) E.coli (Qiagen®) 
were used for transformation with pQE30 derived expression vector constructs prior to 
protein induction, according to manufacturer protocol. Transformants were plated onto 
LB agar enriched with Kan and Amp, and plates incubated upside-down overnight at 
37°C. Large construct pMB20-derivatives were transformed into ElectroMAX™ DH10B™ 
(Invitrogen) using a BioRad GenePulser® II electroporator. No more than 100ng of DNA 
was used to transform cells under the following conditions; 1.8kV, 200Ω and 25µF. 
Transformants were selected with Chl at 12.5µg/ml. For all transformation protocols, 
cells were resuscitated in SOC, plated onto relevant selective medium and incubated 
overnight at 37°C. 
 
2.2.11 Plasmid DNA Extraction. Colonies were picked from overnight selective 
medium plates, inoculated into 2ml of antibiotic selective LB broth, and were incubated 
in a shaking 37°C incubator overnight. Bacterial cultures were harvested by 
centrifugation at 13,000rpm and plasmid DNA extracted from pellet by standard 
protocol, using QIAprep® Spin Miniprep Kit 250 (Qiagen®). Constructs confirmed by 
sequencing analysis were amplified by QIAprep® Maxiprep Kit (25). DNA concentration 
was determined using a NanoDrop® ND-1000 photospectrometer (NanaoDrop 
TechnologiesInc). Samples were assessed at 260nm versus a blank control of the 
elution buffer. DNA from large construct plasmids (ie. pMB20-based) was extracted by 
alternative means (see Section.2.6.5).  
 
2.2.12 Sequencing and Analysis using Bioedit Software. Plasmids were sequenced 
at the Genome Centre (William Harvey Institute, Barts and The London School of 
Medicine). Reactions were set up in 12µl volumes and sequencing PCR carried out on 
a Peltier Thermal Cycler DNA Engine PTC-225 (MJ Research) using BigDye® 
Terminator v3.1 Cycle Sequencing reaction reagent (Applied Biosystems) in 1X 
sequencing buffer (Applied Biosystems), with 10pmol primer and ~400ng template 
DNA. Each clone was sequenced with a minimum of two different primers to generate 
overlapping readings (Table.9). The cycling reaction was: denaturation at 96°C for 
30sec followed by 25 cycles of 30s denaturing at 96°C, 15s annealing at 50°C followed 
by 1 min elongation at 60°C for a final time of ~1.5hours. The PCR products were 
cleaned up, the plate was sealed and PCR products sequenced on an ABI Prism 3700 
DNA Analyzer by capillary electrophoresis (performed by staff at the Genome Centre). 
Chromatograms were analysed using Bioedit software, and 100% identity confirmed by 
BLAST analysis comparing against plasmid sequences created and stored in the 
VectorNTI database by the licence holder (VectorNTI Advance 10, Invitrogen).  
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32651-32674
Primer Name                             Sequence 5’→3’ Ad5 Region (nt)
TABLE 8. Primers Used for PCR Applicationsa
a PCR primers are listed alphabetically. Nucleotide (nt) numbers refer to the primer binding region of the Ad5 genome based on Human
Adenovirus C serotype 5 (AY:339865.1). Engineered restriction sites are underlined and in italics. Introduced mutations are highlighted in
bold and deletions are indicated by an asterisk (*). N/A refers to primers which bind to sequences in shuttle vectors, or modified Ad5
constructs.
XbaI-hNIS-forward
XhoI-ADP-forward
XbaI-12.5K-reverse
XhoI-hNIS-reverse
SfoI-Right-forward
XhoI-Right308-reverse
A20-reverse GCCACCTTTTGAGCCAAC
A20-forward CTGTGCCCAACTTGAGAG
XhoI-Right844-reverse CTCGAGCACGTGGGTTCTGTGGTCC
AdinPCR-forward CCAAAAGTAACATTGTCAGTCAAG
AdinPCR-reverse GCAATGTATGAAAAAGTGTAAGAG
N/A
N/A
32571-32594
32772-32749
33469-33487
CTCGAGCCAGCCGGGGAGAAAGGACTGTGT 32959-32983
GGCGCCCCAAGTGCATACTCTATGTCATTT 32675-32698
CCTCGAGGTCAGAGGTTTGTCTCCTGCTGGTCTCG N/A
BamHI-SfoI-Left-reverse GGATCCGGCGCCAGTTGTGTCTCCTGTTTCCTGTGT
28507-28528
N/A
29349-29375CCTCGAGGCAATTGACTCTATGTGGGATATGCTCC
CTCTAGAGATGGAGGCCGTGGAGACCGGGGAACGG
CTCTAGAGCTGCGCCTTTGGCCTAATAC
SacII-12.5K-forward
KpnI-ADP-reverse
NotI-Left-forward
MutL485K-forward
MutL485K-reverse
Mut6XHIS-forward CACCATCACCATCACCCAAGTGCATACTC
Mut6XHIS-reverse GATGGTGATGGTGATGAGTTGTGTCTCCTG
EGFP-forward CCCACCATGGTGAGCAAGG
EGFP-reverse GACTTGTACAGCTCGTCCATG
CTTTAGAAATGGAGATAAAACTGAAGGCACAGC
GCTGTGCCTTCAGTTTTATCTCCATTTCTAAAG
MutY477A-forward TTCCTGGACCCAGAAGCTTGGAACTTTAGAAAT
MutY477A-reverse ATTTCTAAAGTTCCAAGCTTCTGGGTCCAGGAA
dlTAYT-forward CTGAAGGC*AACGCTGTTGGATTTATG
dlTAYT477-reverse CAACAGCGTT*GCCTTCAGTAAGATCTC
dlTAYT485-reverse CTGAAGGCAACAGCGTT*GCCTTCAGTTTTATCTC
F5Knob-forward TTTAAGGATCCGGTGCCATTACAGTAGGAA
F5Knob-reverse TATATAAGCTTATTCTTGGGCAATGTATGA
32513-32530
32513-32522
32492-32501
N/A
N/A
32195-32213
32762-32782
32675-32688
32661-32675
32450-32482
32450-32482
32473-32505
32473-32505
GCCGCGGGAGCTCGATCAATTTATTCCTAACTTTG 27795-27816
32126-32149GCGGCCGCGGCCTAGAATTTGATTCAAACAAG
29723-29748GGGTACCCGAACATGTGTTTCAGTCCGTCCAATC
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pcDNA3.1/V5-HIS-TOPO
pGV1 derivatives
pQE30 derivatives
pGV1 derivatives
pcDNA3.1/V5-HIS-TOPO
pQE30 derivatives
Primer Name                             Sequence 5’→3’ Ad5 Region (nt)
a Sequencing primers used in this study are listed alphabetically. Nucleotide (nt) numbers refer to the primer binding region in the Ad5
genome, based on Human Adenovirus C serotype 5 (AY:339865.1). Alternatively, the vector backbone for various sequencing applications
is listed.
TABLE 9. Primers Used for Sequencinga
FibreUp-forward
T7-forward
T7-reverse
FibreUp4-forward
LC-forward
EGFP-forward CCCACCATGGTGAGCAAGG
EGFP-reverse GACTTGTACAGCTCGTCCATG
Ad5-reverse
LC-reverse
T3-forward
AdSeq-forward
AdSeq-reverse
E3Seq-forward
E3Seq-reverse
AdinPCR-forward CCAAAAGTAACATTGTCAGTCAAG
AdinPCR-reverse GCAATGTATGAAAAAGTGTAAGAG
pQE-forward
pQE-reverse
CGGATAACAATTTCACACAG
GTTCTGAGGTCATTACTGG
GCCTATACAAACGCTGTTGG
CCAACAGCGTTTGTATAGGC
Ad5.2-reverse
CCCATGATATGATGCTTTTTAAGG
AATTAACCCTCACTAAAGG
GTAATACGACTCACTATAGGGC
GAATTTGGTTCACCTAATGC
GGTTTAGGATGGTGGTGG
GACCTCAATAACTCTGTTTACCAG
GAGATAGGAGATGGCATAGAAG
FibreDown-reverse
GCAACGCTGTTGGATTTATG
CATCCGCACCCACTATCTTCA
GTGTAAGAGGATGTGGCAAAT
33625-33642
32069-32088
32737-32757
31005-31025
32513-32530
28137-28145
28453-28476
pIP5-EGFP
pIP5-EGFP
BGH-reverse
32983-33006
32571-32594
32749-32772
32504-32523
32504-32523
TAATACGACTCACTATAGGG
TAGAAGGCACAGTCGAGG
Ad5.3-reverse
E1ASeq-forward CTTGAGTGCCAGCGAGTAGAGTTTTC 502-527
E1ASeq-reverse GTTAACCAAGTCCTCGATACATTCCAC 1471-1497
CTGCGCTTGTGGTATGATG 33490-33508
GGCTGGAATGCAGTCTACTTC 29860-29880
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Section.2.3 Construction of Shuttle Plasmids for Adenovirus Genome 
Modifications 
 
Restriction digestion and PCR reactions were carried out by standard molecular 
biology techniques, as described in Section.2.2. PCR primers used in the construction 
of shuttle vectors are listed in Table.8, and sequencing primers listed in Table.9. All 
primers were supplied by Sigma-Genosys. All plasmids constructed were verified by 
sequencing. DNA was amplified by miniprep following transformation into chemically 
competent DH10B bacteria, as described previously (Section.2.2.10). 
 
2.3.1 URA3 Integrating Shuttle Vector pGV1. All shuttle vectors constructed in this 
study were assembled using the pGV1 construct as a backbone. A restriction map of 
pGV1 is presented in Fig.2.2A. This construct is a URA3 [Orotidine-5'-phosphate 
(OMP) decarboxylase] integrating shuttle vector, based on a pRS406 (Accession 
number: U03446) construct in which the ARS/CEN (Autonomously replicating 
sequence/Centromere sequence) and yeast replication elements have been removed. 
In addition, the HindIII site within the multicloning site (MCS) was inactivated by 
mutagenesis and the vector renamed pGV1 (Vassaux et al., 1997).  
 
pIP5
5498 bp
AmpR
URA-3
12.5K
ADP
T3
T7
F1 ori
Xho I (3083)
Kpn I (3495)
Xba I (3020)
Sac II (2286)
A B
pGV1
4384 bp
AmpR
URA-3
T3
T7
F1 ori
Bam HI (2311)
Xho I (2362) Not I (2292)
Xba I (2299)
Sac II (2286)Kpn I (2381)
Sac I (2279)
 
 
 
 
 
 
 
Figure.2.2 Restriction Map for URA-integrating Shuttle Vectors. (A) Restriction map for pGV1 (URA3 
integrating shuttle vector). Binding sites for sequencing primers, T3-forward and T7-reverse, are 
highlighted as arrows (T3/T7). (B) Restriction map of pIP5 showing the sites where Ad5 sequence, 
corresponding to E3-region genes 12.5K and ADP, was cloned into the pGV1 backbone. Vector maps are 
to scale and the multi-cloning site (MCS) shows all restriction sites used for cloning strategies described in 
this study. Restriction maps were generated using VectorNTI Software (VectorNTI Advance 10, Academic 
Version, Invitrogen) from sequences generated, and stored in the database by the licence holder. 
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2.3.2 E3 Region Modification; Construction of pIP5. The pIP5 vector was 
constructed previously in the Vassaux Laboratory (Merron et al., 2007; Peerlinck et al., 
2008). A restriction map is presented in Fig.2.2B. Homologous Ad5 sequence flanking 
the non-essential E3 region gene, gp19K, was amplified by PCR from Ad5 template 
DNA (pMB20; provided by Richard Iggo). Sequence spanning the E3 region 12.5K 
gene (nt27793-28524) was amplified by primers, SacII-12.5K-forward and XbaI-12.5K-
reverse, introducing engineered SacII/XbaI restriction sites. Nucleotide sequence 
spanning E3 ADP (nt29349-29750) was amplified using engineered primers, XhoI-
ADP-forward and KpnI-ADP-reverse. Nucleotide numbers refer to the sequence 
location within the Ad5 genome (Accession number: AY339865). The PCR products 
were gel purified using QIAquick® Gel Extraction Kit 50 (Qiagen®), and DNA eluted in 
30μl of H20. Purified DNA was ligated into pcDNA3.1/V5-HIS©-TOPO® (Invitrogen™), to 
create p12.5K-TOPO and pADP-TOPO. Both genes were transferred into the multi 
cloning site (MCS) of pGV1 by sequential rounds of subcloning. Firstly, SacII/XbaI 
restriction digestion of pGV1 and p12.5K-TOPO generated pGV1-12.5K, and 
subsequently XhoI/KpnI digestion of pGV1-12.5K and pADP-TOPO generated pGV1-
12.5K-ADP. This E3 integrating shuttle vector was renamed pIP5. 
pIP5-EGFP
6193 bp
AmpR
URA-3
12.5K
ADP
EGFP
T3
T7
F1 ori
Xba I (3020)
Xho I (3778)
SacII (2286)
SacII (3877)
pIP5
5498 bp
AmpR URA-3T3 T7 F1 ori
SpeI (3026) Xho I (3083)
12.5K ADP
pEGFP-C1
4731 bp
Kan/NeoRCMV f1 ori pUC ori
Xho I (1344)Nhe I (592)
EGFP
A B
C
 
 
 
 
 
 
 
Figure.2.3 Cloning Strategy used to Generate Shuttle Vector, pIP5-EGFP. (A) The pIP5 backbone 
was digested with SpeI/XhoI. (B) In parallel, pEGFP-C1 was digested with NheI/XhoI to release the EGFP 
fragment. (C) SpeI and NheI digestion created compatible, cohesive ends, permitting their ligation. 
Therefore, pIP5-EGFP was generated by ligation of NheI/XhoI-digested EGFP into SpeI/XhoI-digested 
and dephosphorylated pIP5. Vector maps (linear/circular representation) are to scale and the multi-cloning 
site (MCS) and restriction sites used in this cloning strategy are displayed. Restriction maps were 
generated using VectorNTI Software (VectorNTI Advance 10, Academic Version, Invitrogen) from 
sequences generated, and stored in the database by the licence holder. 
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2.3.3 E3 Region Modification; Construction of pIP5-EGFP. The gene for Enhanced 
Green Fluorescent Protein (EGFP) was cloned into SpeI/XhoI digested pIP5, following 
compatible NheI/XhoI digestion from pEGFP-C1 (Clontech). A schematic overview of 
the cloning strategy is shown in Fig.2.3. The pIP5 backbone, and EGFP insert were 
purified using the Qiagen QIAquick® Gel Extraction Kit, the backbone 
dephosphorylated using Antarctic Phosphatase (NEB) and overnight ligations 
transformed into chemically competent DH10B. Plasmid DNA was extracted, purified 
and successful ligations confirmed by restriction digestion, and sequencing using T3-
forward and T7-reverse primers.  
 
2.3.4 Fibre Region Modification; Construction of pIVSfoI. Adenoviral homologous 
sequence flanking the site within the fibre (IV) gene which was selected for 
heterologous A20FMDV2 DNA insertion, was cloned from pAdEasy-1 adenoviral 
template DNA (nt32674-32675). A schematic of the cloning strategy used can be found 
in Fig.2.4. The upstream fragment of the IV (Left/L), corresponding to nucleotides 
32126-32674, was amplified using NotI-Left-forward and BamHI-SfoI-Left-reverse 
primers which introduced engineered restriction sites, NotI and BamHI-SfoI, at the 5’ 
ends, respectively. The downstream IV fragment (Right/R), corresponding to 
nucleotides 32675-32982, was amplified in the same way, using SfoI-Right-forward and 
XhoI-Right308-reverse primers introducing restriction sites, SfoI and XhoI, respectively. 
PCR products were purified following gel excision and were ligated separately into 
pcDNA/V5-HIS©-TOPO®, creating pIVL-TOPO and pIVR308-TOPO.  
 
A further post gel excision incubation step for 10mins at 72°C with an excess of dNTPs 
was required to enhance subsequent TOPO ligation efficiency. These constructs were 
confirmed by sequencing with T7-forward and BGH-reverse primers. The final pIV 
shuttle vector was assembled by successive rounds of subcloning. Firstly, sequence 
confirmed pIVL-TOPO and pGV1 were NotI/BamHI digested in parallel and the pIVL 
fragment ligated into the MCS of the pGV1 shuttle following gel excision purification, 
dephosphorylation and ligation. This vector was named pGV1-IVL and was again 
sequenced with T3-forward, and T7-reverse sequencing primers. The second round of 
subcloning involved the parallel SfoI/XhoI digestion of pGV1-IVL and the previously 
constructed pIVR308-TOPO. This process resulted in the successful assembly of a 
shuttle vector, pIVSfoI containing a unique blunt end restriction site (SfoI) at the site 
identified for insertion of heterlogous DNA, thus facilitating cloning of any potential 
oligoduplex ligand, by blunt end ligation. The sequence confirmed final construct was 
bulked up by QIAprep® Maxiprep DNA extraction. 
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pIVL-TOPO
6092 bp
AmpRf1 Ori pUC Origin
Bam HI (1517)Sfo I (1513)
SfoI (2925)
Not I (955)
pIVR308-TOPO
5843 bp
AmpRf1 Ori pUC Origin
SfoI (956)
SfoI (2676)
Xho I (1268)
pGV1
4384 bp
AmpR URA-3
T3 T7
F1 ori
Bam HI (2311)Not I (2292)
pGV1-IVL
4927 bp
AmpR URA-3
T3 T7
F1 ori
Bam HI (2854)
Not I (2292)
Sfo I (2850)
pIVSfoI
5184 bp
AmpR
URA-3
T3
T7F1 ori
Xho I (3162)
Not I (2292)
Sfo I (2850)
A B
C D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.5 Fibre Region Modification; Construction of pIVA20.  A strategic overview of the 
construction of this vector is shown in Fig.2.5. Terminally phosphorylated, HPLC 
purified, complementary oligonucleotides, spanning the RGDLXXL motif within the VP1 
viral surface protein of Foot and Mouth Disease Virus (FMDV) were obtained from 
SIGMA-Genosys (corresponding to nucleotides 3680-3739 of FMDV; AY593816). 
Sense, and antisense oligonucleotides, 5’-AATGCTGTGCCCAACTTGAGAGGTGACC 
Figure.2.4 Cloning Strategy used to Generate HI-loop modifying Shuttle Vector, pIVSfoI. (A) 
Intermediate holding vector pIVL-TOPO was created by TA cloning of a 5’-NotI, and 3’- BamHI-SfoI 
engineered PCR product. (B) The same strategy was used to create pIVR308-TOPO, from a 5’-SfoI, 3’-
XhoI engineered PCR product. (C) The final vector, pIVSfoI, was assembled by two sequential rounds of 
subcloning. The pGV1 backbone and the intermediate holding vector, pIVL-TOPO, were NotI/BamHI 
digested simultaneously. (D) The released fragment, IVL, was ligated into pGV1, to create pGV1-IVL. This 
construct was sequenced before the final round of subcloning. The pGV1-IVL backbone and the 
intermediate holding vector, pIVR308-TOPO, were SfoI/XhoI digested simultaneously. (E) The released 
fragment, IVR308, was ligated into pGV1-IVL to generate the final construct, pIVSfoI, creating a unique blunt 
end restriction site (SfoI) within the fibre sequence. Vector maps (linear/circular representation) are to scale 
and the multi-cloning site (MCS) and restriction sites used in the cloning strategy are displayed. Restriction 
maps were generated using VectorNTI Software (VectorNTI Advance 10, Academic Version, Invitrogen). 
 84
TTCAAGTGTTGGCTCAAAAGGTGGCACGGACG-3’ and 5’-CGTCCGTGCCACCTTT 
TGAGCCAACACTTGAAGGTCACCTCTCAAGTTGGGCACAGCATT-3’ at 1μM each 
were annealed together in a 50μl reaction volume with 1X annealing buffer (2X: 200mM 
Potassium Acetate, 60mM HEPES-KOH pH7.4 and 4mM Magnesium Acetate), and 
were incubated at 95°C for 4mins followed by 70°C for 10mins. This was followed by 
subsequent reduction in temperature of 5°C every 5mins until 4°C was reached. The 
duplex oligonucleotides were diluted 1:20 and 1μl of the dilution ligated to 100ng of 
SfoI digested, dephosphorylated, pIVSfoI in a final volume of 10μl, by blunt end ligation. 
The ligation reaction was incubated overnight at 16°C, after which 2μl were used to 
transform chemically competent DH10B. Bacterial cultures harvested by centrifugation 
and plasmid DNA extracted from the pellet. Samples were screened by PCR using 
A20-forward/AdinPCR-reverse for the presence of the insert, in conjunction with a 
further PCR screening using AdinPCR-forward/AdinPCR-reverse, to detect a 60bp size 
difference when analysed on a 2% agarose gel. Successful constructs were confirmed 
again by sequencing with T3-forward, T7-reverse, AdinPCR-forward and AdinPCR-
reverse, and were renamed pIVA20.  
 
pIVSfoI
5184 bp
AmpR URA-3
T3 T7
F1 ori
Xho I (3162)Not I (2292)
Sfo I (2850)
pIVA20
5244 bp
AmpR
URA-3
T3
T7
F1 ori
Msc I (2954)
Xho I (3222)
A20FMDV2 oligoduplex
A
B
 
 
 
 
 
 
 
Figure.2.5 Cloning Strategy used to Generate the A20FMDV2 Fibre modified Shuttle Vector, pIVA20.  
(A) Shuttle vector, pIVSfoI, was linearised with a unique blunting restriction enzyme, SfoI, and was 
dephosphorylated. (B) A terminally phosphorylated oligoduplex, with sequence corresponding to the ανβ6-
binding RGDLXXL domain from Foot and Mouth Disease Virus (FMDV), was ligated into SfoI digested 
pIVSfoI, by blunt end ligation to create pIVA20. Vector maps (linear/circular representation) are to scale and 
the multi-cloning site (MCS) and restriction sites used at each step in the cloning strategy are displayed. 
Restriction maps were generated using VectorNTI Software (VectorNTI Advance 10, Academic Version, 
Invitrogen). 
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pIV824-TOPO
6348 bp
AmpRf1 Ori pUC Origin
Xho I (1773)Sfo I (956)
SfoI (1627) SfoI (3181)
pIVR824-TOPO
6348 bp
AmpRf1 Ori pUC Origin
Xho I (1773)Msc I (1000)
MscI (3262)
pIVA20
5244 bp
AmpR
URA-3
A20FMDV2
T3 T7
F1 ori
Msc I (2954) Xho I (3222)
pIV1.4A20
5749 bp
AmpR
URA-3
T3
T7
F1 ori
Msc I (2954)
Xho I (3727)
Not I (2292)
A B
C
D
 
 
 
 
 
 
 
 
 
 
 
 
2.3.6 Fibre Region Modification; Construction of pIV1.4A20.  An extended, 
downstream IV-R fragment (nt32675-33487) was cloned by PCR from pAdEasy-1 
template DNA, using the existing primer SfoI-Right-forward, in combination with a new 
reverse primer XhoI-Right824-reverse, which again introduced engineered restriction 
sites SfoI and XhoI, to facilitate further subcloning into the URA3 integrating shuttle 
Figure.2.6 Cloning Strategy used to Generate the extended A20FMDV2 Fibre modified Shuttle 
Vector, pIV1.4A20.(A) An extended, 1.4kb, IVR fragment was generated by PCR using a similar strategy to 
that used to create pIVR308-TOPO. The XhoI-reverse primer used in this strategy amplified a larger 
fragment (844bp instead of 308bp), and therefore this intermediate holding vector was named pIV844-
TOPO. However, the extended region featured an additional, internal SfoI site, which was not compatible 
with the downstream cloning strategy. (B)  An alternative cloning strategy using MscI/XhoI was employed. 
pIVA20 was MscI/XhoI digested in parallel with pIVR824-TOPO, and the IVR308 fragment substituted for 
the extended IVR844 fragment. (C) The final extended version of the pIVA20 shuttle construct was named 
pIV1.4A20. Vector maps (linear/circular representation) are to scale and the multi-cloning site (MCS) and 
restriction sites used at each step in the cloning strategy are displayed. Restriction maps were generated 
using VectorNTI Software (VectorNTI Advance 10, Academic Version, Invitrogen). 
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vector. A schematic overview of the cloning strategy is presented in Fig.2.6. The 824bp 
PCR product was purified following gel excision and ligated into pcDNA/V5-HIS©-
TOPO®. Constructs were confirmed by sequencing with T7-forward/BGH-reverse 
primers. Successful constructs were named pIVR824-TOPO. However, sequencing of 
pIVR824-TOPO revealed the presence of a second SfoI site within the fibre sequence, 
which was not compatible with the planned cloning strategy. Therefore, the final 
construct, pIV1.4A20 was assembled by parallel MscI/XhoI restriction digestion of 
pIVA20/pIVR824-TOPO and ligation of the pIVR824 fragment into the linearised pIVA20 
shuttle, thus extending it. This newly constructed shuttle was sequenced with primers 
T3-forward, T7-reverse, AdSeq-forward and -reverse, and was renamed pIV1.4A20. 
 
2.3.7 Fibre Region Modification; Construction of pIV-477dlTAYTA20 and pIV-
485dlTAYTA20. In order to introduce CAR-binding ablating mutations, or putative blood 
factor binding deletions, the pIV1.4A20 shuttle vector was modified further. A schematic 
overview of the cloning strategy is presented in Fig.2.7. CAR-binding mutations Y477A 
and L485K were combined with a TAYT deletion (dlTAYT) and constructed as follows; 
pKnob477dlTAYTWT/A20-TOPO and -485dlTAYTWT/A20-TOPO constructs (described in 
Section.2.4.4), were used as templates for subcloning, to transfer the respective 
modifications into pIV1.4A20. Two single restriction sites were identified within the fibre 
sequence of pIV1.4A20, PflMI and MscI, sites which were common to the fibre sequence 
contained within the pKnob477dlTAYTA20-TOPO and -485dlTAYTA20-TOPO constructs. 
In addition, these sites flanked the region containing the introduced mutations. 
Therefore, a PflMI/MscI subcloning strategy was used to transfer the 388bp, 
477dlTAYTA20 or 485dlTAYTA20 fragment into pIV1.4A20 shuttle, in place of the 
corresponding 400bp fragment. Recognition of the PflMI site can be blocked by dcm 
methylation. Therefore, the sequence of the PflMI sites within all vectors to be digested 
were checked to ensure that they did not contain the internal cytosine residues 
required for dcm methylation. Digested fragments were ligated into PflMI/MscI digested 
and dephosphorylated backbone, pIV1.4A20. Successful clones were verified by 
sequencing using T3-forward and T7-reverse sequencing primers. 
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pIV1.4-485dlTAYTA20
5737 bp
AmpR
URA-3
T3
T7
F1 ori
Msc I (2942)
Pfl MI (2554)
pIV1.4-477dlTAYTA20
5737 bp
AmpR
URA-3
T3
T7
F1 ori
Msc I (2942)
Pfl MI (2554)
Fibre477dlTAYTA20
pIV1.4A20
5749 bp
AmpR URA-3T3 T7 F1 ori
Pfl MI (2554) Msc I (2954)
Fibre485dlTAYTA20
pKnob477dlTAYTA20-TOPO
6185 bp
AmpRf1 Ori pUC Origin
Pfl MI (1151) Msc I (1539)
MscI (3099)477Δ
pIV1.4A20
5749 bp
AmpR URA-3T3 T7 F1 ori
Pfl MI (2554) Msc I (2954)
Fibre1.4A20
pKnob485dlTAYTA20-TOPO
6185 bp
AmpRf1 Ori pUC Origin
Pfl MI (1151) Msc I (1539)
MscI (3099)
485Δ Fibre1.4A20
i ii
iii
i ii
iii
A
B
 
 
 
 
 
 
 
 
Figure.2.7 Cloning Strategy used to Generate Blood Factor Binding Ablated and Fibre Modifying 
Shuttle Vectors, pIV477dlTAYTA20 and pIV485dlTAYTA20. (A) i Intermediate TA holding vector, 
pKnob477dlTAYTA20 was generated previously and is described in Section.2.4.4. Two restriction sites, 
PflMI/MscI, were identified which were compatible with subcloning of the 477dlTAYT mutation into the 
pIV1.4A20 shuttle vector. ii) Backbone pIV1.4A20 and pKnob477dlTAYTA20 were digested simultaneously 
with PflMI/MscI. iii Ligation of the 477dlTAYT fragment into pIV1.4A20 resulted in a fibre modifying shuttle 
vector which was renamed pIV1.4-477dlTAYTA20. (B) i An identical strategy using pKnob485dlTAYTA20 
and ii pIV1.4A20 digested simultaneously with PflMI/MscI, resulted in the generation of iii pIV1.4-
485dlTAYTA20. Vector maps (linear/circular representation) are to scale and the multi-cloning site (MCS) 
and restriction sites used at each step in the cloning strategy are displayed. Restriction maps were 
generated using VectorNTI Software (VectorNTI Advance 10, Academic Version, Invitrogen). 
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2.3.8 Fibre Region Modification; Construction of pIV-477dlTAYT6XHIS and pIV-
485dlTAYT6XHIS. In order to construct non-retargeted, but CAR/blood factor binding 
ablated Ad5 mutants, shuttle vectors were generated which featured a 6XHIS epitope 
in place of A20FMDV2. The presence of the 6XHIS epitope permits the amplification of 
these mutant viruses on 293.HissFv.rec cells, HEK293 cells which have been stably 
transfected with an anti-HIS scFv (Douglas et al., 1999). Once again, SOEing PCR was 
used to assemble these constructs, using the pKnob477dlTAYTA20-TOPO and -
485dlTAYTA20-TOPO vectors as template DNA (see Section.2.4.4). The PCR-A 
fragment was amplified using primers, F5Knob-forward and Mut6XHIS-reverse, and the 
PCR-B fragment was amplified using Mut6XHIS-forward and F5Knob-reverse. The 
Mut6XHIS primers were designed so that they were compatible with both the 477, and 
485 templates. The final PCR-AB fragment for each was amplified in Step 3 using 
F5Knob-forward and F5Knob-reverse, and products cloned into pcDNA/V5-HIS©-
TOPO®(Invitrogen™). Constructs were renamed accordingly (eg. pKnob477dlTAYT6XHIS-
TOPO) and sequenced. Subcloning into the pIV1.4A20 shuttle was once again achieved 
by PflMI/MscI digestion, substituting the A20-containing fragment for the corresponding 
6XHIS-containing fragment. 
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Section.2.4 Construction of Expression Vectors and Recombinant Protein 
Production  
 
Vector constructs were generated using standard molecular biological techniques. 
Primers used for PCR, and sequencing are listed in Table.8 and Table.9, respectively. 
Adenoviral fibre sequence corresponding to the knob domain, plus the first seven 
residues of the polylysine repeat motif (nt32195-32782), was cloned by PCR from 
pAdEasy-1 adenoviral template DNA for wildtype KnobWT, and from pIV1.4A20 for A20-
modified KnobA20 using a previously described strategy (Krasnykh et al., 1996). PCR 
primers, F5Knob-forward and F5Knob-reverse, were designed to introduce engineered 
BamHI/HindIII restriction sites, facilitating directional cloning into the pQE30 expression 
vector (Qiagen®). Restriction digestion and ligation reactions were set up as previously 
described and DNA extracted by standard QIAprep® Spin Miniprep Kit (Qiagen®). All 
constructs were screened by sequencing with the pQE Sequencing-Primer Set 
(Qiagen®) using pQE30-SeqIII/IV-forward and pQE30-Seq-reverse primers to ensure 
that inserts were in frame with the N-terminal 6XHIS tag. 
 
2.4.1 pQE30KnobWT. PCR amplification of the WT knob domain of the Ad5 fibre gene 
resulted in a product of 628bp. The PCR product was purified by QIAquick® Gel 
Extraction (Qiagen®) and the insert ligated into pcDNA/V5-HIS©-TOPO® (Invitrogen™) 
by standard protocol, to create pTOPOKnobWT. Constructs were sequenced using T7-
forward/BGH-reverse primers supplied by the manufacturer. Subcloning of KnobWT into 
the pQE30 expression vector was achieved by parallel BamHI/HindIII restriction 
digestion of pQE30/pTOPOKnobWT, separation and identification of the ~3.4kbp/628bp 
bands by gel electrophoresis, and their purification following gel excision. Ligation 
reactions were set up as described previously, pQE-KnobWT constructs sequence 
confirmed and transformed into competent SG13009 E.coli (Qiagen®), harbouring the 
pREP4 repressor plasmid, for subsequent protein expression.   
 
2.4.2 pQE30KnobA20. PCR amplification of the A20-modified knob of the Ad5 fibre 
(from pIV1.4A20) resulted in a product of 694bp, which was purified as described above. 
The insert was again ligated into pcDNA/V5-HIS©-TOPO® (Invitrogen™), to generate 
pTOPOKnobA20, which was confirmed by sequencing, as above. Subcloning into the 
pQE30 expression vector was also achieved by parallel BamHI/HindIII restriction 
digestion of pQE30/pTOPOKnobA20 and purification of the respective bands following 
gel excision.  
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2.4.3 pQE30KnobΔCARWT and pQE30KnobΔCARA20. Sequence confirmed 
pQE30KnobWT /pQE30KnobA20 constructs were used as templates for mutagenic PCR 
as described previously (Section.2.2.5). Mutagenic primers, MutL485K-forward and –
reverse, or MutY477A-forward and –reverse, were used to introduce point mutations at 
sites thought to be critical for CAR binding (Kirby et al., 2000). Following DpnI digestion 
of PCR products, 2µl were used to transform competent DH10B, DNA extracted by 
standard methods, and samples sequenced and verified. Successful clones were 
transformed into SG13009 (pREP4) E.coli, which had been made chemically 
competent, in preparation for protein expression. These were selected on LB agar 
supplemented with Amp/Kan [100µg/ml/25µg/ml]. Constructs were renamed 
accordingly; pQEKnobY477AWT/A20 or pQEKnobL485KWT/A20. 
 
2.4.4 pQE30Knob477dlTAYTA20 and pQE30Knob485dlTAYTA20. The CAR-binding 
mutant pQE-Knob constructs described above were further modified to incorporate a 4 
amino acid deletion (dlTAYT). This modification, in combination with the Y477A 
mutation and a FLAG peptide insertion, has been reported to reduce binding to 
serum/coagulation factors, FIX and C4BP (Gaggar et al., 2007; Shayakhmetov et al., 
2005b). These constructs were generated using a SOEing PCR strategy (see Fig.2.1). 
In Step 1, the PCR-A fragments were amplified using primers F5Knob-forward in 
combination with either dlTAYT477-reverse, or dlTAYT485-reverse, for pQE30KnobWT 
and pQEKnobA20, respectively. The PCR-B fragments were amplified using dlTAYT-
forward and F5Knob-reverse, which were designed so that they were suitable for all 
strategies (ie. 477 or 485, WT or A20). All PCR-AB fragments were amplified in Step 3 
using F5Knob-forward and F5Knob-reverse and the final products cloned individually 
into pcDNA/V5-HIS©-TOPO® (Invitrogen™). Constructs were renamed accordingly (ie. 
pKnob477dlTAYTA20-TOPO) and sequenced.  
 
However, the Y477A mutation resulted in the introduction of an additional HindIII site 
within the Knob477dlTAYTA20 fragment, and therefore subcloning into pQE30 could not 
be achieved using the standard BamHI/HindIII strategy (Fig.2.8A). Conveniently, the 
desired Knob modifications were flanked on either side by the original, and introduced 
HindIII sites. Therefore, a single HindIII digestion strategy was used to subclone the 
Knob477dlTAYTA20 fragment from pKnob477dlTAYTA20–TOPO into the previously 
constructed pQEKnob477A20 vector, which also contained the extra HindIII site (see 
Section.2.4.3).  
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pQEKnob477dlTAYTA20
4065 bp
T5-Lac O
AmpR
6xHIS Tag
ColE1
Hin dIII (420)
Hin dIII (792)
Knob477dlTAYTA20
pKnob477dlTAYTA20-TOPO
6185 bp
AmpRf1 Ori pUC OriginHindIII (903)
Hin dIII (1233) Hin dIII (1605)
pQE477A20
4077 bp
T5-Lac O AmpR
6xHIS Tag
ColE1
Hin dIII (420) Hin dIII (804)
477Δ Y477A
pQEKnob485dlTAYTA20
4065 bp
T5 Lac Operon
AmpR
6xHIS Tag
ColE1
Bam HI (146)
Hin dIII (792)
Knob485dlTAYTA20
pKnob485dlTAYTA20-TOPO
6185 bp
AmpRf1 Ori pUC Origin
BamHI (921)
Bam HI (959)
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Figure.2.8 Cloning Strategy Used to Generate Blood Factor Binding Ablated and Fibre Modifying 
Expression Vectors, pQEKnob477dlTAYTA20 and pQEKnob485dlTAYTA20. (A) i Intermediate holding 
vector, pKnob477dlTAYTA20 was generated previously, and is described in Section.2.4.4. The 
mutagenesis strategy (Y477A) resulted in the generation of an additional, internal HindIII site. Therefore a 
HindIII cloning strategy was used, instead of BamHI/HindIII, to transfer the 477dlTAYTA20-containing 
fragment to the pQE30 expression vector. ii The pQE477A20 vector also features the additional HindIII site 
Therefore, this vector was used as a backbone for HindIII-mediated ligation of the -477dlTAYTA20 
fragment. iii This resulted in the generation of the pQEKnob477dlTAYTA20. (B) i Intermediate holding 
vector, pKnob485dlTAYTA20 was generated previously. ii Expression vector pQE30 was used as the 
backbone for the BamHI/XhoI subcloning of the -485dlTAYTA20 fragment. iii The final construct was 
renamed pQEKnob485dlTAYTA20. Vector maps (linear/circular representation) are to scale and the multi-
cloning site (MCS) and restriction sites used at each step in the cloning strategy are displayed. Restriction 
maps were generated using VectorNTI Software (VectorNTI Advance 10, Academic Version, Invitrogen). 
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The desired HindIII fragment (372bp), released by digestion, was separated from a 
similarly sized fragment (330bp) by gel electrophoresis on a 2% agarose gel. 
Subcloning of the Knob485dlTAYTA20 fragment from the –TOPO holding vector, to the 
pQE30 expression vector, was achieved by BamHI/HindIII digestion (Fig.2.8B). 
Constructs were renamed accordingly; pQEKnob477dlTAYTA20 or pQEKnob485 
dlTAYTA20. A ClustalW protein alignment highlighting the differences between KnobWT, 
KnobA20 and Knob477dlTAYTA20/Knob485dlTAYTA20 can be found in Appendix II.  
 
2.4.5 Recombinant Protein Expression and Purification. Protein expression and 
purification was optimised at the Protein Isolation and Cloning Lab at 44 Lincoln Inn 
Fields (CR-UK). SG13009, pQE30Knob-containing pre-cultures were grown overnight 
in 1L Terrific Broth [1.2 % (w/v) Tryptone, 2.4 % (w/v) Yeast Extract, 0.4% (v/v) 
Glycerol], supplemented with 100ml Potassium phosphate salt solution and Amp 
(100μg/ml) and Kan (25μg/ml). A 10% inoculum was added to a large scale culture 
which was grown at 37°C until an OD600nm=0.6 was reached (~5hrs). Protein 
expression was induced for 2-3hrs on addition of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 0.5-1.0mM. Induced cultures 
were harvested by centrifugation at 4000rpm for 15mins, pellets frozen and stored at -
80˚C. The following day IPTG-induced 1L pellets were resuspended in 50ml of freshly 
made Lysis buffer pH7.9 [50mM Tris-HCl, 300mM NaCl, 1% (w/v) NP40 (Fluka 
Biochemika), 10mM Imidazole (Sigma, UK), 1mM β-mercaptoethanol and 0.1% (v/v) 
Lysozyme (Sigma)], with 1μg/ml DNAse and agitated on a roller at 4°C for 1hr. Cells 
were pelleted by ultracentrifugation at 30,000g for 20mins using a Beckman 35Tii rotor 
in an Optima L-80 XP Ultracentrifuge. The cleared cell lysate was transferred to a clean 
50ml falcon and agitated on a roller for 1hr at 4˚C with 0.5-1.0ml Ni-NTA Agarose 
(Qiagen) per 1L of culture. The lysate-matrix suspension was centrifuged at 1000rpm 
for 10mins, supernatant discarded. Conical Poly-Prep polypropylene columns (Biorad, 
UK) were pre-equilibrated with 50ml Wash buffer pH7.9 [50mM Tris-HCl, 300mM NaCl, 
10mM Imidazole and 1mM β-mercaptoethanol]. The lysate-matrix slurry was mixed 
with 10ml Wash buffer and loaded into the chromatography column, and washed with 
10 column volumes of Wash buffer. Bound protein was eluted by column fractionation 
under native conditions by eluting fractions in Elution buffer pH7.9 with ascending 
Imidazole concentration [50mM, 100mM, 200mM or 300mM Imidazole with 10mM Tris-
HCl, 300mM NaCl and 1mM β-mercaptoethanol]. An elution profile was generated 
following analysis by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). 
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2.4.6 SDS-PAGE and Coomassie Staining. Boiled elution fractions (20μl) were run on 
a 12% SDS-PAGE gel with 5X SDS-PAGE sample buffer [0.225M Tris-HCl pH6.8, 50% 
(v/v) Glycerol, 5% (w/v), 0.05% (w/v) and 0.25M Dithiothreitol (DTT)], alongside a 
whole cell lysate or cleared cell lysate fraction. Samples were run at 200V for ~45mins, 
run against a pre-stained broad range (6-175kDa) protein marker (New England 
Biolabs, USA). Gels were fixed with a solution containing methanol and glacial acetic 
acid [50% (v/v) CH3OH and 10% (v/v) glacial CH3COOH] followed by staining for 1hr 
with Coomassie’s solution [0.25% (w/v) Coomassie Brilliant Blue R250, 45% (v/v) 
CH3OH and 10% (v/v) glacial CH3COOH]. Gels were de-stained overnight in a solution 
containing 45% (v/v) CH3OH and 10% (v/v) glacial CH3COOH. Suitable elution 
fractions (>90% purity) were pooled and dialysed overnight in PBS. 
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Section.2.5 In Vitro Characterisation of Recombinant Knob Proteins 
 
2.5.1 Determination of Protein concentration. The concentrations of purified Knob 
proteins were determined by the Pierce Bicinchoninic acid (BCA) protein assay 
(Thermo Scientific, USA), carried out according to manufacturer’s guidelines. A 
standard curve of bovine IgG, in the range 20-2000μg/ml, was used to calculate protein 
concentrations.  
 
2.5.2 Trimerisation Assay. The ability of fibre modified recombinant Knob proteins to 
form homotrimers, was assessed by SDS-PAGE of boiled and unboiled samples. For 
each Knob protein, 5μg total protein was either boiled at 95˚C for 5mins, or left at room 
temperature for 5mins. Immediately prior to loading on the gel, 5X SDS-PAGE loading 
buffer (without DTT), was added to each sample. Boiled and unboiled samples were 
run in parallel on a 12% SDS-PAGE gel for ~1hr at 200V. Protein migration was 
visualised following Coomassie blue staining.  
 
2.5.3 Validation of the Selectivity of KnobA20 Mutants for ανβ6. An experiment was 
carried out to determine the ability of A20-modified, Knob protein derivatives (KnobA20, 
Knob477dlTAYTA20 or Knob485dlTAYTA20) to bind to ανβ6, and to inhibit the binding of 
an ανβ6-specific antibody, 53A.2. Triplicate samples of 1x105 BT-20 cells (high levels 
of ανβ6 but low levels of the CAR receptor) were incubated on ice for 30 minutes, with 
increasing concentrations of each Knob protein (0.001-10μg/105 cells). Cells were 
washed twice and then incubated with anti- ανβ6 antibody on ice for 45 minutes (53A.2 
at 10μg/ml). A rat isotype control IgG2a (Abcam), and KnobWT (at 10μg/ml) were used as 
negative controls. Preparations were washed twice in DMEM and incubated on ice with 
secondary antibody for a further 30 minutes (goat anti-mouse IgG AlexaFluor488; 
1:250; Invitrogen). Cells were washed twice and resuspended in a final volume of 200µl 
serum free DMEM. Labelled cells were scanned on an LSR1 flow cytometer (Becton-
Dickinson, CA, USA). A gate was set to exclude debris and fluorescence in FL1-H was 
recorded, acquiring 1x104 events. Results were analyzed using CellQuest software. 
Fluorescence values obtained for untreated control cells were taken to be 100% and 
fluorescence of Knob-treated cells expressed relative to this. A dose response curve 
was generated, and IC50 values calculated by non-linear regression analysis using 
GraphPad Prism Version 3.03 (GraphPad Software, San Diego, CA).  
 
2.5.4 Migration Inhibition Assay. Migration assays were carried out to assess the 
ability of the modified adenoviral Knob proteins (KnobA20, Knob477dlTAYTA20 or 
Knob485dlTAYTA20) to inhibit ανβ6-dependent cell motility. Haptotactic cell migration 
 95
assays were performed using matrix coated Transwell® filters (8μm pore size, BD 
Biosciences). The membrane undersurfaces of three wells were coated with protein 
control BSA, but all other wells were coated with LAP (0.5μg/ml in α-MEM) for 1hr at 
37°C. All wells were blocked with migration buffer (0.1% BSA in α-MEM) for 30mins at 
37°C. VB6 cells were incubated with an ανβ6 inhibitory antibody (6.3G9; 10μg/ml), 
isotype control (mouse IgG1; 10μg/ml), or Knob proteins (KnobWT and KnobA20; 10μg/ml) 
for 30mins at 4oC prior to seeding. Cells were plated in the upper chamber at a density 
of 5x104 in 100μl of migration buffer, and allowed to migrate for 24hrs. Cells which 
migrated to the lower chamber (including those attached to the lower surface of the 
membrane) were trypsinised and counted on a Casy 1 counter (Sharfe System GmbH, 
Germany). In order to determine IC50 values for inhibition of migration a separate 
experiment was performed using different concentrations of Knob477dlTAYTA20 or 
Knob485dlTAYTA20 (in the range 0.025-25μg/ml).  
 
2.5.5 Validation of CAR-Binding Ablation Mutations. The ability of the A20-modified, 
or CAR-binding ablated Knob mutants (WT and A20) to bind CAR, was estimated from 
cell-binding experiments on CHO-CAR cells. The capacity for CAR-binding mutant 
proteins KnobL485KWT, KnobL485KA20, Knob485dlTAYTWT, Knob485dlTAYTA20, 
Knob477dlTAYTWT and Knob477 dlTAYTA20, to inhibit Ad5-EGFPWT mediated infection 
was assessed by flow cytometry. The IC50 of KnobWT for inhibition of Ad5-EGFPWT 
infection of CHO-CAR cells (0.115μg/105 cells), has been previously determined (Kirby 
et al., 1999). Therefore, when characterising the CAR-binding capacity of the mutants, 
a single concentration (100μg/105 cells), in excess of the IC50 value was used. Cells 
were seeded (1x105 cells/well) in 24-well plates and incubated overnight. Confluent 
monolayers were washed twice in PBS, and triplicate wells pre-incubated with each of 
the Knob proteins for 1hr at 4˚C. Without washing, Ad5-EGFPWT was added to cells at 
a constant multiplicity of infection (MOI) of 10PFU/cell. Incubation was carried out at 
4˚C for a further hour to promote virus binding, but not internalisation. Cells were 
washed twice in cold PBS to remove unbound virus, and cells covered with pre-
warmed complete medium. Plates were incubated for ~22hrs, after which EGFP gene 
transfer was quantified by the detection of fluorescence in FL1-H, by flow cytometry. As 
adenovirus constructs corresponding to the KnobA20 mutant, and putative blood factor 
binding mutants, Knob485dlTAYTA20 and Knob477dlTAYTA20, were being generated 
simultaneously, we wished to quantify IC50 values for these proteins. Serial dilutions of 
protein were prepared in serum free DMEM, at concentrations ranging from 0.01-
100μg/105 cells. Without washing, either Ad5-EGFPWT, or Ad5-EGFPA20 were added to 
cells, to compete for binding to the CAR receptor. IC50 values were calculated from 
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non-linear regression analysis of sigmoidal dose response curves, using GraphPad 
Prism v3.0 software (GraphPad Software, San Diego).   
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Section.2.6 Generation of Recombinant Adenoviral Genomes 
 
The parental yeast vector used in this study, pMB20 (provided by Richard Iggo, UK), 
contains DNA from human adenovirus type 5 (Ad5), and is maintained in yeast as a 
low copy Yeast/Bacterial Artificial Chromosome (YAC/BAC). This vector possesses 
replication origins for both yeast and bacteria. Transformation of the yeast with a 
relevant URA3 integrating shuttle vector results in part one of a two-step gene 
replacement event, or “pop-in” event, in which intermediate constructs contain a 
duplication of the target sequence (Fig.2.9). Transformants are selected on -HIS -URA 
and screened by PCR analysis following extraction of yeast DNA. All primers used for 
PCR screening and sequence confirmation are listed in Table.8 and Table.9. Removal 
of the selective requirement for URA3 results in a second spontaneous recombination 
event, or “pop-out”, which excises the integrated shuttle retaining the target DNA in 
place of its corresponding region of homology. This is mediated by means of a 
recombination event between the target Ad5 sequence within the shuttle, and the 
adenoviral backbone within the YAC/BAC. “Pop-out” recombinants, which have lost the 
URA3 integrating vector, are selected on -HIS supplemented with 5-Fluro-orotic acid 
(5-FOA) at 0.1-0.2% (w/v). This compound is converted to a toxic metabolite 5’Fluoro-
uracil (5-FU) by the URA3 gene product (orotidine-5’-phosphate decarboxylase), which 
eliminates intermediate stage recombinants, therefore ensuring the selection of the 
excisive recombinant clones.  
 
2.6.1 E3 Region Modification; pMB20-EGFP. YPH857 yeast containing the pMB20 
wildtype Ad5 backbone, were freshly streaked onto -HIS agar and incubated overnight 
at 30°C. A fresh colony was inoculated into 100ml -HIS broth and incubated for 12-24 
hrs at 30°C with aeration, in preparation for lithium acetate transformation using the 
Alkali-Cation Yeast Transformation Kit (Q.BIOgene) the following day. The pIP5-EGFP 
shuttle vector was linearised by NotI restriction digestion. 2μg of shuttle DNA was 
digested in a final volume of 20μl, for 2hrs at 37°C, followed by an enzyme denaturing 
step at 65°C for 15mins. Meanwhile, yeast cells were made competent by treatment 
with a Lithium/Caesium Acetate mixture, according to the manufacturer’s protocol. 
During this time, transformation reactions were set up using four different 
concentrations of DNA from 0.1-1μg, in a maximum volume of 10μl. DNA was 
combined with 5μl Carrier DNA and 5μl Histamine solution, mixed gently with 100μl 
competent host cells and yeast transformed by heat shock at 42°C for 10mins. Cells 
were plated onto -HIS -URA selective agar and incubated at 30°C for 48-72hrs, until 
colonies appeared. Individual colonies were picked and incubated for 12-24hrs in 10ml 
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-HIS -URA broth at 30°C with aeration. Each colony selected for “pop-in” screening 
was recorded and numbered on a reference plate of the same medium. Successful 
integrative recombinants or “pop-ins”, confirmed by PCR analysis on extracted yeast 
DNA (see below), were inoculated from their reference plate into 10ml -HIS broth and 
incubated for 12-24hrs at 30°C with aeration. Following this incubation period, 100μl of 
culture was plated onto -HIS 5-FOA and incubated for 24-48hrs at 30°C, to select for 
“pop-out” recombinants. Individual colonies were again selected, referenced on -HIS 
and screened by PCR following yeast DNA extraction (see Section.2.6.5). Successful 
constructs were transformed into commercially available electrocompetent bacteria, 
ElectroMAX™DH10B™ E.coli (Invitrogen™), BAC DNA extracted and constructs 
sequenced.  
 
2.6.2 Fibre Region Modification; pMB20-EGFPA20. YPH857 yeast containing the 
pMB20-EGFP Ad5 backbone, were freshly streaked onto -HIS agar and incubated 
overnight at 30°C. Cultures were prepared for transformation the next day, as 
described above, using the Alkali-Cation Yeast Transformation Kit (Q.BIOgene). The 
pIVA20 fibre-modifying shuttle vector was linearised by MscI restriction digestion. 
However, several attempts to generate A20-modified pMB20 BACS by homologous 
recombination using this shuttle construct failed. Therefore, a modified derivative of this 
construct, pIV1.4A20, was generated. In an attempt to promote the likelihood of a 
recombination event, the region of homology downstream of the A20-insertion, was 
extended by ~500bp. 2μg of pIV1.4A20 was digested in a final volume of 20μl, for 2hrs 
at 37°C, followed by an enzyme denaturing step at 65°C for 15mins. Recombinants 
were selected as described previously. 
 
2.6.3 Fibre Region Modification; pMB20-477/485dlTAYTA20. YPH857 yeast already 
containing the pMB20-EGFPA20  Ad5 backbone, were freshly streaked onto -HIS agar 
and incubated overnight at 30°C. Cultures were prepared for transformation the next 
day, as described above, using the Alkali-Cation Yeast Transformation Kit 
(Q.BIOgene). The pIV-477/485dlTAYTA20 shuttle vectors (see Section.2.3.7) were 
linearised by digestion with MscI (as above), and recombinant selected as described 
above.  
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2.6.4 Yeast DNA Extraction and Screening PCR. Yeast DNA was extracted from 
overnight cultures following enzymatic digestion of the cell wall resulting in spheroplast 
formation. Cultures were centrifuged at 5000g for 5-10mins after which the supernatant 
was discarded. Pellets were resuspended with 20ml YI solution [36.44% Sorbitol (w/v), 
20% (v/v) 0.5M ethylenediaminetetraacetic acid (EDTA)], and centrifuged for a further 
10mins at 5000g. Cell pellets were subjected to enzymatic digestion by resuspension in 
500μl yeast lytic enzyme solution [36.44% Sorbitol (w/v), 20% (v/v) 0.5M EDTA, 2% 
Figure.2.9 Schematic Overview of Two-Step Homologous Recombination in Yeast or “Pop-in Pop-
out”. (A) Step 1 or “pop-in” results in the integration of a linearised URA3 integrating shuttle vector into a 
large adenoviral genome containing plasmid (ie. pMB20 and its derivatives). Integration results in the 
duplication of the target sequence, one wild type and one mutant. Selection of pop-in recombinants is 
through their ability to metabolise uracil. (B) The selective requirement for URA is removed, and so is no 
longer required for viability. This results in a spontaneous recombination event resulting in the excision of 
the integrated DNA. Successful excision recombinants are selected using 5’-Fluro-orotic acid. This is 
converted to the toxic metabolite 5’-Fluro-uracil in the presence of residual URA-containing recombinants 
which results in their elimination. Two step gene replacement has two resultant events, 1 or 2 (see above), 
the desired mutation or the wild type reversion, respectively. 
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(w/v) Zymolase (MP Biomedical, UK) and 0.1% (v/v) β-mercaptoethanol]. Cells were 
incubated at 30°C for 1hr, after which the spheroplasting process was observed under 
a microscope as cell lysis on addition of 1 drop of 10% Sodium Dodecyl Sulphate 
(SDS). Spheroplasts were pelleted by centrifugation at 5000g for 5mins, and 
resuspended in 300μl of RNAse solution [10mM Tris, 1mM EDTA and 0.005% RNAse 
(v/v)]. Spheroplasts were lysed on addition of 30μl 10% SDS and were incubated at 
65°C for 1hr. Precipitation of debris, protein and genomic DNA was achieved on 
addition of 100μl 5M Potassium Acetate (CH3COOK) followed by centrifugation, in a 
table top centrifuge, at maximum speed for 30mins at 4°C. Supernatant was 
transferred to a 2ml eppendorf and the same volume of room temperature isopropanol 
[(CH3)CHOH] was added before DNA was pelleted by centrifugation at maximum 
speed for 15mins at at 4°C. Supernatant was discarded and pellet washed gently in 
1ml room temperature ethanol (EtOH), ensuring that the pellet floated freely. DNA was 
precipitated by centrifugation at maximum speed for 10mins at 4°C, the pellet air dried 
and resuspended in 30-50μl H20. DNA concentrations were determined using a 
NanoDrop® ND-1000 photospectrometer (NanaoDrop TechnologiesInc). Samples were 
assessed at 260nm versus a blank control. 
 
2.6.5 Transformation of E.coli with Yeast DNA and BAC DNA Extraction. PCR 
confirmed yeast DNA constructs were transformed into ElectroMAX™DH10B™ E.coli 
(Invitrogen™), to facilitate further PCR screening, and confirmation by restriction 
digestion fingerprinting. No more than 100ng of DNA in a final volume of 1μl was used 
to transform competent cells by electroporation using a BioRad GenePulser®II 
Electroporator, under the following conditions; 1.8kV, 200Ω, 25μF. Cells were 
resuscitated in 1ml SOC (Invitrogen™) medium [0.5% (w/v) Yeast extract, 2.0% (w/v) 
tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 20mM MgSO4 and 20mM glucose], at 
37°C with aeration for 1hr. 100μl of this suspension was plated onto prewarmed LB 
agar plates with Chl (25μg/ml) and incubated overnight at 37°C. The following day 
individual colonies were picked off and were inoculated in 5-10ml LB/Chl broth 
(25μg/ml) and incubated overnight at 37°C with aeration. DNA was extracted by a 
slightly modified, miniprep version of Large Con Kit (Qiagen®), which included a second 
alkaline lysis step to eliminate bacterial chromosomal DNA. Cultures were centrifuged 
at 3000g for 10mins at room temperature and the pellets resuspended in 300μl reagent 
P1 (Qiagen®) supplemented with 50μg/ml RNAse A, followed by transfer into a 1.5ml 
eppendorf. Suspensions were incubated at room temperature for 5mins following 
addition of 300μl normal alkaline lysis reagent P2 (Qiagen®). After 5mins, 300μl of pre-
chilled alkaline lysis reagent P3 (Qiagen®) was added and the suspension incubated 
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for 30mins on ice, after which they were centrifuged at maximum speed (15,700g) in a 
refrigerated tabletop centrifuge for 10mins at 4°C. The supernatant was collected, 
transferred to a clean eppendorf to which an equal volume of room temperature 
isopropanol was added, and centrifuged at 15,700g for 10mins at room temperature. 
Supernatant was removed and the pellet resuspended gently in 50μl sdH20 before 
being transferred to another sterile eppendorf, 200μl room temperature ethanol was 
added and the mixture centrifuged at 15,700g for 10mins at room temperature, using a 
tabletop centrifuge. Supernatant was discarded and the pellet resuspended in 30μl 
Elution Buffer (EB). These constructs were further screened analysing their restriction 
digestion fingerprint profile when compared against wildtype pMB20, following 
digestion with XbaI/XhoI. Successful constructs were prepared for large scale DNA 
extraction using the Large Con MaxiPrep Kit (Qiagen®) after which the pellet was 
eluted in H20 if required for sequencing, or in endotoxin-free TE for transfection 
applications.  
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Section.2.7 Adenovirus Production and Validation Techniques 
 
2.7.1 Ad5 Genome Transfection and Rescue. Virus production by transfection of 
HEK293 cells with PacI digested pMB20 plasmid, or its derivatives, was carried out in 
the category 2 tissue culture laboratory. 10μg of pMB20 recombinants were digested 
overnight at 37°C in a final volume of 50μl, with 1U PacI per μg DNA, to release the 
Ad5 genome. The 36kbp fragment was purified as follows; 200μl TEN buffer [10mM 
Tris-HCl pH8.0, 100mM NaCl, 1mM EDTA] was added to the 50μl PacI digest. An 
equal volume of phenol/chloroform/isoamyl alcohol was added, the sample vortexed 
briefly and centrifuged at 15,700g for 5mins at room temperature. The upper aqueous 
layer was collected (~250μl) and an equal volume of chloroform alone added. The 
sample was transferred to a sterile 1.5ml eppendorf, after which 600μl of ice-cold 100% 
EtOH and 0.1 volumes of 3M NaAc were added. The suspension was incubated for 
30mins on ice and then centrifuged at 15,700g for 15mins at room temperature. The 
supernatant was removed carefully and the pellet washed in 1ml 70% EtOH. The 
sample was centrifuged again at 15,700g for 5mins, supernatant removed and the 
pellet allowed to dry for 5mins, after which it was resuspended in ~25μl of endotoxin-
free elution buffer (Qiagen). Purifed viral DNA was transfected into HEK293/HEK293-
β6 cells using FuGENE 6 Transfection reagent (Roche) as follows; FuGENE 6 reagent 
was mixed with viral DNA in ratios of 3:2, 3:1 and 6:1μl/μg, respectively and incubated 
for 15mins. 2 x 105 HEK293/HEK293-β6 cells, in a final volume of 2ml DMEM 10% 
FCS, were added to each well of a 6-well plate. The FuGENE-DNA suspension was 
added in a dropwise manner immediately, and the plate swirled to ensure even 
dispersion. Plates were incubated under standard conditions for 3-11 days during 
which transfection efficiency and cytopathic effects (CPE) were observed by 
visualisation of EGFP by UV light under a microscope. Following cell detachment, the 
cell-medium suspension containing virus was collected and stored in a 15ml falcon at -
80°C, until required for further expansion of the virus. 
 
2.7.2 Virus Propagation and Expansion. A frozen virus suspension collected from 
one of the wells in the initial transfection was used to infect a 10cm2 dish seeded with 
HEK293 cells (5x105/well) grown in DMEM 10% (v/v) FCS, the previous day. CAR-
binding ablated, A20-retargeted viruses were amplified on either HEK293-β6 or A549-
β6 cells, in medium supplemented with puromycin (5μg/ml). Prior to infection the 
medium was removed and replaced with 10-15ml DMEM 2% (v/v) FCS. The viral 
suspension was subjected to three cycles of freeze-thaw lysis after which the entire 
contents of the falcon were tipped onto the 10cm2 plate. Virus/culture medium 
suspension was collected 3-5 days post infection and frozen at -80°C until required for 
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infection of a T175 flask at 70-80% confluency. In preparation for further viral 
amplification, the suspension was again subjected to three cycles of freeze-thaw lysis, 
after which 3-5ml was used to infect the T175. Full CPE was reached within 48-72hrs, 
after which the virus/medium suspension was again collected and frozen at -80°C. 
Freeze thawed virus suspension (6-7ml) was used to infect a confluent CF-10 tower, 
which was harvested within 48-72hrs. Virus produced was collected by 
ultracentrifugation following purification on a Caesium Chloride gradient.   
 
2.7.3 Virus Purification Using CsCl Gradient. Once cells were detached from the 
CF-10 (~48-72hrs post-infection), cells were harvested by centrifugation at 1000g in a 
Sigma 6K15 Centrifuge for 10mins at 4˚C. The pellet was allowed to settle for 10mins 
prior to aspiration off of the supernatant. Each pellet was resuspended in 15ml cold 
PBS. Pellets were centrifuged at 250g for 10mins at 4˚C using a Sigma 6K15 
Centrifuge, and the final pellet re-suspended in 12ml sterile, cold 10mM Tris-HCl 
pH8.0. Pellets were subjected to three rounds of freeze/thaw lysis, and were stored at -
80˚C until ready for caesium chloride (CsCl) banding. A CsCl discontinuous density 
gradient was prepared as follows; 10.4ml of CsCl solution at a density of 1.25g/ml was 
under-layered with 7.6ml of CsCl solution at a density of 1.4g/ml in a 3.5’ 
ultracentrifuge tube (Beckman-Coulter). The previously freeze-thawed viral lysate was 
centrifuged at 8000g for 10mins at 4˚C in a Sigma 6K15 Centrifuge, and the 
supernatant layered carefully on top of the CsCl gradient. Tubes were weighed and 
balanced to within 0.01g, before being centrifuged at 25,000rpm for 2hrs at 15˚C using 
a Beckman 55Ti rotor in an Optima L-80 XP Ultracentrifuge. Following 
ultracentrifugation, functional particles were distinguished from defective particles on 
the basis of their altered buoyant density in a CsCl gradient. Three bands were visible; 
an upper band of cellular debris, a central band containing unpackaged virus and a 
lower band containing successfully encapsulated, functional virus. This fraction was 
extracted from the gradient as follows; the ultracentrifuge tube was restrained using a 
clamp and pierced carefully using a 19 gauge needle attached to a 10ml syringe. The 
band was aspirated carefully in minimal volume of CsCl possible, and transferred to a 
labelled falcon tube. Bands were pooled and layered onto 3ml of 1.35g/ml CsCl 
solution in a ½ x 2’ ultracentrifuge tube, tubes balanced and centrifuged at 40000rpm 
for ~15hrs at 15˚C using a Beckman SW32Ti swing out rotor in an Optima L-80 XP 
Ultracentrifuge. The virus band was collected, as before, and resuspended ~1:2 in 
buffer [96mM NaCl, 0.5mM Na2HPO4, 2.8mM KCl, 0.3mM MgCl2, 0.5mM CaCl2, 30% 
(v/v) glycerol]. The virus-buffer mixture was injected into a 3000MW Slide-a-lyzer 
cassette (Pierce Biotechnology, UK) and dialysed for 24 hours in 2l dialysis solution 
[10mM Tris-HCl pH 7.4, 1.0mM MgCl2, 150m NaCl, 10% (v/v) glycerol]. The following 
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day virus was removed from the dialysis cassette, and aliquots of 50-100μl volumes 
stored at -80°C in cryovials.  
 
2.7.4 Virus Titration (TCID50). Ten-fold serial dilutions of viral stocks were titrated on 
JH293/JH293-β6 cell seeded in 96-well plates the previous day (1x104cells/well). 
Titrations were performed on quadruplicate plates. The cells were incubated with virus 
for ten days at 37°C DMEM with 2% (v/v) FCS, supplemented with puromycin (5μg/ml) 
when required. Infection was detected by induction of CPE and visualisation of EGFP 
fluorescence under UV light. Viral Tissue Culture Infectious Dose-50 (TCID50) titres 
were read according to the method of Reed-Muench. Titres were precisely calculated 
using the Kärber statistical method T =101+d(S-0.5) where d is Log10 of the dilution and S 
is the sum of the ratios. TCID50 values were adjusted (they have been empirically 
determined to be 0.7 Log higher than standard plaque assays) to enable viral titres to 
be expressed as PFU/ml (Kontermann et al., 2003; Wang et al., 2003; Wu & Curiel, 
2008; Zhao et al., 2009). 
 
ie. 1x10x TCID50/ml is adjusted to 1x10X-0.7 PFU/ml.  
 
2.7.5 Virus Particle Quantification (OD260nm). For determination of virus particle 
counts, two 100μl aliquots of purified virus stock were diluted in 100μl 2X Virus Lysis 
Buffer [1% (w/v) SDS and 0.04M Tris-HCl, pH7.4]. A 1:10 dilution of virus, and an 
aliquot of TSG alone, was also included. The virus suspension was heated to 56˚C for 
10mins, after which 300μl sterile distilled H2O was added, and the sample transferred 
to a quartz cuvette. The absorbance constant for Ad5 has been determined previously 
(Maizel et al., 1968). The absorbance of each sample was read at a fixed wavelength 
of 260/280nm (typically ~1.2-1.3 after CsCl purification) and viral particles per ml (PPM) 
calculated from the following formula: 
 
Particles/ml = OD260nm  x  Dilution factor   x 1.12 x 1012 [Absorbance constant for Ad5] 
 
 
 
 
 
 
 
 105
Section.2.8 In Vitro Characterisation of Adenovirus Vectors 
 
2.8.1 Purification of Viral DNA for PCR Applications. Viral DNA was extracted from 
virally infected cells or directly from purified virus stocks using the QIAamp Blood DNA 
mini Kit (Qiagen), according to manufacturer’s instructions. DNA extracted from virally 
infected cells was used for sequencing applications, to confirm the incorporation of 
various mutations within the Ad5 mutants. DNA extracted from purified viral DNA was 
used to create a standard curve (ranging from 109-101 genomes) for quantitative real-
time PCR (qPCR) applications. The concentration of purified vDNA was determined 
using a NanoDrop® ND-1000 photospectrometer (NanoDrop Technologies). The Ad5 
genome is ~36 kilobase pairs (kbp) in size. As the mass of 1bp has been calculated to 
be ~1.096 x 10-21 g/bp we can calculate that the Ad5 genome weighs ~3.95 x 10-17 g. 
Therefore, 1x109 genomes would be equivalent to ~39.456ng. The 1x109 dilution was 
calculated and a 10-fold serial dilution performed to obtain the other dilutions for the 
standard curve. Standard curves consistently had R2 values of ≥ 0.98, and a slope 
approaching -3.23.  
 
2.8.2 In Vitro Infectivity Assays. Using a panel of ανβ6-expressing human carcinoma 
cell lines, the infectivity of the ανβ6-retargeted virus Ad5-EGFPA20 was compared with 
its control, Ad5-EGFPWT. In separate experiments, characterisation of viral entry was 
achieved through the use of competition assays, using KnobWT or KnobA20, or a function 
blocking antibody to ανβ6 integrin (53A.2) to inhibit viral infection. Further function 
blocking experiments were carried out using inhibitors to other integrins 
(ανβ3/ανβ5/ανβ8) in order to demonstrate that the route of infection with Ad5-EGFPA20 
was modulated predominantly through ανβ6. Experiments were performed as follows; 
confluent monolayers were pre-incubated with an excess of KnobWT or KnobA20 
(20μg/ml), or the relevant antibodies (10μg/ml) in serum free medium for 1hr at 4˚C. 
Without washing, Ad5-EGFPWT or Ad5-EGFPA20 were added to cells at a multiplicity of 
infection (MOI) of 10PFU/cell (MOI has been used to describe PFU/cell concentrations 
throughout this thesis). Incubation was carried out at 4˚C for 1 hour to promote virus 
binding without internalisation, monolayers washed twice in cold PBS to remove 
unbound virus, cells covered with pre-warmed complete medium and incubated at 37˚C 
for 22hrs to allow EGFP transgene expression. Viral EGFP gene transfer and 
competition gene transfer assays were quantified by acquisition of EGFP fluorescence 
in FL1-H, by flow cytometry.  
 
2.8.3 Cytotoxicity Assays. Cell viability following viral infection was estimated using 
an MTT (3-2,5-diphenyltetrazolium bromide; Sigma-Aldrich, Poole, UK) assay. 
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Carcinoma cells (2x105) were seeded in 24-well plates and infected with 10-fold serial 
dilutions of virus (MOI 0.0001-100; PFU/cell) in medium with 5% FCS. At 120hrs post-
infection 100μl MTT reagent (5mg/ml) was added to each well, and the plate incubated 
for 2hrs at 37˚C. Supernatant was removed and the MTT crystals dissolved in 500ul 
DMSO after which absorbance at 560nm was read in a 96-well plate using an Opsys 
MR microplate reader (Dynex Technologies Ltd, West Sussex, UK). Cell viability 
assays were carried out in triplicate and repeated on three independent occasions.  
 
2.8.4 Replication Burst Assays. For quantification of viral replication per cell, 1x105 
cells were infected with Ad5-EGFPWT or Ad5-EGFPA20, at MOI 10. Triplicate samples 
for each time-point were harvested at 24, 48 and 72hr post-infection by scraping into 
0.5ml of 0.1M Tris-HCl pH8.0. Cell suspensions were subjected to three rounds of 
freeze-thaw lysis, after which virus released was titrated by serial dilution on JH293 
cells, again carried out in triplicate.  
 
2.8.5 Infectivity +/- FIX, FX and Heparin. Infectivity experiments were carried out on 
CHO-K1, CHO-CAR, DX3puro, DX3-β6, TR126, SKOV3ip1 and BT-20 cells, to assess 
the contribution of coagulation factors human factor IX (FIX), and factor X (FX) on 
infectivity. Cells (1x105) were seeded in 24-well plates and allowed to attach overnight. 
The following day, triplicate wells were infected for 2hrs at 37˚C at MOI 10 with Ad5-
EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20 alone, or mixed with physiological 
concentrations of FIX (3μg/ml, Abcam), FX (1IU/ml, Innovative Research), FX mixed 
with porcine heparin (1 IU/ml; 10μg/ml, Sigma), or heparin alone (10μg/ml). Following 
the 2hr incubation, cells were washed twice in PBS, fresh culture medium replaced and 
the infection allowed to proceed for ~22hrs under standard conditions. The end-point 
for these assays was the quantification of EGFP fluorescence, quantified by flow 
cytometry as described previously.  
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Section.2.9 In Vivo Characterisation of Adenovirus Constructs 
 
All in vivo experiments were performed at the Biological Support Unit (BSU) by qualified 
staff and were done under suitable UK Home Office personal, and project licence 
authority. Dose escalation and hepatotoxicity experiments in immunocompetent mice, 
were carried out at the facility of the Institut d’Investigació Biomèdica de Bellvitge, 
IDIBELL (AAALAC unit 1155) at the Institut Català d'Oncologia (ICO), Barcelona, 
Spain. All animal experiments carried out at this facility were in accordance with the 
regulations of the IDIBELL Ethical Committee for Animal Experimentation.  
 
2.9.1 In Vivo Ovarian Intraperitoneal Xenograft Experiment. This experiment was 
carried out by Professor I.A. McNeish and Jerome Burnet (technician). CD1 nu/nu 
female mice were injected intraperitoneally (i.p) with 1x107 SKOV3ip1 ovarian 
carcinoma cells. Viruses Ad5-EGFPWT, Ad5-EGFPA20 and non-replicating, E1-deleted 
control virus, LM-X (McNeish et al., 2001) were injected on days 12-16 inclusive, at a 
dose of 5x109 particles in 400 µL of 20% icodextrin (Innovata plc, Nottingham, United 
Kingdom) per injection. Mice were assessed daily and were killed when they reached 
Home Office morbidity limits (approaching 20% body weight loss, presence of 
significant ascites and poor well-being, as determined by BSU staff). Survival was 
assessed for Ad5-EGFPWT and Ad5-EGFPA20 however, a comparisson with the non-
replicating vehicle control, Ad LM-X was not possible as it was found to be 
contaminated with replicating Ad5 stock.  
 
2.9.2 Intratumoural Efficacy Experiment Using the Isogeneic DX3puro/DX3-β6 
Model. This experiment was carried out by Professor I.A. McNeish and Jerome Burnet 
(technician). 4x106 DX3puro, or DX3-β6 cells, were implanted subcutaneously onto the 
right flanks of CD1 nude female mice. Tumours were measured weekly until they 
reached approximately 8-10mm (~250mm3 volumes). The intratumoural (i.t.) efficacy of 
both Ad5-EGFPWT and Ad5-EGFPA20 was assessed by in vivo fluorescence imaging, in 
addition to estimation of tumour volume variation. Cohorts of up to eight animals 
received three daily i.t. injections of either Ad5-EGFPWT or Ad5-EGFPA20 (1x1010vp in 
50μl PBS). At fixed time points, including immediately prior to virus administration, mice 
were anesthetised (2% halothane in O2 by inhalation) and imaged using a Xenogen 
IVIS Imaging System 100 system (Xenogen, Alameda, CA), using the fluorescence 
module. Fluorescence data from defined regions of interest were analysed with Living 
Image software (Xenogen) and are presented as the fluorescence efficiency. Mice were 
killed when tumours approached 14mm in diameter. Tumours were excised, and fixed 
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in formol saline after which the tissue was processed, embedded in paraffin and 
sectioned by Pathology Services at the Institute of Cancer.  
 
2.9.3 Experiment to Determine Hepatotoxicity in Immunocompetent Mice 
Following Systemic Delivery. Balb/c immunocompetent mice were used for dose 
escalation toxicity studies following intravenous administration of PBS, Ad5-EGFPWT, 
Ad5-EGFPA20 or Ad5-477dlTAYTA20. Doses of 2.5x1010 and 4x1010vp/mouse were 
administered by tail vein injection, in separate experiments. Mice were assessed daily 
for their body weight variation and overall morbidity. At days 6 or 3 post-infection 
(depending on dose), all cohorts were killed and a blood sample obtained by intra-
cardiac puncture immediately post-mortem. Plasma (150μl) was separated from whole 
blood using Microtainer heparinised tubes (Becton-Dickinson) and samples sent to the 
Falcultat de Veterinària, Universitat Autònoma de Barcelona for quantification of liver 
transaminase levels. When possible, whole blood samples were collected in K2EDTA 
microcontainer capillary tubes (Becton-Dickinson) and sent for haematological 
analysis. Serum samples, required for the quantification of cytokines/chemokines, were 
obtained from whole blood samples using Sarstedt CB300 microvette capillary tubes 
with clot activator (Sarstedt, Germany). Livers and spleens were harvested for tissue 
processing, and quantification of viral genomes by quantitative TaqMan Real Time-
PCR (see Section.2.2.7).   
 
2.9.4 Quantification of Serum Cytokines/Chemokines and Analysis of 
Haematology in Immunocompetent Mice Following Systemic Delivery (24hrs). 
Serum cytokine and haematological profiles were obtained from Balb/c 
immunocompetent mice following systemic administration of PBS, Ad5-EGFPWT, Ad5-
EGFPA20 or Ad5-477dlTAYTA20 (4x1010vp/mouse). Cytokine/chemokine (IL-6, RANTES, 
IFN-γ, TNF-α and IL-12p70) levels were quantified 6hrs and 24hrs post-infection, from 
25μl serum, using a fluorescent cytometrix bead assay (FlowCytomix™, Bender 
MedSystems). The protocol is described in detail in Section.2.1.7. Results were 
analysed using FlowCytomix Pro 2.2 Software. Haematological profiles were assessed 
24hrs post-infection at the Clinical Veterinary Biochemistry Service at the Faculatat de 
Veterinària, Universitat Autònoma de Barcelona from 250μl samples of whole blood. 
Blood samples were obtained by intracardiac puncture immediately post-mortem 
(performed by Francisca Alcayaga and Alena Gros).  
 
2.9.5 Experiment to Assess Tumour Targeting and Hepatotoxicity in Nude Mice 
Following Systemic Delivery. Animal work for this study was carried out by Professor 
Ian. R. Hart, Dr. John F. Marshall and Mr. Arif Mustafa (technician). 4x106 DX3-β6 cells 
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were implanted subcutaneously onto the shoulder of CD1 nude female mice. Once 
tumours reached approximately 125mm3 (~3 weeks), mice were injected with PBS, 
Ad5-EGFPWT or Ad5-EGFPA20 (5x1010 viral particles per mouse) by intravenous tail vein 
injection. Vitamin K-dependent coagulation factors were depleted in identical, but 
separate, groups by a subcutaneous injection of 133μg warfarin (Sigma) dissolved in 
peanut oil (Sigma). Warfarin treatment was carried out at days -1 and -3 prior to viral 
administration. At 1hr post-infection, a 60μl blood sample was obtained from the tail 
vein of non-warfarinised mice, for titration of virus by TCID50. Mice were assessed 
regularly for their overall morbidity, and their body weight was recorded daily. All 
cohorts were killed 72hrs post-infection, blood samples obtained immediately post-
mortem and tumours/organs harvested for analysis. Liver transaminases, alanine 
aminotransferase (ALT), and aspartate aminotransferase (AST), were quantified from 
150μl of mouse serum by Axiom Veterinary Laboratories (Devon, UK).  
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Section.2.10 Histopathological Techniques 
 
2.10.1 Tissue Preservation and Processing. Harvested organs/tumours were treated 
as follows; in preparation for paraffin processing, tissue was fixed overnight in formal 
saline/4% paraformaldehyde, whereas tissue required for frozen sections was 
embedded in O.C.T (Tissue-Tek) containing cryomolds (Tissue-Tek), and frozen at -
80˚C immediately post-necropsy. Tissue was dehydrated in preparation for paraffin 
embedding as follows; immersion in 70% EtOH for 1hr, transfer to 96% EtOH for 1hr, 
96% EtOH for 1hr, transfer to 96% EtOH overnight followed by immersion in 100% 
EtOH for 1hr, 100% EtOH for 1.5hrs, 100% EtOH for 1.5hrs and finally tissue 
transferred to xylene for 1.5hrs after which it was immersed in paraffin (60˚C) for a 
minimum of 12hrs. Paraffin-embedded tissue sectioning, and Haematoxlin and Eosin 
(H&E) staining were carried out by Keyur Trivedi and Dr. Mohammed Ikram (Pathology 
Service, Institute of Cancer). Frozen tissue sections (5μm) were cut using a Cryotom® 
Electronic cryostat (Thermo Electron Corporation) and two sections loaded onto 
charged microscope slides (Thermo Scientific, UK).  
 
2.10.2 Immunostaining on Frozen Tissue; E1A. Frozen liver sections were stained 
for E1A expression using a rabbit anti-Adenovirus E1A polyclonal antibody [M78], 13 S-
5 (Santa Cruz) as follows; pre-cut frozen sections were fixed in ice-cold acetone for 
10mins, rinsed in deionised H20 and blocked for 30mins in 10% normal goat serum 
(Sigma, UK). Primary antibody 13 S-5 (Santa Cruz, USA), or a secondary only (goat 
anti-rabbit AlexaFluor488, Invitrogen) diluted 1:100 in PBS+Tween 0.05% was added, 
and sections incubated for 1hr at room temperature. Sections were washed three times 
in PBS+Tween 0.05%, after which the fluorescent secondary antibody was added for 
1hr at a final dilution of 1:200. Sections were washed, mounted with VectaShield+DAPI 
(Vector Laboratories, UK), coverslips added and slides allowed to dry overnight. 
Immunofluorescence was captured using either an Olympus BX60 fluorescence 
microscope and SpotAdvanced™ software, or a Zeiss laser scanning microscope (LSM 
510META) and LSM 5 Software, version 3.2 (Zeiss, Germany). 
 
2.10.3 Immunostaining on Paraffin Sections; E1A. Tumour xenografts, murine liver 
and/or spleen sections were stained for E1A using mouse anti-Adenovirus [M58] 
antibody (GeneTex, BiogenAutoclear, USA). Automated immunostaining was 
performed at the Pathology Service, Institute of Cancer.  
 
2.10.4 Immunostaining on Paraffin Sections; ανβ6. Paraffin-embedded, tumour 
xenograft sections were cut by staff in Pathology Services at the Institute of Cancer. 
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Two sections were loaded per slide to facilitate ανβ6 staining using mouse anti-human 
mAb, 6.2G2 (provided by Shelia Violette, BiogenIdec, USA) in parallel with its isotype 
control, mouse IgG1 (Dako). Sections (10μm) were de-waxed by immersion in Xylene 
[C6H4(CH3)2] for 5mins, Xylene for 5mins, 100% EtOH for 2mins, 100% EtOH for 2mins, 
95% EtOH for 2mins, 50% EtOH for 2mins, 50% EtOH for 2mins and a final wash in 
distilled H2O for 2mins. The optimal antigen retrieval method for 6.2G2 previously was 
shown to be enzymatic pepsin. Endogenous peroxidase activity was blocked by 
coating the slide in a solution of methanol/hydrogen peroxidase [0.45% (v/v) H2O2 in 
400ml CH3OH] for 15mins at room temperature. Slides were washed twice in PBS for 
2mins each time and excess liquid removed. Sections were circled using a PAP pen 
(Invitrogen, UK) and 200μl pepsin (Invitrogen, UK) added to the sections, which were 
incubated at 37˚C for 5mins. Slides were washed twice in PBS as before. Some tissues 
may have endogenous binding activity for avidin, biotinylated HRP or other 
Biotin/avidin components, and these were blocked using the Avidin/Biotin blocking kit 
(Vector SP-2001, Vector Laboratories, USA) prior to addition of the biotinylated 
antibody.  
 
As the primary antibody 6.2G2 was raised in a mouse, internal mouse immunoglobulin 
(IgG) within the human xenograft tissue was blocked using the MOM kit (Vector BMK-
2202, Vector Laboratories, USA). Both kits were used as directed by the manufacturer. 
One section per slide was incubated overnight at 4˚C with either anti-ανβ6 (6.2G2), at a 
final concentration of 6μg/ml, or isotype control at 10μg/ml. The following day, sections 
were washed twice in PBS for 2mins, after which the MOM biotinylated anti-mouse IgG 
reagent was added for 10mins at room temperature. Sections were rinsed again in 
PBS as before. Using the Elite ABC kit (Vector PK-6102, Vector Laboratories, USA), 
the avidin/biotin-HRP conjugate (ABC reagent) was added, and sections incubated at 
room temperature for 30mins. Slides were washed twice in PBS, after which 
chromogenic DAB substrate [3,3' Diamino Benzidine Tetrahydrochloride C12H14N4N, 
(HCl)4] was added for up to 5mins. Slides were rinsed in running tap water for 
approximately 1min, before counterstaining for nuclei using Mayer’s haematoxylin for 
1min. Stained sections were dehydrated by carrying out the initial steps in reverse; 
immersion in distilled H2O for 2mins, 50% EtOH for 2mins, 50% EtOH for 2mins, 95% 
EtOH for 2mins, 100% EtOH for 2mins, 100% EtOH for 2mins, immersion in Xylene 
[C6H4(CH3)2] for 5mins, and finally Xylene for a further 5mins. Sections were allowed to 
dry after which coverslips were mounted using Permount (Fisher SP15-500,UK). 
Sections were visualised using a Zeiss AxioCam MRc5 camera and Axiovision 
Software (Zeiss, Germany). 
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2.10.5 Pathologic Examination of Immunohistochemistry. Pathologic assessment 
of H&E stained/immunostained tissue samples was carried out by a qualified 
pathologist, Prof. Gareth Thomas. Histological analysis was done blindly, without prior 
knowledge of the specimens.  
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Section.2.11 Statistical Analysis and Software Used 
 
2.11.1 Statistical Analysis. All dose-response curves and statistical analyses were 
generated using GraphPad Prism Version 3.03 (GraphPad Software, San Diego, CA). 
Dose response curves were analysed by non-linear regression analysis, and statistical 
significance determined by comparing the EC50 values of two groups. A two-tailed, 
unpaired Student’s t-test was used to compare means between two samples. The 
Kaplan-Meier curve was analysed using the Mantel-Haenszel, Logrank test to compare 
two groups. A p-value of <0.05 was considered to be statistically significant. Figures 
show representative examples of independent repeats. In vitro data are expressed as 
the mean +/- SD, and in vivo data +/- SEM.  
 
2.11.2 Vector NTI Cloning Software and BioEdit Sequencing Analysis. Vector 
sequences were stored and restriction maps constructed using Vector NTI Advance™ 
Software, using the academic licence (Invitrogen). Analysis of sequencing 
chromatograms was performed using BioEdit Sequence Alignment Editor, version 
7.0.5.3.  
 
2.11.3 Protein Alignments and Structural Analysis. Protein alignments were 
generated using ClustalW multiple sequence alignment programme (EMBL-EBI). 
Structural predictions of helix formation were obtained using AGADIR software, a freely 
available alogorithm which predicts the helical content of peptides (Muñoz & Serrano, 
1997).  
 
2.11.4 Real-Time qPCR Analysis. Analysis of qPCR data were performed using ABI 
Sequence Detection Software v1.3 (Applied Biosystems). 
 
2.11.5 Flow Cytometry Software. Standard flow cytometry was analysed using 
CellQuestPro Software, version 4.0.2 (Becton-Dickinson, CA). Aquisition of cells for 
FACS sorting was performed using Summit v4.0 software and analysis was carried out 
using FlowJo v8.8.4, by Sukhveer Purewal and Carolyn Koh (FACS laboratory, London 
Research Institute). Analysis of serum cytokines/chemokines, quantified using a 
cytometric bead assay, was performed using FlowCytoMix Pro 2.2 Software (Bender 
MedSystems). When necessary, CellQuestPro acquisition files were filtered to exclude 
debris using FCS Filter v1.0.4 Software (Soft Flow, Hungary). 
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Chapter.3 In Vitro Assessment of the Potential for Retargeting Ad5 to ανβ6 
Integrin  
 
The clinical use of Ad5 for cancer therapy is hampered by its often inefficient 
transduction of malignant tissue in vivo, mediated in part by the innate hepatotropism of 
the virus. Additionally, expression levels of the native Ad5 receptor, CAR, have been 
reported to be down-regulated in cancer, which is in contrast with the expression of 
CAR on normal tissue. Therefore, it is clear that the development of prototype vectors 
which exhibit CAR-independent, and high efficiency retargeting to clinically relevant 
markers, would be highly desirable.  
 
The epithelial-specific integrin, ανβ6, represents an attractive target for directed 
therapy since it generally is not expressed on normal adult epithelium, but is 
upregulated in numerous carcinomas, including breast, lung, ovarian, cervical and 
colorectal, where it often correlates with poor prognosis (Ahmed et al., 2002b; Bates et 
al., 2005; Elayadi et al., 2007; Hazelbag et al., 2007). In addition, it has been shown 
previously that over 90% of oral squamous cell carcinomas (OSCC) express ανβ6 
strongly (Nystrom et al., 2006; Thomas et al., 2002) and that upregulation of ανβ6 
expression is associated with increased tumour cell invasion and metastatic potential in 
vivo (Nystrom et al., 2006; Thomas et al., 2001b; Van Aarsen et al., 2008).  
 
Binding to ανβ6 is via the RGD motif in its ligands which include fibronectin, tenascin, 
the latency associated peptides (LAP) of transforming growth factors β1 and β3, in 
addition to the VP1 structural protein of Foot and Mouth Disease Virus (FMDV) for 
which ανβ6 is a native receptor (Jackson et al., 2000). Recent data have demonstrated 
that specificity for ανβ6 is dependent on the inclusion of a DLXXL motif in an extended 
carboxy α-helical loop, with the RGD motif situated at the apex of a hairpin loop domain 
(DiCara et al., 2007). The DLXXL motif was first identified by phage display as the key 
epitope that conferred strong ανβ6 binding with minimal interactions with ανβ3/ανβ5 
integrins (Kraft et al., 1999). Several groups have now reported the selection of ανβ6-
specific peptides containing this motif (Elayadi et al., 2007; Li et al., 2009; Pameijer et 
al., 2007). We have previously documented the analysis of a panel of linear peptides 
containing the ανβ6-selective, RGDLXXL motif (DiCara et al., 2007). These peptides 
were not randomly identified by phage display, but were chosen by rational selection 
from known ανβ6 ligands all of which contained this sequence motif. Functional studies 
identified the A20FMDV2 candidate peptide, derived from the VP1 protein of FMDV, as 
having high affinity and selective binding to ανβ6 (DiCara et al., 2007).  
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The initial aims of this project were to genetically incorporate this targeting entity into 
the HI loop of the Ad5 fibre knob domain, in an attempt to subvert the native tropism of 
Ad5 to ανβ6. It was hoped that a recombinant adenovirus displaying this peptide would 
allow significant improvements in selective delivery to ανβ6-positive tumour xenografts 
in vivo.  
 
a Cell lines used in this study are listed alphabetically. Surface receptor expression profiles were obtained by flow cytometry using an
LSR1 (Becton-Dickinson, CA, USA). Geometric mean fluorescence, and percent positive statistics (1x104 gated events) were
collected using single parameter histograms (FL1-H). Negative control isotype IgG fluorescence values were subtracted from the
geometric mean fluorescence of the test antibody (RmcB/53A.2). Isotype controls; Mouse IgG1 for anti-CAR (RmcB) and Rat IgG2a
for anti-ανβ6 (53A.2). * Indicates cells provided by Dr. Ramon Alemany, Institut Català d’Oncologia (ICO), Barcelona, Spain.
†MCF10CA1a is abbreviated throughout this study as CA1a. ‡ Flow cytometry performed by Marta Gimenez-Alejandre (ICO). ND =
Not determined.
BT-20
A549‡
MCF10CA1a†
CAOV3
HEK293
JH293
H400
BICR56
SKOV3
SKOV3ip1
HSC-3
NP-9*
NP-18*
DLD-1*
TR126
TR138
SiHa
CA1
TABLE 10. Surface Receptor Expression
DX3puro
DX3-β6
SCC25
A549-β6
HEK293-β6
JH293-β6
CHO-K1
CHO-β6
A375puro
A375-β6
C1
VB6
SKOV3ip1-β6
BICR5
CAR ανβ6
97.30
N.D
N.D
2.40
24.90
96.06
99.01
44.88
96.28
95.12
60.92
0.71
0.75
99.66
0.43
0.87
95.94
N.D
52.11
63.90
N.D
N.D
0.89
0.51
0.98
99.17
98.17
98.82
98.05
0.82
97.11
N.D
33.08
N.D
N.D
13.84
22.13
66.90
72.19
17.09
66.97
115.86
15.99
8.60
9.88
76.12
13.18
2.93
51.25
N.D
115.86
23.71
N.D
N.D
20.31
19.06
31.20
114.13
44.31
32.69
153.65
61.07
135.51
N.D
Geometric Mean% Positive cellsGeometric Mean% Positive Cells
5.26
87.70
99.72
97.53
6.50
5.72
91.92
59.91
3.96
56.53
N.D
N.D
N.D
61.21
95.99
96.62
82.57
99.50
99.60
54.37
84.14
99.21
99.31
0.63
12.25
95.82
N.D
14.79
27.21
58.73
77.27
7.83
12.74
37.22
37.30
46.52
71.17
N.D
N.D
N.D
14.77
20.28
39.08
25.76
82.54
93.94
28.02
28.88
81.11
162.72
10.98
12.85
59.47
N.D
N.D N.D
97.76 96.97
N.D N.D
N.D N.D
N.D N.D
CHO-CAR N.D N.D93.12 354.48
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Section.3.1 Characterisation of Cell Lines  
 
3.1.1. Screening of Cell Lines for ανβ6 and CAR Expression. A broad panel of 
human carcinoma cell lines was screened by flow cytometry to determine the levels of 
ανβ6 and CAR expressed on the surface (Table.10). Selected lines were additionally 
screened for levels of ανβ3, ανβ5 and ανβ8 integrins (Table.11); performed by Linda 
Hammond and Sabari Vallath. The integrin ανβ6 is highly expressed in numerous 
carcinomas, whereas the native adenovirus receptor, CAR, has been reported to be 
down-regulated (Anders et al., 2009; Buscarini et al., 2007; Jee et al., 2002; 
Matsumoto et al., 2005; Mikami et al., 2001). In order to reflect this observation, a 
panel of cell lines with high ανβ6 expression and varying CAR expression was selected 
for initial in vitro studies. Most carcinoma cell lines expressed ανβ6. However the vast 
majority of these lines also expressed very high levels of CAR. The BT-20 and TR126 
cells lines were the only endogenous, ανβ6-expressing cell lines which were identified 
as having low CAR. Conveniently, an isogenic matched pair of -β6 transfected, and 
non-transfected cells (DX3puro/DX3-β6), were identified which also had very low CAR 
expression.   
 
a Cell lines are listed alphabetically. Surface receptor expression profiles were obtained by flow cytometry using an LSR1
(Becton-Dickinson, CA, USA). Geometric mean fluorescence, and percent positive statistics (1x104 gated events) were
collected using single parameter histograms (FL1-H). Negative control isotype IgG fluorescence values were subtracted from
the geometric mean fluorescence of the test antibody. Isotype controls; Mouse IgG1 for anti-ανβ3 (23C6), anti-ανβ5 (P1F6)
and anti-ανβ8 (14E5). ND = Not determined. Flow cytometry was performed by Linda Hammond and Sabari Vallath.
A549
TABLE 11. Selected Surface Integrin Expressiona
DX3puro
DX3-β6
A375puro
A375-β6
N.D
98.96
99.31
27.19
N.D
29.63
29.13
9.63
N.D
88.97
2.25
3.98
93.54
N.D
17.69
8.20
8.86
19.11
4.80
78.04
30.82
4.84
86.39
22.30
19.26
9.09
8.36
20.37
ανβ3
Geo. Mean% Positive 
ανβ5
Geo. Mean% Positive 
ανβ8
Geo. Mean% Positive 
97.90 27.32
 
 
3.1.2. Generation of Stable -β6 Expressing Cell Lines. Several -β6 expressing cell 
lines were generated in this study by retroviral transduction of -β6 cDNA (see Table.7). 
In order to facilitate the amplification and titration of non-CAR binding, but A20-
retargeted viral constructs, viral producer cell lines HEK293-β6 and JH293-β6 cells 
were generated which expressed high levels of ανβ6 on the cell surface (Fig.3.1A-D). 
CHO-ανβ6 cells were generated also (Fig.3.2A+B). In an attempt to generate potential 
in vivo models, -β6 cDNA was also introduced into SKOV3ip1 and A549 cells (Fig.3.3 
and Fig.3.4). Several attempts to generate stable -β6-expressing low CAR lines, NP-9 
and CAOV3, failed.  
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3.1.3 FACS Sorting of -β6 Expressing Lines. Transfected cells were selected in 
puromycin-containing medium, and passaged for several weeks. Once sufficient stocks 
had been generated, high expressing populations for HEK293-β6, JH293-β6, CHO-
ανβ6 and SKOV3ip1-ανβ6 cells were selected by cell sorting (FACS), as described in 
Section.2.1.6. Expression profiles were assessed prior to, and, following cell sorting 
(see Fig.3.1-Fig.3.4). 
 
Expression of ανβ6 in Parental JH293 Cells (Pre-sort)
Expression of ανβ6 in Transfected  JH293 Cells (Post-sort)
A
C
B
D
Expression of ανβ6 in Transfected  HEK293 Cells (Pre-sort)
Expression of ανβ6 in Transfected  HEK293 Cells (Post-sort)
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M1
Marker Left, Right % Gated Geo Mean
All    1,  9910 100.00 5.06
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Marker Left, Right % Gated Geo Mean
All    1,  9910 100.00 122.45
M1   16,  9910 97.11 131.57
JH293 Iso.004
0 1000
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FL1-H
M1
Marker Left, Right % Gated Geo Mean
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M1
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0 1000
FSC-H
R1
Marker Left, Right % Gated Geo Mean
All    1,  9910 100.00 114.94
M1   11,  9910 99.17 117.94
 
 
 
 
 
 
Figure.3.1 (A+B) Expression of ανβ6 in HEK293/HEK293-β6 Cells. HEK293 cells were screened by flow 
cytometry, pre- and post- retroviral transduction of -β6 cDNA, for surface expression of ανβ6 integrin. 
Antibodies used were rat, anti-ανβ6 antibody, 53A.2 (IgG2a) and a donkey anti-rat AlexaFluor488 conjugate. 
(C+D) Expression of ανβ6 in JH293/JH293-β6 Cells. Surface levels were determined as before, and a 
high expressing population of each cell line was further selected by fluorescence activated cell sorting 
(FACS). Cells were renamed HEK293-β6/JH293-β6. Labelled cells were scanned onto an LSR1 flow 
cytometer, a gate set to exclude dead cells and debris and 1x104 gated events acquired. Statistics were 
collected from single parameter histograms.  
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Expression of ανβ6 in Transfected  CHO-K1 Cells (Pre-sort)
Expression of ανβ6 in Transfected  CHO-K1 Cells (Post-sort)
A
B
Marker Left, Right % Gated Geo Mean
All     1,  9910 100.00 2.97
M1    11,  9910 0.51 33.82M1
R1
Expression of ανβ6 in Parental CHO-K1 Cells (Pre-sort)
CHO-avb6 unstained.004
0 1000
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R1
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FL1-H
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Marker Left, Right % Gated Geo Mean
All     1,  9910 100.00 10.58
M1     9,  9910 42.07 44.18
CHO-avb6 unstained.002
0 1000
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10 0 10 1 10 2 10 3 10 4
FL1-H
M1
Marker Left, Right % Gated Geo Mean
All     1,  9910 100.00 145.98
M1    15,  9910 98.13 156.44
 
 
 
 
  
 
Figure.3.2 Expression of ανβ6 in CHO-K1/CHO-β6 Cells. (A) CHO-K1 cells were screened by flow 
cytometry, pre- and post- transfection of –β6 cDNA, for surface expression of ανβ6 integrin. Antibodies used 
were rat, anti-ανβ6 antibody, 53A.2 (IgG2a) and a donkey anti-rat AlexaFluor488 conjugate. (B) Expression 
of ανβ6 in CHO-K1 Cells Following Retroviral Transfection of –β6 cDNA. Parental CHO-K1 cells were 
retrovirally transduced with -β6 cDNA, and were selected in puromycin containing medium for several weeks 
following transfection. Surface levels were determined as before, and a high expressing population further 
selected by fluorescence activated cell sorting (FACS). These cells were renamed CHO-ανβ6. Labelled cells 
were scanned onto an LSR1 flow cytometer, a gate set to exclude dead cells and debris and 1x104 gated 
events acquired. Statistics were collected from single parameter histograms.  
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Figure.3.3 Expression of ανβ6 in A549/A549-β6 Cells. (A) A549 cells were screened by flow cytometry, 
pre- and post- transfection of –β6 cDNA, for surface expression of ανβ6 integrin. Antibodies used were rat, 
anti-ανβ6 antibody, 53A.2 (IgG2a) and a donkey anti-rat AlexaFluor488 conjugate. (B) Expression of ανβ6 
in A549 Cells Following Retroviral Transfection of –β6 cDNA. Parental A549 cells were retrovirally 
transduced with -β6 cDNA, and were selected in puromycin containing medium for several weeks following 
transfection. Surface levels were determined as before, and a high expressing population further selected 
by fluorescence activated cell sorting (FACS). These cells were renamed A549-ανβ6. Labelled cells were 
scanned onto an LSR1 flow cytometer, a gate set to exclude dead cells and debris and 1x104 gated events 
acquired. Statistics were collected from single parameter histograms.  
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Expression of ανβ6 in Parental SKOV3ip1 Cells (Pre-sort)
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Section.3.2 In Vitro Characterisation of A20-Modified, Recombinant Ad5 
Knob Proteins 
Figure.3.4 Expression of ανβ6 in SKOV3ip1/SKOV3ip1-β6 Cells. (A) Ovarian SKOV3ip1 cells were 
screened by flow cytometry, pre- and post- transfection with –β6 cDNA, for surface expression of ανβ6 
integrin. Antibodies used were rat, anti-ανβ6 antibody, 53A.2 (IgG2a) and a donkey anti-rat AlexaFluor488 
conjugate. (B) Expression of ανβ6 in SKOV3ip1 Cells Following Retroviral Transfection of –β6 
cDNA. Parental SKOV3ip1 cells were retrovirally transduced with -β6 cDNA, and were selected in 
puromycin containing medium for several weeks following transfection. Surface levels were determined as 
before, and a high expressing population further selected by fluorescence activated cell sorting (FACS). 
These cells were renamed SKOV3ip1-ανβ6. Labelled cells were scanned onto an LSR1 flow cytometer, a 
gate set to exclude dead cells and debris and 1x104 gated events acquired. Statistics were collected from 
single parameter histograms.  
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We previously identified the A20FMDV2 peptide as having high affinity and specificity 
for ανβ6 integrin (DiCara et al., 2008; DiCara et al., 2007). Previous attempts to 
redirect the tropism of adenoviruses through the incorporation of peptide ligands into 
the HI loop, or C-terminus of the fibre knob domain have been successful. These 
insertions have included the insertion of the RGD-4C motif (Dmitriev et al., 1998; 
Krasnykh et al., 1998; Wickham et al., 1997), TAT peptide from HIV-1 (Kurachi et al., 
2007b), or the cationic polylysine (pK7) motif (Cripe et al., 2001; Dmitriev et al., 1998; 
Krasnykh et al., 1998; Wickham et al., 1997), in addition to various other peptides, 
most of which are identified using phage display strategies (Denby et al., 2007; Nicklin 
et al., 2001). However, no prior attempts have been made to retarget Ad5 to ανβ6. We 
proposed that the genetic incorporation of A20FMDV2 into the HI loop of Ad5 would 
permit high efficiency retargeting to ανβ6. 
 
The insertion of heterologous targeting ligands does not automatically correlate with 
the retention of their function in the context of the trimeric fibre, and frequently these 
insertions are incompatible with viral assembly. Therefore, the functionality of the 
A20FMDV2 peptide within the structural constraints of the adenovirus knob domain 
was assessed, prior to generating recombinant Ad5 genomes. A20-modified adenoviral 
knob expression vectors were generated and recombinant KnobA20 protein produced 
and purified. A number of in vitro functional experiments were used to validate and 
characterise these 6XHIS-tagged, A20-modified Knob proteins.  
 
3.2.1 Predictive Modelling of A20 Helix Formation within KnobA20. It has been 
shown previously that the specificity of the A20FMDV2 peptide for ανβ6 is dependent 
on the formation of a critical post-RGD, C-terminal α-helical loop (DiCara et al., 2007). 
To model theoretically whether the A20FMDV2 peptide could assume its critical helical 
conformation within the adenoviral knob protein, Agadir software (http://www.embl-
heidelberg.de/Services/serrano/agadir/agadir-start.html) was used to predict the 
potential helical propensity of A20FMDV2 within KnobA20 (Fig.3.5). This analysis was 
based on the A20FMDV2 protein sequence, flanked by ten native Ad5 residues on 
either side (not shown). The algorithm prediction was favourable; in fact the flanking 
residues appeared to further enhance the helicity. Therefore, we proceeded with the 
construction of the KnobA20 expression vector for in vitro characterisation.  
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3.2.2 Sequencing Analysis of pQEKnob Expression Plasmids. Once the pQE30-
based expression vectors had been constructed, they were screened by PCR and/or 
restriction digestion, and positive clones confirmed by sequencing analysis. 
Sequencing confirmed that the modified Knob sequences were in frame with the N-
terminal, 6XHIS-tag. A ClustalW protein alignment of all modified Knob proteins 
generated in this study can be found in Appendix I.  
 
3.2.3 Recombinant Knob Protein Expression and Purification. Optimisation of 
recombinant protein expression and purification was carried out by Tobias Simmonds 
at the Protein Cloning and Isolation Laboratory, London Research Institute, CR-UK. A 
time course for KnobWT protein expression was performed and ~4hrs post-IPTG 
induction was found to be the adequate time for harvesting cells for protein purification 
(Fig.3.6A). Elution under native conditions was also optimised by Tobias Simmonds 
who produced the first batch of KnobWT and KnobA20. A representative protein 
expression profile following IPTG-induction is shown in Fig.3.6B. Samples were run on 
a 12% SDS-PAGE gel and the approximate molecular weights (Mw) of the monomers 
were detected at ~22.1kDa for KnobWT and ~24.4kDa for KnobA20. Approximate Mw 
values were predicted using VectorNTI software, following translation of the nucleotide 
sequence of the relevant expression vector into amino acid sequence.  
Figure.3.5 Predicted Helical Propensity of A20FMDV2 Determined using AGADIR Software. AGADIR 
is an algorithm which predicts the helical content of peptides (Munoz & Serrano, 1997). The effect of 
adenoviral residues flanking the HI loop insertion site, on helix formation in A20FMDV2, was assessed. 
Ten flanking amino acid residues from Ad5 Knob were included on either side of A20FMDV2 (not shown, 
but included in the analysis). The service is provided by the Serrano group (http://www.embl.de 
/Services/serrano/agadir/agadir-start.html).   
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As expected, uninduced control cells did not over-express Knob protein, whereas, in 
comparison in the induced fractions for KnobWT and KnobA20, the appropriate sized 
bands were clearly visible. In addition, cleared lysate fractions, which were run in 
parallel, also retained the appropriate size band, wash or flowthrough fractions did not. 
Following optimisation of the purification protocol, we performed all subsequent protein 
expression and purification procedures (Fig.3.7). HIS-tagged Knob proteins were 
isolated using an Ni-NTA Agarose column (see Section.2.4.5). KnobA20 was eluted 
under native conditions using a concentration gradient (50mM-300mM Imidazole), and 
eluate fractions analysed by visualisation on an SDS-PAGE gel. Appropriate fractions 
which had high purity (ie. no contaminating bands) were pooled, dialysed overnight 
against PBS, and purified protein concentrations calculated using the Pierce BCA 
protein assay.  
Figure.3.6 (A) Time-course of IPTG-induced KnobWT protein expression. Optimisation of recombinant 
KnobWT protein expression was carried out by Tobias Simmonds at the Protein Cloning and Isolation 
Laboratory, London Research Laboratories, CR-UK. Arrow indicates the ~22.1kDa KnobWT monomer. M = 
Marker (Rainbow Marker, Amersham Biosciences), UC = Uninduced Control. (B) Expression Profile for 
KnobWT and KnobA20 at ~4hrs post-IPTG Induction. M = Marker, UC = Uninduced Control, F = 
Flowthrough, IC = Induced Control, and CL = Cleared Lysate.  Arrows indicate the KnobWT monomer 
(~22.1kDa) and the KnobA20 monomer (~24.4kDa).  
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3.2.4 Trimerisation Assay. It has been reported previously that the HI loop can 
tolerate insertions of up to 83aa with negligible effects on virion integrity, or viral titres 
obtained (Belousova et al., 2002). However, we wished to confirm that the insertion of 
the A20FMDV2 peptide sequence at this site would not affect trimerisation of the fibre, 
prior to amplifying the modified virus. Therefore, the ability of KnobWT, and more 
importantly KnobA20, to form a homotrimer was confirmed by SDS-PAGE carried out 
under semi-denaturing conditions, comparing the migration of boiled and unboiled 
samples, which were run in parallel (data not shown).  
 
3.2.5 Validation of KnobA20 Binding to ανβ6 Integrin. Using a flow cytometry-based 
competition experiment we confirmed that KnobA20 was capable of binding to cells 
expressing ανβ6 (Fig.3.8). It was decided that direct detection of cell-bound KnobA20 
(via the HIS-tag) was not a suitable approach, since we could not eliminate the 
possibility that background binding to CAR would affect the results, even on a low 
CAR-expressing cell line. Therefore, an indirect approach was employed. Using BT-20 
cells (high levels of ανβ6 but low levels of CAR) we tested the ability of increasing 
concentrations of KnobA20 (0.0001μg-10μg/105 cells) to bind to surface ανβ6, and to 
competitively inhibit the subsequent binding of an anti-ανβ6 mAb, 53A.2. Levels of 
bound 53A.2 were detected using a secondary, donkey anti-rat AlexaFluor488-
conjugated antibody, and results were analysed by flow cytometry, acquiring 
fluorescence in FL1-H. BT-20 cells, untreated with recombinant Knob protein, were 
taken to be 100% (=100% antibody binding), and all other values were expressed 
relatively, as a % of the untreated cells. Results demonstrated that KnobA20 exhibited 
dose-dependent inhibition of ανβ6-specific antibody binding, with 50% maximal 
Figure.3.7 Elution Profile for KnobA20. Elution fractions were run on a 12% SDS-PAGE gel and bands 
visualised by Coomassie’s staining. Fractions which were determined to have high purity (≥ 200mM), were 
pooled and dialysed overnight against PBS. M = Marker (NEB Prestained Broad Range 6-175kDa). 
Imidazole concentrations ranging from 50-300mM were used to elute protein under native conditions. Arrow 
indicates the band corresponding to the KnobA20 monomer (~24.4kDa).  
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inhibition at 0.03μg/105 cells. KnobWT was included as a control, but was unable to 
block 53A.2 binding at a high concentration (≥10μg/105 cells) and did not differ from 
untreated cells (p=0.498). This experiment confirmed that the A20FMDV2 peptide, 
within KnobA20, was functional with respect to its ability to bind to ανβ6.  
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3.2.6 Functional Inhibition of ανβ6-Dependent Cell Migration by KnobA20. The 
ability of KnobA20 to functionally inhibit ανβ6-dependent, VB6 cell migration towards the 
latency associated peptide (LAP) of TGF-β1 was confirmed using a Transwell migration 
assay (Fig.3.9A+B). VB6 cells have been modified to express high levels of ανβ6, and 
migrate towards LAP using only ανβ6 (Thomas et al., 2002). A preliminary experiment 
was carried out in order to titrate the effective concentration required for this assay 
(Fig.3.9A). Knob proteins were used at concentrations of μg/ml instead of μg/105 cells 
to permit comparisons with previously titrated function-blocking antibodies. The ability 
of KnobA20 to inhibit ανβ6-dependent cell migration at concentrations in the range of 5-
100μg/ml was assessed over a period of 24hrs. A BSA protein control (no LAP) was 
included in the experiment to represent the basal level of random ανβ6-independent 
cell migration, and each value was normalised to this. KnobA20 successfully abrogated 
cell migration at all concentrations used (p<0.001), as efficiently as an anti-ανβ6 
inhibitory antibody (10D5) even at the lowest concentration used (5μg/ml; p=0.982). 
Figure.3.8 Competitive Inhibition of 53A.2 Binding to ανβ6 Integrin by KnobA20. BT-20 cells (low CAR, 
high ανβ6) were incubated n ice with increasing concentrations of KnobA20 (0.0001-10μg/105 cells), or 
KnobWT (10μg/105 cells). Antibody 53A.2 was added to cells without washing and cells incubated at 4˚C for 
1hr. Binding was analysed by flow cytometry following the addition of a secondary donkey anti-rat 
AlexaFluor488 conjugate. Untreated cells were taken as 100% fluorescence and all other values 
expressed relative to this (see Section.2.5.3). KnobWT produced no significant effect at 10μg/105 cells 
(p=0.498), and is indicated by a single point on the graph. The affinity of of KnobA20 for ανβ6 has not been 
detemined directly. Results were analysed by non-linear regression fitted to a sigmoidal curve, using 
GraphPad Prism Version 3.03 (GraphPad Software, San Diego, USA). Data represent the mean ± SD of 
triplicate samples (no bars represent SD values smaller than the symbol used).  
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Figure.3.9 (A) KnobA20 Inhibition of ανβ6-Dependent Cell Migration. KnobA20 abrogates the ανβ6-
dependent migration of VB6 cells towards Latency Associated Peptide (LAP) of TGF-β1. A BSA protein 
control was included to represent the basal level of non ανβ6-dependent cell migration, and all results 
normalised to this control. An ανβ6-specific, function blocking antibody (10D5) was included as a positive 
control for inhibition of migration. KnobA20 inhibited ανβ6-dependent migration at all concentrations used. 
(B) KnobA20 Inhibition of ανβ6-Dependent Cell Migration. The migration experiment was repeated to 
include the relevant controls; BSA protein control, LAP control and IgG1 isotype control. Additionally 
KnobWT was included at an equivalent concentration to KnobA20 and an ανβ6-specific function blocking 
antibody 63G.9 (all used at 10μg/ml). Data represent the mean ± SD of triplicate samples. Statistical 
significance was determined using the unpaired Student’s t-test comparing the means of two samples (**** 
indicates a P-value of <0.0001, *** p<0.001, NS p>0.05). Statistics displayed above the histogram, refer to 
the difference when compared to the LAP positive control.  
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In a separate experiment, the migration assay was repeated to include an isotype 
antibody (IgG1), and KnobWT as non-inhibitory controls (Fig.3.9B). Again, KnobA20 
significantly inhibited VB6 cell migration towards LAP (p=0.002), functioning as 
efficiently as 6.3G9, an ανβ6-inhibitory antibody (p=0.595). In contrast, KnobWT, used at 
an equal concentration (10μg/ml), produced no significant effect (p=0.173). In this 
particular experiment, the background migration (BSA protein control) was not 
subtracted from the overall migration, but is represented on the graph to show that 
KnobA20 is capable of reducing cell migration to basal levels. These data confirmed that 
the A20FMDV2 insertion, within the structural constraints of the adenovirus Knob 
protein, was functional with respect to abrogation of ανβ6 function.  
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Section.3.3 Generation of ανβ6 Retargeted, Fibre-Modified Adenoviruses 
  
Viral genome-containing YAC/BACs, generated by homologous recombination in yeast, 
were transformed into bacteria and screened by PCR for the incorporation of the 
A20FMDV2 sequence. Clones which were positive by PCR screening were sequenced 
and verified prior to viral production and expansion. 
 
3.3.1 PCR Screening of Shuttle Vectors and A20-Modified, Ad5-containing YACs. 
The A20FMDV2 oligoduplex sequence was blunt end ligated into SfoI digested pIVSfoI 
to generate the A20-modifying shuttle pIVA20. In order to select clones which had a 
single A20FMDV2 insertion and not a duplication of the sequence, pIVA20 plasmid 
minipreps were screened by PCR using primers AdinPCR-forward and AdinPCR-
reverse (Fig.3.10). pIVSfoI was used as a negative control, generating a product of 
~184bp. A ~244bp PCR product was generated for positive clones which had 
incorporated a single A20FMDV2 oligoduplex. Selected clones were further confirmed 
by sequencing analysis, using T3-forward and T7-reverse primers. At a later stage, the 
region of homology within pIVA20 was extended to improve the probability of 
recombination, creating pIV1.4A20. This cloning strategy did not affect the A20FMDV2 
insertion, and the pIV1.4A20 shuttle was created using pIVA20 as a template (see 
Fig.2.6). The pIV1.4A20 construct was also sequenced using T3-forward and T7-reverse 
primers. 
 
244bp
184bp
M       1        2       3       4       5       6       7       8        9       10     ─     ++bp
1636
3054
1018
506
201
396
298
*                        *                              *
 
 
 
 
  
 
 
 
 
A20-modified, Ad5-containing YACs were screened at each stage of recombination. An 
overview of the “pop-in/pop-out” method of homologous recombination in yeast can be 
found in Fig.2.9. Intermediate stage or “pop-in” recombinants which had incorporated 
Figure.3.10 PCR Screening of A20-modified Shuttle Vectors. A20FMDV2 modified pIVSfoI clones were 
selected by PCR screening using primers AdinPCR-forward and AdinPCR-reverse. Positive clones were 
distinguished from negative clones by the presence of a 60bp shift, detected by visualisation under UV 
light following gel electrophoresis on a 2% agarose gel.  M = Marker (1kb DNA Ladder, Invitrogen), #1-10 
indicates clone number, ─ indicates negative control (pIVSfoI vector) and ++ indicates a clone with a 
duplicate A20FMDV2 insertion. Arrows highlight the size in bp of the negative clones (184bp) and the 
positive clones (244bp). An asterix highlights the clones selected for sequencing.  
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the integrating shuttle vector were screened by PCR on purified yeast DNA, using 
primers AdinPCR-forward and AdinPCR-reverse (Fig.3.11A). Clones which were 
positive for the integrative event, generated either two bands at ~478bp and 418bp, or 
a single band at ~478bp. Negative clones produced a band at 418bp only. Only 
positive clones were selected for subsequent recombination (ie. “pop-out” stage). Final 
stage, or “pop-out” recombinants were screened by PCR using a different strategy 
(Fig.3.11B). Successfully modified Ad5 constructs were screened using a forward 
primer which had homology to the A20FMDV2 sequence (A20-forward), and a reverse 
primer (Ad5.2-reverse) which had homology to Ad5 sequence, external to that which 
had been cloned into the shuttle vector, pIV1.4A20. This was to ensure that we did not 
obtain false positives by PCR (amplified from the intermediate “pop-in” stage of 
recombination, in which the shuttle vector sequence was integrated into the Ad5-
containing YAC/BAC). Clones which failed to incorporate the A20FMDV2 insertion did 
not generate a PCR product.  
 
bp     M      1       2      3      4      5      6      7      8     9     10     11      ─
*    *     *           *     *           *     *
bp M          1           2          3          4          5          6         7         +
*         *        *       *        *        *
478bp
418bp
874bp
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.3.11 (A) PCR Screening of “Pop-in” A20-modified Ad5-Containing YACS. Integrative 
recombination results in a duplication of the target sequence; the shuttle derived fibre sequence containing 
the mutation, and the YAC DNA containing unmodified Ad5 fibre sequence. Positive clones were identified 
by the presence of a ~60bp shift or by the presence of duplicate PCR products, of ~478bp and ~418bp, 
corresponding to the integrated pIV1.4A20 shuttle and the Ad5 backbone DNA, respectively. M = Marker 
(1kb DNA Ladder, Invitrogen), #1-11 indicates clone number, ─ indicates negative control (pMB20, 
unmodifed Ad5-containing YAC DNA). Arrows highlight the size in bp of the positive clones (478bp) and 
the negative clones (418bp). An asterix highlights the clones selected for subsequent recombination 
events. (B) PCR Screening of “Pop-out” A20-modified, Ad5-Containing Yeast Artificial 
Chromosomes. Successful “pop-out” clones were screened by PCR using primers A20-forward and 
Ad5.2-reverse, so that a PCR product would be observed only when the A20FMDV2 insertion had been 
incorporated successfully. M = Marker (1kb DNA Ladder, Invitrogen), #1-7 indicates clone number, + 
indicates positive control (#3 from A). Arrows highlight the size in bp of the positive clones (244bp). An 
asterix highlights the clones selected for transformation into competent E.coli, and subsequent sequencing 
analysis.  
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3.3.2 Sequencing Analysis of Modified Ad5 Viral Genomes. An overview of the 
A20-fibre modification strategy is shown in Fig.3.12A. A sequencing chromatogram for 
the original, unmodified Ad5 fibre sequence is presented, highlighting the insertion site 
within the HI-loop. Additionally, the sequencing chromatogram obtained following the 
successful modification of the fibre region, generating Ad5-EGFPA20, also is presented 
(Fig.3.12B).  
 
Original Ad5 Fibre Sequence
5’-A GGA GAC ACA ACT CCA AGT GCA TAC TCT ATG T-3’
Ad5-EGFPA20 Sequence
5’-A GGA GAC ACA ACT GGC –A20- GCC CCA AGT GCA TAC TCT ATG T-3’
G D T T G N A V P N L R G D L Q V L A Q K V A R T A P S A Y
G   D   T   T   P   S   A   Y   S   M
Gly   Asp    Thr   Thr Pro   Ser   Ala   Tyr   Ser    Met
G   D   T   T   G  -A20- A   P   S   A   Y   S   M
Gly   Asp    Thr   Thr   Gly Ala   Pro   Ser   Ala   Tyr   Ser    Met
A
B
 
 
 
 
 
 
 
 
 
 
Figure.3.12 (A) Sequencing Confirmation of the Native Ad5 Fibre Sequence Prior to Modification. A 
schematic showing the original nucleotide and amino acid sequence of the Ad5 fibre. Sequencing 
chromatogram shows the original, unmodified sequence. The arrow highlights the site selected for the 
insertion of the A20FMDV2 oligoduplex sequence. (B) Sequencing Confirmation of the A20-Modified 
Fibre Sequence. Nucleotide sequence and amino acid sequence, as before. The sequencing 
chromatogram confirms the successful insertion of the A20FMDV2 sequence by blunt end ligation into the 
unique engineered SfoI site (see Section.2.3.4 and Section.2.3.5). The red box highlights the A20FMDV2 
sequence, flanked on either side by wildtype Ad5 fibre sequence. The arrow again indicates the insertion 
site for A20FMDV2. Sequencing chromatograms were analysed using BioEdit Sequence Alignment 
Editor, version 7.0.5.3.  
 132
3.3.3 Comparative Infectivity on a Panel of ανβ6-Expressing Carcinoma Lines. 
The ability of the ανβ6-retargeted virus, Ad5-EGFPA20, to enhance the infection of a 
panel of ανβ6-expressing human carcinoma cell lines was assessed relative to its 
control, Ad5-EGFPWT (Fig.3.13). A constant amount of virus (MOI 10) was added to 
cells for 1hr at 4˚C, to permit virus binding but not internalisation. Cells were incubated 
at 37˚C for 22hrs after which EGFP transgene expression was quantified by flow 
cytometry. Ad5-EGFPA20 succeeded in enhancing the transduction of all cell lines 
investigated, even those which expressed high levels of CAR (p<0.0001 for all). 
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Moreover, the high efficiency transduction observed with Ad5-EGFPA20 in low CAR cell 
lines, which were previously refractory or relatively insensitive to Ad5-EGFPWT 
mediated transduction, suggested that ανβ6 was capable of acting as an efficient 
Figure.3.13 Comparative Infectivity on a Panel of ανβ6-Expressing Human Carcinoma Lines. A 
panel of cell lines was selected on the basis of their ανβ6, and CAR expression status (see Table.10). The 
transduction efficiency of Ad5-EGFPA20 was compared with Ad5-EGFPWT at an MOI 10 (PFU/cell). Cells 
were exposed to virus for 1hr at 4˚C, to dissociate virus binding from internalisation, and EGFP gene 
transfer quantified by flow cytometry ~22hrs post-infection (see Section.2.8.2). The histogram represents 
the % EGFP positive cells and cells arranged are in order of increasing CAR expression levels (ranging 
from <5-92%, see Table.10). Data represent the mean ± SD of triplicate samples and are representative of 
at least two independent experiments. Statistical significance was determined using the unpaired 
Student’s t-test comparing the means of the Ad5-EGFPWT and Ad5-EGFPA20 groups for each cell line (**** 
indicates a P-value <0.00001, bars indicate SD, no bars represent SD values smaller than the symbol 
used). †CA1a is abbreviated from MCF10CA1a throughout this study.  
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surrogate receptor for attachment/entry. In low CAR-expressing cell lines, a ~50-fold 
increase in transduction was observed on BT-20 and DX3-β6 cells infected with Ad5-
EGFPA20, when compared with Ad5-EGFPWT. Increases of ~13-fold, ~11-fold, ~10-fold 
and ~3-fold were also observed for DX3puro, CA1a, TR126 and CAOV3 cells, 
respectively. On cells which had moderate-to-high levels of CAR-expression, increases 
in transduction of ~5-fold, ~2-fold and ~1.5-fold were observed for SKOV3ip1/HSC-3, 
TR138 and SCC25 cells, respectively.  
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3.3.4 Calculation of the IC50 of KnobA20 for Inhibition of Ad5-EGFPA20 Infection. 
Exploiting the fact that exogenously added Ad5 knob protein can inhibit the attachment 
of the virus from which it is derived (Freimuth et al., 1999; Santis et al., 1999), we 
compared the ability of KnobWT and KnobA20 to inhibit the subsequent infection of Ad5-
EGFPA20. However, prior to the use of KnobA20 in several competition assays, we 
calculated its IC50 value for inhibition of Ad5-EGFPA20 mediated infection (Fig.3.14). BT-
20 cells were chosen for their high ανβ6 expression and low CAR expression. Cells 
Figure.3.14 Competitive Inhibition of Ad5-EGFPA20 Mediated Transduction by KnobA20. KnobA20 binds 
to ανβ6 on BT-20 cells and inhibits the binding of, and therefore the transduction of, Ad5-EGFPA20 in a 
dose-dependent manner. BT-20 cells (low CAR, high ανβ6) were incubated with increasing concentrations 
of KnobA20 (0.0001-10μg/105 cells), or KnobWT (10μg/105 cells). Cells were incubated with Knob proteins for 
1hr at 4˚C after which they were infected with a constant MOI of Ad5-EGFPA20 (10) for a further hour at 
4˚C. Virus was removed and EGFP gene transfer quantified ~22hrs later by flow cytometry. Untreated cells 
were taken as 100% fluorescence and all other values expressed relative to this (see Section.2.8.2). 
KnobWT produced no significant effect at 10μg/105 cells and is indicated as a single point on the graph. 
Results were analysed by non-linear regression fitted to a sigmoidal curve, using GraphPad Prism Version 
3.03 (GraphPad Software, San Diego, USA). Data represent the mean ± SD of triplicate samples (no bars 
represent SD values smaller than the symbol used).   
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were pre-incubated with increasing concentrations of KnobA20 (0.0001-10μg/105 cells), 
and then super-infected with Ad5-EGFPA20 (MOI 10; PFU/cell). The virus-protein 
mixture was removed by washing, and cells processed for detection of EGFP gene 
transfer by flow cytometry 22hrs later, as described previously. Cells treated with virus 
alone were taken as 100% infection, and all other values expressed relative to this. The 
IC50 of KnobA20 was calculated to be 0.008μg/105 cells. A high concentration of KnobWT 
(10μg/105 cells), which was included as a control in this experiment, produced no 
significant effect (p=0.969). These data further confirmed that the enhanced infection 
mediated by Ad5-EGFPA20 was modulated through the insertion of the A20FMDV2 
peptide into the HI loop region.  
 
3.3.5 Characterisation of the Altered Tropism of Ad5-EGFPA20. Data obtained 
previously confirmed that the enhanced infectivity observed with Ad5-EGFPA20, was 
due to the insertion of the A20FMDV2 peptide sequence. However, we also wanted to 
demonstrate clearly, that this new tropism was mediated primarily through an 
interaction with ανβ6 integrin (Fig.3.15).  
 
A suitable panel of ανβ6-expressing cell lines was chosen for this experiment; low 
CAR-expressing lines, BT-20, DX3-β6 and TR126, and moderate-high expressing 
lines, SKOV3ip1, TR138 and SCC25. To characterise the tropism determinant for Ad5-
EGFPA20 fully, infectivity experiments were carried out in the presence of the following 
inhibitors; KnobWT, KnobA20, or a function-blocking antibody to ανβ6, 53A.2. Ad5-
EGFPWT was included as a control (data not shown), producing similar levels of 
infectivity as shown in Fig.3.13. KnobWT successfully inhibited Ad5-EGFPWT infection 
(data not shown). KnobWT did not affect the entry of Ad5-EGFPA20 on any cell line 
(p>0.200 for all), except in SKOV3ip1 cells (p=0.01). In contrast, pre-incubation of all 
cell lines with KnobA20 resulted in a significant reduction in Ad5-EGFPA20 infectivity 
(p<0.0001 for all). Function blocking of ανβ6, using 53A.2, resulted in the significant 
reduction of Ad5-EGFPA20 mediated infection, over the entire panel of cell lines 
(p<0.0001 for all). This reduction was most apparent in lines which had low CAR. 
These data confirmed that ανβ6 was the predominant determinant of Ad5-EGFPA20 
entry in vitro. Additionally, the ability of Ad5-EGFPA20 to mediate infection in the 
presence of an excess of KnobWT, confirmed that Ad5-EGFPA20 was capable of CAR-
independent entry.  
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3.3.6 Investigation of the Role of Alternative Integrins in Ad5-EGFPA20 Infectivity. 
It has been shown previously that the A20FMDV2 peptide does not interact with ανβ3 
or ανβ5 integrins (DiCara et al., 2007). However, to ensure that Ad5-EGFPA20 infection 
was independent of an interaction with either of these integrins, further infectivity 
experiments were carried out in the presence of function blocking antibodies to ανβ6, in 
parallel with function blocking antibodies to ανβ3/ανβ5/ανβ8 (Fig.3.16A+B). Antibodies 
used are listed in Table.7. We obtained some unexpected results when comparing the 
infectivity of both viruses in DX3puro cells (see Fig.3.13). DX3puro cells do not express 
ανβ6, yet an ~13-fold increase in infectivity with Ad5-EGFPA20 was observed when 
compared with Ad5-EGFPWT. Previous characterisation of the A20FMDV2 peptide, 
Figure.3.15 Characterisation of the Tropism Determinants for Ad5-EGFPA20. A panel of cell lines was 
selected to investigate the determinants of the enhanced tropism seen with Ad5-EGFPA20. Cells were pre-
incubated for 1hr at 4˚C with 10μg/ml of KnobWT, KnobA20 or an anti-ανβ6 antibody (53A.2), after which a 
constant MOI (10) of Ad5-EGFPA20 was added for 1hr at 4˚C. The virus-protein mixture was removed and 
EGFP gene transfer quantified ~22hrs post-infection (see Section.2.8.2). Data represent the mean ± SD of 
triplicate samples and are representative of at least two independent experiments. Statistical significance 
was determined using the unpaired Student’s t-test comparing the means of the Ad5-EGFPWT and Ad5-
EGFPA20 groups for each cell line (**** indicates a P-value <0.0001, bars indicate SD, no bars represent 
SD values smaller than the symbol used).  
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carried out on the same DX3puro/DX3-β6 isogenic cell line pair (DiCara et al., 2007), 
demonstrated that the peptide had no affinity for the non-β6 expressing line, DX3puro. 
However, based on these results it seemed possible that the A20FMDV2 insertion, at 
least within Ad5-EGFPA20, had some affinity for an alternative, as yet unknown receptor 
which was expressed on these cells. As the integrin ανβ8 had been previously 
implicated in native infection with Foot and Mouth Disease virus (Jackson et al., 2004), 
we decided to include an anti-ανβ8 antibody (14E5) in the competition experiment. 
 
This experiment was performed as described previously, using EGFP transgene 
expression as the end-point for the assay. Cells infected with Ad5-EGFPA20, but which 
were untreated with inhibitors, were taken as 100% (% EGFP positive cells), and all 
other values expressed relative to this. Ad5-EGFPWT was included as a control for both 
cell lines investigated (DX3puro/DX3-β6), yielding similar transduction efficiencies as 
seen in Fig.3.13. It was clear that neither ανβ3 nor ανβ5 contributed significantly to 
Ad5-EGFPA20 mediated entry in either cell line, as simultaneous inhibition of both of 
these integrins resulted in only ~12%, and ~9% reductions for DX3puro and DX3-β6, 
respectively (p>0.05 for both). In DX3puro cells, inhibition with 53A.2 had no effect on 
Ad5-EGFPA20 entry, an expected result as these cells do not express ανβ6.  
Conversely, inhibition of ανβ6 on the -β6 transfected DX3-β6 line, using 53A.2, resulted 
in a ~81% reduction in transduction (p<0.0001), supporting its role as the primary 
tropism determinant for Ad5-EGFPA20.  
 
Function blocking of the αν integrin subunit using a pan αν inhibitor (L230) resulted in 
~60%, and 50% decreases in transduction in both DX3puro and DX3-β6, respectively 
(p=0.0013 and p=0.0029). This effect was particularly interesting for the DX3puro cells 
(-β6 negative) as it indicated that Ad5-EGFPA20 was capable of utilising an alternative 
αν integrin for entry in these cells. This alternative receptor was confirmed to be ανβ8. 
Using an anti-ανβ8 inhibitor (14E5), an ~75% reduction in transduction in DX3puro 
cells was observed (p=0.0003). Due to the compensatory effect of ανβ6, transduction 
in DX3-β6 cells was affected to a lesser extent by inhibition of ανβ8 (~44% reduction), 
although the effect was significant (p=0.0028). Interestingly, function blocking of both 
ανβ6 and ανβ8 simultaneously with 53A.2/14E5, almost completely ablated Ad5-
EGFPA20 transduction, reducing entry by ~95% (p<0.0001). These data confirmed that 
Ad5-EGFPA20 was capable of utilising both ανβ6 and ανβ8 for entry, although this 
interaction appeared to be more efficient with ανβ6. 
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3.3.7 Comparative Replication Kinetics of Ad5-EGFPWT and Ad5-EGFPA20. The 
replication kinetics of viruses Ad5-EGFPWT and Ad5-EGFPA20 were compared at 24, 48 
Figure.3.16 (A) Ad5-EGFPA20 Transduction of DX3puro Cells in the Presence of Integrin Inhibitors. 
The DX3puro/DX3-β6 cell lines were selected to investigate the role of other integrins (ie. ανβ3, ανβ5 and 
ανβ8) on the enhanced tropism seen with Ad5-EGFPA20. Both cell lines have low CAR expression and 
high integrin expression, however DX3puro does not express ανβ6 (see Table.10 and Table.11). Cells 
were pre-incubated for 1hr at 4˚C with 10μg/ml of a pan-αν inhibitor (L230), anti-ανβ3 (LM609), anti-ανβ5 
(P1F6), anti-ανβ8 (14E5), anti-ανβ6 antibody (53A.2) and LM609/P1F6 and 14E5/53A.2 in combination.  
Ad5-EGFPA20 was added at an MOI 10 for 1hr at 4˚C, and EGFP gene transfer quantified ~22hrs post-
infection (see Section.2.8.2). (B) Ad5-EGFPA20 Transduction of DX3-β6 Cells in the Presence of 
Integrin Inhibitors. Experiment was performed exactly as described above. Data represent the mean ± 
SD of triplicate samples and are representative of two independent experiments. Statistical significance 
was determined using the unpaired Student’s t-test comparing the means of each treated Ad5-EGFPA20 
group (**** indicates a P-value <0.00001, *** p<0.001, ** p<0.01, * p<0.05, bars indicate SD, no bars 
represent SD values smaller than the symbol used).  
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and 72hr time-points for the following cell lines; DX3puro, DX3-β6, TR126, TR138, 
SCC25, SKOV3ip1, BT-20 and HSC-3 (Fig.3.17). All cell lines in the panel were 
infected at an MOI of 10, and intracellular viral titres per cell (PFU/cell) calculated by 
TCID50 from cells harvested at the relevant time-points.  
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Figure.3.17 Comparative Replication Kinetics of Ad5-EGFPWT and Ad5-EGFPA20. Intracellular viral 
titre production (PFU/cell) was assessed for DX3puro, DX3-β6, TR126, TR138, SCC25, SKOV3ip1, BT-20 
and HSC-3 at 24, 48 and 72hrs post-infection with an MOI 10. Cells were harvested at each time-point 
and titrated on JH293 cells using a standard end point dilution assay (TCID50). Data represent the mean ± 
SD of triplicate samples, titrated on triplicate plates, and are representative of two independent 
experiments.  
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Figure.3.18 Overview of Intracellular Viral Production (PFU/cell), 24 (A) and 48hrs (B) Post-
Infection. The intracellular viral titres produced by Ad5-EGFPWT and Ad5-EGFPA20 (input dose = MOI 10 
PFU/cell) on a panel of cell lines was compared by titration (TCID50) of virus in cells harvested 24/48hrs 
post-infection. The unpaired Student’s t-test was used to compare the means of Ad5-EGFPWT and Ad5-
EGFPA20 for each cell line (**** indicates a P-value <0.0001, ** p<0.01, * p<0.05, N = 3, bars indicate SD, 
no bars represent SD values smaller than the symbol used).  
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At 24hrs, Ad5-EGFPA20 titres were higher than Ad5-EGFPWT for all lines, (except 
DX3puro which produced equivalent titres). This was presumably a reflection of the 
high efficiency attachment and infectivity through ανβ6 integrin seen in previous 
experiments (Fig.3.13). Differences in viral titres were most notable in BT-20, TR126, 
TR138, SCC25 and DX3-β6 cells, where Ad5-EGFPA20 production was increased ~10-
100-fold compared to Ad5-EGFPWT. Viral titres produced with Ad5-EGFPWT at an early 
time-point (24hrs), did not appear to correspond with CAR expression levels (see 
Table.10). Surprisingly, the highest titres were obtained in TR126 cells which express 
very low levels of CAR. However, entry/spread in this particular experiment would also 
be affected by differential levels of integrins involved in internalisation, in addition to 
interactions with other lower affinity receptors. 
 
Virus yields increased between 24 and 48hrs for both viruses. However, at 48hrs Ad5-
EGFPA20 viral titres were reduced, or reached a plateau in TR126 and TR138 cells, 
respectively. This effect was most likely a result of increased virus-induced cytotoxicity 
due to the high uptake of input dose at early time-points in these cells. At later time-
points, 48-72hrs, replication was reduced or reached a plateau in all cell lines infected 
with Ad5-EGFPA20. However, in BT-20 and DX3-β6 cells at 48hr time-points, Ad5-
EGFPWT titres were still increasing and were only beginning to reach the 48hr titre of 
Ad5-EGFPA20. A comparative overview of viral titres produced at 24 and 48hr time 
points is presented in histogram format in Fig.3.18A and B.  
 
3.3.8 Comparative Cytotoxicity of Ad5-EGFPWT and Ad5-EGFPA20. Comparative 
cytotoxicity profiles (MTT) for Ad5-EGFPWT and Ad5-EGFPA20 were assessed on a 
selected panel of human carcinoma cell lines (Fig.3.19 and Fig.3.20). Cells were 
infected with doses of virus ranging from MOI 0.0001-100PFU/cell and cytotoxicity 
assessed 120hrs post-infection. Ad5-EGFPA20 exhibited significantly increased 
cytotoxicity on all cell lines which had low-moderate levels of CAR (Fig.3.19 and see 
Table.10). Results obtained on the isogenic matched lines DX3puro and DX3-β6, were 
unusual, although consistent with data described previously (see Fig.3.13 and 
Fig.3.16A+B). As expected, Ad5-EGFPA20 improved the cytotoxicity in an ανβ6-
expressing cell line, DX3-β6, reducing the EC50 value ~90-fold when compared with the 
control, Ad5-EGFPWT. However, in the non-β6 expressing line, DX3puro, the EC50 
values obtained with Ad5-EGFPA20, were also reduced ~25-fold relative to Ad5-
EGFPWT, probably a reflection of its alternate interaction with ανβ8.  
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Figure.3.19 Comparative Cytotoxicity Profiles for Ad5-EGFPWT and Ad5-EGFPA20 on a panel of Low-
Moderate CAR-Expressing Cell Lines. Cytotoxicity was determined by MTT assay, carried out 120hrs 
post-infection, with virus concentrations ranging from 0.0001-100 PFU/cell and mean percentage survival 
was expressed as a percentage of uninfected cells (Uninfected cells are represented on the X-axis as 0, 
following a break in the logarithmic scale). Cell lines investigated were; isogenic matched pair (A) 
DX3puro and (B) DX3-β6, HNSCC lines (C) TR126 and (D) TR138, Ovarian carcinoma lines (E) CAOV3 
and (F) SKOV3ip1 and Breast carcinoma lines (G) BT-20 and (H) †CA1a, abbreviated from MCF10CA1a. 
Dose-response curves were generated by non-linear regression analysis using GraphPad Prism Version 
3.03 (GraphPad Software, San Diego, CA). EC50 values for the dose response curves are displayed in 
Table.12. Cytotoxicity profiles shown are representative of at least two independent repeat experiments 
carried out on triplicate samples on different occasions. The unpaired Student’s t-test was used to 
demonstrate the significance of the difference in EC50 values for each virus (**** is indicates a P-value 
<0.0001, NS = not statistically significant, p>0.05, N = 3, bars indicate SD, no bars represent SD values 
smaller than the symbol used).  
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Table 12. EC50 Values (PFU/Cell)a
a EC50 represents half the maximal effective concentration of virus per cell. Viability was assessed by MTT assay and results
analysed by non-linear regression fitted to a sigmoidal curve. Values are expressed in Plaque Forming Units (PFU/Cell). †CA1a is
abbreviated from MCF10CA1a.
Ad5-EGFPA20
Ad5-EGFPWT
0.04
19.13
0.29
5.02
BT-20
0.12
10.33
DX3-β6
0.003
0.05
TR126 SKOV3ip1
0.009
0.3
TR138
0.28
7.06
DX3puro
0.24
3.1
CAOV3
0.03
0.56
CA1a†
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In HNSCC lines, TR126 and TR138, the EC50 values for Ad5-EGFPA20 were reduced by 
~17-fold and ~33-fold respectively, when compared to Ad5-EGFPWT (p=0.0011 and 
p<0.0001). Infection of ovarian carcinoma lines CAOV3 and SKOV3ip1 with Ad5-
EGFPA20 also resulted in reduced EC50 values, ~13-fold and ~17-fold, respectively.  
Similarly, in breast carcinoma lines BT-20 and CA1a (abbreviated from MCF10CA1a), 
EC50 values were reduced ~480-fold and ~18-fold, when compared with Ad5-EGFPWT 
(p<0.0001 and p=0.0001, respectively). 
 
Several high CAR expressing cell lines were also investigated (Fig.3.20 and Table.10). 
These included isogenic matched pairs C1 and VB6, A375puro and A375-β6 and 
HNSCC lines, Detroit-562 and SCC25, and lung carcinoma lines, H441 and A549. C1 
cells were found to be less sensitive to Ad5-EGFPA20 than to Ad5-EGFPWT, with the 
EC50 value increased ~2.5-fold in this cell line (p=0.025). However, in the -β6 
transfected derivative of this line, a slight increase (~1.5-fold) in cytotoxicity was 
observed, although this was not statistically significant (p=0.450). There was no 
significant difference in cytotoxicity between Ad5-EGFPWT and Ad5-EGFPA20 for either 
A375puro, or A375-β6 and EC50 values obtained were almost identical (p=0.663 and 
p=0.07, respectively). Similar results were seen in the HNSCC lines, Detroit 562, 
SCC25 and HSC-3; again no significant changes in EC50 values (p=0.552, p=0.318 and 
p=0.491, respectively). In lung carcinoma line H441, slight differences in EC50 values 
were detected, but again these were not significant (p=0.291).  
 
It is clear that in cell lines which express high levels of CAR, retargeting to ανβ6 does 
not confer an efficacy advantage, failing to improve cytotoxicity in vitro. Therefore, 
these high CAR cell lines were not considered to be useful for future experiments. 
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Figure.3.20 Comparative Cytotoxicity Profiles for Ad5-EGFPWT and Ad5-EGFPA20 on a panel of High 
CAR-Expressing Cell Lines. Cytotoxicity was determined by MTT assay, carried out 120hrs post-
infection, with virus concentrations ranging from 0.0001-100 PFU/cell and mean percentage survival was 
expressed as a percentage of uninfected cells (Uninfected cells are represented on the X-axis as 0, 
following a break in the logarithmic scale). Cell lines investigated were; isogenic matched pairs (A) C1 and 
(B) VB6, (C) A375puro and (D) A375-β6, HNSCC lines (E) Detroit 562, (F) SCC25 and (G) HSC-3 and 
Lung carcinoma line (H) H441. Dose-response curves were generated by non-linear regression analysis 
using GraphPad Prism Version 3.03 (GraphPad Software, San Diego, CA). EC50 values for the dose 
response curves are displayed in Table.13. Cytotoxicity profiles shown are representative of at least two 
independent repeat experiments carried out on triplicate samples on different occasions. The unpaired 
Student’s t-test was used to demonstrate the significance of the difference in EC50 values for each virus 
(NS = not statistically significant, p>0.05, N = 3, bars indicate SD, no bars represent SD values smaller 
than the symbol used).  
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TABLE 13. EC50 Values (PFU/Cell)a
Ad5-EGFPA20
Ad5-EGFPWT
HSC-3
2.75
4.74
VB6
4.25
2.83
A375puro
2.02
2.19
SCC25
1.20
1.37
A375-β6
0.71
2.31
0.94
C1 Detroit 562
7.69
6.31
H441
0.79
1.24
0.50
a EC50 represents half the maximal effective concentration of virus per cell. Viability was assessed by MTT assay and results
analysed by non-linear fitted to a sigmoidal curve. Values are expressed in Plaque Forming Units (PFU/Cell).  
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Section.3.4 In Vivo Assessment of Retargeting to ανβ6 Following Local 
Delivery 
 
3.4.1 Ovarian Intraperitioneal Xenograft Experiment. Using an ovarian 
intraperitoneal model, we assessed the median survival of cohorts treated with either 
non-replicating control virus LM-X, Ad5-EGFPWT or Ad5-EGFPA20 (5x109vp/mouse). 
1x107 SKOV3ip1 cells were injected intraperitoneally (i.p) and 12 days later, virus was 
injected intraperitoneally for 5 consecutive days (days 12-16 inclusive). A Kaplan-Meier 
curve is presented in Fig.3.21. Unfortunately, the LM-X non-replicating control virus 
was found to be contaminated with wildtype replicating Ad5 and therefore, is not 
indicated on the graph. Ad5-EGFPA20 treated cohorts displayed improved median 
survival when compared to those treated with Ad5-EGFPWT (61 days compared with 57 
days), although this was not statistically significant (p=0.06).  
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3.4.2 Noninvasive In Vivo Fluorescence Imaging of Ad5-EGFPWT and Ad5-
EGFPA20 Replication Following Local Delivery. In this study, both Ad5-EGFPWT and 
Ad5-EGFPA20 were constructed so that EGFP was under the control of the endogenous 
E3 promoter, in place of the E3-6.7K/gp19K cassette (Hawkins et al., 2001). 
Noninvasive fluorescence imaging with EGFP inserted at this site has recently been 
Figure.3.21 Kaplan Meier Survival Curve; SKOV3ip1 Intraperitoneal Model. SKOV3ip1 ovarian 
carcinoma cells (1x107) were injected intraperitoneally into 6-8 week old CD1 nu/nu female mice (N=10). 
Viruses, Ad5-EGFPWT and Ad5-EGFPA20 were injected on days 12-16 inclusive (5x109vp/mouse in 400μl 
of 20% icodextrin). Animals were killed once they reached Home Office morbidity limits (approaching 20% 
body weight loss, presence of significant ascites and poor well being, as determined by BSU staff). Kaplan 
Meier survival curves were generated, and non-parametric log rank analysis performed using GraphPad 
Prism Version 3.03 (GraphPad Software, San Diego, CA). Median survival for each cohort was calculated 
to be 57 days for Ad5-EGFPWT, and 61 days for Ad5-EGFPA20 (p=0.06).  
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evaluated, and was shown to correlate well with viral DNA replication (Ono et al., 
2005). In fact, it has been shown previously that strong reporter gene expression from 
this promoter is dependent on efficient viral genome replication (Mittal et al., 1993). 
Thus, the in vivo viral replication kinetics of Ad5-EGFPWT and Ad5-EGFPA20 were 
assessed indirectly using a noninvasive fluorescence-based optical imaging system 
(Fig.3.22A and Fig.3.23A). 
 
Using the isogenic cell line pair DX3puro and DX3-β6 (ανβ6-/ανβ6+), fluorescence 
efficiency was assessed following local injection (performed by Jerome Burnet and 
Prof. Iain McNeish). DX3puro/DX3-β6 cells (4x106) were implanted subcutaneously 
onto the right flanks of CD1 nude female mice. Once tumours had reached ~250mm3, 
1x1010vp of either non-replicating control virus LM-X, Ad5-EGFPWT or Ad5-EGFPA20, 
were administered intratumourally.  
 
In the DX3puro xenografts, the fluorescence efficiency detected in the Ad5-EGFPA20 
groups was dramatically superior to that of the Ad5-EGFPWT treated cohort 
(Fig.3.22A+C). The DX3puro cell line does not express ανβ6 (see Table.10), however it 
does express high levels of ανβ8 (see Table.11). Previous data presented in this 
chapter demonstrated that the Ad5-EGFPA20 virus can efficiently utilise ανβ8 as an 
alternative receptor for entry in the absence of ανβ6 (see Fig.3.16A). A statistically 
significant difference in fluorescence was detected between Ad5-EGFPA20 and Ad5-
EGFPWT on day 4 (p=0.013). EGFP expression was reduced for both cohorts on days 7 
and 11 post-infection and fluorescence detected did not differ (p>0.05). However, a 
dramatic peak in EGFP expression was observed in the Ad5-EGFPA20 treated groups 
on day 14 post-infection, which differed significantly from Ad5-EGFPWT (p<0.0001). 
This difference was maintained through to day 21 (p<0.0001 for all time-points). By day 
24, the EGFP fluorescence detected from both groups were identical (p>0.05).  
 
Unexpectedly, there were no dramatic differences in EGFP fluorescence detected 
between Ad5-EGFPWT and Ad5-EGFPA20 in the ανβ6-expressing DX3-β6 tumours 
(Fig.3.23A+C). Fluorescence levels for both groups closely mirrored each other and did 
not differ significantly at any time-points (p>0.05). Interestingly, Ad5-EGFPWT appeared 
to replicate more efficiently in the DX3-β6 xenograft, than in the DX3puro xenograft 
(see Fig.3.22A and Fig.3.23A). 
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Figure.3.22 DX3puro Xenografts; In Vivo Fluorescence Imaging and Anti-tumoral Efficacy following 
Local Delivery of Virus. (A) DX3puro tumour xenografts were implanted subcutaneously onto the right 
flanks of 6-8 week old CD1 nude female mice (N=6-10). Once the tumours had reached ~250mm3, 
1x1010vp of non-replicating control virus (LM-X), Ad5-EGFPWT or Ad5-EGFPA20 was injected intra-
tumourally. EGFP fluorescence efficiency was measured on eight separate occasions using an Xenogen 
IVIS Imaging System 100, using the fluorescence nodule. (B) Tumour volume was measured on average 
three times weekly for the duration of the experiment. Once tumours reached ~8-10mm diameter animals 
were killed in accordance with Home Office Licence Regulations (C) Noninvasive in vivo fluorescence 
imaging was recorded for cohorts treated with Ad5-EGFPWT and Ad5-EGFPA20 (days 11 and 14 post-
infection). (D) Immunohistochemical analysis of DX3puro tumour pathology (control tumours shown). 
From left to right; H&E staining and anti-ανβ6 immunostaining with 6.2G2 which confirmed the absence of 
ανβ6 expression in these tumours. Sections were photographed at a magnification of 200X using a Zeiss 
AxioCam Mrc5 camera and Axiovision Software (Zeiss, Germany). 
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Figure.3.23 DX3-β6 Xenografts; In Vivo Fluorescence Imaging and Anti-tumoral Efficacy following 
Local Delivery of Virus. (A) DX3-β6 tumour xenografts were implanted subcutaneously onto the right 
flanks of 6-8 week old CD1 nude female mice (N=8-10). Once the tumours had reached ~250mm3, 1x1010vp 
of non-replicating control virus (LM-X), Ad5-EGFPWT or Ad5-EGFPA20 was injected intra-tumourally. EGFP 
fluorescence efficiency was measured on eight separate occasions using an Xenogen IVIS Imaging System 
100, using the fluorescence nodule. (B) Tumour volume was measured on average three times weekly for 
the duration of the experiment. Once tumours reached ~8-10mm diameter animals were sacrificed in 
accordance with Home Office Licence Regulations (C) Noninvasive in vivo fluorescence imaging was 
recorded for cohorts treated with Ad5-EGFPWT and Ad5-EGFPA20 (days 11 and 14 post-infection). (D) 
Immunohistochemical analysis of DX3-β6 tumour pathology (control tumours shown). From left to right; H&E 
staining, anti-ανβ6 immunostaining with 6.2G2 showing a region of poor expression taken from a tumour 
harvested at the end of the experiment and anti-ανβ6 immunostaining with 6.2G2 showing a region of high 
expression taken from a tumour harvested at an early time-point (~3 weeks). Sections were photographed 
at a magnification of 200X using a Zeiss AxioCam Mrc5 camera and Axiovision Software (Zeiss, Germany). 
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3.4.3 Anti-Tumoural Efficacy Following Local Delivery. DX3puro/DX3-β6 tumours 
were measured three times weekly in order to establish the efficacy of each treatment 
(Fig.3.22B and Fig.3.23B). Animals were killed once tumours reached ~8-10mm in 
diameter. In animals bearing DX3puro xenografts, the tumour volumes of both Ad5-
EGFPWT and Ad5-EGFPA20 treated groups differed from vehicle control (p=0.005 and 
p=0.03, respectively), on day 72 post-infection (Fig.3.22B). Unfortunately, the dramatic 
differences in EGFP fluorescence noted between Ad5-EGFPWT and Ad5-EGFPA20, 
which suggested superior viral replication of the latter within the tumour, did not confer 
an enhanced anti-tumoural effect (Fig.3.22B). In animals harbouring DX3-β6 tumours, 
again, both viruses, Ad5-EGFPWT and Ad5-EGFPA20, displayed enhanced anti-tumoural 
efficacy when compared with vehicle control at day 65 post-infection (p=0.0025 and 
p=0.0002, respectively), but did not differ significantly from each other (p>0.05). 
 
3.4.4 Histological Examination of Tumour Xenografts; H&E Staining and 
Immunostaining for ανβ6 Integrin. Tumours were excised at time of death, fixed 
appropriately and processed for paraffin embedding and sectioning (Pathological 
Services, Institute of Cancer). All sections were assessed histologically following 
haematoxylin and eosin (H&E) staining. Additionally, sections from both DX3puro and 
DX3-β6 tumours were immunostained with an anti-ανβ6 antibody, 6.2G2, in parallel 
with an isotype control antibody.  
  
As expected the DX3puro tumours did not express ανβ6 (Fig.3.22D). Pathological 
assessment of H&E stained tissue revealed regions of necrosis within the tissue. 
Additionally, histological analysis of the DX3-β6 tumours also identified large necrotic 
areas (Fig.3.23D). Regions of viable tumour cells (without necrosis) were selected for 
presention of ανβ6 immunostaining, as necrotic tissue shows high levels of non-
specific staining. However, necrotic regions were present in all samples analysed (data 
not shown). Interestingly, immunohistochemistry identified that there was a loss of 
ανβ6-expression within the DX3-β6 xenografts over time. Tumours which were 
harvested at earlier time-points in the experiment, retained high level expression 
throughout the tumour mass (far right), whereas tumours harvested later in the 
experiments had reduced expression levels (centre).  
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Chapter.3 Discussion 
 
To date, several strategies for the selective targeting of ανβ6, both in vitro and in vivo 
have been reported. These have included the generation of a chimeric T-cell antigen 
receptor expressing a 12mer ανβ6-specific ligand, which successfully redirected 
cytotoxic T lymphocytes to ανβ6-expressing primary ovarian lines (Pameijer et al., 
2007), the administration of ανβ6 blocking antibodies or soluble TGF-β inhibitors in an 
attempt to functionally inhibit ανβ6 in vivo (Van Aarsen et al., 2008; Weinreb et al., 
2004; Xue et al., 2001), the generation of a humanised scFv directed to ανβ6 
(Kogelberg et al., 2008) or the use of radiolabelled A20FMDV2 or other ανβ6-targeting 
peptides for non-invasive, in vivo imaging of ανβ6-positive tumours (Hausner et al., 
2009a; Hausner et al., 2007; Hausner et al., 2009b; Li et al., 2009). However, to date, 
there have been no attempts to redirect an adenovirus to ανβ6 for therapeutic 
applications. 
 
 
Section.3.1 Characterisation of Cell Lines 
 
The extensive characterisation of a broad range of human carcinoma lines resulted in 
the identification of a panel suitable for in vitro characterisation of our constructs. 
Several attempts were made to establish tumour xenograft models for TR126, TR138 
and BT-20 cells, but these were unsuccessful. Unfortunately, the established tumour 
xenograft models used in our laboratory were not considered suitable for in vivo 
applications with Ad5-EGFPA20, due to the lack of efficacy in vitro (ie. A375puro/A375-
β6, and C1/VB6 models). 
 
 
Section.3.2 In Vitro Characterisation of A20-Modified KnobA20 Proteins 
 
The resolution of the crystal structure of the Ad5 knob domain by X-ray crystallography 
identified the HI loop region as a locale suitable for peptide incorporation (Xia et al., 
1994). The rationale supporting this was that the HI loop was exposed on the surface 
of the fibre knob structure but had no involvement in cell binding and, importantly, 
possessed a flexible structure whose length varied greatly between Ad serotypes. To 
date, the HI loop has been shown to tolerate the insertion of ligands of up to 83aa with 
negligible effects on the structural integrity of the virus (Belousova et al., 2002). The 
A20FMDV2 peptide itself has an innate structure which is critical to its function, and it 
has been found that cysteine-induced cyclicisation attenuates its affinity and specificity 
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(Dr. Mark Howard, personal communication). Thus, we did not consider the use of a 
cysteine-constrained A20FMDV2 insertion in this study. Alternatively, we hypothesised 
that the innate flexibility of the Ad5 HI loop would permit the A20FMDV2 insertion to 
assume its critical conformation, and result in a retargeted adenovirus with high affinity 
binding to ανβ6. 
 
Initial in vitro experiments with the A20-modified recombinant knob protein were very 
encouraging. The insertion of the ανβ6-targeting peptide, A20FMDV2, into the HI loop 
of the Ad5 knob domain, resulted in the successful binding and functional inhibition of 
ανβ6, in a dose dependent manner. The reduced KnobA20 monomer is approximately 
24.4kDa inclusive of its 6XHIS tag, and the corresponding homotrimer was consistently 
observed at ~62kDa by SDS-PAGE. The calculated IC50 for KnobA20 mediated inhibition 
of 53A.2 (anti-ανβ6 antibody) binding, corresponded to a concentration of ~2.5nM (IC50 
= 0.03μg/105 cells in a 200μl volume). KnobA20 was also capable of completely 
abrogating ανβ6-dependent cell migration and invasion at a concentration of 80nM 
(5μg/ml), the lowest concentration tested in these experiments. Importantly, the 
incorporation of the peptide did not appear to preclude native fibre assembly, as 
confirmed by the ability of KnobA20 to form a homotrimer (data not shown).  
 
Strategies to target ανβ6 for in vivo imaging or therapeutic applications (function 
blocking), currently are being investigated (Hausner et al., 2009a; Hausner et al., 2007; 
Li et al., 2009; Van Aarsen et al., 2008). Therefore, the functional characteristics of 
KnobA20 reported in this study suggest it may prove useful for similar targeting 
strategies. The 99mTc-iodinatation of adenoviral knob proteins has been described 
previously (Awasthi et al., 2004; Zinn et al., 1998). Consistent with the innate 
hepatotropic profiles of various Ad serotypes in vivo, accumulation of these 99mTc-Knob 
proteins predominantly was in the liver. Interestingly, these labelled knobs were 
proposed to be accumulated and internalised through CAR, independently of integrins 
(Awasthi et al., 2004). In support of this proposed receptor-mediated entry process, 
depletion of Kupffer cells using GdCl3 did not affect the liver accumulation of 99mTc-
Knob (Zinn et al., 1998). Therefore, a native CAR-binding ablated KnobA20 may prove 
useful for such imaging applications in vivo, limiting the non-specific sequestration in 
the liver and maximising tumour targeting through ανβ6. In further support for its 
potential utility, the knob trimer is sufficiently large (~62kDa) such that it could avoid 
rapid clearance by the renal system, but small enough that it could achieve deeper 
tumour penetration (Awasthi et al., 2004). Additionally, its size may also permit it to 
avoid degradation by serum peptidases in vivo. Taken together, these qualities suggest 
it may suffice as an alternative to current peptide/antibody-based imaging strategies. 
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In summary, the data presented in this section confirmed a high affinity interaction 
between KnobA20 and ανβ6 and supported the possibility that the genetic incorporation 
of A20FMDV2 into Ad5 would permit efficient retargeting to ανβ6. 
 
 
Section.3.3 In Vitro Characterisation of A20-Modified Ad5-EGFPA20 
 
In vitro viral transduction experiments demonstrated the success of the retargeting 
strategy. Ad5-EGFPA20 exhibited superior transduction over Ad5-EGFPWT (p<0.0001 for 
all cells), and also was capable of enhancing entry in cell lines (BT-20, TR126 and 
DX3-β6) which were previously refractory to native Ad5-EGFPWT infection. Inhibitory 
experiments, using anti-ανβ6 53A.2, demonstrated that ανβ6 was the major tropism 
determinant for Ad5-EGFPA20 entry in ανβ6-expressing cells (Fig.3.15). Moreover, the 
finding that KnobA20 had an IC50 of 0.008μg/105 cells (~1.3nM) for inhibition of Ad5-
EGFPA20, a value approximately 15-fold less than the IC50 published previously for 
KnobWT-mediated inhibition of Ad5 infection (Kirby et al., 2000), suggested that the 
interaction between Ad5-EGFPA20 and ανβ6 was one of high affinity. In addition to 
enhancing transduction through ανβ6, the replication kinetics of Ad5-EGFPA20 in low 
CAR, high ανβ6-expressing cells (DX3-β6, TR126, TR138 and BT-20) were superior to 
Ad5-EGFPWT (Fig.3.17 and Fig.3.18). However, viral titres obtained did not always 
correspond with transduction efficiency, an expected finding as intracellular host factors 
can also determine sensitivity to Ad5 replication (Wang et al., 2009). Cytotoxicity was 
also improved dramatically in low CAR, high ανβ6-expressing cells (Fig.3.19), but was 
not comparably enhanced in high CAR-expressing lines (Fig.3.20).  
 
Overall, the interpretation of the in vitro data was not difficult. However, there were 
some unexpected observations which warranted further investigation. In particular, the 
DX3puro cell line (non ανβ6-expressing) yielded some unusual results which were 
inconsistent with the hypothesis that ανβ6 was the sole determinant for entry with Ad5-
EGFPA20 (see Fig.3.13 and Fig.3.19). The critical DLXXL motif which confers ανβ6 
specificity has been reported to have minimal interactions with ανβ3/ανβ5 integrins 
(DiCara et al., 2007). However, in addition to ανβ6, the integrins ανβ1, ανβ3 and ανβ8 
have been implicated in Foot and Mouth Disease Virus (FMDV) infection (Jackson et 
al., 2004; Jackson et al., 2002; Jackson et al., 1997; Jackson et al., 2000). Therefore, 
in an attempt to delineate, or indeed to exclude a role for alternative integrins in the 
infection of Ad5-EGFPA20, gene transfer assays were repeated in the presence, and 
absence of inhibitors to these receptors (Fig.3.16). Although a significant proportion of 
infection with Ad5-EGFPA20 could be modulated through ανβ8, it was clear that ανβ6 
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remained the predominant tropism determinant. However, these data finally offered an 
explanation as to why DX3puro cells supported significantly higher transduction/ 
cytotoxicity when compared with Ad5-EGFPWT. Interestingly, ανβ8 is expressed to a 
high level in the lung, central nervous system (CNS) and on dendritic cells (McCarty et 
al., 2005; Mu et al., 2002; Nishimura et al., 1998; Travis et al., 2007). Therefore, the 
identification that Ad5-EGFPA20 can promote infection through ανβ8 suggests that Ad5-
EGFPA20 may prove useful for future retargeting strategies, or may have broader 
experimental applications. 
 
The development of CAR-independent targeting strategies has once again become an 
important consideration in the design of Ad5-based vectors for applications in human 
disease. This is due to the discovery that human erythrocytes can aggregate Ad5 
through CAR binding and impede targeted delivery (Carlisle et al., 2009; Seiradake et 
al., 2009), in addition to reports that CAR-binding can activate the inflammatory 
response to Ad5 in epithelial cells, and in hepatic tissue, following retro-orbital 
administration (Schoggins et al., 2005; Tamanini et al., 2006). The ability of Ad5-
EGFPA20 to mediate high efficiency entry, in a CAR-independent manner was promising 
and suggested that ablation of CAR-binding determinants would not impair the efficacy 
of Ad5-EGFPA20. Therefore, the in vitro characteristics of Ad5-EGFPA20, suggested that 
it could potentially have advantages over Ad5-EGFPWT in vivo, in terms of its ability to 
infect, replicate and induce cytotoxicity to a greater extent in CAR-deficient cell lines 
which express ανβ6.   
 
 
Section.3.4 In Vivo Characterisation of A20-Modified Ad5-EGFPA20 
 
The results obtained following local delivery of Ad5-EGFPA20 compared with Ad5-
EGFPWT were, largely, disappointing. Based on extensive in vitro characterisation, we 
had determined that enhanced efficacy with Ad5-EGFPA20 was most pronounced in cell 
lines which had high ανβ6 expression but low CAR expression. Downregulated CAR 
expression in pathological specimens and primary cell lines derived from human 
tumours, has been reported extensively (Anders et al., 2009; Buscarini et al., 2007; Jee 
et al., 2002; Matsumoto et al., 2005; Mikami et al., 2001; Rauen et al., 2002). 
Additionally, loss of CAR expression is thought to correlate with disease progression 
(Anders et al., 2009; Mikami et al., 2001; Vincent et al., 2009). In contrast, ανβ6 is 
significantly upregulated in numerous human carcinomas where it is responsible for 
conferring a pro-invasive phenotype which correlates with poor prognosis. For these 
reasons, we wanted to assess comparatively the in vivo efficacy of Ad5-EGFPWT and 
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Ad5-EGFPA20 using low CAR, high ανβ6-expressing models, as we believed that this 
profile may more accurately reflect the scenario in vivo. However, we failed to identify a 
large number of cell lines which displayed this profile (see Table.10). Moreover, a large 
number of those cell lines which we did identify, were not tumourigenic, and several 
attempts to grow BT-20, TR126 and TR138 cells in nude mice failed.  
 
Ad5-EGFPA20 had significantly enhanced cytotoxicity in SKOV3ip1 cells when 
compared with Ad5-EGFPWT, despite having only moderate levels of CAR:ανβ6 
expression on the cell surface (see Table.10). However, we hypothesised that the 
enhanced in vitro cytotoxicity may confer a survival advantage in vivo when using the 
SKOV3ip1 intraperitoneal xenograft model for ovarian carcinoma. This was not the 
case. Ad5-EGFPA20 treatment improved median survival by only 5 days, and this was 
not statistically significant (p=0.06).  
 
Subsequently, we decided to perform an in vivo fluorescence imaging, and anti-
tumoural efficacy experiment using the isogenic matched lines, DX3puro/DX3-β6. The 
choice of this model was not our first as it is a rapidly growing tumour which becomes 
extensively necrotic. Therefore, it is not ideal for assessing the in vivo replication and 
spread of adenovirus. Additionally, it had been found during the course of prior 
experiments using this model, that the DX3-β6 xenografts lost expression of ανβ6 in 
vivo (Dr. Antonio Saha, unpublished observations). Furthermore, we demonstrated in 
previous in vitro experiments that Ad5-EGFPA20 could also mediate infection through 
ανβ8 in the non-ανβ6 expressing DX3puro cells. Indeed, it appeared that this 
characteristic was retained, if not enhanced in vivo, as EGFP fluorescence expressed 
by Ad5-EGFPA20 suggested it was capable of efficient intra-tumoural replication in the 
DX3puro xenografts, when compared with Ad5-EGFPWT. In fact, Ad5-EGFPWT failed to 
replicate to any great extent within the DX3puro tumour. However, one of the key 
limitations of fluorescence imaging is the lack of penetration. Therefore, it is possible 
that the lack of EGFP expression detected with Ad5-EGFPWT may be due to differences 
in injection site within the tumour. Indeed, despite injecting equal doses of virus on the 
same day, there was a great deal of variation within each treated cohort. However, it 
was reassuring that in both tumour models viral replication with both viruses appeared 
to peak at an early time-point post infection, drop at 11 days, and peak again 14 days 
post-infection.   
 
Unexpectedly, in the DX3-β6 xenografts, EGFP expression in the Ad5-EGFPWT treated 
groups effectively mirrored the Ad5-EGFPA20 treated cohorts. However, the loss of 
ανβ6 expression in these tumours may have contributed to the lack of difference 
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detected between Ad5-EGFPWT and Ad5-EGFPA20. Interestingly, the fluorescence 
efficiency detected in the DX3-β6 xenografts on the first day of imaging (day 4 post-
infection), was approximately 2-3 fold higher than detected in the DX3puro xenografts 
at the same time-point. Thus, it appeared that at early time-points in vivo, the DX3-β6 
line better supported the replication of both Ad5-EGFPWT and Ad5-EGFPA20. Tumour 
sections from DX3puro and DX3-β6 xenografts displayed extensive regions of necrosis 
when analysed histologically following sacrifice of the animals. It is possible that 
differing level of necrosis within the tumours at the time of imaging, affected 
intratumoural replication and spread at early time-points.  
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Chapter.4 In Vitro Characterisation of Ad5 Detargeting from CAR/ 
Coagulation Factors Combined with Retargeting to ανβ6 Integrin 
 
Limited adenoviral uptake in malignant tissue, as a result of off-target sequestration in 
the reticuloendothelial system, remains a major obstacle to the application of 
therapeutic adenoviruses for the treatment of disseminated metastasis. In addition, the 
lack of selectivity associated with current retargeting strategies (ie. Ad5-RGD-4C and 
Ad5-K7), combined with the broad expression of the native CAR receptor, restricts the 
therapeutic index. The recent finding that human, but not murine, erythrocytes express 
CAR on their surface supports the importance of developing CAR-independent 
retargeting strategies, or indeed the use of relevant in vivo models for the study of 
intravenously administered Ad5 vectors (Carlisle et al., 2009; Seiradake et al., 2009). 
Therefore, it is clear that combining transductionally retargeted, cancer selective Ad5 
vectors with primary receptor (CAR) ablation, with strategies for avoidance of the 
reticuloendothelial system and/or blood components, are key requirements in the 
development of realistic, systemically administered therapies for cancer. 
 
The molecular determinants critical for CAR binding have been described extensively, 
as have reports regarding the generation of various CAR-binding ablated Ad5 vectors 
(Jakubczak et al., 2001; Kirby et al., 1999; 2000; Roelvink et al., 1999; Santis et al., 
1999). Substitution mutations at critical residues S408E, P409A, Y477A and L485K 
have been shown to ablate CAR binding in vitro. However, CAR-binding ablation 
strategies alone have not proven useful in limiting the extensive liver transduction of 
Ad5 in vivo, or in altering the overall biodistribution of the vector (Alemany & Curiel, 
2001; Leissner et al., 2001; Martin et al., 2003; Mizuguchi et al., 2002; Nicol et al., 
2004; Smith et al., 2002). Recently, it has become clear that various serum factors 
(FIX, FX, C4BP and Protein C) dictate hepatocyte transduction, and that CAR-
mediated entry is redundant in vivo, at least in the context of sequestration within the 
reticuloendothelial system (Alba et al., 2009; Kalyuzhniy et al., 2008; Parker et al., 
2006; Shayakhmetov et al., 2005b; Vigant et al., 2008; Waddington et al., 2008). 
Shayakhmetov and colleagues have described an Ad5 mutant, Ad5mut, which featured 
a set of mutations within the fibre which abrogated binding to FIX and C4BP in vitro. 
This vector displayed significantly reduced liver transduction and toxicity, and a failure 
to co-localise with Kupffer cells in vivo (Shayakhmetov et al., 2005b). Conveniently, the 
set of incorporated mutations included the Y477A amino acid substitution, at a tyrosine 
residue described previously to be a critical determinant for CAR-binding  (Kirby et al., 
2000; Roelvink et al., 1999). This modification was combined with a TAYT deletion 
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within the FG loop of the fibre, and the insertion of a non-targeting FLAG peptide within 
the HI loop.  
 
A combination of high affinity tumour-selective targeting in vectors genetically 
engineered for avoidance of the reticuloendothelial system has not yet been achieved. 
Therefore, the aim of this part of the project was to generate CAR-binding ablated Ad5 
mutants, Ad5-Y477A and Ad5-L485K with both wildtype and A20-modified fibres. 
Subsequent aims were to incorporate the Y477AdlTAYT set of mutations into the Ad5-
EGFPA20 vector, in an attempt to create a virus which featured tumour targeting (via the 
interaction between A20FMDV2 and ανβ6), and reduced toxicity in vivo, through 
limiting off-target sequestration of the virus in the liver.  
 
 
Section.4.1 Validation of ΔCAR/Blood Factor Binding Ablated Knob 
Mutants  
 
4.1.1 Sequencing Analysis of Modified pQE30Knob Expression Plasmids. Several 
modified pQE30-based expression vectors were generated to facilitate the expression 
of, and purification of mutant recombinant proteins. These included CAR-binding 
mutants; KnobY477AWT, KnobY477AA20, KnobL485KWT and KnobL485KA20 and 
combination mutants; Knob477dlTAYTWT, Knob477dlTAYTA20, Knob485dlTAYTWT and 
Knob485dlTAYTA20, which featured CAR-binding mutations (Y477A or L485K) in 
addition to the putative blood factor binding mutation (dlTAYT). Amino acid 
substitutions were introduced by mutagenic PCR and combination mutants 
subsequently were assembled using a SOEing PCR approach (see Fig.2.1 for an 
overview of the strategy). All successful modifications were confirmed by sequencing 
and constructs were checked to ensure that the sequences were in frame with the N-
terminal 6X-HIS tag (Fig.4.1-Fig.4.4). An overview of some of the fibre mutants 
generated in this study can be found as a ClustalW protein alignment (Appendix II).  
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Original Sequence
5’-C TTC CTG GAC CCA GAA TAT TGG AAC TTT AGA A-3’
F   L   D   P   E   Y   W   N   F   R ___
Phe  Leu  Asp   Pro  Glu   Tyr Trp  Asn   Phe   Arg
pQE30KnobΔCAR: MutY477A
5’-C TTC CTG GAC CCA GAA GCT TGG AAC TTT AGA A-3’
F   L   D   P   E   A W   N   F   R ___
Phe  Leu   Asp  Pro  Glu  Ala Trp  Asn   Phe  Arg 
A
pQE30KnobΔCAR: MutY477A
B
Original Sequence
 
 
 
 
 
 
 
 
Figure.4.1 Generation of pQE30KnobΔCARWT/A20 (Y477A) by Site Directed Mutagenesis. (A) Original 
nucleotide and amino acid sequence without mutation (top). A schematic showing the desired nucleotide 
and amino acid sequence, with Y477A to be introduced by mutagenic PCR (bottom). The red box 
highlights the nucleotide changes from TAT to GCT, with the sequence to be mutated, and the resultant 
amino acid substitution highlighted in bold and underlined in black. (B) Sequencing chromatogram 
showing the original CAR-binding determinant (477Y) within the adenoviral fibre gene (top), and its 
conversion to 477A, following successful site directed mutagenesis (bottom).  
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Original Sequence
5’-C TTT AGA AAT GGA GAT CTT ACT GAA GGC ACA GC-3’
F   R   N   G   D   L   T   E   G   T   A
Phe  Arg   Asn  Gly   Asp  Leu Thr  Glu   Gly  Thr  Ala
pQE30KnobΔCAR: MutL485K
5’-C TTT AGA AAT GGA GAT AAA ACT GAA GGC ACA GC-3’
F   R   N   G   D   K T   E   G   T   A
Phe  Arg   Asn  Gly   Asp  Lys Thr  Glu   Gly  Thr  Ala
A
pQE30KnobΔCAR: MutL485K
B
Original Sequence
 
 
 
 
 
 
 
 
Figure.4.2 Generation of pQE30KnobΔCARWT/A20 (L485K) by Site Directed Mutagenesis. (A) Original 
nucleotide and amino acid sequence without mutation (top). A schematic showing the desired nucleotide 
and amino acid sequence, with L485K to be introduced by mutagenic PCR (bottom). The red box 
highlights the nucleotide changes from CTT to AAA, with the sequence to be mutated and the resultant 
amino acid substitution highlighted in bold and underlined in black. (B) Sequencing chromatogram 
showing the original CAR-binding determinant (485L) within the adenoviral fibre gene (top), and its 
conversion to 485K, following successful site directed mutagenesis (bottom).  
 162
Original Sequence
5’-TAT TGG AAC TTT AGA AAT GGA GAT CTT ACT GAA GGC ACA GCC TAT ACA AAC-3’
Y   W   N   F   R   N   G   D   L   T   E   G   T   A   Y   T   N  ___ 
Tyr Trp  Asn  Phe  Arg  Asn  Gly  Asp  Leu  Thr  Glu   Gly  Thr  Ala  Tyr  Thr  Asn
pQE30Knob477dlTAYTA20
5’-GCT TGG AAC TTT AGA AAT GGA GAT CTT ACT GAA GGC --- --- --- --- AAC-3’ 
A W   N   F   R   N   G   D   L   T   E   G   - - - - N  ___ 
Tyr Trp  Asn  Phe  Arg  Asn  Gly  Asp  Leu  Thr  Glu   Gly  Thr  Ala  Tyr  Thr  Asn
pQE30Knob477dlTAYTA20
B
Original Sequence
A
ΔTAYT
 
 
 
 
 
 
 
 
Figure.4.3 Results for site directed mutagenesis of pQE30Knob477dlTAYTWT and 
pQE30Knob477dlTAYTA20. (A) Original Ad5 nucleotide and amino acid sequence without modification 
(top). A schematic showing the desired nucleotide and amino acid sequence (bottom). Mutants were 
generated using SOEing PCR. The red boxes highlight the nucleotide changes from TAT to GCT, and 
the TAYT deletion. Nucleotide sequences to be mutated/deleted and the resultant changes are 
highlighted in bold and underlined in black. (B) Sequencing chromatogram showing the original Ad5 
sequence (top), and the pQEKnob477dlTAYTA20 sequence following successful assembly of the 
modified regions by SOEing PCR (bottom).  
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Original Sequence
5’-AAT GGA GAT CTT ACT GAA GGC ACA GCC TAT ACA AAC GCT GTT GGA TTT ATG-3’
N   G   D   L   T   E   G   T   A   Y   T   N   A   V   G   F   M  ___ 
Asn  Gly  Asp  Leu  Thr  Glu   Gly  Thr  Ala  Tyr  Thr  Asn  Ala  Val  Gly  Phe  Met
pQE30Knob485dlTAYTA20
5’-AAT GGA GAT AAA ACT GAA GGC --- --- --- --- AAC GCT GTT GGA TTT ATG-3 -
3’ 
N   G   D   K   T   E   G   - - - - N   A   V   G   F   M ___ 
Asn  Gly  Asp  Lys  Thr  Glu   Gly  Thr  Ala  Tyr  Thr  Asn  Ala  Val  Gly  Phe  Met
pQE30Knob485dlTAYTA20
B
Original Sequence
A
ΔTAYT
 
 
 
 
 
 
 
 
 
 
Figure.4.4 Results for site directed mutagenesis of pQE30Knob485dlTAYTWT and 
pQE30Knob485dlTAYTA20. (A) Original Ad5 nucleotide and amino acid sequence without modification 
(top). A schematic showing the desired nucleotide and amino acid sequence (bottom). Mutants were 
generated using SOEing PCR. The red boxes highlight the nucleotide changes from CTT to AAA, and the 
TAYT deletion. Nucleotide sequences to be mutated/deleted and the resultant changes are highlighted in 
bold and underlined in black. (B) Sequencing chromatogram showing the original Ad5 sequence (top), and 
the pQEKnob485dlTAYTA20 sequence following successful assembly of the modified regions by SOEing 
PCR (bottom).  
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4.1.2 Recombinant Knob Protein Expression and Purification. CAR-binding 
ablated mutant proteins, KnobL485KWT and KnobL485KA20, were produced by Tobias 
Simmonds, at the Protein Isolation laboratory, CR-UK. The KnobY477AWT and 
KnobY477AA20 pQE-based plasmids were generated, however the corresponding 
proteins were not expressed or purified. Alternatively, the plasmids were used as 
templates for the generation of the Knob477dlTAYTWT and Knob477dlTAYTA20 
constructs. Using the protocol which had been optimised previously, mutant proteins 
Knob485dlTAYTWT, Knob485dlTAYTA20, Knob477dlTAYTWT and Knob477dlTAYTA20 
were expressed and purified. 
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25
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50mM    100mM   200mM    300mM
kDa
16.5
B
A
 
 
 
 
 
 
 
 
 
Elution profiles for Knob477dlTAYTWT and Knob477dlTAYTA20 are shown in Fig.4.5A 
and B. Uninduced control and elution fractions were run in parallel on a 12% SDS-
PAGE gel. Columns loaded with cell lysate-matrix slurry, were washed several times 
prior to elution of protein using imidazole, and a sample of the first wash was run in 
Figure.4.5 Elution Profile for Knob477dlTAYTWT (A) and Knob477dlTAYTA20 (B). Elution fractions (50-
300mM imidazole) were run on a 12% SDS-PAGE gel, and bands visualised by Coomassie’s staining. 
Fractions which were determined to have high purity (≥ 100mM for Knob477dlTAYTWT, or ≥ 200mM for 
Knob477dlTAYTA20), were pooled and dialysed overnight against PBS. Abbreviations are as follows; kDa 
= kilodalton, M = Marker (NEB Prestained Broad Range 6-175kDa) and UC represents uninduced control 
fraction. Arrows indicate the bands corresponding to the Knob477dlTAYTWT (~21.5kDa) and the 
Knob477dlTAYTA20 monomer (~23.8kDa).  
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parallel with the elution fractions. As expected, the uninduced control fractions did not 
contain protein, whereas in the elution fractions for both Knob477dlTAYTWT and 
Knob477dlTAYTA20, the appropriate sized bands were clearly visible. Approximate 
molecular weights of the monomers were predicted to be ~21.5kDa for 
Knob477dlTAYTWT, and ~23.8kDa for Knob477dlTAYTA20 (using VectorNTI software to 
translate the nucleotide sequence into protein, inclusive of the 6XHIS Tag).  
 
Elution profiles for Knob485dlTAYTWT (data not shown) and Knob485dlTAYTA20 
(Fig.4.6), were also obtained. Again, proteins were eluted under native conditions using 
a concentration gradient in the range of 100mM-300mM imidazole, and fractions 
analysed following SDS-PAGE. For each protein, appropriate fractions which had high 
purity (ie. minimal contaminating bands) were pooled, dialysed overnight against PBS 
and purified protein concentration calculated, as before, using the Pierce BCA protein 
assay. 
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4.1.3. Trimerisation Assay. We wanted to genetically incorporate the 477dlTAYT and 
485dlTAYT modifications into the Ad5-EGFPA20 virus backbone. Therefore the ability of 
Knob477dlTAYTA20 (data visualised but not recorded) and Knob485dlTAYTA20 (Fig.4.7) 
to form a homotrimer was confirmed by SDS-PAGE under semi-denaturing conditions. 
This was not assessed for the WT counterparts (Knob477dlTAYTWT and 
Knob485dlTAYTWT), which were generated purely as controls for in vitro CAR-binding 
experiments (see Fig.4.11A). 
Figure.4.6 Elution Profile for Knob485dlTAYTA20. Elution fractions (50-300mM imidazole) were run on a 
12% SDS-PAGE gel, and bands visualised by Coomassie’s staining. Fractions which were determined to 
have high purity (300mM) were pooled and dialysed overnight against PBS. Abbreviations are as follows; 
kDa = kilodalton, M = Marker (NEB Prestained Broad Range 6-175kDa) and W represents wash fraction. 
An arrow indicates the band corresponding to the KnobA20 monomer (~23.9kDa). The elution profile for 
Knob485dlTAYTWT was visualised but not recorded. 
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4.1.4. Validation of ΔCAR/Blood Factor KnobA20 Mutants; Binding to ανβ6. In order 
to eliminate the possibility that the introduced set of mutations (ΔCAR/Blood factor 
binding mutations) had altered the ability of the A20FMDV2 insertion to recognise 
ανβ6, the recombinant Knob477dlTAYTA20 and Knob485dlTAYTA20 mutants were 
tested for their ability to bind ανβ6 in vitro (Fig.4.8A+B). This experiment was carried 
out exactly as described previously for KnobA20 (Section.3.2.5). BT-20 cells (high levels 
of ανβ6 but low levels of CAR) were incubated with increasing concentrations of each 
protein (0.0001μg-10μg/105 cells), after which unbound ανβ6 was detected using anti-
ανβ6 mAb, 53A.2. Levels of bound 53A.2 were detected using a secondary, donkey 
anti-rat AlexaFluor488 antibody and results were analysed by flow cytometry, acquiring 
fluorescence in FL1-H. The fluorescence level for BT-20 cells untreated with 
recombinant Knob protein was taken to be 100% (or otherwise 100% antibody binding) 
and all other values were expressed as a % of this untreated control.  
Figure.4.7 Trimerisation Assay KnobA20, KnobL485KA20 and Knob485dlTAYTA20. Purified KnobA20, 
KnobL485KA20 and Knob485dlTAYTA20 protein samples (~5μg) were boiled at 95˚C for 5mins, or left at 
room temperature. Immediately prior to loading onto a 10% SDS-PAGE gel, 5X SDS-PAGE buffer (without 
DTT) was added to each sample (1X). Samples were run in parallel under semi-denaturing conditions in 
order to approximate trimer, dimer and monomer formation (indicated by an arrow). Abbreviations are as 
follows; kDa = kilodalton, M = Marker (NEB Pre-stained Broad Range 6-175kDa), RT = Room 
temperature.  
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The results confirmed that the incorporation of the various modifications (an amino acid 
substitution, in addition to a TAYT deletion) did not affect the interaction between the 
A20FMDV2 insertion and ανβ6 integrin. Each protein (Knob477dlTAYTA20 and 
Knob485dlTAYTA20) exhibited dose-dependent inhibition of an ανβ6-specific antibody 
binding, with 50% maximal inhibition at an identical concentration to that found for 
Figure.4.8 Competitive Inhibition of 53A.2 Binding to ανβ6 Integrin by Knob477dlTAYTA20 (A) and 
Knob485dlTAYTA20 (B). Both recombinant knob proteins were capable of blocking ανβ6 on the surface of 
BT-20 cells, inhibiting the binding of an ανβ6-specific antibody (53A.2) in a dose-dependent manner (see 
Section.2.5.3). BT-20 cells (low CAR, high ανβ6) were incubated on ice with increasing concentrations of 
A20-modified Knob proteins (0.0001-10μg/105 cells), or KnobWT at a single concentration (10μg/105 cells). 
53A.2 was added to cells, and its binding analysed by flow cytometry following the addition of a secondary 
donkey anti-rat AlexaFluor488 conjugate. Untreated cells were taken as 100% fluorescence and all other 
values expressed relative to this (see Section.2.5.3). KnobWT produced no significant effect at 10μg/105 
cells (p=0.168) and is represented as a single point on the graph. The affinity of of Knob477/485dlTAYTA20 
for ανβ6 has not been detemined directly. Results were analysed by non-linear regression fitted to a 
sigmoidal curve, using GraphPad Prism Version 3.03 (GraphPad Software, San Diego, USA). Data 
represent the mean ± SD of triplicate samples (no bars represent SD values smaller than the symbol 
used). 
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KnobA20 (0.03μg/105 cells; see Fig.3.8). KnobWT, included as a control in the 
experiment, was unable to block 53A.2 binding at a high concentration (10μg/105 cells) 
and results did not differ from untreated cells (p=0.168). These data confirmed that the 
A20FMDV2 peptide, when combined with the introduced ΔCAR/Blood factor binding 
mutations, retained a fully functional ability to bind ανβ6.  
 
4.1.5 Validation of ΔCAR/Blood Factor KnobA20 Mutants; Functional Inhibition of 
ανβ6. We wanted to confirm that the modified Knob477dlTAYTA20 and 
Knob485dlTAYTA20 proteins also retained their ability to functionally inhibit ανβ6-
dependent, VB6 cell migration towards the latency-associated peptide (LAP) of TGF-β1 
(Fig.4.9A and B). The ability of increasing concentrations (0.025-25μg/ml) of 
Knob477dlTAYTA20 or Knob485dlTAYTA20 to inhibit ανβ6-dependent cell migration was 
assessed over a period of 24hrs, using a Transwell migration assay. BSA protein-
coated wells were included in the experiment as a control for ανβ6-independent 
(random) cell migration. KnobWT was also used as a control in both experiments 
(Fig.4.9A and B), but produced no significant effect (p=0.489 and p=0.548, 
respectively).  
 
Both Knob477dlTAYTA20, and Knob485dlTAYTA20 significantly inhibited VB6 cell 
migration towards LAP at all concentrations tested 0.025-25μg/ml (p<0.05). At a 
concentration of 0.025μg/ml, Knob477dlTAYTA20 completely inhibited ανβ6-dependent 
cell migration towards LAP, reducing it to basal BSA levels (p=0.116). In comparison, a 
concentration of 0.25μg/ml Knob485dlTAYTA20 was the lowest concentration which 
effectively reduced migration to basal levels (p=0.117). Knob477dlTAYTA20 was as 
effective as an anti-ανβ6 inhibitory antibody (6.3G9) at concentrations of 2.5μg/ml 
(p=0.101), whereas Knob485dlTAYTA20 required the higher concentration of 25μg/ml to 
produce an equivalent effect (p=0.106). In these experiments, the background 
migration (BSA protein control) was not subtracted from the overall migration, but is 
represented on the graph to show the level of background, ανβ6-independent cell 
migration.  
 
An overview of the ability of A20-modified knob proteins KnobA20, Knob477dlTAYTA20 
and Knob485dlTAYTA20 to inhibit ανβ6-dependent migration is presented in Fig.4.10. In 
this experiment, all knob proteins were used at a single concentration of 10μg/ml. 
These data, combined with those presented in Fig.4.8 and Fig.4.9, confirmed that the 
integrity of the A20FMDV2 insertion was not disrupted, but that it retained its function 
despite the close proximity of the introduced mutations. 
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Figure.4.9 Knob477dlTAYTA20 Inhibition of ανβ6-Dependent Cell Migration (A), and 
Knob485dlTAYTA20 (B). Both A20-modified, recombinant knob proteins were capable of abrogating the 
ανβ6-dependent cell migration of VB6 cells towards the Latency Associated Peptide (LAP) of TGF-β1, in a 
Transwell migration assay (see Section.2.5.4). Controls for migration included; a BSA protein negative 
control (cells untreated with LAP) representing basal, non ανβ6-dependent migration, and a LAP positive 
control representing the level of ανβ6-dependent migration. Cells were treated with the following; KnobWT 
(10μg/ml), increasing concentrations of either Knob477dlTAYTA20 or Knob485dlTAYTA20 (0.025-25μg/ml), 
or a function blocking antibody to ανβ6, 6.3G9 (10μg/ml). Data represent the mean ± SD of triplicate 
samples and are representative of a single experiment carried out within a single plate. Statistical 
significance was determined using the unpaired Student’s t-test comparing the means of each sample 
when compared with the LAP control, or between treated groups, as indicated on the histogram (* 
indicates a P-value of <0.05, ** p<0.01, *** p<0.001, **** p<0.0001, bars indicate SD,  NS = not statistically 
significant, p>0.05). 
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4.1.6 Validation of the ΔCAR-Binding Mutant Knob Proteins. The use of 
recombinant knob or fibre protein to block the infection of a virus from which it was 
derived, is a well established assay (Freimuth et al., 1999; Santis et al., 1999). 
Therefore, once the complete panel of CAR-binding and/or blood factor binding 
mutants had been generated and purified to sufficient quantities, we analysed their 
CAR-binding capacity in parallel (Fig.4.11A). CHO-CAR cells (generously provided by 
Dr. George Santis) were pre-incubated with a single concentration of each protein 
(100μg/105 cells) for 1hr on ice. This was followed by super-infection with Ad5-EGFPWT 
(MOI 10) for a further hour under the same conditions, after which the suspension was 
removed, and infection allowed to proceed for ~22hrs. Successful EGFP gene transfer 
Figure.4.10 Overview of KnobA20, Knob477dlTAYTA20 and Knob485dlTAYTA20 Mediated Inhibition of
ανβ6-Dependent Cell Migration. All A20-modified, recombinant knob proteins were compared in a VB6 
cell migration assay (see Section.2.5.4). Controls for migration included; a BSA protein negative control 
(cells untreated with LAP) representing basal, non ανβ6-dependent migration, a LAP positive control 
representing the level of ανβ6-dependent migration and an isotype control (IgG1) for 6.3G9. All 
recombinant proteins (KnobWT, KnobA20, Knob477dlTAYTA20 and Knob485dlTAYTA20), and antibodies, 
IgG1 and 6.3G9, were used at a final concentration of 10μg/ml. Data represent the mean ± SD of triplicate 
samples and are representative of a single experiment carried out within a single plate. Statistical 
significance was determined using the unpaired Student’s t-test comparing the means of each sample 
when compared with the LAP control, or between treated groups, as indicated on the histogram (** 
indicates a P-value of <0.01, bars indicate SD,  NS = not statistically significant, p>0.05).  
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was quantified by flow cytometry. Ad5-EGFPWT infected cells which were untreated 
with recombinant protein were expressed as 100% infectivity, and all other values 
expressed relative to this.  
 
As expected both KnobWT and KnobA20 significantly inhibited Ad5-EGFPWT infection, by 
~96% and ~95% respectively (p<0.0001 for both). Recombinant protein, Knob485WT, 
featuring the L485K point mutation at a previously described CAR-binding determinant, 
was unable to inhibit Ad5-EGFPWT infection, confirming that its native binding had been 
ablated. However, rather unexpectedly, the A20-modified version of this protein 
completely inhibited infection (p<0.0001; data not shown), in a manner comparable to 
CAR-binding KnobWT or KnobA20 (p=0.0001, compared to both). This was later 
explained by the discovery that Protein Production Services had accidentally purified 
KnobA20 instead of KnobL485KA20 (personal communication). KnobY477AWT and 
KnobY477AA20 were not expressed as recombinant protein due to time constraints, and 
therefore not included in the analysis. 
 
CAR-binding mutants which had been combined with the modification of putative blood 
factor binding sites were also assessed. Knob477dlTAYTWT was unable to inhibit the 
infection of Ad5-EGFPWT (p=0.057). Unexpectedly, Knob477dlTAYTA20 was capable of 
inhibiting ~12% of Ad5-EGFPWT infection at 100μg/105 cells, not a dramatic result, 
although it was found to be statistically significant (p=0.02). As expected, both the 
Knob485dlTAYTWT, and Knob485dlTAYTA20 mutants, failed to inhibit Ad5-EGFPWT 
infection (p=0.233 and p=0.508, respectively), confirming the successful ablation of 
their CAR-binding ability.  
 
In order to further characterise the unusual result found with Knob477dlTAYTA20 in 
Fig.4.11A, the experiment was repeated (Fig.4.11B), however this time comparing 
increasing concentrations (0.001-100μg/105 cells) of both KnobA20 and 
Knob477dlTAYTA20. Knob485dlTAYTA20 was not assessed. The IC50 for KnobWT 
mediated inhibition of native Ad5 infection has been published (Kirby et al., 2000). This 
value was determined to be 0.115μg/105 cells, and was obtained using the same CHO-
CAR cells, and a similar experimental approach. Therefore, we chose only to include 
KnobWT as a control in this experiment at two concentrations, 0.01μg and 0.1μg/105 
cells (data not shown). As expected, KnobA20 was capable of inhibiting Ad5-EGFPWT 
infection with an IC50 of 0.34μg/105 cells, confirming that KnobA20 retained native CAR 
binding, albeit with slightly impaired efficiency when compared to KnobWT. As shown in 
Fig.4.11B, Knob477dlTAYTA20 did not substantially inhibit Ad5-EGFPWT infection at 
concentrations of up to 10μg/105 cells, although inhibition was found to be significant at 
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100μg/105 cells (p=0.04), consistent with the result obtained in Fig.4.11A. This effect 
was explained, to an extent, by results obtained in subsequent experiments (see 
Fig.4.14A).  
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Section.4.2 Validation of CAR-Binding Ablated Viral Mutants; Infectivity 
and Cytotoxicity  
Figure.4.11 (A) Comparative Analysis of a Panel of CAR-Binding Mutant Knob Proteins. All modified 
Knob proteins generated in this study were compared, in a single experiment, for their ability to inhibit 
native Ad5-EGFPWT entry to CHO-CAR cells. Cells were incubated with a single concentration of each 
Knob protein (100μg/105 cells) for 1hr at 4˚C after which they were infected with Ad5-EGFPWT (MOI 10: 
PFU/cell) for a further hour at 4˚C. EGFP gene transfer was quantified ~22hrs later by flow cytometry. 
Untreated cells were taken as 100% fluorescence and all other values expressed relative to this (see 
Section.2.8.2). (B) Characterisation of the CAR-binding Capacity of Knob477dlTAYTA20. KnobA20 and 
Knob477dlTAYTA20 were assessed for their ability to inhibit the infection of Ad5-EGFPWT. CHO-CAR cells 
were incubated with increasing concentrations of KnobA20 or Knob477dlTAYTA20 (0.001-100μg/105 cells). 
KnobWT was included as a control at concentrations of 0.01- and 0.1μg/105 cells (data not shown), and the 
experiment performed exactly as described above. Results were analysed by non-linear regression fitted 
to a sigmoidal curve, using GraphPad Prism Version 3.03 (GraphPad Software, San Diego, USA). Data 
represent the mean ± SD of triplicate samples and are representative of two independent experiments 
carried out on different occasions. Statistical significance was determined using the unpaired Student’s t-
test comparing the means of each sample when compared with the virus alone sample, or between 
treated groups, as indicated on the histogram (* indicates a P-value of <0.05, **** p<0.0001, bars indicate 
SD, NS = not statistically significant, p>0.05). 
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Once the combination mutation virus, Ad5-477dlTAYTA20, had been generated and 
purified to sufficient titres, its in vitro characteristics were compared with Ad5-EGFPWT 
and Ad5-EGFPA20. Additionally, the Ad5-485dlTAYTA20 mutant was generated and 
purified, although its titres were substantially lower than the other viruses generated in 
this study (Table.14). Therefore, it was not selected for in vivo studies and accordingly, 
in vitro characterisation of this construct is limited to date.  
 
Table 14. Titres of Virus Constructs Used in this Studya
Ad5-EGFPA20
Virus Name                  Modification (E3)        Modification (Fibre)    Titre (VP/ml)    Titre (PFU/ml)   Ratio (VP/PFU)
Ad5-485dlTAYTA20
Ad5-EGFPWT
Ad5-477dlTAYTA20
a Viruses generated in this study are listed. Viral titres were obtained by TCID50 end-point dilution assay (PFU/ml), and spectrophotometrically at an
absorbance of OD600nm (VP/ml). Abbreviations are as follows; VP = Viral particle, PFU = Plaque forming unit, EGFP = Enhanced green fluorescent
protein, N.A = Not applicable, FMDV = Foot and Mouth Disease Virus, HIS = Histidine, Y = Tyrosine, A = Alanine, L = Leucine, K = Lysine, hNIS =
Human sodium iodide symporter, N.D = Not determined.
Δ6.7K/gp19K-EGFP
Δ6.7K/gp19K-EGFP
Δ6.7K/gp19K-EGFP
Δ6.7K/gp19K-EGFP
N.A
A20FMDV2 insertion
A20FMDV2 insertion, 
Y477A and dlTAYT
A20FMDV2 insertion, 
L485K and dlTAYT
1.79 x 1012
1.26 x 1012
3.71 x 1011
1.98 x 1010
1.80 x 1010
3.61 x 109
9.51 x 1084.65 x 1011
90
70
100
480
Ad5-485dlTAYT6XHIS
Ad5-477dlTAYT6XHIS Δ6.7K/gp19K-EGFP
Δ6.7K/gp19K-EGFP
A20FMDV2 insertion, 
Y477A and dlTAYT
A20FMDV2 insertion, 
L485K and dlTAYT
N.D
N.D
Ad5-hNISA20 Δ6.7K/gp19K-hNIS A20FMDV2 insertion N.D N.D N.D
Ad5-Δ24-EGFPA20 Δ6.7K/gp19K-EGFP A20FMDV2 insertion N.D N.D N.D
N.D N.D
N.D N.D
 
 
4.2.1 Comparative Infectivity of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 
on a Panel of ανβ6-Expressing Cell Lines. The transduction efficiency of Ad5-
477dlTAYTA20 was compared with Ad5-EGFPWT, and Ad5-EGFPA20 using a selected 
panel of carcinoma lines (Fig.4.12). In agreement with results obtained in previous 
transduction experiments (see Fig.3.13), Ad5-EGFPA20 displayed significantly improved 
infectivity in all cell lines tested (p<0.0001). Importantly, the CAR-binding ablated 
mutant Ad5-477dlTAYTA20 retained this ability, also significantly enhancing the 
transduction of all cell lines tested (p<0.0001). In fact, the transduction efficiency of 
Ad5-477dlTAYTA20 in CAOV3 and DX3-β6 cells was superior to that of Ad5-EGFPA20 
(p<0.0001 and p=0.033, respectively). Thus, we concluded that the introduction of the 
477dlTAYT set of mutations into the fibre did not interfere with the ability of the 
A20FMDV2 peptide to promote viral entry through ανβ6.  
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4.2.2 Comparative Cytotoxicity of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-
477dlTAYTA20 on a Panel of ανβ6-Expressing Lines. A comparative cytotoxicity 
profile (MTT) was generated using a selected panel of human carcinoma cell lines, 
comparing Ad5-477dlTAYTA20, with Ad5-EGFPWT and Ad5-EGFPA20 (Fig.4.13A-F). 
Cells (A549, BT-20, CA1a, CAOV3, SKOV3ip1 and TR126), were infected with doses 
of virus ranging from MOI 0.0001-100 PFU/cell, and cytotoxicity determined 120hrs 
post-infection.  
 
When compared to Ad5-EGFPWT, Ad5-477dlTAYTA20 exhibited increased cytotoxicity 
(EC50) in low-moderate CAR-expressing lines; BT-20 (~13-fold, p=0.0006), CA1a (~8-
fold, p=0.002), CAOV3 (~8-fold, p=0.049), SKOV3ip1 (~28-fold, p<0.0001) and TR126 
(~3-fold, p>0.05, not significant). Additionally, non-CAR binding virus Ad5-
485dlTAYTA20, also displayed improved cytotoxicity over Ad5-EGFPWT in each of the 
low-moderate CAR-expressing cell lines tested; CA1a (~14-fold, p=0.0001), CAOV3 
(~7-fold, p=0.151, not significant) and SKOV3ip1 cells (~80-fold, p<0.0001). 
Figure.4.12 Comparative Infectivity of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 on a 
Panel of ανβ6-Expressing Cell Lines. The transduction efficiency of each virus was assessed following 
infection at an MOI 10 (PFU/cell). Cells were exposed to virus for 1hr at 4˚C, and EGFP transgene 
expression quantified by flow cytometry ~22hrs post-infection (see Section.2.8.2). Histogram shows the 
% EGFP positive cells gated in FL1-H, arranged in order of ascending CAR-expression (see Table.10). 
Data represent the mean ± SD of triplicate samples, from a single experiment. Statistical significance 
was determined using the unpaired Student’s t-test to compare the means of each group (**** indicates a 
P-value <0.0001, NS = not statistically significant, p>0.05, bars indicate SD, no bars represent SD values 
smaller than the symbol used. †CA1a is abbreviated from MCF10CA1a.  
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a EC50 values represent half the maximal effective concentration of virus per cell . Viability was assessed
by MTT assay and results analysed by non-linear regression fitted to a sigmoidal curve . Values
expressed in Plaque Forming Units (PFU/Cell) . N.D = Not determined . †CA1a is abbreviated from
MCF10CA1a.
Table 15. EC50 Values (PFU/Cell)a
CAOV3 SKOV3ip1 
0.24
0.37
7.10
0.38
0.25
0.14
0.40
A549
0.46
2.05Ad5-485dlTAYTA20 N.D 0.04 N.D0.42 0.09
3.09
 
 
 
 
 
 
 
 
 
However, both CAR-modified viruses displayed decreased cytotoxicity in high CAR, 
A549 cells, resulting in ~6-fold decrease for Ad5-477dlTAYTA20 (p=0.002) and a ~15-
Figure.4.13 Comparative Cytotoxicity Profiles for Ad5-EGFPWT, Ad5-EGFPA20, Ad5-477dlTAYTA20
and Ad5-485dlTAYTA20 on a Panel of ανβ6-Expressing Cell Lines. Cytotoxicity was determined by 
MTT assay, carried out 120hrs post-infection, with virus concentrations ranging from 0.0001-100 PFU/cell 
and mean percentage survival was expressed as a percentage of uninfected cells (Uninfected cells are 
represented on the X-axis as 0, following a break in the logarithmic scale). Cell lines investigated were; 
(A) A549 and (B) BT-20, (C) †CA1a (D) CAOV3 (E) SKOV3ip1 and (F) TR126. Dose-response curves 
were generated by non-linear regression analysis using GraphPad Prism Version 3.03 (GraphPad 
Software, San Diego, CA). EC50 values for the dose response curves are displayed in Table.15. 
Cytotoxicity profiles shown are representative of a single experiment carried out using triplicate samples. 
The unpaired Student’s t-test was used to demonstrate the significance of the difference in EC50 values for 
each virus (N.D = Not Determined, NS = not statistically significant, p>0.05, bars indicate SD, no bars 
represent SD values smaller than the symbol used). †CA1a is abbreviated from MCF10CA1a.  
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fold decrease for Ad5-485dlTAYTA20 (p=0.003). However, the latter result was 
expected, as the native CAR-binding of these vectors is ablated and A549 cells 
express almost negligible levels of ανβ6 and ανβ8 (<5%, see Table.10 and Table.11), 
precluding CAR-independent entry via these surrogate receptors. When compared with 
Ad5-EGFPA20, the CAR-binding ablated viruses also varied in their ability to induce 
cytotoxicity. The cytotoxic effect of Ad5-477dlTAYTA20 was impaired in BT-20 cells (~4-
fold reduction, p=0.002) and TR126 cells (~6-fold reduction, p=0.024). However, in the 
majority of the cell lines tested, the cytotoxicity of Ad5-477dlTAYTA20 was either 
increased significantly (SKOV3ip1; ~1.5-fold, p=0.034), or did not differ from Ad5-
EGFPA20 (A549; p=0.255, CA1a; p=0.435 and CAOV3; p=0.366). When compared to 
Ad5-EGFPA20, Ad5-485dlTAYTA20 displayed a ~4-fold decrease in cytotoxicity in A549 
cells, however this was not significant (p=0.124). In fact, EC50 values obtained for this 
virus did not differ significantly from Ad5-EGFPA20 in two further cell lines investigated 
(CA1a; p=0.968 and CAOV3; p=0.166). Moreover, it displayed significantly increased 
cytotoxicity in SKOV3ip1 cells (p=0.0009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section.4.3 Validation of ΔCAR/Blood Factor Binding Ablated A20-
Modified Viral Mutants 
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A fundamental role for serum/coagulation factors (ie. FVII, FIX, FX, Protein C and 
C4BP) in directing liver uptake of Ad5 following systemic delivery in mice, has been 
demonstrated in recent years (Alba et al., 2009; Kalyuzhniy et al., 2008; Parker et al., 
2006; Shayakhmetov et al., 2005b; Vigant et al., 2008; Waddington et al., 2008). 
Coagulation factor mediated hepatocyte transduction is thought to result from 
engagement with heparan sulphate proteoglycans (HSPGs), and/or low-density 
lipoprotein receptor-related protein, LRP. FX-mediated enhancement of hepatocyte 
transduction in vivo has been reported to occur through a direct interaction between FX 
and Ad5 hexon (Alba et al., 2009; Kalyuzhniy et al., 2008; Vigant et al., 2008; 
Waddington et al., 2008). Conversely, FIX and C4BP have been shown to interact with 
the fibre knob domain (Gaggar et al., 2007; Shayakhmetov et al., 2005b). The 
477dlTAYT set of mutations which was genetically incorporated into the fibre, to 
generate Ad5-477dlTAYTA20, has been reported to ablate binding to FIX and C4BP (the 
reported vector had a FLAG epitope in place of the A20 peptide). The authors reported 
that this fibre modified vector had reduced liver transduction, and limited co-localisation 
with Kupffer cells in vivo following intravenous delivery (Shayakhmetov et al., 2005b).  
 
4.3.1 Comparative Infectivity +/- FIX, FX and Heparin on CHO-K1 Cells. Using an in 
vitro assay, we decided to investigate if FIX and/or FX could enhance the Ad5-
EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20-mediated infection of HSPG-expressing 
CHO-K1 cells (Fig.4.14A). We did not assess the levels of HSPGs on the surface of 
CHO-K1 cells for a number of reasons; firstly, suitable antibodies for detection by flow 
cytometry are limited, and expensive, due to the complexity of the post-translationally 
modified glycosaminoglycan (GAG) side chains. Additionally, CHO-K1 cells have 
previously been published as a suitable in vitro model for assessing coagulation factor 
mediated Ad-enhancement (Liu et al., 2009; Parker et al., 2006). C4BP was not 
assessed as it was not commercially available when these experiments were 
performed. Cells were co-incubated for 2hrs at 37˚C with each virus (MOI 10), and 
physiological concentrations of commercially available human FIX, FX, or FX with 
porcine heparin to inhibit HSPGs. We did not have sufficient stocks of FIX to test in 
combination with heparin. Indeed, in this study approximately 3.5% infection was 
observed with Ad5-EGFPWT in the absence of any treatment with blood factors. 
Treatment with both FIX and FX resulted in enhancing the infectivity of Ad5-EGFPWT 
~4-fold and ~6-fold, respectively (p=0.001 and p<0.0001). The effect of FX was 
completely inhibited in the presence of heparin, confirming that the enhancement was 
mediated through HSPGs. In addition, the low level infection observed with Ad5-
EGFPWT alone was also completely inhibited upon co-incubation with heparin, 
suggesting that the basal level of infectivity was due to entry via HSPGs. However, this 
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was not an unusual observation, as HSPGs have previously been reported to act as an 
alternative, lower affinity receptor for Ad5 in the absence of CAR (Dechecchi et al., 
2001, 2002). Similarly, Ad5-EGFPA20 alone infected CHO-K1 cells to a low level (~3% 
infected cells). Interestingly, FIX did not appear to enhance the infectivity of Ad5-
EGFPA20 (p=0.101), despite the fact that this virus does not contain any of the putative 
blood factor binding mutations which would eliminate an interaction between FIX and 
the fibre. As expected, FX improved entry very effectively (~11-fold increase, 
p=0.0004), and again this FX-mediated infectivity enhancement was ablated in the 
presence of heparin (p=0.0004). In agreement with results obtained for Ad5-EGFPWT, 
heparin alone also inhibited Ad5-EGFPA20 infection of these cells (p=0.018).  
Unexpectedly, the Ad5-477dlTAYTA20 virus alone infected ~30% of the CHO-K1 cells. 
No significant infectivity enhancement was observed upon co-incubation of this virus 
with physiological concentrations of FIX (p=0.052), which was consistent with 
previously published data for this mutant, which is mutated for binding to FIX and C4BP 
(Shayakhmetov et al., 2005). FX significantly enhanced the infectivity of Ad5-
477dlTAYTA20 (~2-fold, p<0.0001), an effect which was again inhibited by co-incubation 
with heparin. Interestingly, heparin alone completely inhibited all infection with Ad5-
477dlTAYTA20. This suggested that the Ad5-477dlTAYTA20 had a greatly enhanced 
interaction with HSPGs, when compared with the lower level interaction with Ad5-
EGFPWT and Ad5-EGFPA20. This effect was reproduced in repeat experiments, and in 
CHO-CAR cells (below, Fig.4.14B).  
 
4.3.2 Comparative Infectivity +/- FIX, FX and Heparin on CHO-CAR cells. An 
identical experiment, to that described above, was carried out using CHO-CAR cells 
(Fig.4.14B). As expected, both Ad5-EGFPWT and Ad5-EGFPA20 infected CHO-CAR 
cells to a high level (~93%), although Ad5-EGFPA20 was marginally less efficient at 
doing so (~86%, p=0.0005). The 2hr incubation with an MOI 10 of both these viruses 
resulted in infectivity levels which were so high that it was difficult to interpret the 
effects of FIX or FX-mediated enhancement. However, results mirrored those obtained 
on CHO-K1 cells (Fig.4.14A), demonstrating that FX significantly enhanced the 
infection of both Ad5-EGFPWT and Ad5-EGFPA20 (p=0.019 and p<0.0001, respectively), 
whereas FIX enhanced only the infection of Ad5-EGFPWT (p=0.004), but not that of 
Ad5-EGFPA20 or Ad5-477dlTAYTA20 (p=0.057 and p=0.815, respectively). These data, 
when considered collectively with data obtained in CHO-K1 cells, suggested that these 
viruses do not interact with FIX in vitro to promote enhanced infection.  
 179
NS
NS
****
*
**
****
****
0
10
20
30
40
50
60
70
80
90
100
Ad5-EGFPWT
Ad5-EGFPA20
Ad5-477dlTAYTA20
%
 E
G
FP
 P
os
iti
ve
 C
el
ls
U
ni
nf
ec
te
d
Vi
ru
s 
A
lo
ne
+F
IX
+F
X
+H
ep
+H
ep
/F
X
U
ni
nf
ec
te
d
Vi
ru
s 
A
lo
ne
+F
IX
+F
X
+H
ep
+H
ep
/F
X
U
ni
nf
ec
te
d
Vi
ru
s 
A
lo
ne
+F
IX
+F
X
+H
ep
+H
ep
/F
X
***
NS
NS
****
****
***
****
U
ni
nf
ec
te
d
Vi
ru
s 
A
lo
ne
+F
IX
+F
X
+H
ep
+H
ep
/F
X
U
ni
nf
ec
te
d
V
iru
s 
A
lo
ne
+F
IX
+F
X
+H
ep
+H
ep
/F
X
U
ni
nf
ec
te
d
Vi
ru
s 
A
lo
ne
+F
IX
+F
X
+H
ep
+H
ep
/F
X0
10
20
30
40
50
60
70 Ad5-EGFPWT
Ad5-EGFPA20
Ad5-477dlTAYTA20
%
 E
G
FP
 P
os
iti
ve
 C
el
ls
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.4.14 (A) Comparative Infectivity +/- FIX, FX and Heparin on CHO-K1 Cells. The effect of 
coagulation factors FIX and FX, on the infectivity of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20, 
was assessed on CHO-K1 cells. Ad5 interactions with FIX/FX promote entry via engagement with 
Heparan Sulphate Proteoglycans (HSPGs), therefore porcine heparin was included as an inhibitor for 
blood factor mediated entry (used at 10μg/ml). Cells were infected for 2hrs at 37˚C with virus alone (MOI 
10; PFU/cell), or virus co-incubated with physiological concentrations of blood factors FIX, FX or 
FX/Heparin. EGFP gene transfer was assessed by flow cytometry (see Section.2.8.5). (B) Comparative 
Infectivity +/- FIX, FX and Heparin on CHO-CAR Cells. This experiment was carried out exactly as 
described above, and in parallel to (A). Data are representative of 2-3 independent repeat experiments, 
using triplicate samples (N=3). The unpaired Student’s t-test was used to demonstrate the significance of 
the difference of the mean of each group (*** indicates a P-value of <0.001, **** p<0.0001, NS = not 
statistically significant, p>0.05, bars indicate SD, no bars represent SD values smaller than the symbol 
used). Statistics displayed above the histogram for Ad5-477dlTAYTA20 +Hep, and +FX/Hep, in both figures 
refer to the difference when compared to the corresponding virus+FX sample.  
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Ad5-477dlTAYTA20 is a non-CAR binding virus and therefore should not, theoretically, 
infect CHO-CAR cells. However, as its infectivity profile in CHO-CAR cells was found to 
be identical to that in CHO-K1 cells, this confirmed that its entry was CAR-independent, 
and modulated by an alternative receptor, which is expressed on both CHO-K1 and 
CHO-CAR cells. Results obtained on both cell lines when co-incubating Ad5-
477dlTAYTA20 with heparin confirmed this, demonstrating that this construct efficiently 
utilises HSPGs as an alternative mode of entry.  
 
4.3.3 Comparative Infectivity +/- FIX, FX and Heparin on Human Carcinoma Lines, 
BT-20 and TR126. Coagulation factors have been implicated in tumour transduction in 
vivo, in addition to their roles in promoting uptake of Ad5 by the reticuloendothelial 
system (Coughlan et al., 2009; Gimenez-Alejandre et al., 2008; Koski et al., 2009; Liu 
et al., 2009; Shashkova et al., 2008). Therefore, it was thought that investigating the 
effects of FIX and FX on enhancing viral uptake in human carcinoma lines in vitro 
could, potentially, help to predict the success of tumour transduction in vivo (personal 
communication, Dr. Ramon Alemany), particularly if coagulation factors are depleted. 
The ability of FIX and FX to enhance the infection of human carcinoma cell lines, BT-20 
and TR126 was assessed using the same approach as described above.  
 
In BT-20 cells (Fig.4.15A), both FIX and FX significantly enhanced the infection of Ad5-
EGFPWT (~2.5-fold; p=0.003 and ~4-fold; p=0.0003, respectively) and again, the FX-
mediated enhancement through HSPGs was inhibited upon co-incubation of the virus-
FX suspension with heparin (p<0.0001). Interestingly, in these cells, neither FIX, nor 
FX improved the infection of Ad5-EGFPA20 or Ad5-477dlTAYTA20. The inability of FIX to 
mediate infectivity enhancement of Ad5-EGFPA20 (p=0.906), and Ad5-477dlTAYTA20 
(p=0.96) was expected, corroborating results obtained on CHO-K1 and CHO-CAR cells 
which suggest that the A20-modified viruses do not interact with FIX. However, the lack 
of enhancement with FX was unexpected. The interaction with FX is modulated 
through the hexon, and this interaction succeeded in enhancing the infection of both 
Ad5-EGFPA20 and Ad5-477dlTAYTA20 in previous experiments (Fig.4.14A and B). 
Therefore, the apparent lack of enhancement in BT-20 cells may be due to a saturating 
effect of the virus, or perhaps as a result of lower level expression of HSPGs (or at 
least those HSPG forms required for the FX-interaction).  
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Figure.4.15 (A) Comparative Infectivity +/- FIX, FX and Heparin on BT-20 Breast Carcinoma Cells. 
The effect of coagulation factors FIX and FX, on the infectivity of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-
477dlTAYTA20, was assessed on BT-20 cells. Ad5 interactions with FIX/FX promote entry via engagement 
with Heparan Sulphate Proteoglycans (HSPGs) therefore porcine heparin was included as an inhibitor for 
blood factor mediated entry (used at 10μg/ml). Cells were infected for 2hrs at 37˚C with virus alone (MOI 
10; PFU/cell), or virus co-incubated with physiological concentrations of blood factors FIX, FX or 
FX/Heparin. EGFP gene transfer was assessed by flow cytometry (see Section.2.8.5). (B) Comparative 
Infectivity +/- FIX, FX and Heparin on TR126 HNSCC Cells. The effect of coagulation factors FIX and 
FX, on viral infectivity was assessed on TR126 cells. This experiment was carried out exactly as described 
above. Data are representative of two independent repeat experiments, using triplicate samples (N=3). 
The unpaired Student’s t-test was used to demonstrate the significance of the difference of the mean of 
each group (** indicates a P-value of <0.01, *** p<0.001, **** p<0.0001, NS = not statistically significant, 
p>0.05, bars indicate SD, no bars represent SD values smaller than the symbol used). Statistics displayed 
above the histogram for +FX/Hep samples refer to the difference when compared to the corresponding 
virus+FX sample.  
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In TR126 cells (Fig.4.15B), both FIX and FX significantly enhanced the infection of 
Ad5-EGFPWT (~7-fold increased for both, p<0.0001), and FX-mediated enhancement 
was inhibited with heparin (p<0.0001). Consistent with results obtained with CHO-K1, 
CHO-CAR and BT-20 cells, FIX did not enhance the infection of Ad5-EGFPA20 
(p=0.786). As expected, infection of TR126 cells with Ad5-EGFPA20 was enhanced 
significantly in the presence of FX (p=0.008), and this enhancement was ablated by co-
incubation with heparin (p=0.002). A similar profile was found with Ad5-477dlTAYTA20; 
once again FIX did not augment infectivity (p=0.384), but FX enhanced infection 
significantly (p=0.001), an effect which was reversed in the presence of heparin 
(p=0.0013). 
 
4.3.4 Comparative Infectivity +/- FIX, FX and Heparin on -β6 Expressing DX3-β6 
Cells. As an in vivo DX3-β6 xenograft model had already been established in the 
Tumour Biology Laboratory, we decided to investigate the ability of coagulation factors, 
FIX and FX, to enhance the infectivity of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-
477dlTAYTA20 in these -β6 transfected cells (Fig.4.16A and B). At an MOI 10, FIX 
enhanced the infectivity of Ad5-EGFPWT (p=0.011), but had no significant effect on the 
infectivity of Ad5-EGFPA20 or Ad5-477dlTAYTA20 (p=0.686 and p=0.457, respectively). 
FX augmented Ad5-EGFPWT infectivity approximately 20-fold (p<0.0001), and also 
enhanced the entry of Ad5-EGFPA20 and Ad5-477dlTAYTA20, although the effect was 
not clearly visible due to high level transduction at MOI 10 (p=0.008 and p=0.018, 
respectively). FX-induced Ad5-EGFPWT enhancement was completely ablated upon co-
incubation with heparin; however inhibition of HSPGs did not completely ablate 
infection with Ad5-EGFPA20 and Ad5-477dlTAYTA20 which were capable of high 
efficiency entry through ανβ6 integrin.  
 
This experiment was repeated using an MOI of 1.0, and similar effects were observed 
(Fig.4.16B). However, at this low concentration of virus FIX did not enhance the 
infectivity of Ad5-EGFPWT, Ad5-EGFPA20 or Ad-477dlTAYTA20. Consistent with data 
obtained previously, FX enhanced the infection of Ad5-EGFPWT, Ad5-EGFPA20 and 
Ad5-477dlTAYTA20 significantly (p<0.0001, p=0.0005 and p=0.0008), and again heparin 
reversed this effect (p<0.0001, for all). Heparin did not impair the transduction of A20-
modified viruses, Ad5-EGFPA20 and Ad5-477dlTAYTA20, which maintained high level 
transduction through alternative receptor, ανβ6.  
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Figure.4.16 (A) Comparative Infectivity +/- FIX, FX and Heparin on DX3-β6 Transfected Cell Line 
(MOI 10). The effect of coagulation factors FIX and FX, on the infectivity of Ad5-EGFPWT, Ad5-EGFPA20 
and Ad5-477dlTAYTA20, was assessed on DX3-β6 cells. Ad5 interactions with FIX/FX promote entry via 
engagement with Heparan Sulphate Proteoglycans (HSPGs) therefore porcine heparin was included as 
an inhibitor for blood factor mediated entry (used at 10μg/ml). Cells were infected for 2hrs at 37˚C with 
virus alone (MOI 10; PFU/cell), or virus co-incubated with physiological concentrations of blood factors 
FIX, FX or FX/Heparin. EGFP gene transfer was assessed by flow cytometry (see Section.2.8.5). (B) 
Comparative Infectivity +/- FIX, FX and Heparin on DX3-β6 Transfected Cell Line (MOI 1). This 
experiment was carried out exactly as described above, however cells were infected with a lower MOI (1). 
Data are representative of two independent repeat experiments, using triplicate samples (N=3). The 
unpaired Student’s t-test was used to demonstrate the significance of the difference of the mean of each 
group (* indicates a P-value of <0.05, ** p<0.01, *** p<0.001, **** p<0.0001, NS = not statistically 
significant, p>0.05, bars indicate SD, no bars represent SD values smaller than the symbol used). 
Statistics displayed above the histogram for +FX/Hep samples refer to the difference when compared to 
the corresponding virus+FX sample.  
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Chapter.4 Discussion  
 
In this chapter, we have shown in vitro that Ad5-477dlTAYTA20, a CAR- and blood 
factor binding ablated Ad5 vector retargeted to ανβ6, retains its high efficiency 
interaction with its target in a manner comparable to the parental vector, Ad5-EGFPA20. 
We have also verified that the native CAR receptor binding capacity of this virus is 
ablated, as is its ability to interact with FIX to promote infectivity enhancement through 
HSPGs. Furthermore, we have observed that the combination of the various introduced 
mutations (477dlTAYTA20) in this virus have conferred an unexpected affinity for 
HSPGs, in excess of the basal level often observed with Ad5-EGFPWT. This may have 
implications for the in vivo characteristics of this virus. Additionally, and again 
unexpectedly, we have verified that the Ad5-EGFPA20 vector fails to interact with FIX in 
promoting infectivity enhancement, an effect presumably mediated indirectly by the 
insertion of the A20FMDV2 peptide in the HI loop of the fibre knob.  
 
 
Section.4.1 In Vitro Characterisation of ΔCAR/FIX-Binding KnobA20 Mutants 
 
The recombinant knob proteins generated in this study proved very useful in 
characterising the functional effects of the various mutations introduced, prior to 
contemplating their incorporation into the Ad5-EGFPA20 background by homologous 
recombination. Mutant Knob proteins which featured CAR-binding ablation mutations 
Y477A, or L485K, were generated early in these studies, when the initial objectives 
were to generate a CAR-binding ablated, A20-retargeted Ad5 vector. In time, 
increasing evidence reported in the literature highlighted the redundancy of CAR in the 
hepatotropism and biodistribution of Ad5 (Alemany & Curiel, 2001; Leissner et al., 
2001; Martin et al., 2003; Mizuguchi et al., 2002; Nicol et al., 2004; Smith et al., 2002), 
and emphasised the importance of various blood components in governing successful 
targeting in vivo (Kalyuzhniy et al., 2008; Lyons et al., 2006; Parker et al., 2006; 
Shayakhmetov et al., 2005b; Vigant et al., 2008; Waddington et al., 2008). Therefore, 
the focus of the project shifted to the generation of a vector which was retargeted to 
ανβ6, while simultaneously detargeted from CAR, and coagulation factor binding.  
 
The Y477A and L485K, CAR-binding mutant pQE plasmids had been constructed early 
in this study but, only KnobL485KWT was produced as recombinant knob protein. 
However, both plasmids were subsequently used as templates for the construction and 
generation of Knob477dlTAYTA20 and Knob485dlTAYTA20, and their corresponding WT 
controls. The ability of the A20-modified Knob proteins to form homotrimers was 
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confirmed to ensure that the introduced mutations were compatible with fibre assembly, 
which is critical for the formation of a functional Ad5 particle (Hong & Engler, 1996; 
Novelli & Boulanger, 1991). These constructs were further validated to demonstrate 
that they retained the high efficiency binding and functional inhibition of ανβ6 observed 
with KnobA20 in earlier experiments (see Fig.3.8, Fig.3.9 and Fig.3.10) and, finally, the 
relative success of each CAR-binding mutation was assessed for each mutant.  
 
Both Knob477dlTAYTA20 and Knob485dlTAYTA20 retained their affinity for binding to 
ανβ6, in a manner comparable to KnobA20 (Fig.4.8A and B). In a flow cytometry based 
competition experiment, using an anti-ανβ6 antibody (53A.2) the IC50 values obtained 
for each protein were found to be identical to the value calculated for KnobA20 
(IC50=0.03μg/105 cells) in a previous experiment (see Fig.3.8). Furthermore, both 
mutant proteins also completely abrogated ανβ6-dependent VB6 cell migration towards 
LAP, at concentrations equivalent to KnobA20 (≤10μg/ml, Fig.4.10). Collectively, these 
data confirmed that the incorporation of the 477/485dlTAYT set of mutations had 
negligible effects on the function of the A20FMDV2 peptide within the structural 
confines of the Ad5 fibre knob domain. 
 
Next, we wished to validate the success of the CAR/dlTAYT mutations in ablating 
native Ad5 receptor binding (Fig.4.11A). The use of recombinant Knob or fibre to inhibit 
the infection of the virus from which it was derived, is a well established assay 
(Freimuth et al., 1999; Santis et al., 1999). Competition experiments with Ad5-EGFPWT, 
and each mutant Knob protein were carried out on CHO-CAR cells (generously 
provided by Dr. George Santis). Parental CHO cells are sufficiently refractory to human 
adenovirus infection, such that transfection of the CAR receptor facilitates Ad5 infection 
in a CAR-dependent manner. Thus, in principle, Knob proteins which retained CAR-
binding would inhibit Ad5-EGFPWT infection, and those which featured successfully 
ablated CAR-binding determinants, would be unable to do so.  
 
As expected, CAR-binding intact proteins, KnobWT and KnobA20, inhibited >95% of the 
infection with Ad5-EGFPWT (p<0.0001). With the exception of KnobL485KA20 and 
Knob477dlTAYTA20, all CAR-binding mutant Knob proteins failed to significantly inhibit 
Ad5-EGFPWT infection (MOI 10), even at the high concentration of Knob protein used 
(100μg/105 cells), which was ~1000-fold higher than the calculated IC50 for KnobWT 
mediated inhibition of native Ad5 infection (Kirby et al., 2000). Knob477dlTAYTA20 
marginally reduced Ad5-EGFPWT infection, although this reduction was statistically 
significant (p=0.02). This result was unexpected, especially as the corresponding WT 
control, Knob477dlTAYTWT completely failed to inhibit infection with Ad5-EGFPWT. 
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However, this effect was possibly explained by results obtained in later experiments 
with the Ad5-477dlTAYTA20 virus construct (see Fig.4.14A and B) in which we 
confirmed, through inhibition with heparin, that this virus has some affinity for HSPGs, 
found on the surface of both CHO-K1, and CHO-CAR cells. Therefore, it is plausible 
that the high concentration of Knob477dlTAYTA20 (100μg/105 cells) used in this 
experiment may have promoted binding of this protein to HSPGs, perhaps creating a 
steric hindrance to subsequent binding of Ad5-EGFPWT, or potentially inhibiting the 
portion of Ad5-EGFPWT infection which is mediated through HSPGs.  
 
 
Section.4.2 In Vitro Characterisation of ΔCAR/FIX-Binding Ad5-EGFPA20 Mutants; 
Infectivity and Cytotoxicity 
 
In recent years, the importance of removing the CAR-binding capacity of Ad5 vectors 
lost its critical appeal. This was due, in part, to various conflicting reports regarding the 
role of CAR in liver transduction (Einfeld et al., 2001; Leissner et al., 2001; Martin et al., 
2003; Smith et al., 2002; Smith et al., 2003a), in addition to the lack of altered 
biodistribution in vivo following administration of CAR-binding ablated mutant Ads 
(Alemany & Curiel, 2001). However, CAR detargeting has once again become an 
important consideration when designing vectors for clinical applications, as new 
evidence has shown that human, but not murine erythrocytes express CAR on their 
surface (Carlisle et al., 2009; Seiradake et al., 2009). This has highlighted yet another 
challenge to achieving successful tumour targeting in vivo, as it has been shown that 
Ad5-based vectors can be sequestered by erythrocytes in the circulation, failing to 
reach their target tissue (Carlisle et al., 2009).  
 
Ad5 binding to CAR represents the initial event in cell attachment in vitro (Bergelson et 
al., 1998; Kirby et al., 2000). However, through the incorporation of targeting ligands at 
various sites on the capsid, this dependence on CAR can be circumvented, rendering 
CAR-binding dispensable. Therefore, the relative efficiency of Ad5-477dlTAYTA20, in 
promoting high efficiency infection through ανβ6, was compared with that of Ad5-
EGFPA20 and Ad5-EGFPWT (Fig.4.12). In the previous chapter, using a panel of ανβ6-
expressing human carcinoma lines, we demonstrated that the entry of Ad5-EGFPA20 
was superior to that of Ad5-EGFPWT, and was dependent on the inclusion of the 
A20FMDV2 peptide in the HI loop of the fibre (see Fig.3.13 and Fig.3.15). However, we 
wanted to absolutely confirm that the introduction of the 477dlTAYT set of mutations 
did not detrimentally affect this interaction with ανβ6. This concern was unfounded, as 
Ad5-477dlTAYTA20 successfully mediated infection in a manner almost identical to the 
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unmodified, CAR-binding intact virus Ad5-EGFPA20, retaining superior transduction 
levels over Ad5-EGFPWT.   
 
We also compared the relative cytotoxicity of Ad5-477dlTAYTA20, and in some cases 
Ad5-485dlTAYTA20, with Ad5-EGFPA20 and Ad5-EGFPWT (Fig.4.13). Overall, the 
ablation of CAR binding did not appear to impair the ability of Ad5-477dlTAYTA20 or 
Ad5-485dlTAYTA20 to exert cytotoxic effects on the cells investigated. In fact, 
cytotoxicity was substantially improved when compared with Ad5-EGFPWT, and was 
generally comparable to Ad5-EGFPA20. As expected, Ad5-485dlTAYTA20 performed 
less efficiently in A549 cells. However, the EC50 value obtained for Ad5-477dlTAYTA20 
in A549 cells (0.4 PFU/cell) indicated that these cells were still relatively sensitive to 
infection with Ad5-477dlTAYTA20, despite the lack of known receptors for this virus 
(ανβ6 or ανβ8), and its inability to utilise CAR for attachment. A possible explanation for 
this can be that entry, and/or intracellular spread, was compensated by its ability to use 
HSPG as an alternative attachment receptor (see Fig.4.14A).  
 
Expression of the CAR receptor is restricted to the tight junctions, where it acts as a 
cell-adhesion molecule, forming trans-epithelial homodimeric complexes (Cohen et al., 
2001; Farmer et al., 2009; Honda et al., 2000; Ito et al., 2000). Recently, Ad5 
interactions with CAR have been shown to promote the homodimerisation of the 
molecule in addition to inducing the activation of -β1 and β3 integrin subunits, through 
the activation of the p44/42 MAPK signal transduction pathway (Farmer et al., 2009). 
This may represent a strategy on the part of the virus to enhance its own infection. 
Interestingly, an alternative function for fibre binding to CAR has been described; in 
which excess fibre produced by Ad5 competitively inhibits CAR homodimer formation, 
thus disrupting tight junction integrity and permitting efficient intracellular spread and 
viral escape (Walters et al., 2002). Therefore, it is important to consider that CAR-
binding ablated viruses may be impaired in their ability to spread via paracellular 
spaces. However, intra-epithelial barriers are often dysregulated in the context of 
human epithelial cancers, and therefore the aforementioned function of the fibre-CAR 
interactions may be redundant in tumour cells (Dhawan et al., 2005; Hoover et al., 
1998). Indeed, in support of this we did not observe significant loss of cytotoxic efficacy 
with the CAR-binding ablated constructs, at least in the cell lines tested.  
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Section.4.3 In Vitro Characterisation of ΔCAR/FIX-Binding Ad5-EGFPA20 Mutants; 
Interactions with Coagulation Factors 
 
An Ad5 interaction with vitamin K-dependent coagulation factors now has been shown 
to be critical in directing hepatocyte transduction in vivo (Alba et al., 2009; Kalyuzhniy 
et al., 2008; Parker et al., 2006; Shayakhmetov et al., 2005b; Vigant et al., 2008; 
Waddington et al., 2008). Additionally, coagulation factors have been shown to 
enhance the infection of human carcinoma lines in vitro and have been also implicated 
in tumour transduction in vivo (Coughlan et al., 2009, Liu et al., 2009, Gimenez-
Alejandre et al., 2008, Shaskova et al., 2008, Shayakhmetov et al., 2005). However, 
this remains controversial. Depletion of vitamin-K dependent coagulation factors using 
warfarin has been reported to reduce viral uptake in the tumour following systemic 
delivery (Coughlan et al., 2009; Gimenez-Alejandre et al., 2008) whereas in contrast, it 
has also been reported that warfarin pre-treatment can enhance Ad5-mediated, anti-
tumoural efficacy (Shashkova et al., 2008). In addition, selective depletion of FX alone 
using X-bp (Factor X-binding protein) has been shown to improve tumour transduction 
with an Ad5/35 vector, presumably through its increased bioavailability as a direct 
result of the liver avoidance strategy employed (Liu et al., 2009). Taken as a whole, it is 
clear that the precise mechanisms which govern efficient tumour transduction with Ad5 
in vivo currently are not well characterised, and thus warrant further investigation.  
 
Prior to experiments where we assessed the tumour targeting efficiency of Ad5-
EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 following systemic delivery, we wanted 
to characterise the differential interactions of these constructs with coagulation factors 
FIX, and FX. For initial proof of principle studies we chose to use CHO-K1 cells, as 
they not readily infectable with Ad5 but express HSPGs, and therefore are most 
suitable for investigating coagulation factor dependent enhancement of infection. 
Studies on these and other cells (CHO-CAR, BT-20, TR126 and DX3-β6) yielded some 
interesting, and unexpected results. In all lines tested, except BT-20, FX successfully 
enhanced the infectivity of Ad5-EGFPWT, Ad5-EGFPA20 and A5-477dlTAYTA20 
(Fig.4.14A+B, Fig.4.15B and Fig.4.16). In BT-20 cells, FX failed to significantly 
enhance the infection of Ad5-EGFPA20 or Ad5-477dlTAYTA20, and its enhancement of 
Ad5-EGFPWT infection was not marked, although significant (Fig.4.15A). This 
suggested that these cells express low levels of HSPGs, or at least those variants 
required for the FX interaction. However, it is possible that other factors are involved, 
as the exact mechanisms which facilitate Ad5:FX:HSPG-mediated entry to cells, both 
in vitro and in vivo, have not been identified.  
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FIX enhanced the infectivity of Ad5-EGFPWT in all cell lines tested (except DX3-β6 cells 
infected at MOI 1.0, see Fig.4.16B). Interestingly however, FIX consistently failed to 
enhance the infection of Ad5-EGFPA20 and Ad5-477dlTAYTA20 in all cell lines 
investigated (Fig.4.14A+B, Fig.4.15A+B and Fig.4.16A+B). This finding was anticipated 
for Ad5-477dlTAYTA20, a viral mutant which features a range of mutations designed to 
abrogate FIX binding. However, the apparent inability of FIX to interact with unmodified 
Ad5-EGFPA20 was unexpected. The A20FMDV2 insertion within the HI loop is in close 
proximity to the putative blood factor binding molecular determinants (477dlTAYT) 
described by Shayakhmetov and colleagues (Shayakhmetov et al., 2005b). Therefore it 
is plausible that the A20FMDV2 modification has conferred a structural or steric 
hindrance which precludes FIX binding, even in the absence of the specific mutations.  
 
Another unexpected finding was that Ad5-477dlTAYTA20 appeared to have acquired an 
affinity for HSPGs, effectively utilising them as an alternative receptor for 
attachment/entry. HSPG receptors are known to bind to stretches of charged lysine (K) 
or arginine (R) residues (Fromm et al., 1995). However, analysis of the amino acid 
sequence of the knob domain of both Ad5-EGFPA20 and Ad5-477dlTAYTA20 did not 
reveal any differences in their lysine/arginine content, both having 12 and 5 residues, 
respectively (see Appendix II). Therefore, it seems likely that the 477dlTAYT set of 
g (E1A) of Frozen Liver Tissue Following Systemic Delivery of Virus 
e). Immediately post-necropsy, liver tissue (left lobe) was frozen at -80˚C in OCT-
ng cryomolds. Frozen tissue sectionfectivity enhancement of tumour cells in vitro 
(Gimenez-Alejandre et al., 2008; Liu et al., 2009; Shayakhmetov et al., 2005b), and 
interestingly, dysregulation of HSPGs have been described in various 
pathophysiological conditions, including cancer (Blackhall et al., 2001). Therefore, it will 
be important to ascertain if, and to what extent, HSPGs facilitate coagulation factor 
dependent tumour uptake in vivo, and whether the ability of the Ad5-477dlTAYTA20 
vector to utilise HSPGs for entry, will compete with, or complement, this pathway. 
 
The ability of the Ad5-EGFPA20 and Ad5-477dlTAYTA20 viruses alone to achieve 
infection levels equivalent to, or superseding that of Ad5-EGFPWT +FX in the tumour 
cell lines tested, suggested that these viruses may overcome the dependency on FX 
for high efficiency targeting in vivo, when delivered intravenously. Therefore, an in vivo 
targeting experiment was designed in which vitamin K-dependent coagulation factors 
would be depleted, using a previously described warfarin pre-treatment regime (see 
Chapter.6).  
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Chapter.5 In Vivo Assessment of Vector-Induced Toxicity in 
Immunocompetent Mouse Models 
 
Kupffer cells (KCs), the resident macrophages of the liver, are largely responsible for 
the rapid clearance of systemically delivered Ad5-based vectors from the circulation in 
mice (Lieber et al., 1997; Worgall et al., 1997). Depletion, or saturation of KCs, with 
high doses of Ad5, permits efficient hepatocyte transduction (Kuzmin et al., 1997; Liu et 
al., 2003; Schiedner et al., 2003b; Tao et al., 2001; Wolff et al., 1997), through a FX-
hexon dependent interaction (Alba et al., 2009; Kalyuzhniy et al., 2008; Vigant et al., 
2008; Waddington et al., 2008). Haemodynamic responses to Ad5 are causatively 
associated with the activation of hepatic endothelial cells by Ad-stimulated KCs 
(Schiedner et al., 2003a). Additionally, interactions between Ad5 and platelets, cause 
acute thrombocytopenia and can contribute to the development of coagulopathic 
conditions (Othman et al., 2007; Stone et al., 2007b). These co-ordinate interactions 
contribute to the extensive hepatocellular damage, and these many of these effects 
can be attributed to the induction of potent anti-viral innate immune responses. 
Consequently, these various interactions pose a major challenge to the clinical utility of 
Ad5.  
 
An Ad5 mutant, featuring a set of mutations (Y477A-dlTAYT) to inhibit binding of FIX 
and C4BP to the fibre knob, has previously been described (Shayakhmetov et al., 
2005b). This vector displayed reduced co-localisation with KCs, in addition to 
significantly reduced hepatotoxicity (ALT) and cytokine (IL-6, IFN-γ) induction in vivo. In 
this study, we incorporated this set of mutations into the Ad5-EGFPA20 genetic 
background to generate Ad5-477dlTAYTA20. Therefore, we wanted to compare the in 
vivo biodistribution, toxicity and haematological profiles of Ad5-477dlTAYTA20, Ad5-
EGFPWT and Ad5-EGFPA20 using different doses (2.5 and 4.0x1010vp/mouse), and 
different time-points post-infection (6 days, 4 days and 24hrs). Additionally, selected 
chemokine and cytokine profiles were obtained 6hrs and 24hrs post-infection with 4.0x 
1010vp/mouse (see Section.2.1.7).  
  
 
Section.5.1 Dose Escalation Hepatotoxicity Studies in Balb/c 
Immunocompetent Mice 
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All animal experiments were carried out at the facility of the Institut d’Investigació 
Biomèdica de Bellvitge, at the Institut Català d’Oncologia (ICO) in accordance with the 
regulations of the IDIBELL Ethical Committee for Animal Experimentation. Intravenous 
administration of virus was performed by Blanca Luena (technical staff). Necropsies 
were assisted by Dr. Manel Cascalló, Alena Gros, Francisca Alcayaga and Juan José 
Rojas. Blood samples were obtained immediately post-mortem by intra-cardiac 
puncture (performed by Francisca Alcayaga and Alena Gros). Quantification of 
AST/ALT from heparinised plasma and analysis of haematological profiles were carried 
out by the Clinical Veterinary Biochemistry Service at the Facultat de Veterinària, 
Universitat Autònoma de Barcelona. 
 
5.1.1 Determination of In Vivo Hepatotoxicity and Haematological Profiling (2.5 x 
1010vp/mouse). In order to assess comparatively the toxicity induced by Ad5-EGFPWT, 
Ad5-EGFPA20 and Ad5-477dlTAYTA20, immunocompetent Balb/c female mice (6 weeks) 
were administered intravenously with 2.5x1010vp/mouse. A control vector, Ad5-
477dlTAYT6XHIS was generated successfully by homologous recombination, but was not 
amplified, or purified prior to these experiments, due to time constraints. Animals were 
killed 6 days post-infection, a blood sample obtained by intracardiac puncture 
immediately post-mortem. Haematological profiles were obtained from whole blood 
samples and liver transaminase (ALT/AST) levels quantified from heparinised plasma.  
 
Significant loss of body weight can be an indirect indicator of virus-induced toxicity 
(Cascallo et al., 2007; Duncan et al., 1978). Therefore, body weight variations (%) were 
assessed for each cohort at various time-points post-infection (Fig.5.1A). On day 1 
post-virus administration, there was no difference in the percentage weight change of 
any of the viral groups when compared to the PBS control (p=0.073, p=0.46 and 
p=0.146 for Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20, respectively). 
However, the Ad5-EGFPWT group (-3.4±3.1%) did differ significantly from the Ad5-
EGFPA20 (p=0.043), and Ad5-477dlTAYTA20 (p=0.019) groups, both of which showed 
overall increases in body weight of +0.5±1.9 and +1.23±1.68%, respectively. On day 4, 
only the Ad5477dlTAYTA20 treated group differed significantly from the PBS control 
(+3.86±1.7%, p=0.022), or from the Ad5-EGFPWT treated group (p=0.073).  On day 5, 
both the Ad5-EGFPA20 and Ad5-477dlTAYTA20 groups had increased body weights 
(+3.6±1.5% and +5.72±1.98%), and these groups differed from both the PBS control 
group (p=0.035 and p=0.007) and the Ad5-EGFPWT group (p=0.032 and p=0.006). At 
the time of euthanasia (day 6), again only the Ad5-477dlTAYTA20 group differed 
significantly from the PBS, or Ad5-EGFPWT groups (p=0.005 and p=0.012, 
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respectively), with an overall gain in body weight of +5.49±1.71%, compared with -
1.2±3.5% and +0.40±3.1% for PBS and Ad5-EGFPWT respectively.  
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Transaminase levels were quantified for each cohort (Fig.5.1B+C). The Ad5-EGFPWT 
group had ALT levels which were elevated slightly over baseline, when compared to 
the Ad5-EGFPA20 and Ad5-477dlTAYTA20 groups, although the differences observed 
were not significant (p>0.05). This was further supported by the fact that AST levels did 
not differ significantly for each of the virus groups, nor did the levels differ from those 
obtained for the PBS control group (p>0.05 for all). 
 
Figure.5.1 Determination of Toxicity in Immunocompetent Balb/c Mice Following Systemic 
Administration of Virus (2.5x1010vp/mouse). (A) Body weight variation (%) was assessed on a daily 
basis for cohorts which received intravenous delivery of PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-
477dlTAYTA20 (2.5x1010vp/mouse). (B) Blood samples were obtained immediately post-mortem by 
intracardiac puncture (6 days after virus administration) and alanine transaminase (ALT) levels were 
quantified for each group; PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20. (C) Aspartate 
aminotransferase (AST) levels were also quantified for all groups. Data presented show the mean ± SEM 
(N=5 female mice). Statistical significance was determined using the unpaired Student’s t-test comparing 
the means of two samples (differences which were not found to be significant had a P-value >0.05; not 
marked, bars indicate SEM). 
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A full haematological profile was obtained for each of the cohorts; including PBS 
control, Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 groups (Fig.5.2). At this 
dose (2.5x1010vp/mouse) and time-point (day 6), no differences in total lymphocyte 
numbers were observed for any cohort (p>0.05 for all).  Both Ad5-EGFPWT and Ad5-
477dlTAYTA20 showed ~2.5-fold increased neutrophil counts versus PBS control 
(p=0.004 and p=0.027, respectively). In contrast, total neutrophils remained at a basal 
level (equivalent to PBS) in cohorts which had been infected with Ad5-EGFPA20 
(p=0.134). Platelet levels frequently are affected by systemically administered 
adenovirus, which can induce acute transient thrombocytopenia (Cichon et al., 1999; 
Othman et al., 2007; Stone et al., 2007b; Wolins et al., 2003). However, no changes to 
overall platelet levels were observed (p>0.05 for all). In addition, total monocyte levels 
were not affected significantly, except for the Ad5-477dlTAYTA20 group, which was 
increased ~1.5-fold above basal level (p=0.017). There were no significant changes to 
either total basophil, or eosinophil populations for any group (p>0.05 for all).  
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Figure.5.2 Haematological Profiles Obtained from Immunocompetent Balb/c Mice Following 
Systemic Delivery of Virus (2.5x1010vp/mouse). Whole blood samples (250μl) from each of the treated 
groups (PBS, Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20) were obtained immediately post-
mortem by intracardiac puncture (day 6 post-infection). Haematological profiles were assessed at the 
Clinical Veterinary Biochemistry Service at the Falcultat de Veterinària, Universitat Autònoma de 
Barcelona. Data presented show the mean ± SEM (N=5 female mice). Statistical significance was 
determined using the unpaired Student’s t-test comparing the means of each group to that of the PBS 
control group (* indicates a P-value of <0.05, ** p<0.01, differences which were not found to be significant 
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5.1.2. Determination of In Vivo Hepatotoxicity and Haematological Profiling 
(4x1010vp/mouse). A dose of 2.5x1010vp/mouse did not induce significant toxicity in 
any cohort, so therefore a higher dose of 4x1010vp/mouse was used, in a separate 
experiment, in order to obtain comparative toxicological and haematological profiles for 
Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20. On day 3 post-virus 
administration, the weight of the Ad5-EGFPWT group (-4.5±1.2%) varied significantly 
from the PBS control (p=0.0007), which showed increases in overall body weight 
+3.7±3.4% (Fig.5.3A). The A20-modified groups, Ad5-EGFPA20 and Ad5-477dlTAYTA20 
did not differ significantly, both displaying increases in body weight, +2.6±1.3% and 
+1.23±1.68%, respectively. In addition, both of the A20-modified groups, differed 
significantly from the Ad5-EGFPWT treated animals (p=0.0002 and p<0.0001, 
respectively). On the day of euthanasia (day 4), both Ad5-EGFPA20 and Ad5-
477dlTAYTA20, had body weights comparable to the PBS control group (p=0.437 and 
p=0.076), whereas the Ad5-EGFPWT cohort differed significantly having lost 6.0±2.4% 
of its body weight (p=0.0007).  
 
In agreement with these results, transaminase levels were found to be altered 
significantly between the Ad5-EGFPWT and A20-retargeted groups (Fig.5.3B+C). The 
Ad5-EGFPWT treated group displayed markedly elevated ALT levels, ~35-fold above 
basal PBS levels (p<0.0001). In comparison, the elevation of ALT in the Ad5-EGFPA20 
and Ad5-477dlTAYTA20 treated groups was much less, increased ~4.5-fold (p=0.027) 
and ~9-fold (p=0.008), respectively. Accordingly, there were significant differences 
between the levels of ALT induced by the Ad5-EGFPWT and A20-modified groups 
(p<0.0001 and p=0.0001). AST levels were also similarly affected by each virus. Ad5-
EGFPWT treatment induced high levels of AST, ~15-fold above basal level (p<0.0001). 
However, neither the Ad5-EGFPA20 nor Ad5-477dlTAYTA20 groups succeeded in 
elevating AST levels above basal PBS levels (p>0.05 for both).  
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A full haematological profile was obtained for each of the cohorts; PBS control, Ad5-
EGFPA20 and Ad5-477dlTAYTA20 (Fig.5.4). Unfortunately, only one blood sample was 
obtained for the Ad5-EGFPWT group, and therefore no statistical analysis can be 
determined for this group. Furthermore, a large proportion of these blood samples were 
coagulated prior to analysis. Therefore, the results obtained are not entirely 
trustworthy, as the basal level cell populations (eg. lymphocytes, monocytes and 
basophils) are not consistent with results obtained in previous, or subsequent 
haematological analyses (see Fig.5.2 and Fig.5.11). At a dose of 4.0x1010vp/mouse, no 
significant changes in total lymphocyte, neutrophil, platelet or monocyte numbers were 
observed for any cohort, excluding Ad5-EGFPWT from analysis (p>0.05 for all). Total 
basophil counts were increased in each of the virus treated groups; a ~3-fold, but non-
Figure.5.3 Determination of Toxicity in Immunocompetent Balb/c Mice Following Systemic 
Administration of Virus (4.0x1010vp/mouse). (A) Body weight variation (%) was assessed on a daily 
basis for cohorts which received intravenous delivery of PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-
477dlTAYTA20 (2.5x1010vp/mouse). (B) Blood samples were obtained immediately post-mortem (4 days 
after virus administration) and alanine transaminase (ALT) levels were quantified for each group; PBS, 
Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20. (C) Aspartate aminotransferase (AST) levels were 
quantified for all groups; PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20. Data presented show 
the mean ± SEM (N=5 female mice). Statistical significance was determined using the unpaired Student’s 
t-test comparing the means of two samples (**** indicates p<0.0001, NS indicates p>0.05, bars indicate 
SEM). Statistics displayed directly above the histogram for Ad5-EGFPA20/Ad5-477dlTAYTA20 samples, 
refer to the difference when compared to the corresponding PBS control sample.  
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significant increase in the Ad5-EGFPA20 group, and a ~2-fold increase in the Ad5-
477dlTAYTA20 group (p=0.011). No differences were found in total eosinophil counts for 
any cohort (p>0.05 for all).  
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5.1.3 Quantification of Viral Genomes (qPCR) in Murine Liver (4x1010vp/mouse). 
Immunocompetent, female Balb/c mice (6 weeks) which had been administered with 
4x1010vp/mouse were killed 4 days post-infection, and their livers and spleens 
harvested for analysis. Absolute viral genome numbers in the liver were quantified by 
qPCR for each of the Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 treated 
Figure.5.4 Haematological Profiles Obtained from Immunocompetent Balb/c Mice Following 
Systemic Delivery of Virus (4.0x1010vp/mouse). Whole blood samples (250μl) from each of the treated 
groups (PBS, Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20) were obtained immediately post-
mortem by intracardiac puncture (day 4 post-infection). Haematological profiles were assessed at the 
Clinical Veterinary Biochemistry Service at the Falcultat de Veterinària, Universitat Autònoma de 
Barcelona. Data presented show the mean ± SEM (N=5 female mice, except Ad5-EGFPWT; N=1). 
Statistical significance was determined using the unpaired Student’s t-test comparing the means of two 
samples (* indicates a P-value of <0.05, differences which were not found to be significant had a P-value 
>0.05; not marked, bars indicate SEM). Statistics displayed directly above the histogram for the Ad5-
477dlTAYTA20 group (basophils), refer to the difference when compared to the corresponding PBS control 
sample.  
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groups, using probes and primers to detect the hexon region of the genome (Fig.5.5). 
As expected, a significant amount of Ad5-EGFPWT was detected in the liver. However, 
in comparison ~7.5-fold fewer Ad5-EGFPA20 (p=0.002), and ~5.5-fold fewer Ad-
477dlTAYTA20 (p=0.002) genomes were detected in the liver. 
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5.1.4 Histological Examination of Liver Tissue; H&E Staining and 
Immunostaining for E1A. Haematoxylin and eosin staining of the liver sections 
supported these findings, revealing distinct histological differences between Ad5-
EGFPWT and Ad5-EGFPA20/Ad5-477dlTAYTA20 treated groups (Fig.5.6). The livers from 
mice administered with Ad5-EGFPWT showed striking hepatocyte atypia; there was 
evidence of ballooning degeneration of cells and individual cell necrosis. Additionally a 
prominent peri-portal lymphocytic inflammatory infiltrate was present in the livers of 
animal which received Ad5-EGFPWT. This infiltration was not evident in any fields of 
view within the liver sections of Ad5-EGFPA20 or Ad5-477dlTAYTA20 treated animals.  
 
The histological appearances we observed in H&E sections were further supported by 
immunostaining for viral antigen (E1A) in frozen liver sections (Fig.5.7). A clear 
reduction in the level of E1A expression within the hepatocytes of the Ad5-EGFPA20 
and Ad5-477dlTAYTA20 treated groups was evident when compared with the Ad5-
EGFPWT group (20X magnification). This confirmed that the A20-retargeted viruses 
Figure.5.5 Quantification of Viral Genomes in Murine Liver Following Systemic Delivery 
(4.0x1010vp/mouse). Balb/c immunocompetent, female mice were injected either with PBS, Ad5-EGFPWT, 
Ad5-EGFPA20 or Ad5-477dlTAYTA20 by intravenous tail vein injection (150μl). Mice were killed 4 days post-
infection, necropsy performed and total DNA extracted from liver tissue. Absolute viral genomes were 
quantified by TaqMan Real-Time Quantitative qPCR using a probe to detect the hexon region of the 
genome (see Section.2.2.7). Data presented show the mean ± SEM (N=5 mice). Statistical significance 
was determined using the unpaired Student’s t-test comparing the means of two samples (* indicates a P-
value of <0.05, ** p<0.01, NS indicates p>0.05, bars indicate SEM). 
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displayed not only reduced accumulation in the liver, but reduced hepatocyte 
transduction when compared to Ad5-EGFPWT. 
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Figure.5.6 Haematoxylin and Eosin Staining of Liver Tissue Following Systemic Delivery of Virus 
(4.0x1010vp/mouse). Liver sections for each cohort PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-
477dlTAYTA20 were cut, stained with H&E (performed by Pathology Services, Institute of Cancer) and 
assessed histopathologically. Histological analysis was performed blindly by a qualified pathologist (Prof. 
Gareth Thomas), without prior knowledge of the specimens. Sections were photographed at a 
magnification of 200X using a Zeiss AxioCam MRc5 camera and Axiovision Software (Zeiss, Germany).   
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Figure.5.7 Immunostaining (E1A) of Frozen Liver Tissue Following Systemic Delivery of Virus 
(4.0x1010vp/mouse). Immediately post-necropsy, liver tissue (left lobe) was frozen at -80˚C in OCT-
containing cryomolds. Frozen tissue sections (5μm) were stained with an anti-E1A antibody (13 S-5) 
followed by a goat anti-rabbit AlexaFluor488 conjugated secondary antibody. Sections were 
counterstained for DAPI using VectaShield reagent. Sections were visualised at a magnification of 20X 
using an Olympus BX60 fluorescence microscope and images were acquired using SpotAdvanced™ 
software.  
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5.1.5 Quantification of Viral Genomes (qPCR) in Murine Spleen (4x1010 
vp/mouse). Total DNA was extracted from the spleens of the same animals (Balb/c 
immunocompetent female mice) and absolute viral genome copy numbers quantified 
as before. The A20-modified viruses (Ad5-EGFPA20/Ad5-477dlTAYTA20) also displayed 
a significantly altered accumulation in the spleen when compared to Ad5-EGFPWT 
(Fig.5.8). Absolute Ad5-EGFPA20 and Ad5477dlTAYTA20 genome levels in the spleen 
were found to be ~2.6-fold lower than Ad5-EGFPWT (p=0.0008 and p=0.007, 
respectively). No differences were noted between Ad5-EGFPA20 and Ad5-477dlTAYTA20 
treated cohorts (p=0.929). 
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5.1.6 Histological Examination of Spleen Tissue; H&E Staining. Histological 
examination of H&E stained sections of spleen tissue, again suggested differences 
between the Ad5-EGFPWT and A20-groups (Fig.5.9). In the Ad5-EGFPWT treated 
animals, the white pulp region appeared enlarged, and there was evidence of follicular 
hyperplasia when compared with the control PBS group. This effect was not as 
dramatic in the Ad5-EGFPA20 or Ad5-477dlTAYTA20 groups.  
Figure.5.8 Quantification of Viral Genomes in Murine Spleen Following Systemic Delivery 
(4.0x1010vp/mouse). Balb/c immunocompetent, female mice were injected either with PBS, Ad5-EGFPWT, 
Ad5-EGFPA20 or Ad5-477dlTAYTA20 by intravenous tail vein injection (150μl). Mice were killed 4 days post-
infection, necropsy performed and total DNA extracted from spleen tissue. Absolute viral genomes were 
quantified by TaqMan Real-Time Quantitative qPCR using a probe to detect the hexon region of the 
genome (see Section.2.2.7). Data presented show the mean ± SEM (N=5 mice). Statistical significance was 
determined using the unpaired Student’s t-test comparing the means of two samples (** indicates a P-value 
of <0.01, *** p<0.001, NS indicates p>0.05, bars indicate SEM). 
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Figure.5.9 Haematoxylin and Eosin Staining of Spleen Tissue Following Systemic Delivery of Virus 
(4.0x1010vp/mouse). Spleen sections for each cohort PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-
477dlTAYTA20 were cut, stained with H&E (performed by Pathology Services, Institute of Cancer) and 
assessed histopathologically. Histological analysis was performed blindly by a qualified pathologist (Prof. 
Gareth Thomas), without prior knowledge of the specimens. Sections were photographed at a 
magnification of 50X using a Zeiss AxioCam MRc5 camera and Axiovision Software. (Zeiss, Germany).  
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Section.5.2 Biodistribution, Haematology and Cytokine/Chemokine 
Profiling at Early Time-Points Post-Infection 
 
Intravenous delivery of Ad5 induces rapid innate immune responses, which are 
characterised by the release of various pro-inflammatory cytokines and chemokines (Di 
Paolo et al., 2009a; Lieber et al., 1997; Liu et al., 2003; Shayakhmetov et al., 2005c; 
Zhang et al., 2001). Several studies have shown previously that Ad5-induced cytokine 
and chemokine responses peak 6-12hrs post-infection and return to near basal levels 
by 24hrs. Therefore, we also chose these time-points for analysis. In order to 
investigate the effects of each virus at an earlier time-point (24hrs), additional 
experiments were carried out at the laboratory of Dr. Ramon Alemany (ICO, 
Barcelona). An identical dose (4.0x1010vp/mouse) and mouse strain (6 week old, 
Balb/c immunocompetent female mice) were again chosen in order to permit as much 
comparison to previous studies as possible. In vivo biodistribution was assessed by 
qPCR quantification of absolute viral genomes in the liver, spleen, lung, kidney and 
heart. Serum cytokine/chemokine levels (IL-6, RANTES, IFN-γ, TNF-α, IL-12p70) were 
quantified 6hrs, and 24hrs post-infection using a cytometric bead assay, and full 
haematological profiles were obtained at time of death (24hrs). 
 
5.2.1 Quantification of Serum Cytokines/Chemokines 6hrs and 24hrs Following 
Systemic Delivery of Virus (4.0x1010vp/mouse). Ad5-EGFPWT administration resulted 
in significant elevations in serum cytokine/chemokine concentrations [pg/ml] 6hrs post-
infection (Fig.5.10A-C). IL-6 levels in mice treated with Ad5-EGFPWT or Ad5-
477dlTAYTA20 were elevated ~22-fold (p<0.0001) and ~7-fold (p=0.021) over baseline 
PBS levels (Fig.5.10A). However, Ad5-EGFPA20 did not increase IL-6 levels at this 
time-point (p=0.063). Moreover, both A20-retargeted viruses differed significantly from 
Ad5-EGFPWT, inducing substantially lower serum IL-6 levels (p<0.0001 and p=0.0006, 
respectively). There were no differences observed between Ad5-EGFPA20 and Ad5-
477dlTAYTA20 (p=0.358).  
 
RANTES and IFN-γ levels were also elevated above baseline in all virus treated 
cohorts (p<0.01), however there were significant differences between the Ad5-EGFPWT 
treated group and the A20-retargeted groups (Fig.5.10B and C). When compared to 
the PBS control group, Ad5-EGFPWT induced high levels of RANTES (~13-fold 
elevation, p<0.0001), whereas Ad5-EGFPA20 and Ad5-477dlTAYTA20 induced markedly 
lower levels (~4-fold elevation, p<0.004 and ~7-fold elevation, p=0.001, respectively).  
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Figure.5.10 Quantification of Serum Cytokines/Chemokines from Immunocompetent Balb/c Mice 
Following Systemic Delivery of Virus (4.0x1010vp/mouse). Balb/c immunocompetent, female mice 
were injected either with PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20 by intravenous tail vein 
injection (150μl). Serum cytokines were quantified at 6hrs (A-D) and 24hrs (E-H) post-injection. 
Approximately 200μl of whole blood was collected using capillary tubes following a tail snip procedure. 
Serum was separated, and 25μl used for quantification of cytokines/chemokines (IL-6, RANTES, IFN-γ, 
TNF-α, and IL-12p70†) using a fluorescent bead, sandwich ELISA-based technology (FlowCytomix™, 
Bender MedSystems). Samples were acquired by flow cytometry, and analysed using FlowCytomix Pro 
2.2 Software (see Section.2.1.7). Data presented show the mean ± SEM (N=6/8 female mice). Statistical 
significance was determined using the unpaired Student’s t-test comparing the means of two samples (* 
indicates a P-value of <0.05, ** p<0.01, NS indicates p>0.05, bars indicate SEM). Statistics displayed 
directly above the histogram for the Ad5-EGFPA20/Ad5-477dlTAYTA20 groups, refer to the difference when 
compared to the corresponding PBS control sample. †No elevations in serum IL-12(p70) were detected at 
either time-point (data not shown).  
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Both Ad5-EGFPA20 and Ad-477dlTAYTA20 differed significantly from Ad5-EGFPWT 
(p<0.0001 and p=0.005, respectively). Additionally, Ad5-EGFPA20 induced less 
RANTES than Ad5-477dlTAYTA20 (p=0.028). Similarly, serum IFN-γ concentrations 
were dramatically elevated above baseline by Ad5-EGFPWT (~1400-fold, p<0.0001), but 
to a lesser extent by Ad5-EGFPA20 and Ad5-477dlTAYTA20 (~120-fold elevation, 
p=0.023 and ~200-fold elevation, p=0.009, respectively). Again, both Ad5-EGFPA20 and 
Ad5-477dlTAYTA20 differed significantly from Ad5-EGFPWT (p<0.0001 for both), 
however did not differ from each other (p=0.258). There was no significant elevation of 
TNF-α at this time-point for any virus (p>0.05 for all), which was consistent with a 
previous study (Zhang et al., 2001). IL-12(p70) levels were unaffected and remained at 
baseline level (data not shown). However, this is possibly due to poor sensitivity of the 
assay, as elevations have been reported at this time-point, albeit at a significantly 
higher dose (Zhang et al., 2001). Additionally, IL-12 exists as two isoforms (p40 and 
p70), so it is possible that IL-12(p40), and not necessarily IL-12(p70), is differentially 
regulated in response to Ad5 administration. 
 
With the exception of RANTES, all cytokine/chemokine concentrations [pg/ml] returned 
approximately to basal levels by 24hrs (Fig.5.10E-H). The sustained upregulation of 
RANTES we observed is consistent with previous studies (Liu et al., 2003). At this 
time-point, serum IL-6 levels were not increased over baseline for any virus-treated 
group (p>0.05). RANTES levels were reduced when compared with the 6hr time-point, 
however they remained elevated over basal levels in Ad5-EGFPWT (~11-fold, p=0.003) 
and Ad5-EGFPA20 (~3-fold, p=0.007) treated cohorts, but not in those treated with Ad5-
477dlTAYTA20 (p=0.104). Again, at this time-point both Ad5-EGFPA20 and Ad5-
477dlTAYTA20 differed significantly from Ad5-EGFPWT (p=0.003 and p=0.045, 
respectively), but not from each other (p=0.376). IFN-γ levels had also returned to 
basal levels 24hrs post-infection, however serum concentrations remained elevated in 
Ad5-EGFPWT treated cohorts (~70-fold, p=0.019). There were no significant elevations 
of TNF-α for any virus at this time-point and dose (p>0.05 for all) and as before, IL-
12(p70) levels remained unaffected (data not shown). 
 
5.2.2 Haematological Profiles Obtained 24hrs Following Systemic Delivery of 
Virus (4.0x1010vp/mouse). A full haematological profile was obtained, 24hrs post-
infection, for each of the cohorts; PBS control, Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-
477dlTAYTA20 (Fig.5.11). There were significant reductions (>2-fold) in total 
lymphocytes for all virus treated groups when compared with the PBS control group 
(p<0.0001 for all). Additionally, there were clear differences between the Ad5-EGFPWT 
group and the A20-retargeted groups, Ad5-EGFPA20 and Ad5-477dlTAYTA20 (p<0.0001 
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and p=0.048, respectively). Total neutrophil levels were not affected when comparing 
virus treated groups with the PBS control cohort (p>0.05). However, there was a 
difference between the Ad5-EGFPWT and Ad5-477dlTAYTA20 treated group at this time-
point (p=0.03).  
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Systemic administration of Ad5 has been associated with acute transient 
thrombocytopenia in various species (Varnavski et al., 2005), and has been reported to 
occur between 5mins and 24hrs post-infection in mice (Othman et al., 2007). 
Interestingly, only Ad5-EGFPWT induced thrombocytopenia (~2-fold reduction, 
p=0.003), whereas neither of the A20-retargeted viruses, Ad5-EGFPA20 or Ad5-
Figure.5.11 Haematological Profiles Obtained from Immunocompetent Balb/c Mice 24hrs Following 
Systemic Delivery of Virus (4x1010vp/mouse). Whole blood samples (250μl) from each of the treated 
groups (PBS, Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20) were obtained immediately post-
mortem by intracardiac puncture (24hrs post-infection). Haematological profiles were assessed at the 
Clinical Veterinary Biochemistry Service at the Facultat de Veterinària, Universitat Autònoma de 
Barcelona. Data represent the mean ± SEM (N=6/8 mice). Statistical significance was determined using 
the unpaired Student’s t-test comparing the means of two samples (* indicates a P-value of <0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001, differences which were not found to be significant had a P-value 
>0.05; not marked, bars indicate SEM). 
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477dlTAYTA20, differed significantly from the PBS control group (p=0.228 and p=0.213, 
respectively). The thrombocytopenia induced by Ad5-EGFPWT was also found to be 
significant when compared directly with Ad5-EGFPA20 and Ad5-477dlTAYTA20 treated 
groups (p=0.011 and p=0.005). Overall platelet levels in Ad5-EGFPA20 and Ad5-
477dlTAYTA20 treated cohorts were almost identical (p=0.956). Total monocyte levels 
were also affected significantly in all virus treated cohorts when compared to the PBS 
group (>3-fold reductions, p<0.001 for all). Again, Ad5-EGFPWT differed from Ad5-
EGFPA20, but not from Ad5-477dlTAYTA20 (p=0.016 and p=0.196, respectively). No 
significant differences were observed in overall basophil or eosinophil populations 
(p>0.05).  
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5.2.3 Quantification of Viral Genomes (qPCR) in Murine Liver 24hrs Post-
Infection (4.0x1010vp/mouse). Immunocompetent Balb/c mice which had been 
administered systemically with 4x1010vp/mouse were killed 24hrs post-infection, and 
their livers harvested for analysis. Absolute genome copy numbers in the liver were 
quantified by quantitative real time PCR (qPCR) for each of the virus treated cohorts; 
Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 (Fig.5.12). Approximately 17-fold 
fewer Ad5-EGFPA20 genomes, and ~27-fold fewer Ad5-477dlTAYTA20 genomes were 
detected in the liver when compared with Ad5-EGFPWT (p<0.0001 for both). No 
differences were found between the A20-retargeted groups (p=0.207). 
 
Figure.5.12 Quantification of Viral Genomes in Murine Liver 24hrs Following Systemic Delivery 
(4.0x1010vp/mouse). Balb/c immunocompetent, female mice were injected either with PBS, Ad5-EGFPWT, 
Ad5-EGFPA20 or Ad5-477dlTAYTA20 by intravenous tail vein injection (150μl). Mice were killed 24hrs post-
infection, necropsy performed and total DNA extracted from liver tissue. Absolute viral genomes were 
quantified by TaqMan Real-Time Quantitative qPCR using a probe to detect the hexon region of the 
genome (see Section.2.2.7). Data presented show the mean ± SEM (N=6/8 mice). Statistical significance 
was determined using the unpaired Student’s t-test comparing the means of two samples (**** indicates a 
P-value of <0.0001, NS indicates p>0.05, bars indicate SEM). 
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5.2.4 Histological Examination of Liver Tissue; Haematoxylin and Eosin Staining 
and Immunostaining for E1A. Liver tissue was assessed histopathologically following 
H&E staining (Fig.5.13). We observed slight, but not dramatic differences between the 
Figure.5.13 Haematoxylin and Eosin Staining of Liver Tissue 24hrs Following Systemic Delivery of 
Virus (4.0x1010vp/mouse). Liver sections for each cohort PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-
477dlTAYTA20 were cut, stained with H&E (performed by Pathology Services, Institute of Cancer) and 
assessed histopathologically. Histological analysis was performed blindly by a qualified pathologist (Prof. 
Gareth Thomas), without prior knowledge of the specimens. Sections were photographed at a 
magnification of 200X using a Zeiss AxioCam MRc5 camera and Axiovision Software (Zeiss, Germany).  
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Ad5-EGFPWT and Ad5-EGFPA20/Ad5-477dlTAYTA20 treated cohorts at this time-point 
(24hrs). The hepatocytes in animals treated with Ad5-EGFPWT appeared swollen, with 
some nuclear abnormalities evident. In comparison, the Ad5-EGFPA20/Ad5-
477dlTAYTA20 groups retained an appearance more similar to the PBS control group. 
 
Immunostaining of frozen liver sections for viral antigen (E1A), again highlighted the 
dramatic differences between the Ad5-EGFPWT, and Ad5-EGFPA20/Ad5-477dlTAYTA20 
treated groups (Fig.5.14). Substantially less E1A expression was detected in the livers 
of cohorts which received the A20-retargeted viruses. These findings further supported 
the significantly reduced levels of viral genomes detected in the livers of these animals 
by qPCR (see Fig.5.12).  
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5.2.5 Quantification of Viral Genomes (qPCR) in Murine Spleen 24hrs Post-
Infection (4.0x1010vp/mouse). Absolute genome copy numbers in the spleen were 
quantified, as before, for each of the virus treated cohorts; Ad5-EGFPWT, Ad5-EGFPA20 
and Ad5-477dlTAYTA20 (Fig.5.15). Approximately 2-fold fewer Ad5-EGFPA20, and Ad5-
477dlTAYTA20 genomes, were detected in the spleen when compared with Ad5-
Figure.5.14 Immunostaining (E1A) of Frozen Liver Tissue 24hrs Following Systemic Delivery of 
Virus (4.0x1010vp/mouse). Immediately post-necropsy, liver tissue (left lobe) was frozen at -80˚C in OCT-
containing cryomolds. Frozen tissue sections (5μm) were stained with an anti-E1A antibody (13 S-5) 
followed by a goat anti-rabbit AlexaFluor488 conjugated secondary antibody. Sections were 
counterstained for DAPI using VectaShield reagent. Sections were visualised at a magnification of 20X 
using an Olympus BX60 fluorescence microscope and images acquired using SpotAdvanced™ software.  
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EGFPWT (p=0.013 and p=0.007, respectively). No differences were found between the 
A20-retargeted groups (p=0.627). 
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5.2.6 Histological Examination of Spleen Tissue; Haematoxylin and Eosin 
Staining. Spleen tissue was assessed histopathologically following H&E staining 
(Fig.5.16). Lymphoid follicles were prominent in all viral treated groups. No other 
differences were noted. 
 
 
 
 
 
 
 
 
 
Figure.5.15 Quantification of Viral Genomes in Murine Spleen 24hrs Following Systemic Delivery 
(4.0x1010vp/mouse). Balb/c immunocompetent mice were injected either with PBS, Ad5-EGFPWT, Ad5-
EGFPA20 or Ad5-477dlTAYTA20 by intravenous tail vein injection (150μl). Mice were killed 24hrs post-
infection, necropsy performed and total DNA extracted from spleen tissue. Absolute viral genomes were 
quantified by TaqMan Real-Time Quantitative qPCR using a probe to detect the hexon region of the 
genome (see Section.2.2.7). Data presented show the mean ± SEM (N=6/8 mice). Statistical significance 
was determined using the unpaired Student’s t-test comparing the means of two samples (* indicates a P-
value of <0.05, ** p<0.001, NS indicates p>0.05, bars indicate SEM). 
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Figure.5.16 Haematoxylin and Eosin Staining of Spleen Tissue 24hrs Following Systemic Delivery 
of Virus (4.0x1010vp/mouse). Spleen sections for each cohort PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-
477dlTAYTA20 were cut, stained with H&E (performed by Pathology Services, Institute of Cancer) and 
assessed histopathologically. Histological analysis was performed blindly by a qualified pathologist (Prof. 
Gareth Thomas), without prior knowledge of the specimens. Sections were photographed at a 
magnification of 50X using a Zeiss AxioCam MRc5 camera and Axiovision Software (Zeiss, Germany)  
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5.2.7 Quantification of Viral Genomes (qPCR) in Murine Lung, Kidney and Heart 
24hrs Post-Infection (4.0x1010vp/mouse). In the same experiment, the lung, kidney 
and heart of each animal was harvested for a comparative biodistribution analysis of 
viral genomes (Fig.5.17A-C). Again, absolute viral genome copy numbers were 
quantified by qPCR following extraction of total DNA from each respective tissue, using 
primers and probes to detect the hexon region of the genome.  
 
Approximately ~3-fold, and ~2-fold fewer Ad5-EGFPA20 and Ad5-477dlTAYTA20 
genomes were detected in the lung than Ad5-EGFPWT (p=0.0024 and p=0.015, 
respectively). Ad5-477dlTAYTA20 displayed a slightly enhanced uptake in the lung when 
compared with Ad5-EGFPA20 (p=0.045). In addition, ~2-fold less Ad5-EGFPA20 and Ad5-
477dlTAYTA20 genomes were detected in the kidney, when compared with Ad5-
EGFPWT (p=0.012 and p=0.019, respectively). There were no differences between Ad5-
EGFPA20 and Ad5-477dlTAYTA20 in this organ (p=0.995). In the heart, the levels of Ad5-
EGFPWT and Ad5-EGFPA20 were similar (p=0.425). However, the levels of Ad5-
477dlTAYTA20 appeared to be elevated ~6-fold, although this was not found to be 
significant (p=0.09).  
 213
Ad5-EGFPWT
Ad5-EGFPA20
Ad5-477dlTAYTA20
1.0×1003
2.0×1003
3.0×1003
4.0×1003
5.0×1003
Vi
ra
l G
en
om
es
/ 2
0n
g 
To
ta
l
DN
A
Ad5-EGFPWT
Ad5-EGFPA20
Ad5-477dlTAYTA20
1.0×1003
1.0×1006
2.0×1006
3.0×1006
Vi
ra
l G
en
om
es
/ 2
0n
g 
To
ta
l
DN
A
A
B
Ad5-EGFPWT
Ad5-EGFPA20
Ad5-477dlTAYTA20
1.0×1003
1.1×1004
2.1×1004
3.1×1004
Vi
ra
l G
en
om
e/
 2
0n
g 
To
ta
l
DN
A
C
**
*
*
*
*
NS
NS
 
 
 
 
 
 
 
 
 
 
Figure.5.17 (A) Quantification of Viral Genomes in Murine Lung 24hrs Following Systemic Delivery 
(4.0x1010vp/mouse). Balb/c immunocompetent, female mice were injected either with PBS, Ad5-EGFPWT, 
Ad5-EGFPA20 or Ad5-477dlTAYTA20 by intravenous tail vein injection (150μl). Mice were killed 24hrs post-
infection, necropsy performed and total DNA extracted from lung tissue. (B) Quantification of Viral Genomes 
in Murine Kidney 24hrs Following Systemic Delivery (4.0x1010vp/mouse).  Total DNA was extracted from 
the kidneys of the cohorts described above. (C) Quantification of Viral Genomes in Murine Heart 24hrs 
Following Systemic Delivery (4.0x1010vp/mouse). Absolute viral genomes were quantified by TaqMan Real-
Time Quantitative qPCR using a probe to detect the hexon region of the genome (see Section.2.2.7). Data 
presented show the mean ± SEM (N=6/8 mice). Statistical significance was determined using the unpaired 
Student’s t-test comparing the means of two samples (* indicates a P-value of <0.05, ** p<0.001, NS indicates 
p>0.05, bars indicate SEM). 
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Chapter.5 Discussion 
 
The systemic delivery of Ad5 in many pre-clinical animal models elicits a robust 
inflammatory response directed against both the viral particle, and its expressed genes 
(Elkon et al., 1997; Wolins et al., 2003; Zhang et al., 2001). Consequently, 
heterologous transgene expression can be short-lived, serving to limit the therapeutic 
effect. The rapid induction of innate immune responses to Ad5 also contributes 
significantly to the characteristic liver pathology (hepatocyte necrosis, elevation of liver 
transaminases and a monocytic/lymphocytic infiltrate). These effects are mediated 
primarily through the action of pro-inflammatory cytokines/chemokines (Koizumi et al., 
2007; Liu & Muruve, 2003; Muruve et al., 1999; Shayakhmetov et al., 2005c; Zhang et 
al., 2001). Recent evidence also suggests that Ad5-induced complement activation in 
vivo may also contribute to these effects, heightening the inflammatory response 
(Kiang et al., 2006; Tian et al., 2009).  
 
In addition to inducing pro-inflammatory cascades, systemically delivered adenoviral 
vectors can cause haemodynamic changes and induce acute transient 
thrombocytopenia, which potentially exacerbates pre-existing coagulopathic conditions 
(Othman et al., 2007; Schiedner et al., 2003a; Stone et al., 2007b; Wolins et al., 2003). 
The precise mechanisms by which Ad5 induces thrombocytopenia are complex, and 
currently unclear, although several hypotheses have been proposed. It has been 
shown previously that direct binding of the Ad5 particle to platelets results in the 
formation of platelet-leukocyte aggregates which are cleared by the reticuloendothelial 
system (Stone et al., 2007b). Subsequently, it was found that formation of the Ad5-
platelet-leukocyte complex was dependent on P-selectin and von Willebrand factor 
(Othman et al., 2007). In another study, it was proposed that complement C3 
activation, in response to Ad5-mediated cell damage, also contributes significantly to 
the induction of acute thrombocytopenia (Kiang et al., 2006).  
 
Murine models currently are the most commonly used for assessing the in vivo effects 
of Ad delivery. Many of the cellular interactions which contribute to the toxicity of 
systemically delivered Ad5s in murine models are applicable to humans (Herman et al., 
1999; Klinger et al., 1998; Mistchenko et al., 1994; Schnell et al., 2001) however many 
are not relevant, or remain controversial (Carlisle et al., 2009; Eggerman et al., 2002; 
Seiradake et al., 2009). Clearly, significant hurdles remain which hamper the efficacy, 
and subsequently the development of adenoviral vectors for therapeutic applications. 
Therefore, understanding the underlying mechanisms which result in the induction of 
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innate immune responses is critical to the development of vectors with improved safety 
profiles, and extended therapeutic duration in vivo.  
 
Section.5.1 In Vivo Biodistribution and Hepatotoxicity in Immunocompetent Mice 
 
Non-specific sequestration of systemically delivered Ad5 vectors in KCs leads to a 
nonlinear dose response of hepatocyte transduction (Tao et al., 2001). The threshold 
dose for saturation of KCs ranges from 1010-1011vp/kg (Manickan et al., 2006). 
Therefore, we performed dose escalation studies in immunocompetent Balb/c mice to 
assess the in vivo hepatotropism and toxicity of Ad5-EGFPWT, Ad5-EGFPA20 and the 
putative liver de-targeted vector, Ad5-477dlTAYTA20. Initial experiments using a dose of 
2.5x1010vp/mouse (~1011vp/kg) failed to induce significant toxicity in any cohort. The 
experiment was repeated using a higher dose (4.0x1010vp/mouse) in order to 
comparatively analyse transaminase levels, haematological profiles, vector 
biodistribution and histopathology (liver/spleen) for each group, 4 days post-infection.   
 
In agreement with previously published data, the Ad5-477dlTAYTA20 vector had 
significantly reduced hepatotropism and toxicity in vivo (Shayakhmetov et al., 2005b). 
Unexpectedly, Ad5-EGFPA20 also displayed this profile, despite the absence of the 
putative blood factor binding ablating mutations. Animals administered with Ad5-
EGFPA20 or Ad5-477dlTAYTA20, displayed overall well-being throughout the duration of 
the experiment, with limited serum transaminase elevations and a dramatically reduced 
accumulation of virion DNA in the liver at time of death, which correlated with reduced 
E1A expression in hepatocytes. In comparison, the Ad5-EGFPWT treated groups were 
showing signs of cachexia, and had significantly elevated serum transaminases, with 
higher levels of viral DNA and extensive E1A expression within their livers, at the time 
of death. Additionally, histological examination of H&E sections of liver tissue revealed 
distinct differences between the groups. In addition to the lack of hepatocellular 
dysregulation in Ad5-EGFPA20 and Ad5-477dlTAYTA20 treated groups, the absence of 
an inflammatory infiltrate was obvious when compared to Ad5-EGFPWT treated cohorts.  
 
The dramatic reductions in liver accumulation and hepatotoxicity with Ad5-EGFPA20 
were not anticipated. However, these initial in vivo studies were performed prior to 
extensively characterising the interactions of these viruses with FIX/FX in vitro 
(described in Chapter.4). In these subsequent experiments, it was confirmed that both 
A20-modified vectors, Ad5-EGFPA20 and Ad5-477dlTAYTA20, failed to interact with FIX 
to promote infectivity enhancement in various cell lines (CHO-K1, CHO-CAR, BT-20, 
TR126 and DX3-β6). Unfortunately, we were unable to investigate the potential role of 
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C4BP in these in vitro studies as it was commercially unavailable at the time. Based on 
these in vitro findings, we hypothesised that the insertion of the A20FMDV2 peptide 
into the HI loop of the fibre was inducing a conformational change, or steric hindrance 
which disrupted binding of FIX and/or C4BP to the fibre. However, evidence provided in 
recent years has confirmed that a FX-hexon interaction is the predominant determinant 
of hepatocyte transduction in vivo following systemic delivery of Ad5 (Alba et al., 2009; 
Kalyuzhniy et al., 2008; Vigant et al., 2008; Waddington et al., 2008). Therefore, it was 
unexpected that these fibre modified viruses, both of which retain a fully functional 
capacity for FX-mediated infectivity enhancement in vitro, should display such an 
altered hepatotropism in vivo.  
 
Several other vectors (Ad9, Ad11, Ad35, Ad40) which display reduced transduction of 
hepatocytes in vivo have been described previously, however these effects are thought 
to be due to inefficient vector trafficking, or the lack of available functional receptors on 
the surface of liver cells (Liu et al., 2009; Nakamura et al., 2003; Sakurai et al., 2003; 
Shayakhmetov et al., 2004a; Shayakhmetov et al., 2004b; Stone et al., 2005). Despite 
their limited hepatocyte transduction, many of these vectors have been shown to 
accumulate in the liver at levels equivalent to Ad5 at early time-points (Sakurai et al., 
2003; Shayakhmetov et al., 2004b; Stone et al., 2005). In contrast, we have shown that 
the lack of hepatocyte transduction observed with Ad5-EGFPA20 and Ad5-
477dlTAYTA20, is accompanied by significant reductions in genome accumulation in the 
liver (4 days post-infection). This was further substantiated in later experiments which 
demonstrated that these vectors also displayed reduced liver accumulation 24hrs post-
infection. In vitro data presented in Chapter.4 demonstrated that both Ad5-EGFPA20 
and Ad5-477dlTAYTA20 possess an ability to utilise either CAR, or HSPGs (in addition 
to ανβ6), as receptors for efficient infection. Additionally, in vitro infectivity experiments 
using numerous cell lines confirmed that the intracellular trafficking of these fibre-
modified vectors is not impaired as a result of the A20FMDV2 insertion. Therefore, we 
can eliminate the possibility that the factors described above which result in limiting the 
hepatotropism of other Ad serotypes (Ad9, Ad11, Ad35, Ad40), are responsible for the 
effects observed with Ad5-EGFPA20 and Ad5-477dlTAYTA20.  
 
Recent evidence has highlighted the importance of the spleen as a major site for the 
induction of innate immune responses directed towards intravenously delivered Ads, 
and it has been proposed that vectors which have limited splenic accumulation would 
be safer vehicles for gene therapy applications (Di Paolo et al., 2009b; Fejer et al., 
2008; Koizumi et al., 2007; Zhang et al., 2001). Therefore, it was reassuring that both 
Ad5-EGFPA20 and Ad5-477dlTAYTA20 also displayed a reduced tropism for the spleen. 
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This is in contrast with Ad35-based vectors, currently being investigated for their 
tumour targeting potential via CD46, which display enhanced splenic sequestration 
when compared to Ad5 (Liu et al., 2009; Stone et al., 2007a). Interestingly, another 
fibre modified virus (Ad5-K7 featuring a polylysine motif in the C-terminus of the fibre 
knob) which displays a biodistribution profile similar to the A20-modified viruses, has 
been described previously (Koizumi et al., 2007). In this study, the authors also 
reported reductions in liver toxicity, as measured by serum AST levels and histological 
examination when compared with the conventional Ad5 control vector.  This profile was 
partially attributed to reduced serum IL-6 levels, which they believed to be a direct 
result of lower level vector uptake in the spleen (Koizumi et al., 2007). It was argued 
that IL-6 signalling from splenic dendritic cells plays a critical role in liver toxicity in vivo, 
due to the fact that administration of an anti-IL-6R antibody partially reduced Ad5-
induced hepatopathology and serum AST levels (Koizumi et al., 2007). Based on these 
data, we hypothesised that the reduced toxicity (lower AST/ALT and minimal liver 
damage histologically) we observed with Ad5-EGFPA20 and Ad5-477dlTAYTA20 in this 
study, may also be due in part to limited splenic sequestration, and consequently 
diminished IL-6 signalling.  
 
In order to address this, and the possibility that the reduced hepatotropism was due to 
increased uptake in alternative organs, we decided to repeat these experiments at an 
earlier time-point (24hrs), expanding our biodistribution analysis (liver, spleen, lung, 
heart, kidney), in addition to quantifying a panel of cytokines/chemokines (IL-6, 
RANTES, IFN-γ, TNF-α and IL-12).  
 
 
Section.5.2 In Vivo Biodistribution and Induction of Innate Immunity at Early 
Time-Points Post-Infection (6-24hrs) 
 
The early phase of the innate response to Ad5 is dose-dependent and occurs 
independently of viral gene expression (Liu & Muruve, 2003; Liu et al., 2003; Muruve et 
al., 1999; Zhang et al., 2001). Characteristic elevations in serum chemokines and 
cytokines [IL-1α, IL-1-β, IL-5, IL-6, IL-12, TNF-α, IFN-γ, GM-CSF, IP-10, MIP-1β and 
RANTES] are frequently observed, especially when high doses of vector are 
administered intravenously (Di Paolo et al., 2009a; Kiang et al., 2006; Koizumi et al., 
2007; Lieber et al., 1997; Liu et al., 2003; Lozier et al., 2002; Muruve et al., 1999; 
Muruve et al., 2004; Shayakhmetov et al., 2005c; Zhang et al., 2001). These responses 
can be triggered by interactions with pattern recognition receptors, including TLR9, and 
can involve the activation of Type I IFNs (Appledorn et al., 2008; Cerullo et al., 2007; 
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Fejer et al., 2008; Muruve et al., 2008; Zhu et al., 2007). Recently, an alternative 
activation pathway has been described, which is independent of TLRs and IFNs (Di 
Paolo et al., 2009a). The authors demonstrated the importance of a penton-RGD 
interaction with -β3 integrin expressed on macrophages, in triggering the activation of 
IL-1α. The activation of pro-inflammatory effectors contributes to vector related toxicity, 
and to the extensive liver pathology observed with Ad5 (Koizumi et al., 2007; Lieber et 
al., 1997; Stone et al., 2007a). However, the precise cellular sources of these immune 
effectors remain unclear, although KCs, splenic marginal zone macrophages and 
dendritic cells have been implicated (Di Paolo et al., 2009a; Fejer et al., 2008; Koizumi 
et al., 2007; Zhang et al., 2001).  
 
Compared to Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 once again displayed 
a reduced accumulation in the liver and spleen, 24hrs post-infection. Unexpectedly, 
absolute viral genome levels detected 24hrs post-infection (Fig.5.5 and Fig.5.8), were 
lower than those than those detected 4 days post-infection (Fig.5.12 and Fig.5.15). It 
has previously been shown that >90% Ad5 is eliminated from the liver by 
approximately 24hrs (Lieber et al., 1997; Worgall et al., 1997). However, as all the 
vectors used in this study are replicating viruses it is possible that genome replication 
(but not productive virion production) may explain this discordance. Alternatively, 
although identical virus stocks, mouse strain and doses were used, these experiments 
were performed a year apart and genomes were quantified using a different Real Time 
PCR system (ABI 7300). These factors may also have contributed to the differences 
observed.  
 
In addition to displaying a reduced hepatotropsim (reduced accumulation of viral 
genomes, limited E1A expression and low level transaminase elevations), the A20-
retargeted viruses, Ad5-EGFPA20 and Ad5-477dlTAYTA20, induced distinctly altered 
cytokine/chemokine profiles to Ad5-EGFPWT, characterised by significantly reduced 
serum concentrations of IL-6, RANTES and IFN-γ. With respect to Ad5-477dlTAYTA20, 
these findings are in agreement with previously published data for Ad5mut (an Ad5-
477dlTAYT-based vector), and provide support for the hypothesis that abrogation of 
FIX/C4BP binding to the fibre results in a vector with reduced cytokine induction and 
hepatotoxicity (Shayakhmetov et al., 2005b). However, the precise mechanism which 
results in this phenotype is currently unclear, and is complicated by the interactions of 
Ad5 with multiple cell types and blood components following systemic delivery.  
 
In addition to the mechanisms outlined previously (inefficient vector trafficking/lack of 
functional receptors), rapid vector clearance from the liver has also been shown to limit 
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hepatocyte transduction. This can occur either through displacement to/successful 
retargeting to other organs (ie. Ad5Luc-OvF), or through increased vector degradation 
(ie. Ad35) by non-parenchymal cells (Nakayama et al., 2006; Sakurai et al., 2003; 
Stone et al., 2007a). The originally described 477dlTAYT fibre mutated virus, Ad5mut, 
was shown to have reduced co-localisation with KCs in vivo (Shayakhmetov et al., 
2005b). In support of this, subsequent studies have demonstrated that Ad5 uptake by 
KCs via scavenging receptor A (SR-A) can be inhibited by soluble Ad5 knob protein, 
although this remains to be investigated in vivo (Haisma et al., 2009). The A20-
modified vectors appear to retain all other characteristics of Ad5mut in vivo, therefore it 
appears unlikely that they would be increasingly degraded by KCs. Microbe scavenging 
by KCs induces the release of pro-inflammatory mediators which contribute to the 
destruction of neighbouring hepatocytes, in addition to functioning as chemo-
attractants for infiltrating neutrophils (Lieber et al., 1997). Interestingly, Ad5-induced 
neutrophil recruitment (via MIP-2 induction) has been directly associated with acute 
hepatic injury and elevation of serum transaminases, ALT/AST (Muruve et al., 1999). 
Therefore, the limited induction of pro-inflammatory effectors IL-6, RANTES and IFN-γ, 
reduced ALT/AST levels, minimal hepatic injury (histopathologically) and the distinct 
absence of an inflammatory infiltrate observed with Ad5-EGFPA20 and Ad5-
477dlTAYTA20, again does not reconcile with the hypothesis that the A20-modified 
vectors could be scavenged more rapidly by KCs. However, we do not currently 
possess any evidence to confirm a differential interaction between Ad5-EGFPA20/Ad5-
477dlTAYTA20 and KCs, and so we cannot eliminate this possibility. Alternatively, it is 
possible that redirecting the tropism of these vectors could, potentially, lead to 
divergent endosomal or lysosomal trafficking in KCs, with a differential outcome (eg. 
viral degradation, without the activation of KCs and subsequent release of cytokines). 
Nonetheless, it is important to note that increased vector degradation does not 
necessarily preclude efficient tumour targeting in vivo, if the affinity for the target 
receptor is sufficiently high (Liu et al., 2009).  
 
In addition to a reduced accumulation of A20-modified vectors in the liver, these 
viruses were also deposited in the spleen to a lesser extent than Ad5-EGFPWT. KC 
depletion with GdCl3 has been shown to reduce TNF-α levels, but increase IL-6 levels 
(Lieber et al., 1997). It is possible that the selective depletion of KCs, increases vector 
availability for uptake in the spleen, and contributes to the subsequent increase in IL-6. 
Broader depletion of tissue macrophages and dendritic cells using clodronate 
liposomes (Cl2MBP) has been shown to limit the production of IL-6, IL-12 and TNF-α 
(Liu & Muruve, 2003; Zhang et al., 2001). This is consistent with the theory that splenic 
dendritic cells are a major source of IL-6 following intravenous delivery of Ad5 (Koizumi 
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et al., 2007). Therefore, it is likely that the reduced IL-6 levels associated with Ad5-
EGFPA20 and Ad5-477dlTAYTA20 are a direct reflection of the reduced splenic 
sequestration of these vectors.  
 
In addition to interacting directly with innate immune cells, Ad5 has been shown to 
interact with complement, natural antibodies, platelets and various other blood 
components (Kiang et al., 2006; Lyons et al., 2006; Othman et al., 2007; 
Shayakhmetov et al., 2005b; Stone et al., 2007b; Tian et al., 2009; Waddington et al., 
2008; Xu et al., 2008). Moreover, several of these interactions have been shown to, or 
at least suggested to, contribute to KC-mediated vector clearance; either through 
opsonisation of the Ad5 particle with complement and/or natural antibodies (Kiang et 
al., 2006; Xu et al., 2008), or by platelet-mediated sequestration in the liver and 
subsequent phagocytosis of the Ad5-platelet-leukocyte aggregates by KCs (Stone et 
al., 2007b). Ad5-induced thrombocytopenia following intravenous delivery is a well 
reported effect, and although not dangerous in itself, can exacerbate coagulopathic 
conditions (Othman et al., 2007; Raper et al., 2002; Stone et al., 2007b). Interestingly, 
we did not observe any induction of thrombocytopenia at 24hrs upon infection with 
Ad5-EGFPA20 or Ad5-477dlTAYTA20, whereas in comparison Ad5-EGFPWT treated 
animals had significantly reduced circulating platelet levels. This can possibly be 
explained to some extent by the lack of hepatic transduction observed with Ad5-
EGFPA20 and Ad5-477dlTAYTA20, and the recent finding that C3 activation by damaged 
hepatocytes, contributes to the development of acute thrombocytopenia (Kiang et al., 
2006; Tian et al., 2009).   
 
Lymphopenia was observed in all virally treated groups at the 24-hour time-point, but 
not at later time-points (in a previous, but separate experiment assessed 4 days post-
infection). Type I IFN is induced during the acute phase of viral infections, including 
following systemic administration of Ad5 (Fejer et al., 2008). Interestingly, induction of 
Type I IFN is causatively associated with the development of transient lymphopenia 
(Kamphuis et al., 2006). In addition to lymphocytes, monocytic populations were also 
dramatically reduced in all virally infected cohorts. It is evident that distinct differences 
exist between the interactions of Ad5 with murine, and with human blood cells (Carlisle 
et al., 2009; Lyons et al., 2006; Nicol et al., 2004). This has fundamental relevance to 
future clinical applications with Ad5, especially the discovery that Ad5 can bind to 
human erythrocytes through CAR (Carlisle et al., 2009; Seiradake et al., 2009), 
potentially impairing efficient tumour transduction. It will be interesting to determine 
whether or not the CAR-binding ablated virus, Ad5-477dlTAYTA20, proves useful in 
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avoiding the agglutination of human erythrocytes, especially as this vector retains all of 
the liver avoidance, and tumour targeting efficiency of Ad5-EGFPA20 (see Chapter.6).  
 
Finally, the restricted tissue distribution of ανβ6 in humans is well defined, where it is 
associated with epithelial remodelling events such as embryogenesis, wound healing 
and carcinogenesis (Breuss et al., 1995). Conversely, its biodistribution in murine 
models is not established. The integrin, ανβ6, has been shown previously to be 
constitutively expressed at low levels in the lung, where it is retained in a complex with 
TGF-β and plays a role in maintaining immunological homeostasis (Munger et al., 
1999). We did not detect an increased accumulation of Ad5-EGFPA20 or Ad5-
477dlTAYTA20 relative to Ad5-EGFPWT in the lung, or indeed in any other organs 
analysed in this study (liver/spleen/kidney/heart). Clearly, factors other than receptor 
availability play a definitive role in the biodistribution of systemically delivered Ad5-
based vectors. The anatomical accessibility of the organ, in addition to direct 
interactions between the virus and various components within the circulation, contribute 
to the distribution of Ad vectors (Carlisle et al., 2009; Manickan et al., 2006; 
Waddington et al., 2008). Furthermore, it is difficult to propose a mechanism which 
underlies the altered tissue distribution of the A20-modified vectors, as the factors 
which determine non-retargeted Ad5 vectors are currently not well understood.  
 
In summary, in our analysis of Ad5-EGFPA20 and Ad5-477dlTAYTA20, we have 
uncovered some very interesting and potentially exploitable characteristics. However, it 
is currently unclear whether the attributes of these A20-modifed viruses are a direct 
result of abrogating an interaction with FIX/C4BP in vivo, or whether their 
characteristics are solely associated with the biological effects of the A20FMDV2 
targeting ligand. We previously generated, by homologous recombination, a non-
retargeted control for the 477dlTAYTA20 virus, pMB20-477dlTAYT6XHIS, which features a 
6XHIS epitope within the HI loop. This construct was never been produced, or purified 
as virus due to time constraints. However, it may be interesting in the future to confirm 
if the unusual effects observed, at least in relation to Ad5-477dlTAYTA20, can be 
attributed to the 477dlTAYT mutation, or in fact to the A20FMDV2 insertion. 
Nonetheless, minimising vector related toxicity and off target sequestration are highly 
desirable qualities which need to be considered in the design of therapeutic Ads, as 
they can permit the use of higher doses, maximising efficacy. Therefore, a vector which 
displays a reduced tropism for the reticuloendothelial system, coupled with an 
improved safety profile following systemic delivery, may represent a means of 
overcoming some of the limitations of current Ad5 therapy. 
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Chapter.6 In Vivo Characterisation of Viruses; Analysis of Tumour 
Targeting by A20-Modified Adenoviruses Following Systemic Delivery 
 
High efficiency retargeting to cancer-specific markers is highly desirable if adenoviral 
vectors are to have realistic clinical applications, particularly for the treatment of 
disseminated disease. However, the off-target sequestration of Ad5 in the liver remains 
a major obstacle to achieving this goal. A role for coagulation factors in directing liver 
uptake following systemic delivery has been demonstrated in recent years, and has 
prompted the experimental use of anti-coagulants, such as warfarin, in an attempt to 
increase the bioavailability of the virus (Coughlan et al., 2009; Gimenez-Alejandre et 
al., 2008; Koski et al., 2009; Shashkova et al., 2008; Shashkova et al., 2009; 
Waddington et al., 2007). However, the development of approaches based on this 
strategy remain in their infancy. To date, a genetically modified vector which combines 
high efficiency tumour-selective targeting combined with liver avoidance strategies 
and/or reduced hepatotoxicity has not been reported.  
 
We obtained convincing in vitro data to support the possibility that high affinity targeting 
to ανβ6 in vivo, could supersede the dramatic enhancement conferred by the presence 
of coagulation factors. Therefore, an assessment of how these modified vectors 
performed in vivo in the presence of, and absence of, coagulation factors was pertinent 
and critical to these studies. An in vivo tumour targeting experiment was designed in 
which separate cohorts of mice (N=5) were administered with each virus, with or 
without warfarin pre-treatment to deplete vitamin-K dependent coagulation factors. A 
subcutaneous injection of warfarin, dissolved in peanut oil, was administered at days -3 
and -1 prior to virus administration by Mr. Arif Mustafa and Dr. John Marshall, 
respectively. The following procedures were performed by Professor Ian R. Hart; 
intravenous injection of virus, extraction of blood from the tail vein, extraction of blood 
from the cardiac cavity immediately post-mortem, and necropsy. Liver transaminase 
levels were quantified from mouse serum (Axiom Veterinary Laboratories, Devon, UK).  
 
Section.6.1 Tumour Targeting, Hepatotoxicity and Biodistribution 
 
6.1.1. Quantification of Viral Genomes (qPCR) in DX3-β6 Xenografts. The in vivo 
tumour targeting efficiency of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 was 
assessed following systemic delivery. Using a previously established xenograft model, 
4x106 DX3-β6 cells (low CAR, high ανβ6) were implanted into the right shoulder of CD1 
nude female mice. A single dose of each virus (5x1010vp/mouse) was administered by 
tail vein injection to separate cohorts which had, or had not, received a warfarin pre-
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treatment at days -3 and -1 prior to virus administration. Mice were killed 72hrs later, 
tumours excised and absolute viral genome levels determined by fluorogenic 
quantitative real-time PCR (Fig.6.1). In non-warfarin treated cohorts, both Ad5-EGFPA20 
and Ad5-477dlTAYTA20 displayed enhanced tumour uptake when compared with Ad5-
EGFPWT, improving delivery ~2-fold (p>0.05, not significant) and ~3-fold (p=0.019), 
respectively. Pre-treatment with warfarin, marginally improved tumour uptake of Ad5-
EGFPWT, although not significantly (p=0.395). Interestingly, warfarin pre-treatment 
reduced uptake of Ad5-EGFPA20 (~1.6-fold decrease; not significant) and Ad5-
477dlTAYTA20 (~3-fold decrease; p=0.004) when compared with the corresponding 
non-warfarinised groups.  
 
6.1.2 Histological Examination of DX3-β6 Tumour Xenografts; H&E Staining and 
Immunostaining for ανβ6 Integrin. Previous attempts to demonstrate anti-tumoural 
efficacy using the DX3-β6 xenograft model had failed (see Chapter.3). This possibly 
was due to a combination of factors, including the fact that the -β6 expression in these 
cells in vivo appeared to be lost over time. In addition, this model is a poorly 
vascularised tumour which rapidly becomes necrotic. Therefore, it is not ideal for 
studying the effects of Ad5, especially in longer term experiments. However, we had 
observed in previous experiments that the tumours which were harvested from animals 
sacrificed at early time points (~3 weeks), retained high level expression of -β6 (see 
Fig.3.23D). Several attempts to develop other low CAR, high ανβ6 expressing 
xenograft models were not successful (TR126, TR138 and BT-20 cells injected into 
CD1 nude mice did not result in tumours). Therefore, we had no alternative but to use 
the DX3-β6 model for this short term targeting experiment (~3 weeks). 
 
4x106 DX3-β6 cells were implanted subcutaneously into the right shoulder of CD1 nude 
female mice. When tumours reached approximately 125mm3 (~3 weeks) animals were 
subjected to various treatments (see Section.6.1.1). Animals were killed 3 days after 
virus delivery, and tumours harvested for analysis and histological examination. 
Fortunately, large areas of the DX3-β6 tumours stained strongly positive for -β6 
expression, despite extensive necrosis throughout the tissue (Fig.6.1B). An IgG control 
antibody was used to confirm that the -β6 immunostaining was specific. 
Immunostaining of warfarinised tumours yielded some unexpected results. All sections 
were processed on the same day, using identical reagents, (antibody dilutions, blocking 
kits) however the warfarin pre-treated tumours showed extensive staining even in the 
IgG controls (Fig.6.1C). Therefore, we cannot determine the -β6 expression status of 
these tumours, and indeed whether or not warfarin pre-treatment affects or down-
regulates surface expression of ανβ6 in vivo.  
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 Figure.6.1 (A) Quantification of Viral Genomes in DX3-β6 Tumour Xenografts Following Systemic 
Delivery. CD1 nude female mice, bearing DX3-β6 xenografts, were injected either with PBS, Ad5-
EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20 (5x1010vp/mouse) by intravenous tail vein injection, without 
(-) or with (+) a pre-dose of warfarin (133μg) at days -3 and -1 prior to virus administration (day 0). Mice 
were killed after 72hrs, necropsy performed and DNA extracted from tumours. Absolute viral genomes 
were quantified by TaqMan Real-Time Quantitative PCR (qPCR) using a probe to detect the hexon region 
of the genome (see Section.2.2.7). Data presented represent the mean ± SEM (N=4/5 mice) of triplicate 
qPCR samples and are representative of two independent qPCR experiments. Statistical significance was 
determined using the unpaired Student’s t-test to compare the means of two samples (* indicates a P-
value of <0.05, ** p<0.01, bars indicate SEM). Statistics displayed above the histograms for warfarin pre-
treated cohorts refer to the difference when compared to the corresponding untreated cohort. (B) 
Histology and Immunohistochemical Analysis of DX3-β6 Tumours (Non-warfarinised). From left to 
right; Haematoxylin and Eosin staining showing a region of necrosis within a DX3-β6 tumour section, IgG1 
control antibody staining, and immunostaining for ανβ6 using 6.2G2. Sections were photographed at a 
magnification of 200X using a Zeiss AxioCam MRc5 camera and Axiovision Software (Zeiss, Germany). 
(C) Histology and Immunohistochemical Analysis of DX3-β6 Tumours (Warfarinised). From left to 
right; Haematoxylin and Eosin staining of DX3-β6 tumour section, IgG1 control antibody staining, and 
immunostaining for ανβ6 using 6.2G2. Sections were photographed at a magnification of 200X using a 
Zeiss AxioCam MRc5 camera and Axiovision Software (Zeiss, Germany).  
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6.1.3 Quantification of Viral Genomes (qPCR) in Murine Liver. Absolute numbers of 
viral genomes in the liver, for both non-warfarinised and warfarinised groups, were 
measured by quantitative real time PCR (Fig.6.2). As expected for this dose 
(5x1010vp/mouse), there was significant sequestration of Ad5-EGFPWT in the livers of 
non-warfarinised animals. In agreement with our results (see Chapter.5), and data 
published by Shayakhmetov and colleagues, the putative FIX/C4BP-binding ablated 
vector, Ad5-477dlTAYTA20, displayed a significantly reduced liver tropism with ~5-fold 
fewer genomes detected (p<0.0001) when compared to Ad5-EGFPWT (Shayakhmetov 
et al., 2005b). Again, in agreement with data presented in Chapter.5, Ad5-EGFPA20 
Figure.6.2 Quantification of Viral Genomes in Murine Liver Following Systemic Delivery. CD1 nude 
female mice, bearing DX3-β6 xenografts, were injected either with PBS, Ad5-EGFPWT, Ad5-EGFPA20 or 
Ad5-477dlTAYTA20 (5x1010vp/mouse) by intravenous tail vein injection, without (-) or with (+) a pre-dose of 
warfarin (133μg) at days -3 and -1 prior to virus administration (day 0). Mice were killed after 72hrs, 
necropsy performed and DNA extracted from liver tissue. Absolute viral genomes were quantified by 
TaqMan Real-Time Quantitative PCR (qPCR) using a probe to detect the hexon region of the genome 
(see Section.2.2.7). Data presented represent the mean ± SEM (N=4/5 mice) of triplicate qPCR samples 
and are representative of two independent qPCR experiments. Statistical significance was determined 
using the unpaired Student’s t-test to compare the means of two samples (* indicates a P-value of <0.05, 
** p<0.01, *** p<0.001, **** p<0.0001, bars indicate SEM). Statistics displayed above the histograms for 
warfarin pre-treated cohorts refer to the difference when compared to the corresponding untreated cohort. 
Inset: Frozen liver sections (5μm) were immunostained with anti-E1A antibody (13 S-5) for Ad5-EGFPWT 
and Ad5-EGFPA20 groups only, with/without warfarin pre-treatment. Immunofluorescence was visualised 
using a Zeiss laser scanning microscope (LSM 510META) and pictures captured using LSM 5 Software, 
version 3.2 (Zeiss, Germany).  
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displayed an identical profile (p=0.0002). Additionally, this profile was consistent with in 
vitro results presented in Chapter.4, where we observed that Ad5-EGFPA20, in addition 
to Ad5-477dlTAYTA20, failed to interact with FIX to promote infectivity enhancement. 
These differences were further supported by immunostaining for viral antigen, E1A 
(Fig. 6.2;inset and Fig.6.3A). In animals subjected to warfarin pre-treatment, a 
significant reduction in E1A expression (Fig.6.2;inset and Fig.6.4A), in addition to an 
overall reduction in viral genome levels (~9-fold, p<0.0001), was found in the Ad5-
EGFPWT group. However, warfarin had a more striking effect on the liver sequestration 
of the A20-modified vectors, Ad5-EGFPA20 and Ad5-477dlTAYTA20, with viral genomes 
reduced by ~160-fold (p=0.035), and ~34-fold (p=0.006) respectively, when compared 
with the untreated Ad5-EGFPA20/Ad5-477dlTAYTA20 groups. 
 
6.1.4 Histological Examination of Murine Liver Tissue; H&E Staining and 
Immunostaining for E1A. Immunostaining of paraffin embedded liver tissue 
demonstrated a clear reduction in the extent of E1A expression in the Ad5-EGFPA20 
and Ad5-477dlTAYTA20 groups, when compared to the Ad5-EGFPWT group (Fig.6.3A). 
Moreover, haematoxylin and eosin staining of non-warfarinised liver sections also 
revealed distinct histological differences between the non-warfarinised Ad5-EGFPWT 
group, and the Ad5-EGFPA20/Ad5-477dlTAYTA20 groups (Fig.6.3B+C), supporting the 
data shown in Fig.6.3A and Fig.6.2;inset. At a magnification of 200X, the livers of the 
Ad5-EGFPWT treated mice showed prominent hepatocyte atypia, with loss of cellular 
and nuclear definition, in addition to widespread hepatocyte necrosis (Fig.6.3B). In 
contrast, the hepatocytes of mice which had been treated with Ad5-EGFPA20 or Ad5-
477dlTAYTA20 more closely resembled the untreated PBS control group, with intact 
cellular junctions and nuclei. These irregularities were more evident at higher 
magnifications (400X), where several enlarged, hyperchromatic nuclei could be 
observed in the Ad5-EGFPWT group (Fig.6.3C). Moreover, the lack of cellular integrity in 
the tissue of this group was dramatic, especially when compared with tissue obtained 
from the Ad5-EGFPA20 and Ad5-477dlTAYTA20 treated cohorts.  
 
In warfarin pre-treated animals, no E1A expression was detected in the livers of any 
cohort (Fig.6.4A). This was consistent with the significantly reduced levels of viral 
genomes sequestered in the livers of these animals (see Fig.6.2). Furthermore, 
histological assessment of this tissue (H&E) did not show any major differences 
between the PBS, and virus treated groups although, again, the Ad5-EGFPWT treated 
groups appeared to display slight abnormalities (enlarged cells and slightly swollen 
nuclei were visible).   
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Figure.6.3 (A) E1A Immunostaining of Non-Warfarinised Murine Liver Sections (100X 
Magnification). CD1 nude female mice, bearing DX3-β6 xenografts, were injected either with PBS, Ad5-
EGFPWT, Ad5-EGFPA20, or Ad5-477dlTAYTA20 (5x1010vp/mouse) by intravenous tail vein injection (day 0). 
Mice were killed after 72hrs, livers harvested and tissue processed for paraffin embedding. Tissue 
sectioning and E1A immunostaining, using anti-Adenovirus/E1A [M58], was performed by Keyur Trivedi 
(Pathology Services) at the Institute of Cancer. (B) Haematoxylin and Eosin (H&E) Staining of Non-
Warfarinised Murine Liver Sections (200X Magnification). Liver sections for each cohort; PBS control, 
Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 were stained with H&E (performed by Keyur Trivedi, 
as above), and tissue assessed histopathologically. Histological analysis was performed blindly by a 
qualified pathologist (Prof. Gareth Thomas), without prior knowledge of the specimens. (C) Haematoxylin 
and Eosin (H&E) Staining of Non-Warfarinised Murine Liver Sections (400X Magnification). Sections 
from PBS, Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 cohorts were also examined 
histopathologically. All sections were photographed using a Zeiss AxioCam MRc5 camera and Axiovision 
Software (Zeiss, Germany).  
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Figure.6.4 (A) E1A Immunostaining of Warfarinised Murine Liver Sections (100X Magnification). 
CD1 nude female mice, bearing DX3-β6 xenografts, were pre-treated with warfarin (133μg) on days -3, 
and -1 after which they were injected either with PBS, Ad5-EGFPWT, Ad5-EGFPA20, or Ad5-477dlTAYTA20 
(5x1010vp/mouse) by intravenous tail vein injection (day 0). Mice were killed after 72hrs, livers harvested 
and tissue processed for paraffin embedding. Tissue sectioning and E1A immunostaining, using anti-
Adenovirus/E1A [M78], was performed by Keyur Trivedi (Pathology Service), at the Institute of Cancer. (B) 
Haematoxylin and Eosin (H&E) Staining of Warfarinised Murine Liver Sections (200X 
Magnification). Liver sections for each warfarin pre-treated cohort; PBS control, Ad5-EGFPWT, Ad5-
EGFPA20 and Ad5-477dlTAYTA20 were stained with H&E (performed by Keyur Trivedi, as above), and 
tissue assessed histopathologically. Histological analysis was performed blindly by a qualified pathologist 
(Prof. Gareth Thomas), without prior knowledge of the specimens. Sections were photographed at a 
magnification of 200X using a Zeiss AxioCam MRc5 camera and Axiovision Software (Zeiss, Germany).  
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6.1.5 Determination of Toxicity. The hepatotoxicity induced following systemic 
delivery of replicating adenoviruses in murine models is dose-limiting (Cascallo et al., 
2007; Engler et al., 2004). Therefore, we compared the toxicity induced upon systemic 
delivery of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 (5x1010vp/mouse), 
assessing % body weight variation on a daily basis and in addition, serum 
transaminase (ALT and AST) levels in serum, obtained at the time of death (Axiom 
Veterinary Laboratories, Devon, UK). 
 
In non-warfarinised mice, there were significant variations in body weight (%) between 
the Ad5-EGFPWT group, and the A20-modified groups Ad5-EGFPA20/Ad5-477dlTAYTA20 
(Fig.6.5A). Variation in the Ad5-EGFPWT group on day 2 was -8.2±1.3%. There were 
significant differences between the Ad5-EGFPWT group and the Ad5-EGFPA20 (-
4.0±1.4%, p=0.003), and Ad5-477dlTAYTA20 (-1.98±2.17%, p=0.002) treated groups, 
which more closely resembled the PBS control cohort (p>0.05). At this time-point only 
Ad5-EGFPWT differed statistically from the PBS control group (p=0.0006). On day 3, the 
percentage weight variation in the Ad5-EGFPWT group was -11.7±2.2%, differing 
significantly from the Ad5-EGFPA20 group (p=0.004), which remained largely 
unchanged from day 2 at -3.8±3.2%. In addition, no significant variation in the Ad5-
477dlTAYTA20 group (-1.83±1.72%) from day 2-3 was observed, which differed 
significantly when compared to Ad5-EGFPWT (p=0.0001) on day 3. In warfarin treated 
groups no significant weight variation was observed at any time point (Fig.6.5B), except 
for Ad5-EGFPWT on day 1 when compared with PBS control (p=0.031).  
 
In the non-warfarinised Ad5-EGFPWT group, there were significant elevations in both 
serum ALT (Fig.6.5C) and AST (Fig.6.5E) levels, which were substantially lower in both 
of the A20-modified virus groups. ALT levels in Ad5-EGFPA20 and Ad5-477dlTAYTA20 
treated groups were ~3-fold (p=0.025), and ~10-fold (p=0.009) lower than Ad5-
EGFPWT. In addition, when compared to Ad5-EGFPWT, AST levels were ~3-fold 
(p=0.0003), and ~10-fold (p<0.0001) lower in Ad5-EGFPA20 and Ad5-477dlTAYTA20 
treated groups, respectively. These data corroborated previous results (Fig.6.3B+C 
and Chapter.5), confirming that the A20-modifed viruses have reduced hepatotoxicity in 
vivo.  
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Figure.6.5 Determination of Toxicity Following Systemic Administration of Virus. (A) Body weight 
variation (%) was assessed on a daily basis for CD1 nude cohorts which received intravenous delivery of 
PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20 (5x1010vp/mouse). (B) Percentage body weight 
variation was assessed for each cohort as described in (A), which had also received a warfarin pre-dose 
at days -1 and -3, prior to virus administration (day 0). (C) Blood samples were obtained immediately post-
mortem (72hrs after virus administration) and serum alanine transaminase (ALT) levels were quantified for 
each of the non-warfarinised groups; PBS, Ad5-EGFPWT, Ad5-EGFPA20 or Ad5-477dlTAYTA20. (D) Serum 
ALT levels were quantified for warfarin pre-treated cohorts, as described in (C). (E) Serum aspartate 
aminotransferase (AST) levels were quantified for all non-warfarinised groups; PBS, Ad5-EGFPWT, Ad5-
EGFPA20 or Ad5-477dlTAYTA20. (F) Serum AST levels were quantified for all groups which received a 
warfarin pre-dose, as described in (E). Data represent the mean ± SEM (N=4/5 mice), with the exception 
of the Ad5-EGFPA20 warfarin pre-treated group in (D) and (F), for which only one blood sample was 
obtained (N=1). Statistical significance was determined using the unpaired Student’s t-test comparing the 
means of two samples (* indicates a P-value of <0.05, ** p<0.01, *** p<0.001, **** p<0.0001, bars indicate 
SD). 
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As warfarin pre-treatment can reduce the hepatic uptake of wild-type Ad5 significantly, 
serum levels of ALT (Fig.6.5D) and AST (Fig.6.5F) were also analysed for Ad5-
EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 warfarin pre-treated groups. Compared 
with untreated groups, pre-treatment with warfarin significantly reduced ALT and AST 
levels for Ad5-EGFPWT (ALT ~15-fold reduction; p=0.007 and AST ~20-fold; p<0.0001). 
Unfortunately, only one blood sample was obtained for the warfarinised Ad5-EGFPA20 
group, therefore we were unable to perform statistical analysis on this group. However, 
warfarin pre-treatment did not further reduce the already low levels of ALT induced by 
Ad5-477dlTAYTA20 when compared to the corresponding, untreated control group 
(p=0.263). Similarly, AST levels were not reduced significantly upon warfarin pre-
treatment (p=0.29).  
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6.1.6 Quantification of Viral Genomes (qPCR) in Murine Spleen. In addition to 
differences in liver sequestration, the splenic uptake of Ad5-EGFPA20 and Ad5-
477dlTAYTA20 was significantly altered when compared with Ad5-EGFPWT. In non-
warfarinised groups, absolute Ad5-EGFPWT genome levels in the spleen (Fig.6.6) were 
Figure.6.6 Quantification of Viral Genomes in Spleen Following Systemic Delivery. CD1 nude 
female mice, bearing DX3-β6 xenografts, were injected either with PBS, Ad5-EGFPWT, Ad5-EGFPA20 or 
Ad5-477dlTAYTA20 (5x1010vp/mouse) by intravenous tail vein injection, without (-) or with (+) a pre-dose of 
warfarin (133μg) at days -3 and -1 prior to virus administration (day 0). Mice were killed after 72hrs, 
necropsy performed and DNA extracted from spleen tissue. Absolute viral genomes were quantified by 
TaqMan Real-Time Quantitative PCR (qPCR) using a probe to detect the hexon region of the genome 
(see Section.2.2.7). Data presented represent the mean ± SEM (N=4/5 mice) of triplicate qPCR samples 
and are representative of two independent qPCR experiments. Statistical significance was determined 
using the unpaired Student’s t-test to compare the means of two samples (* indicates a P-value of <0.05, 
** p<0.01, bars indicate SEM). Statistics displayed above the histograms for warfarin pre-treated cohorts 
refer to the difference when compared to the corresponding untreated cohort.  
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significantly higher than the Ad5-EGFPA20 (~3-fold, p=0.046), and Ad5-477dlTAYTA20 
groups (~5-fold, p=0.037). Warfarin pre-treatment reduced Ad5-EGFPWT accumulation 
in the spleen (~7-fold, p=0.012), albeit only to a level equivalent to Ad5-EGFPA20 
(p=0.316), or Ad5-477dlTAYTA20 alone (p=0.224). Warfarin pre-treatment did not further 
enhance the splenic detargeting already observed with the Ad5-EGFPA20 (p=0.206), 
however it did reduce the sequestration of Ad5-477dlTAYTA20 in the spleen significantly 
(p=0.03).  
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6.1.7 Quantification of Viral Genomes (qPCR) in Murine Lung. In non-warfarinised 
animals, the A20-modified viruses, Ad5-EGFPA20 and Ad5-477dlTAYTA20, were also 
differentially distributed in the lung when compared to Ad5-EGFPWT (Fig.6.7). Ad5-
EGFPA20 and Ad5-477dlTAYTA20 appear to naturally be detargeted from murine lung 
tissue (~9-fold reduction, p<0.0001), and (~5-fold reduction, p<0.0001), when 
compared with Ad5-EGFPWT. Warfarin pre-treatment reduced significantly the 
pulmonary accumulation of all viruses, Ad5-EGFPWT (~9-fold, p<0.0001), Ad5-EGFPA20 
(~3-fold, p=0.003) and Ad5-477dlTAYTA20 (~4-fold, p=0.02). However, the Ad5-EGFPWT 
Figure.6.7 Quantification of Viral Genomes in Murine Lung Following Systemic Delivery. CD1 nude 
female mice, bearing DX3-β6 xenografts, were injected either with PBS, Ad5-EGFPWT, Ad5-EGFPA20 or 
Ad5-477dlTAYTA20 (5x1010vp/mouse) by intravenous tail vein injection, without (-) or with (+) a pre-dose of 
warfarin (133μg) at days -3 and -1 prior to virus administration (day 0). Mice were killed after 72hrs, 
necropsy performed and DNA extracted from lung tissue. Absolute viral genomes were quantified by 
TaqMan Real-Time Quantitative PCR (qPCR) using a probe to detect the hexon region of the genome 
(see Section.2.2.7). Data presented represent the mean ± SEM (N=4/5 mice) of triplicate qPCR samples 
and are representative of two independent qPCR experiments. Statistical significance was determined 
using the unpaired Student’s t-test to compare the means of two groups (* indicates a P-value of <0.05, ** 
p<0.01, **** p<0.0001, bars indicate SEM). Statistics displayed above the histogram for warfarin pre-
treated cohorts refer to the difference when compared to the corresponding untreated cohort.  
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treated with warfarin did not differ significantly from the untreated Ad5-EGFPA20 
(p=0.948), or Ad5-477dlTAYTA20 cohorts (p=0.205).  
 
6.1.8 Quantification of Viral Genomes (qPCR) in Murine Stomach. Prior studies 
have identified that murine stomach tissue expresses ανβ6 (Dr. Antonio Saha, 
unpublished data with permission). Immunostaining for ανβ6 integrin in murine 
stomach tissue was performed using 6.2G2 (Fig.6.8B). We also quantified the levels of 
viral genomes, for each cohort, in the stomach (Fig.6.8A). No significant differences in 
viral genome numbers were detected between the ανβ6-retargeted viruses, Ad5-
EGFPA20 and Ad5-477dlTAYTA20, and the non-retargeted virus, Ad5-EGFPWT (p=0.100, 
p=0.136, respectively). When compared with untreated, warfarin pre-treatment did not 
alter Ad5-EGFPWT genome levels in the stomach (p=0.706), however it did alter 
significantly the accumulation of Ad5-EGFPA20 and Ad5-477dlTAYTA20 (both ~2-fold 
reduction, p=0.025 and p=0.069, respectively).  
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Chapter.6 Discussion 
Figure.6.8 (A) Quantification of Viral Genomes in Murine Stomach Following Systemic Delivery. 
CD1 nude female mice, bearing DX3-β6 xenografts, were injected either with PBS, Ad5-EGFPWT, Ad5-
EGFPA20 or Ad5-477dlTAYTA20 (5x1010vp/mouse) by intravenous tail vein injection, without (-) or with (+) a 
pre-dose of warfarin (133μg) at days -3 and -1 prior to virus administration (day 0). Mice were killed after 
72hrs, necropsy performed and DNA extracted from stomach tissue. Absolute viral genomes were 
quantified by TaqMan Real-Time Quantitative PCR (qPCR) using a probe to detect the hexon region of 
the genome (see Section.2.2.7). Data presented represent the mean ± SEM (N=4/5 mice) of triplicate 
qPCR samples and are representative of two independent qPCR experiments. Statistical significance was 
determined using the unpaired Student’s t-test to compare the means of two groups (* indicates a P-value 
of <0.05, NS p>0.05, bars indicate SEM). Statistics displayed on the histogram for warfarin pre-treated 
cohorts refer to the difference when compared to the corresponding untreated cohort.  (B) 
Immunostaining of Stomach Tissue for Murine ανβ6 Integrin. Immunostaining was performed by Dr. 
Antonio Saha using anti-ανβ6 antibody, 6.2G2 (unpublished data, with permission). 
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Hepatotoxicity is a dose-limiting factor for the systemic delivery of many adenoviral 
vectors (Alemany et al., 2000a; Alemany & Curiel, 2001; Lieber et al., 1997). Therefore, 
high efficiency, tumour-specific targeting with Ad5 is desirable as it can permit the 
reduction of vector dose administered in vivo, and ultimately limit vector-related toxicity 
(Engler et al., 2004). The overexpression of ανβ6 in a wide range of epithelial 
malignancies and fibrotic conditions, coupled with its prognostic associations in 
common cancers such as breast, ovarian, pancreatic, lung and colorectal carcinoma, 
make it an attractive target for engineered adenoviruses (Ahmed et al., 2002b; Bates et 
al., 2005; Elayadi et al., 2007; Sipos et al., 2004). However, despite extensive evidence 
supporting the potential for ανβ6 as a molecular target (Ahmed et al., 2002b; Bates et 
al., 2005; Breuss et al., 1995; Elayadi et al., 2007; Hazelbag et al., 2007; Marsh et al., 
2008; Thomas et al., 2001a; Thomas et al., 2001b; Thomas et al., 2006a; Van Aarsen 
et al., 2008), there have been no previous attempts to design an adenoviral vector 
redirected to ανβ6 for therapeutic applications.  
 
 
Section.6.1 In Vivo Effects of Coagulation Factor Depletion on Tumour/Liver 
Targeting and Biodistribution Following Systemic Delivery 
 
We used the DX3-β6 xenograft model (low CAR, high ανβ6) to compare the tumour 
targeting efficiency of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20 following 
systemic delivery and, in a parallel experiment, assessed the effects of coagulation 
factor depletion on uptake of each vector in the tumour and the liver. Vector induced 
hepatotoxicity was determined by observing the daily body weight variation of the 
animals, and was detected post-mortem by histological examination of liver tissue, and 
quantification of serum transaminases (AST/ALT). In addition, a limited biodistribution 
was carried out for each virus, quantifying viral genome DNA levels in the liver, spleen, 
lung, and stomach by real time quantitative PCR.  
 
The biodistribution profiles of the A20-retargeted vectors, Ad5-EGFPA20 and Ad5-
477dlTAYTA20, were altered distinctly from that of Ad5-EGFPWT. Most importantly 
however, both retargeted viruses displayed an increased accumulation of genomes in 
the tumour relative to Ad5-EGFPWT, although this difference was not as dramatic as 
initially hoped. The Ad5-477dlTAYTA20 vector appeared to perform slightly more 
efficiently than Ad5-EGFPA20 in its ability to reach the tumour, possibly due to its 
auxiliary affinity for HSPGs (see Chapter.4). It is possible that this produced an additive 
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targeting effect when combined with the ability of Ad5-477dlTAYTA20 to interact with 
ανβ6 through the A20-insertion.  
 
In agreement with a previous study, which demonstrated that the 477dlTAYT 
modification was sufficient to significantly reduce the hepatic sequestration of the 
corresponding vector (Shayakhmetov et al., 2005b), reductions in both the hepatocyte 
transduction, and liver accumulation, of Ad5-477dlTAYTA20 genomes, were observed. 
Interestingly, there was also a significant reduction in the level of absolute genomes 
detected in the liver with Ad5-EGFPA20 (~5-fold, p=0.0002) when compared with Ad5-
EGFPWT. These findings were paralleled by the significantly reduced hepatotoxicity and 
lack of transaminitis induced by both A20-modified vectors. Furthermore, these data 
supported the hypothesis that the Ad5-EGFPA20 vector, which failed to interact with FIX 
in vitro to promote infectivity enhancement, was phenotypically similar to Ad5-
477dlTAYTA20, despite lacking the genetic modification of the putative blood factor 
binding determinants. This strengthened our hypothesis that the insertion of 
A20FMDV2 conferred a conformational or steric alteration which precluded FIX binding 
to the fibre. Collectively, these data accurately reflected our previous findings where we 
assessed biodistribution and toxicity in immunocompetent, non-tumour bearing animals 
(see Chapter.5).  
 
Warfarin mediated depletion of various coagulation factors has been employed as a 
liver avoidance strategy, with the aim of increasing the blood persistence and 
bioavailability for the tumour. The level of success of this strategy has been 
controversial, with some reports of enhanced tumour uptake (Shashkova et al., 2008), 
and others describing negligible effects or even reductions in tumour uptake (Coughlan 
et al., 2009; Gimenez-Alejandre et al., 2008; Koski et al., 2009). Despite observing a 
slight, but non-significant, increase in the quantity of Ad5-EGFPWT viral genomes 
delivered to the tumour in warfarin pre-treated groups, tumour uptake in both A20-
retargeted groups was impaired relative to the corresponding untreated groups. The 
similarities between our results and those of Gimenez-Alejandre and colleagues (who 
compared a virus with wildtype capsid, with the corresponding RGD-4C integrin-
retargeted construct) may suggest that integrin-directed retargeting might be sensitive 
to the anti-coagulative effects of warfarin in vivo.  
 
However, it is also becoming increasingly evident that the mechanism of action of 
warfarin is not restricted to its function as an anti-coagulative agent. Thus, it is worth 
considering that warfarin may affect the tumour uptake of systemically delivery 
adenoviruses, independently of its direct effects on vitamin K-dependent coagulation 
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factors. For example, warfarin has been described to have pleiotropic, immuno-
modulatory effects, and has been shown to be anti-inflammatory, directly influencing 
the signal transduction of various cytokines, including IL-6 (Kater et al., 2002). Warfarin 
also has been shown to inhibit the replication of Human Immunodeficiency Virus (HIV-
1) through the modification of cysteine residues in its protease, thus preventing viral 
polyprotein processing (Bourinbaiar et al., 1993; Davis et al., 1996; Tummino et al., 
1994). Interestingly, the Ad5 protease, adenain (L3-23K), which is required for efficient 
viral entry, disassembly and mature virion processing, also features conserved cysteine 
residues (Cotten & Weber, 1995; Greber, 1998; Rancourt et al., 1994; Ruzindana-
Umunyana et al., 2002), and it has been shown previously that various protease 
inhibitors can inhibit Ad5 entry in vitro (Cotten & Weber, 1995). Therefore, warfarin also 
may be capable of modifying cysteine residues in adenain, affecting its function. 
Alternatively, warfarin has been shown to inhibit p44/p42 (ERK1/2) phosphorylation 
and activation (Nagai et al., 2003). Recent research has shown that the binding of Ad5 
to CAR triggers the activation of this signalling pathway, resulting in the 
homodimerisation of CAR and the activation of -β1 and -β3 integrins (Farmer et al., 
2009). As CAR, ανβ1 and ανβ3 are known receptors for Ad5 infection, inhibition of 
p44/p42 may therefore affect viral entry (Davison et al., 2001; Li et al., 2001; Santis et 
al., 1999; Wickham et al., 1993). Finally, warfarin has also been reported to inhibit 
clathrin-mediated endocytosis, by impairing actin polymerisation as a result of inducing 
epithelial to fibroblastoid conversion (Murata & Sakamoto, 2008). Classical adenovirus  
internalisation is via clathrin-mediated endocytosis (Leopold & Crystal, 2007; Meier et 
al., 2002; Meier & Greber, 2003; Worgall et al., 2000). Internalisation of ανβ6 is 
clathrin-dependent (Ramsay et al., 2007). Therefore, warfarin-mediated inhibition of 
endocytosis may also have contributed to the impaired tumour transduction we 
observed in this study.  
 
As reported in many published studies, warfarin significantly reduced the liver uptake 
and hepatic toxicity induced by Ad5-EGFPWT, along with all other viruses used in this 
study (Di Paolo et al., 2009b; Gimenez-Alejandre et al., 2008; Shashkova et al., 2008; 
Waddington et al., 2007). Serum transaminase levels in all warfarin pre-treated animals 
were reduced to basal levels when compared with the corresponding untreated groups 
(p>0.05; excluding the Ad5-EGFPA20 group for which statistical analysis cannot be 
performed). Interestingly, there were dramatic differences in the levels of virions 
accumulated in the livers of the A20-modifed groups (~160-fold, p=0.035, and ~34-fold, 
p<0.0001, respectively), which contrasted with the modest reduction observed in the 
warfarinised Ad5-EGFPWT group (~9-fold, p<0.0001). The reason for this remains 
unclear.  
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Through its function as a vitamin K antagonist, warfarin abrogates Ad5:FX-
opsonisation, predominantly affecting transduction of hepatocytes (Parker et al., 2006; 
Waddington et al., 2007). Interestingly, it has been shown previously that in warfarin 
treated animals, total virion accumulation in the liver is not altered drastically at early 
time-points post-infection (Di Paolo et al., 2009b; Kalyuzhniy et al., 2008; Waddington 
et al., 2007). This suggests that viral uptake by KCs and/or other non-parenchymal 
cells, is not mediated by coagulation factors (Di Paolo et al., 2009b; Shashkova et al., 
2008). It has been shown that systemically administered Ad vectors can accumulate in 
the hepatic sinusoid endothelial cells of the liver, and can be retained in the space of 
Disse by redundant mechanisms (Di Paolo et al., 2009b; Shayakhmetov et al., 2005b). 
Therefore, it also is possible that the A20-retargeted viruses are sequestered to a 
lesser extent at these alternative sites. This may account for the dramatic differences in 
genome levels detected in livers of warfarin pre-treated animals. Additionally, warfarin 
actually has been shown to increase the sequestration of Ad5 virions in Kupffer cells in 
vivo (Xu et al., 2008). Therefore, it is possible that increased, warfarin-induced 
accumulation of viruses Ad5-EGFPA20 and Ad5-477dlTAYTA20 in KCs, contributed to 
the loss of tumour targeting efficiency seen in this study.  
 
In the absence of warfarin, Ad5-EGFPA20 and Ad5-477dlTAYTA20 displayed an altered 
biodistribution when compared with Ad5-EGFPWT, resulting in significantly reduced 
splenic and pulmonary uptake of virus. We detected approximately 3-fold, and ~9-fold 
less Ad5-EGFPA20 genomes in the spleens, and lungs of non-warfarinised animals 
(p=0.046 and p<0.0001, respectively). Almost identical reductions were observed with 
Ad5-477dlTAYTA20 (p=0.037 and p<0.0001, respectively). Interestingly, the distribution 
in the untreated Ad5-EGFPA20 and Ad5-477dlTAYTA20 groups effectively paralleled the 
profile seen for the warfarin pre-treated Ad5-EGFPWT group, in terms of accumulation 
in the spleen and lung. These organs have previously been described as auxiliary sites 
for Ad5 accumulation in vivo (Manickan et al., 2006), although the precise factors which 
determine uptake at these sites have not been identified. A recent study has suggested 
that Ad-loaded dying KCs are displaced from the liver within 24hrs of intravenous 
delivery, and relocate to the lung where they can be detected co-localised together 
(Manickan et al., 2006). Therefore, the reduced pulmonary sequestration of the A20-
retargeted viruses could be a reflection of their reduced accumulation in KCs, conferred 
by their failure to interact with FIX in vivo.  
 
As stated in the previous chapter, vectors which have reduced accumulation in the 
spleen have been shown to have reduced toxicity, and therefore improved safety 
profiles in vivo (Koizumi et al., 2007; Zhang et al., 2001). The mechanisms which 
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govern the accumulation of Ad5 in the spleen currently are under-characterised, 
although uptake appears to have an element of coagulation factor dependency. Thus, 
warfarin can reduce sequestration significantly, and FX-complementation can reverse 
this effect (Parker et al., 2006; Waddington et al., 2007). Alternatively, warfarin has 
been shown to induce increases in KC-mediated accumulation of Ads, which may act 
to preclude efficient dissemination to other sites, such as the spleen (Xu et al., 2008). 
However, how FX-complementation in warfarinised mice could reverse KC-mediated 
accumulation, and restore splenic sequestration, remains unclear.  
 
An altered in vivo biodistribution has already been described for RGD-modified 
adenoviruses; where modest increases in gene expression are often detected in the 
liver, spleen, lung or heart (Kanerva et al., 2002b; Rein et al., 2004; Reynolds et al., 
1999). This tropism in vivo would be consistent with the broad tissue distribution of 
ανβ3 and ανβ5 integrins, the target receptors for Ad5-RGD-4C (Lord et al., 2006; Nagel 
et al., 2003). The tissue expression of ανβ6 in murine models is not well characterised, 
however it is known to be expressed constitutively in the lung (Munger et al., 1999). 
Recent work in our laboratory has also identified that ανβ6 is expressed to high levels 
in the stomach and intestine of mice (Dr. Antonio Saha, unpublished data). Therefore, 
we included these organs in our analysis of vector biodistribution, but did not detect an 
increased accumulation of A20-retargeted vectors at these sites, or in fact any other 
organs assessed in this study (liver, spleen, lung, stomach, kidney and heart).  
 
It is becoming increasingly clear that receptor-dependent entry may not necessarily 
effectively determine the localisation and biodistribution of systemically delivered Ads. 
Clearly, the interactions between Ad5 and various components of the circulatory 
system play a critical role in dictating the outcome and efficacy of Ads as therapeutic 
vehicles (Carlisle et al., 2009; Gimenez-Alejandre et al., 2008; Lyons et al., 2006; 
Parker et al., 2006; Seiradake et al., 2009; Waddington et al., 2008). We currently are 
unable to confirm the exact mechanism which underlies the reduced hepatotropism 
and altered biodistribution associated with Ad5-EGFPA20 and Ad5-477dlTAYTA20. 
Therefore, in the future it will be important to perform a full biodistribution analysis for 
the A20-modifed vectors, to confirm whether or not their reduced tropism for the 
reticuloendothelial system is a result of effective retargeting to another murine organ. 
However, what is clear is that these retargeted vectors are capable of locating to ανβ6-
positive tumours in vivo following systemic delivery with increased efficiency relative to 
the wildtype control, and do so with reduced toxicity and impaired induction of pro-
inflammatory responses.  
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Chapter.7 Final Discussion and Future Directions 
 
In this study, we describe the successful in vitro retargeting of Ad5 to ανβ6 through the 
introduction of a previously characterised ανβ6-selective peptide, A20FMDV2. We 
have demonstrated that the resultant vector, Ad5-EGFPA20, is capable of dramatically 
enhancing the infection of a panel of ανβ6-expressing human carcinoma cell lines in a 
CAR-independent manner. Combining this retargeting strategy with CAR-binding, and 
FIX-binding ablation mutations (Ad5-477dlTAYTA20), did not impair the interaction with 
ανβ6. In vivo, the retargeting efficiency was improved, although not dramatic. However, 
in vivo assessment of the Ad5-EGFPA20 and Ad5-477dlTAYTA20 constructs, uncovered 
some interesting features which highlight their potential for future therapeutic 
applications. 
 
Achieving tumour selective delivery is an important goal for cancer gene therapy. The 
integrin ανβ6 represents a highly attractive target, due to its restricted expression on 
normal tissue but high level expression in numerous human carcinomas (Ahmed et al., 
2002b; Bates et al., 2005; Breuss et al., 1995; Elayadi et al., 2007; Hazelbag et al., 
2007; Marsh et al., 2008; Nystrom et al., 2006; Thomas et al., 2001b; Van Aarsen et 
al., 2008). Other Ad5-integrin retargeting strategies (eg.Ad5-RGD-4C) have resulted in 
the RGD-dependent enhancement of CAR-negative cell lines which express ανβ3/5 
integrins (Dmitriev et al., 1998; Nagel et al., 2003). Likewise, retargeting through 
HSPGs using Ad5-pK7 has been shown to enhance the CAR-independent infection of 
myeloma, glioma, rhabdosacrcoma and various carcinoma cells in vitro and in vivo 
(Gonzalez et al., 1999; Ranki et al., 2007; Rein et al., 2004; Staba et al., 2000; Wu et 
al., 2002). CD40 over-expression also has been identified as a potential target for Ad5 
delivery in ovarian carcinoma cells and Hakkarainen et al have reported in vitro 
infectivity enhancements of up to 40-fold when using Ad5 pre-complexed with a CD40-
targeting molecule (Hakkarainen et al., 2003). More recently, vectors which target 
CD46 (eg. Ad35 or Ad5/35) are being investigated for tumour targeting applications in 
vivo (Liu et al., 2009; Sakurai et al., 2003; Sakurai et al., 2008; Seshidhar Reddy et al., 
2003; Vogels et al., 2003). However, the disadvantage of current retargeting strategies 
is that these vectors do not necessarily exhibit cancer selective transduction as, 
ανβ3/5, HSPGs, CD46 and CD40 expression in vivo is not limited to malignant tissue 
(Alderson et al., 1993; Galy & Spits, 1992; Hsu et al., 1997; Ni et al., 2005; 
Sasisekharan et al., 2002; Tsujimura et al., 1998). It could also be argued the 
translational relevance of some of these vectors has been impaired by the relatively 
poor choice of in vivo model systems. The restricted tissue distribution of ανβ6 in 
humans and non-human primates is well established (Breuss et al., 1995; Breuss et al., 
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1993). This is in contrast with CD46, which displays a broad tissue distribution in 
humans and non-human primates, though not in rodent species where it is restricted to 
the testis (Ni et al., 2005). Therefore, pre-clinical in vivo studies performed in non-
human primates with vectors retargeted to ανβ6 may have more translational relevance 
for human cancer therapy applications.  
 
The interaction of the A20FMDV2 peptide with ανβ6 is one of high affinity, displaying a 
dose-dependent inhibition of adhesion of biotinylated peptide (to immobilised 
recombinant ανβ6) with an IC50 of ~0.15nM, and a dose-dependent inhibition of ανβ6-
dependent cell adhesion in the order of 1.2nM (DiCara et al., 2007). Additionally, the 
affinity of binding (Kd) of A20FMDV2 to cellular ανβ6 has been determined to be 
~1.7nM (Dr. Antonio Saha; unpublished data with permission). However, the precise 
binding affinity of A20FMDV2, within the trimeric Ad5 knob domain (KnobA20/Ad5-
EGFPA20), has never formally been determined. This will be important in order to 
comparatively assess its potential as a high affinity in vivo targeting ligand when 
compared with other Ad-based tumour-selective targeting strategies. For example, 
Ad35 is currently undergoing investigation for tumour targeting studies, due to its high 
affinity interaction with CD46. The binding affinity of Ad35 for CD46 (Kd = 14.64nM) has 
been shown to be comparable to that of Ad5 for CAR, which was shown previously to 
be ~14.8nM (Kirby et al., 2000; Wang et al., 2008). Furthermore, Wang and colleagues 
generated Ad35 knob mutants with point mutations which resulted in affinities for CD46 
almost 23-fold higher (Kd = 0.63nM) than wildtype Ad35. Interestingly, these mutants 
did not result in enhanced transduction in vitro, however did result in improved uptake 
in vivo in CD46high liver metastases. Thus, it will be important to ascertain whether or 
not the A20FMDV2-engineered Ad5 fibre could achieve comparable affinities. This 
would further strengthen its potential for clinical use, especially when considered with 
the restricted expression profile of ανβ6 in humans. 
 
Achieving successful tumour targeting following systemic delivery of adenoviral vectors 
is complicated by the sequestration of the virus in off-target locations, as a result of 
virus interactions with various blood components (Carlisle et al., 2009; Kalyuzhniy et 
al., 2008; Lyons et al., 2006; Parker et al., 2006; Seiradake et al., 2009; Shayakhmetov 
et al., 2005b; Stone et al., 2007b; Waddington et al., 2008; Xu et al., 2008). Local 
delivery strategies can help to avoid, or minimise, some of these limitations. 
Unfortunately, using our chosen in vivo models, we did not observe any significant 
improvements in efficacy when comparing Ad5-EGFPWT and Ad5-EGFPA20 following 
intraperitoneal, or intratumoural delivery. However, in vitro, we observed significant 
improvements in Ad5-EGFPA20-mediated transduction efficiency when using several 
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Head and Neck Squamous Cell Carcinoma (HNSCC) lines (TR126, TR138, HSC-3 and 
SCC25). Interestingly, several Ad-based vectors currently are undergoing clinical 
investigation for the management and treatment of HNSCC (Vattemi & Claudio, 2009). 
For example, a non-replicating Ad5 vector expressing functional p53 (Gendicine), 
recently has been licenced in China for the treatment of HNSCC (Peng, 2005). 
Furthermore, ONYX-dl1520 is in use as a mouthwash preparation for the prophylactic 
treatment of malignant oral dysplasia (Rudin et al., 2003). Expression of ανβ6 is found 
at high levels in oral dysplasia and HNSCC and expression is maintained throughout 
disease progression where it correlates with poor prognosis, invasion and metastasis 
(Nystrom et al., 2006; Thomas et al., 2001a; Thomas et al., 2001b; Van Aarsen et al., 
2008). Conversely, CAR expression has been reported to be downregulated in HNSCC 
(Jee et al., 2002). Moreover, as CAR expression is restricted to tight membrane 
junctions, it is perhaps limited in its accessibility for infection by Ad5 (Walters et al., 
2002). Therefore, it seems possible that an A20-retargeted Ad5 could help to maximise 
local transduction, especially when using an oral preparation treatment similar to that of 
ONYX-dl1520.  
 
One of the ultimate goals of cancer therapy is to achieve successful delivery to solid 
tumours and disseminated metastases. This requires the use of systemically delivered 
treatment modalities. However, efficient retargeting in vitro does not always correlate 
with successful delivery and/or efficacy in vivo. In this study, we investigated the effects 
of introducing the 477dlTAYT modification (CAR/FIX-binding ablation mutations) into a 
vector which simultaneously was retargeted to ανβ6. The introduction of this set of 
mutations has previously been described to reduce the hepatotropism and toxicity of a 
similar vector, Ad5mut, following intravenous delivery (Shayakhmetov et al., 2005b). 
Indeed, these findings were reproduced with Ad5-477dlTAYTA20. However, rather 
unexpectedly, Ad5-EGFPA20, which lacked these mutations, also mirrored this profile in 
vivo.    
 
We can now propose a number of possible explanations for the altered biodistribution 
of Ad5-EGFPA20, particularly with regard to the reticuloendothelial system. It is well 
established that Ad interactions with serum factors play a more significant role in vivo 
than conventional in vitro interactions with CAR and ανβ3/ανβ5 integrins 
(Shayakhmetov et al., 2005b; Waddington et al., 2008; Xu et al., 2008). The sole 
structural modification within the Ad5-EGFPA20 vector is the insertion of 20aa into the HI 
loop of the fibre knob, such that the altered hepatotropism observed is unlikely to be 
due to interference with FX-hexon binding. However, FIX and C4BP previously have 
been described to bind to the knob domain of Ad5 (Gaggar et al., 2007; Shayakhmetov 
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et al., 2005b). Interestingly, the 477dlTAYT set of mutations described are in close 
proximity to the site of insertion of A20FMDV2, and so it is plausible that this 
modification has conferred a conformational change or steric hindrance which may 
abrogate FIX and/or C4BP binding to Ad5-EGFPA20. Indeed, in vitro infectivity 
experiments performed in the presence, and absence, of FIX support this hypothesis. 
However, it currently remains unclear whether the phenotype of the A20-viruses is a 
direct (ie. biological function of the peptide), or indirect (structural disruption) result of 
the insertion of A20FMDV2, into the HI loop of the Ad5 fibre. Structural disruptions to 
the overall 3D structure of the knob domain could be confirmed, or at least predicted in 
the future using protein modelling algorithms in combination with published 
crystallographic data. Functional in vivo comparisons between Ad5-477dlTAYT6XHIS 
(non-ανβ6 retargeted 477dlTAYT control) and Ad5-477dlTAYTA20 may also prove 
interesting. Furthermore, in vivo relevance of a differential Ad5-FIX/C4BP interaction 
warrants further investigation, especially as FX now has been identified as the 
dominant determinant of hepatocyte transduction (Alba et al., 2009; Kalyuzhniy et al., 
2008; Vigant et al., 2008; Waddington et al., 2008). 
 
Alternatively, it is worth considering that the insertion of the strongly cationic 
A20FMDV2 peptide (pI=11.32) has altered the overall electrostatic properties of the 
predominantly negative Ad5 particle in vivo (Alemany et al., 2000b). This may preclude 
uptake by scavenging receptors on KC, which preferentially recognise negatively 
charged materials (Alemany et al., 2000b; Furumoto et al., 2004; Haisma et al., 2008). 
More recently, opsonisation by complement (C3 and C4), in combination with natural 
IgM antibodies, has been proposed as an alternative mechanism for the uptake of Ads 
by scavenging receptors on Kupffer cells in vivo (Xu et al., 2008). Interestingly, the 
electrostatic characteristics of Ad5 can also dictate the extent of recognition by serum 
proteins, including complement (Chonn et al., 1991; Furumoto et al., 2004). It will be 
important to investigate whether or not, like Ad5mut, Ad5-EGFPA20 and Ad5-
477dlTAYTA20 exhibit a reduced co-localisation with Kupffer cells. Selective depletion of 
Kupffer cells at early time-points, using GdCl3 or broader depletion of tissue 
macrophages with clodronate liposomes may help to delineate the differential hepatic 
interactions of the A20-retargeted constructs when compared to Ad5-EGFPWT. This 
may also permit more legitimate comparisons to published FX studies, in which Kupffer 
cells often are depleted (Alba et al., 2009; Waddington et al., 2008). Furthermore, it 
would be interesting to assess whether or not the A20-retargeted viruses have a 
differential interaction with sinusoidal endothelial cells, at early time-points post-
infection.  
 
 249
With regard to the efficiency of tumour targeting following systemic delivery, both Ad5-
EGFPA20 and Ad5-477dlTAYTA20 achieved superior delivery over Ad5-EGFPWT, 
although only Ad5-477dlTAYTA20 was found to be statistically significantly different. In 
addition to their role in hepatocyte transduction, coagulation factors have been 
implicated previously in directing Ad5 tumour transduction (Gimenez-Alejandre et al., 
2008; Liu et al., 2009; Shashkova et al., 2008). In agreement with other studies, in vivo 
depletion of coagulation factors using warfarin pre-treatment did not enhance tumour 
targeting (Gimenez-Alejandre et al., 2008; Koski et al., 2009). In fact tumour uptake 
was reduced in the warfarinised, A20-retargeted cohorts. The reason for this remains 
unclear. However, it would be interesting to see if complementation with FX could 
rescue tumour uptake, as it is capable of restoring Ad5 accumulation in the liver and 
spleen in warfarin treated animals (Parker et al., 2006; Waddington et al., 2007). 
Likewise, it may be useful to combine the A20FMDV2 retargeting entity with hexon 
modified vectors, which are ablated for FX-binding.  
 
We are aware that the in vitro findings, which demonstrate that Ad5-EGFPA20, and Ad5-
477dlTAYTA20 can also utilise ανβ8 and/or HSPGs, limits the specificity of the current 
retargeting approach. The auxiliary affinity of Ad5-EGFPA20 for ανβ8 was unexpected, 
as extensive prior characterisation of the A20FMDV2 peptide, using the same 
DX3/DX3-β6 cell lines, demonstrated that its specificity was for ανβ6 integrin (DiCara et 
al., 2007). However, natural Foot and Mouth disease virus (FMDV) infection has been 
shown to utilise both ανβ6 and ανβ8 (Berryman et al., 2005; Burman et al., 2006; 
DiCara et al., 2008; Jackson et al., 2004). Therefore, the conformation of the 
A20FMDV2 peptide within the Ad5 fibre knob domain may be structurally, and 
biologically more similar to FMDV. Interestingly, mutation of the RGDLXXL motif to 
RGDRXXL has been shown to inhibit binding to ανβ8, without compromising binding to 
ανβ6 (Burman et al., 2006). Therefore, the selectivity of the A20-retargeted vectors 
may be refined further for future studies, if required. However, it is important to note 
that neither Ad5-EGFPA20 nor Ad5-477dlTAYTA20 displayed an expanded tissue tropism 
in vivo, and in fact exhibited a more restricted biodistribution profile than Ad5-EGFPWT. 
Furthermore, the HSPG-binding capacity of Ad5-477dlTAYTA20 did not result in 
augmented hepatocyte transduction, a feature which is observed with the Ad5-K7 
vector, which is retargeted specifically to HSPGs (Koizumi et al., 2007).  
 
In the limited biodistribution analysis performed with these vectors (liver, spleen, lung, 
heart, kidney and stomach) we did not detect any increased genome accumulation with 
the A20-retargeted vectors when compared to control Ad5-EGFPWT. This was 
reassuring, however warrants further investigation in future studies. It will be important 
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to determine the blood persistence kinetics of each of the viruses, and to confirm 
whether or not the enhanced tumour uptake observed with Ad5-EGFPA20 and Ad5-
477dlTAYTA20 is a reflection of increased bioavailability. Furthermore, it will be 
necessary to expand the range of organs analysed, to obtain a full biodistribution and 
to assess the relative distribution of virus when adjusted for size of organs. 
 
The A20-retargeted viruses displayed dramatically reduced toxicity, and limited 
induction of pro-inflammatory mediators in vivo. These features may permit their use at 
a higher dose, which could enhance anti-tumoural efficacy in vivo. Furthermore, these 
vectors may permit prolonged transgene expression in vivo, as a result of reduced 
clearance by the immune cells which are actively recruited by various Ad-induced pro-
inflammatory effectors. It may also be interesting to investigate whether or not the A20-
retargeted vectors have differential interactions with human/rodent blood cell fractions, 
when compared with Ad5-EGFPWT. Vectors which are devoid of CAR-binding 
determinants may prove useful in preventing agglutinating interactions with human 
erythrocytes (Carlisle et al., 2009; Nicol et al., 2004; Seiradake et al., 2009). 
Alternatively, as expression of the integrin ανβ8 has been detected in total splenocytes, 
CD4+ T-cells and dendritic cells, it may be worth investigating any possible increased 
interaction with these cells (Travis et al., 2007). However, the lack of splenic 
accumulation, the similarity of our results in immunocompetent and nude mice and the 
lack of inflammation induced by Ad5-EGFPA20/Ad5-477dlTAYTA20 in vivo do not provide 
much support for this possibility. 
 
In summary, using Ad5-EGFPA20 and Ad5-477dlTAYTA20 in the absence of warfarin 
pre-treatment, we improved liver-tumour-ratios significantly when compared to Ad5-
EGFPWT (100:1 and 72:1, respectively, compared with 900:1). Warfarin pre-treatment 
further improved these ratios, resulting in ratios of 1:1 and 7:1 for Ad5-EGFPA20 and 
Ad5-477dlTAYTA20, compared with 70:1 for Ad5-EGFPWT. Thus, we believe that the 
vectors generated in this study may have potential for future clinical applications. To 
our knowledge, the data presented within this thesis comprise the first report of 
successful retargeting of Ad5 to ανβ6 (Coughlan et al., 2009). However, in the future 
further in vivo validation of these constructs is warranted. The characterisation of the 
precise mechanisms underlying the reduced hepatotropism, the limited biodistribution 
and lack of immune activation, will be important. Additionally, we recently have 
identified two suitable in vivo models (ie. A431 and CA1a) in which to compare the anti-
tumoural efficacy of Ad5-EGFPWT, Ad5-EGFPA20 and Ad5-477dlTAYTA20. If these 
experiments are successful, combining the A20/477dlTAYTA20 fibre mutations with a 
vector backbone featuring transcriptional selectivity will help to further refine the 
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therapeutic index, permit dose escalation and enhance potency. Furthermore, an 
assessment of vector performance, in terms of targeting and efficacy, in 
immunocompetent, and/or pre-immunised and permissive models will also be required. 
Much of these future experiments will be performed by Marta Gimenez-Alejandre, 
under the supervision of Dr. Ramon Alemany, at the Institut Català d’Oncologia, 
Barcelona, Spain as part of our ongoing collaborative agreement.  
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CLUSTAL 2.0.10 multiple sequence alignment 
 
 
Ad5_WT          MKRARPSEDTFNPVYPYDTETGPPTVPFLTPPFVSPNGFQESPPGVLSLRLSEPLVTSNG 60 
Ad5_A20         MKRARPSEDTFNPVYPYDTETGPPTVPFLTPPFVSPNGFQESPPGVLSLRLSEPLVTSNG 60 
                ************************************************************ 
 
Ad5_WT          MLALKMGNGLSLDEAGNLTSQNVTTVSPPLKKTKSNINLEISAPLTVTSEALTVAAAAPL 120 
Ad5_A20         MLALKMGNGLSLDEAGNLTSQNVTTVSPPLKKTKSNINLEISAPLTVTSEALTVAAAAPL 120 
                ************************************************************ 
 
Ad5_WT          MVAGNTLTMQSQAPLTVHDSKLSIATQGPLTVSEGKLALQTSGPLTTTDSSTLTITASPP 180 
Ad5_A20         MVAGNTLTMQSQAPLTVHDSKLSIATQGPLTVSEGKLALQTSGPLTTTDSSTLTITASPP 180 
                ************************************************************ 
 
Ad5_WT          LTTATGSLGIDLKEPIYTQNGKLGLKYGAPLHVTDDLNTLTVATGPGVTINNTSLQTKVT 240 
Ad5_A20         LTTATGSLGIDLKEPIYTQNGKLGLKYGAPLHVTDDLNTLTVATGPGVTINNTSLQTKVT 240 
                ************************************************************ 
 
Ad5_WT          GALGFDSQGNMQLNVAGGLRIDSQNRRLILDVSYPFDAQNQLNLRLGQGPLFINSAHNLD 300 
Ad5_A20         GALGFDSQGNMQLNVAGGLRIDSQNRRLILDVSYPFDAQNQLNLRLGQGPLFINSAHNLD 300 
                ************************************************************ 
 
Ad5_WT          INYNKGLYLFTASNNSKKLEVNLSTAKGLMFDATAIAINAGDGLEFGSPNAPNTNPLKTK 360 
Ad5_A20         INYNKGLYLFTASNNSKKLEVNLSTAKGLMFDATAIAINAGDGLEFGSPNAPNTNPLKTK 360 
                ************************************************************ 
                   
 
                                                                        
Ad5_WT          IGHGLEFDSNKAMVPKLGTGLSFDSTGAITVGNKNNDKLTLWTTPAPSPNCRLNAEKDAK 420 
Ad5_A20         IGHGLEFDSNKAMVPKLGTGLSFDSTGAITVGNKNNDKLTLWTTPAPSPNCRLNAEKDAK 420 
                ************************************************************ 
                    
 
 
Ad5_WT          LTLVLTKCGSQILATVSVLAVKGSLAPISGTVQSAHLIIRFDENGVLLNNSFLDPEYWNF 480 
Ad5_A20         LTLVLTKCGSQILATVSVLAVKGSLAPISGTVQSAHLIIRFDENGVLLNNSFLDPEYWNF 480 
                ************************************************************ 
 
 
                        
Ad5_WT          RNGDLTEGTAYTNAVGFMPNLSAYPKSHGKTAKSNIVSQVYLNGDKTKPVTLTITLNGTQ 540 
Ad5_A20         RNGDLTEGTAYTNAVGFMPNLSAYPKSHGKTAKSNIVSQVYLNGDKTKPVTLTITLNGTQ 540 
                ************************************************************ 
                      
    
 
                        
Ad5_WT          ETGDTT----------------------PSAYSMSFSWDWSGHNYINEIFATSSYTFSYI 578 
Ad5_A20         ETGDTTGNAVPNLRGDLQVLAQKVARTAPSAYSMSFSWDWSGHNYINEIFATSSYTFSYI 600 
                ******                      ******************************** 
 
Ad5_WT          AQE 581 
Ad5_A20         AQE 603 
                *** 
*DG Loop (463-515)
A
B C D
E F G H
I J
AB Loop (402-419)
CD Loop (440-454)
GH Loop (521-529)
HI Loop (536-550) IJ Loop (557-573)
Ψ
 
 
 
 
 
 
 
 
 
 
Appendix I. Structural Alignment of WT and A20-Modified Ad5 Fibre with Major Structural 
Regions Highlighted.  ClustalW protein alignment highlighting the structural domains of the fibre region 
of Ad5-EGFPWT and modified Ad5-EGFPA20 (A20FMDV2 peptide sequence in red). Block yellow 
indicates the A-J strand regions of the monomeric structure, and boxed sequence represents the loop 
domains, with approximated nucleotide numbers (Adapted from Xia et al., 1994). *The small β-sheets E 
and F are considered to be part of the DG Loop. Amino acids highlighted in bold and underlined indicate 
Ser408, Pro409, Tyr477 and Leu485, all identified as critical residues involved in CAR binding (Kirby et 
al., 2000). Ψ highlights the TAYT epitope which is thought to confer binding to FIX/C4BP (Shayakhmetov 
et al., 2005b).  
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CLUSTAL 2.0.10 multiple sequence alignment 
 
 
KnobWT    HHHHHHGSGAITVGNKNNDKLTLWTTPAPSPNCRLNAEKDAKLTLVLTKCGSQILATVSV 60 
KnobA20   HHHHHHGSGAITVGNKNNDKLTLWTTPAPSPNCRLNAEKDAKLTLVLTKCGSQILATVSV 60 
Knob485dlTAYTA20  HHHHHHGSGAITVGNKNNDKLTLWTTPAPSPNCRLNAEKDAKLTLVLTKCGSQILATVSV 60 
Knob477dlTAYTA20  HHHHHHGSGAITVGNKNNDKLTLWTTPAPSPNCRLNAEKDAKLTLVLTKCGSQILATVSV 60 
   ************************************************************  
 
 
KnobWT    LAVKGSLAPISGTVQSAHLIIRFDENGVLLNNSFLDPEYWNFRNGDLTEGTAYTNAVGFM 120 
KnobA20   LAVKGSLAPISGTVQSAHLIIRFDENGVLLNNSFLDPEYWNFRNGDLTEGTAYTNAVGFM 120 
Knob485dlTAYTA20  LAVKGSLAPISGTVQSAHLIIRFDENGVLLNNSFLDPEYWNFRNGDKTEG----NAVGFM 116 
Knob477dlTAYTA20  LAVKGSLAPISGTVQSAHLIIRFDENGVLLNNSFLDPEAWNFRNGDLTEG----NAVGFM 116 
   ************************************** ******* ***    ******  
 
 
KnobWT    PNLSAYPKSHGKTAKSNIVSQVYLNGDKTKPVTLTITLNGTQETGDTT------------ 168 
KnobA20   PNLSAYPKSHGKTAKSNIVSQVYLNGDKTKPVTLTITLNGTQETGDTTGNAVPNLRGDLQ 180 
Knob485dlTAYTA20  PNLSAYPKSHGKTAKSNIVSQVYLNGDKTKPVTLTITLNGTQETGDTTGNAVPNLRGDLQ 176 
Knob477dlTAYTA20  PNLSAYPKSHGKTAKSNIVSQVYLNGDKTKPVTLTITLNGTQETGDTTGNAVPNLRGDLQ 176 
   ************************************************  
 
 
KnobWT    ----------PSAYSMSFSWDWSGHNYINEIFATSSYTFSYIAQE 203  
KnobA20   VLAQKVARTAPSAYSMSFSWDWSGHNYINEIFATSSYTFSYIAQE 225 
Knob485dlTAYTA20  VLAQKVARTAPSAYSMSFSWDWSGHNYINEIFATSSYTFSYIAQE 221  
Knob477dlTAYTA20  VLAQKVARTAPSAYSMSFSWDWSGHNYINEIFATSSYTFSYIAQE 221   
               ***********************************  
CD Loop
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Appendix II. Structural Alignment of KnobWT, KnobA20, Knob485dlTAYTA20 and Knob477dlTAYTA20.  
ClustalW protein alignment highlighting the sequence differences between the modified Knob proteins 
(A20FMDV2 peptide sequence in red). Block yellow indicates the A-J strand regions of the monomeric 
structure, and boxed sequence represent the loop domains, with approximated nucleotide numbers 
(Adapted from Xia et al., 1994). *The small β-sheets E and F are considered to be part of the DG Loop. 
Amino acids highlighted in bold and underlined indicate Ser408, Pro409, Tyr477 and Leu485, all 
identified as critical residues involved in CAR binding (Kirby et al., 2000). Ψ highlights the TAYT epitope 
which is thought to confer binding to FIX/C4BP (Shayakhmetov et al., 2005b). * identifies sequence 
identity. 
 255
References 
 
Ahmed, N., Niu, J., Dorahy, D. J., Gu, X., Andrews, S., Meldrum, C. J., Scott, R. J., 
Baker, M. S., Macreadie, I. G. & Agrez, M. V. (2002a). Direct integrin 
alphavbeta6-ERK binding: implications for tumour growth. Oncogene 21, 1370-
1380. 
Ahmed, N., Riley, C., Rice, G. E., Quinn, M. A. & Baker, M. S. (2002b). 
Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial 
ovarian cancer. J Histochem Cytochem 50, 1371-1380. 
Akhurst, R. J. & Balmain, A. (1999). Genetic events and the role of TGF beta in 
epithelial tumour progression. J Pathol 187, 82-90. 
Akhurst, R. J. & Derynck, R. (2001). TGF-beta signaling in cancer--a double-edged 
sword. Trends Cell Biol 11, S44-51. 
Alba, R., Bradshaw, A. C., Parker, A. L., Bhella, D., Waddington, S. N., Nicklin, S. 
A., van Rooijen, N., Custers, J., Goudsmit, J., Barouch, D. H., McVey, J. H. 
& Baker, A. H. (2009). Identification of coagulation factor (F)X binding sites on 
the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and 
gene transfer. Blood. 
Alderson, M. R., Armitage, R. J., Tough, T. W., Strockbine, L., Fanslow, W. C. & 
Spriggs, M. K. (1993). CD40 expression by human monocytes: regulation by 
cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178, 
669-674. 
Alemany, R., Balague, C. & Curiel, D. T. (2000a). Replicative adenoviruses for 
cancer therapy. Nat Biotechnol 18, 723-727. 
Alemany, R. & Curiel, D. T. (2001). CAR-binding ablation does not change 
biodistribution and toxicity of adenoviral vectors. Gene Ther 8, 1347-1353. 
Alemany, R., Suzuki, K. & Curiel, D. T. (2000b). Blood clearance rates of adenovirus 
type 5 in mice. J Gen Virol 81, 2605-2609. 
Anders, M., Vieth, M., Rocken, C., Ebert, M., Pross, M., Gretschel, S., Schlag, P. 
M., Wiedenmann, B., Kemmner, W. & Hocker, M. (2009). Loss of the 
coxsackie and adenovirus receptor contributes to gastric cancer progression. Br 
J Cancer 100, 352-359. 
Annes, J. P., Rifkin, D. B. & Munger, J. S. (2002). The integrin alphaVbeta6 binds 
and activates latent TGFbeta3. FEBS Lett 511, 65-68. 
Appledorn, D. M., Patial, S., McBride, A., Godbehere, S., Van Rooijen, N., 
Parameswaran, N. & Amalfitano, A. (2008). Adenovirus vector-induced innate 
inflammatory mediators, MAPK signaling, as well as adaptive immune 
 256
responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 181, 
2134-2144. 
Arihiro, K., Kaneko, M., Fujii, S., Inai, K. & Yokosaki, Y. (2000). Significance of 
alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. 
Breast Cancer 7, 19-26. 
Arnberg, N., Edlund, K., Kidd, A. H. & Wadell, G. (2000a). Adenovirus type 37 uses 
sialic acid as a cellular receptor. J Virol 74, 42-48. 
Arnberg, N., Kidd, A. H., Edlund, K., Olfat, F. & Wadell, G. (2000b). Initial 
interactions of subgenus D adenoviruses with A549 cellular receptors: sialic 
acid versus alpha(v) integrins. J Virol 74, 7691-7693. 
Atencio, I. A., Grace, M., Bordens, R., Fritz, M., Horowitz, J. A., Hutchins, B., 
Indelicato, S., Jacobs, S., Kolz, K., Maneval, D., Musco, M. L., Shinoda, J., 
Venook, A., Wen, S. & Warren, R. (2006). Biological activities of a 
recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial 
infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther 13, 169-181. 
Au, T., Thorne, S., Korn, W. M., Sze, D., Kirn, D. & Reid, T. R. (2007). Minimal 
hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor 
in normal liver. Cancer Gene Ther 14, 139-150. 
Awasthi, V., Meinken, G., Springer, K., Srivastava, S. C. & Freimuth, P. (2004). 
Biodistribution of radioiodinated adenovirus fiber protein knob domain after 
intravenous injection in mice. J Virol 78, 6431-6438. 
Babiss, L. E., Ginsberg, H. S. & Darnell, J. E., Jr. (1985). Adenovirus E1B proteins 
are required for accumulation of late viral mRNA and for effects on cellular 
mRNA translation and transport. Mol Cell Biol 5, 2552-2558. 
Bandara, L. R. & La Thangue, N. B. (1991). Adenovirus E1a prevents the 
retinoblastoma gene product from complexing with a cellular transcription 
factor. Nature 351, 494-497. 
Barnett, B. G., Crews, C. J. & Douglas, J. T. (2002). Targeted adenoviral vectors. 
Biochim Biophys Acta 1575, 1-14. 
Barton, E. S., Forrest, J. C., Connolly, J. L., Chappell, J. D., Liu, Y., Schnell, F. J., 
Nusrat, A., Parkos, C. A. & Dermody, T. S. (2001). Junction adhesion 
molecule is a receptor for reovirus. Cell 104, 441-451. 
Bates, R. C., Bellovin, D. I., Brown, C., Maynard, E., Wu, B., Kawakatsu, H., 
Sheppard, D., Oettgen, P. & Mercurio, A. M. (2005). Transcriptional activation 
of integrin beta6 during the epithelial-mesenchymal transition defines a novel 
prognostic indicator of aggressive colon carcinoma. J Clin Invest 115, 339-347. 
Bauerschmitz, G. J., Guse, K., Kanerva, A., Menzel, A., Herrmann, I., Desmond, R. 
A., Yamamoto, M., Nettelbeck, D. M., Hakkarainen, T., Dall, P., Curiel, D. T. 
 257
& Hemminki, A. (2006). Triple-targeted oncolytic adenoviruses featuring the 
cox2 promoter, E1A transcomplementation, and serotype chimerism for 
enhanced selectivity for ovarian cancer cells. Mol Ther 14, 164-174. 
Bayo-Puxan, N., Cascallo, M., Gros, A., Huch, M., Fillat, C. & Alemany, R. (2006). 
Role of the putative heparan sulfate glycosaminoglycan-binding site of the 
adenovirus type 5 fiber shaft on liver detargeting and knob-mediated 
retargeting. J Gen Virol 87, 2487-2495. 
Bazan-Peregrino, M., Carlisle, R. C., Hernandez-Alcoceba, R., Iggo, R., Homicsko, 
K., Fisher, K. D., Hallden, G., Mautner, V., Shen, Y. & Seymour, L. W. 
(2008). Comparison of molecular strategies for breast cancer virotherapy using 
oncolytic adenovirus. Hum Gene Ther 19, 873-886. 
Belousova, N., Krendelchtchikova, V., Curiel, D. T. & Krasnykh, V. (2002). 
Modulation of adenovirus vector tropism via incorporation of polypeptide ligands 
into the fiber protein. J Virol 76, 8621-8631. 
Belousova, N., Mikheeva, G., Gelovani, J. & Krasnykh, V. (2008). Modification of 
adenovirus capsid with a designed protein ligand yields a gene vector targeted 
to a major molecular marker of cancer. J Virol 82, 630-637. 
Bennett, E. M., Bennink, J. R., Yewdell, J. W. & Brodsky, F. M. (1999). Cutting 
edge: adenovirus E19 has two mechanisms for affecting class I MHC 
expression. J Immunol 162, 5049-5052. 
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., 
Hong, J. S., Horwitz, M. S., Crowell, R. L. & Finberg, R. W. (1997). Isolation 
of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. 
Science 275, 1320-1323. 
Bergelson, J. M., Krithivas, A., Celi, L., Droguett, G., Horwitz, M. S., Wickham, T., 
Crowell, R. L. & Finberg, R. W. (1998). The murine CAR homolog is a 
receptor for coxsackie B viruses and adenoviruses. J Virol 72, 415-419. 
Berget, S. M., Moore, C. & Sharp, P. A. (1977). Spliced segments at the 5' terminus 
of adenovirus 2 late mRNA. Proc Natl Acad Sci U S A 74, 3171-3175. 
Berget, S. M. & Sharp, P. A. (1977). A spliced sequence at the 5'-terminus of 
adenovirus late mRNA. Brookhaven Symp Biol, 332-344. 
Berk, A. J. (1986a). Adenovirus promoters and E1A transactivation. Annu Rev Genet 
20, 45-79. 
Berk, A. J. (1986b). Functions of adenovirus E1A. Cancer Surv 5, 367-387. 
Berk, A. J., Lee, F., Harrison, T., Williams, J. & Sharp, P. A. (1979). Pre-early 
adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. 
Cell 17, 935-944. 
 258
Berryman, S., Clark, S., Monaghan, P. & Jackson, T. (2005). Early events in integrin 
alphavbeta6-mediated cell entry of foot-and-mouth disease virus. J Virol 79, 
8519-8534. 
Bhat, N. R. & Fan, F. (2002). Adenovirus infection induces microglial activation: 
involvement of mitogen-activated protein kinase pathways. Brain Res 948, 93-
101. 
Bierman, H. R., Crile, D. M., Dod, K. S., Kelly, K. H., Petrakis, N. L., White, L. P. & 
Shimkin, M. B. (1953). Remissions in leukemia of childhood following acute 
infectious disease: staphylococcus and streptococcus, varicella, and feline 
panleukopenia. Cancer 6, 591-605. 
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, 
J. A., Sampson-Johannes, A., Fattaey, A. & McCormick, F. (1996). An 
adenovirus mutant that replicates selectively in p53-deficient human tumor 
cells. Science 274, 373-376. 
Blackhall, F. H., Merry, C. L., Davies, E. J. & Jayson, G. C. (2001). Heparan sulfate 
proteoglycans and cancer. Br J Cancer 85, 1094-1098. 
Bluming, A. Z. & Ziegler, J. L. (1971). Regression of Burkitt's lymphoma in 
association with measles infection. Lancet 2, 105-106. 
Bortolanza, S., Alzuguren, P., Bunuales, M., Qian, C., Prieto, J. & Hernandez-
Alcoceba, R. (2007). Human adenovirus replicates in immunocompetent 
models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 18, 681-690. 
Bortolanza, S., Bunuales, M., Alzuguren, P., Lamas, O., Aldabe, R., Prieto, J. & 
Hernandez-Alcoceba, R. (2009). Deletion of the E3-6.7K/gp19K region 
reduces the persistence of wild-type adenovirus in a permissive tumor model in 
Syrian hamsters. Cancer Gene Ther. 
Bosher, J., Robinson, E. C. & Hay, R. T. (1990). Interactions between the adenovirus 
type 2 DNA polymerase and the DNA binding domain of nuclear factor I. New 
Biol 2, 1083-1090. 
Bourinbaiar, A. S., Tan, X. & Nagorny, R. (1993). Effect of the oral anticoagulant, 
warfarin, on HIV-1 replication and spread. Aids 7, 129-130. 
Bouvet, M., Fang, B., Ekmekcioglu, S., Ji, L., Bucana, C. D., Hamada, K., Grimm, 
E. A. & Roth, J. A. (1998). Suppression of the immune response to an 
adenovirus vector and enhancement of intratumoral transgene expression by 
low-dose etoposide. Gene Ther 5, 189-195. 
Branton, P. E. & Rowe, D. T. (1985). Stabilities and interrelations of multiple species 
of human adenovirus type 5 early region 1 proteins in infected and transformed 
cells. J Virol 56, 633-638. 
 259
Bray, F., Sankila, R., Ferlay, J. & Parkin, D. M. (2002). Estimates of cancer incidence 
and mortality in Europe in 1995. Eur J Cancer 38, 99-166. 
Breuss, J. M., Gallo, J., DeLisser, H. M., Klimanskaya, I. V., Folkesson, H. G., 
Pittet, J. F., Nishimura, S. L., Aldape, K., Landers, D. V., Carpenter, W. & et 
al. (1995). Expression of the beta 6 integrin subunit in development, neoplasia 
and tissue repair suggests a role in epithelial remodeling. J Cell Sci 108 ( Pt 6), 
2241-2251. 
Breuss, J. M., Gillett, N., Lu, L., Sheppard, D. & Pytela, R. (1993). Restricted 
distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem 
Cytochem 41, 1521-1527. 
Brown, J. M. & Giaccia, A. J. (1998). The unique physiology of solid tumors: 
opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416. 
Brunetti-Pierri, N., Palmer, D. J., Beaudet, A. L., Carey, K. D., Finegold, M. & Ng, 
P. (2004). Acute toxicity after high-dose systemic injection of helper-dependent 
adenoviral vectors into nonhuman primates. Hum Gene Ther 15, 35-46. 
Burman, A., Clark, S., Abrescia, N. G., Fry, E. E., Stuart, D. I. & Jackson, T. (2006). 
Specificity of the VP1 GH loop of Foot-and-Mouth Disease virus for alphav 
integrins. J Virol 80, 9798-9810. 
Buscarini, M., Quek, M. L., Gilliam-Hegarich, S., Kasahara, N. & Bochner, B. 
(2007). Adenoviral receptor expression of normal bladder and transitional cell 
carcinoma of the bladder. Urol Int 78, 160-166. 
Campos, S. K., Parrott, M. B. & Barry, M. A. (2004). Avidin-based targeting and 
purification of a protein IX-modified, metabolically biotinylated adenoviral vector. 
Mol Ther 9, 942-954. 
Carlisle, R. C., Di, Y., Cerny, A. M., Sonnen, A. F., Sim, R. B., Green, N. K., Subr, 
V., Ulbrich, K., Gilbert, R. J., Fisher, K. D., Finberg, R. W. & Seymour, L. W. 
(2009). Human erythrocytes bind and inactivate type 5 adenovirus by 
presenting Coxsackie virus-adenovirus receptor and complement receptor 1. 
Blood 113, 1909-1918. 
Carmody, R. J., Maguschak, K. & Chen, Y. H. (2006). A novel mechanism of nuclear 
factor-kappaB regulation by adenoviral protein 14.7K. Immunology 117, 188-
195. 
Cascallo, M., Alonso, M. M., Rojas, J. J., Perez-Gimenez, A., Fueyo, J. & Alemany, 
R. (2007). Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective 
oncolytic adenovirus based on the pRB pathway. Mol Ther 15, 1607-1615. 
Cepko, C. L. & Sharp, P. A. (1982). Assembly of adenovirus major capsid protein is 
mediated by a nonvirion protein. Cell 31, 407-415. 
 260
Cerullo, V., Seiler, M. P., Mane, V., Brunetti-Pierri, N., Clarke, C., Bertin, T. K., 
Rodgers, J. R. & Lee, B. (2007). Toll-like receptor 9 triggers an innate immune 
response to helper-dependent adenoviral vectors. Mol Ther 15, 378-385. 
Chappell, J. D., Gunn, V. L., Wetzel, J. D., Baer, G. S. & Dermody, T. S. (1997). 
Mutations in type 3 reovirus that determine binding to sialic acid are contained 
in the fibrous tail domain of viral attachment protein sigma1. J Virol 71, 1834-
1841. 
Chen, M., Mermod, N. & Horwitz, M. S. (1990). Protein-protein interactions between 
adenovirus DNA polymerase and nuclear factor I mediate formation of the DNA 
replication preinitiation complex. J Biol Chem 265, 18634-18642. 
Cheng, C. Y., Blanchette, P. & Branton, P. E. (2007). The adenovirus E4orf6 E3 
ubiquitin ligase complex assembles in a novel fashion. Virology 364, 36-44. 
Chillon, M., Lee, J. H., Fasbender, A. & Welsh, M. J. (1998). Adenovirus complexed 
with polyethylene glycol and cationic lipid is shielded from neutralizing 
antibodies in vitro. Gene Ther 5, 995-1002. 
Chiu, C. Y., Wu, E., Brown, S. L., Von Seggern, D. J., Nemerow, G. R. & Stewart, 
P. L. (2001). Structural analysis of a fiber-pseudotyped adenovirus with ocular 
tropism suggests differential modes of cell receptor interactions. J Virol 75, 
5375-5380. 
Cho, W. K., Seong, Y. R., Lee, Y. H., Kim, M. J., Hwang, K. S., Yoo, J., Choi, S., 
Jung, C. R. & Im, D. S. (2004). Oncolytic effects of adenovirus mutant capable 
of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 10, 938-
949. 
Chonn, A., Cullis, P. R. & Devine, D. V. (1991). The role of surface charge in the 
activation of the classical and alternative pathways of complement by 
liposomes. J Immunol 146, 4234-4241. 
Chow, L. T., Gelinas, R. E., Broker, T. R. & Roberts, R. J. (1977). An amazing 
sequence arrangement at the 5' ends of adenovirus 2 messenger RNA. Cell 12, 
1-8. 
Christensen, J. B., Byrd, S. A., Walker, A. K., Strahler, J. R., Andrews, P. C. & 
Imperiale, M. J. (2008). Presence of the adenovirus IVa2 protein at a single 
vertex of the mature virion. J Virol 82, 9086-9093. 
Chroboczek, J., Ruigrok, R. W. & Cusack, S. (1995). Adenovirus fiber. Curr Top 
Microbiol Immunol 199 ( Pt 1), 163-200. 
Chu, Y., Heistad, D., Cybulsky, M. I. & Davidson, B. L. (2001). Vascular cell 
adhesion molecule-1 augments adenovirus-mediated gene transfer. Arterioscler 
Thromb Vasc Biol 21, 238-242. 
 261
Cichon, G., Schmidt, H. H., Benhidjeb, T., Loser, P., Ziemer, S., Haas, R., Grewe, 
N., Schnieders, F., Heeren, J., Manns, M. P., Schlag, P. M. & Strauss, M. 
(1999). Intravenous administration of recombinant adenoviruses causes 
thrombocytopenia, anemia and erythroblastosis in rabbits. J Gene Med 1, 360-
371. 
Cohen, C. J., Shieh, J. T., Pickles, R. J., Okegawa, T., Hsieh, J. T. & Bergelson, J. 
M. (2001). The coxsackievirus and adenovirus receptor is a transmembrane 
component of the tight junction. Proc Natl Acad Sci U S A 98, 15191-15196. 
Cohen, S. N., Chang, A. C. & Hsu, L. (1972). Nonchromosomal antibiotic resistance 
in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc 
Natl Acad Sci U S A 69, 2110-2114. 
Colcher, D., Pavlinkova, G., Beresford, G., Booth, B. J., Choudhury, A. & Batra, S. 
K. (1998). Pharmacokinetics and biodistribution of genetically-engineered 
antibodies. Q J Nucl Med 42, 225-241. 
Cotten, M. & Weber, J. M. (1995). The adenovirus protease is required for virus entry 
into host cells. Virology 213, 494-502. 
Coughlan, L., Vallath, S., Saha, A., Flak, M., McNeish, I. A., Vassaux, G., Marshall, 
J. F., Hart, I. R. & Thomas, G. J. (2009). In vivo retargeting of adenovirus type 
5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor 
uptake following systemic delivery. J Virol 83, 6416-6428. 
Cox, J. H., Bennink, J. R. & Yewdell, J. W. (1991). Retention of adenovirus E19 
glycoprotein in the endoplasmic reticulum is essential to its ability to block 
antigen presentation. J Exp Med 174, 1629-1637. 
Crawford-Miksza, L. & Schnurr, D. P. (1996). Analysis of 15 adenovirus hexon 
proteins reveals the location and structure of seven hypervariable regions 
containing serotype-specific residues. J Virol 70, 1836-1844. 
Cripe, T. P., Dunphy, E. J., Holub, A. D., Saini, A., Vasi, N. H., Mahller, Y. Y., 
Collins, M. H., Snyder, J. D., Krasnykh, V., Curiel, D. T., Wickham, T. J., 
DeGregori, J., Bergelson, J. M. & Currier, M. A. (2001). Fiber knob 
modifications overcome low, heterogeneous expression of the coxsackievirus-
adenovirus receptor that limits adenovirus gene transfer and oncolysis for 
human rhabdomyosarcoma cells. Cancer Res 61, 2953-2960. 
Crompton, J., Toogood, C. I., Wallis, N. & Hay, R. T. (1994). Expression of a foreign 
epitope on the surface of the adenovirus hexon. J Gen Virol 75 ( Pt 1), 133-139. 
Cuesta, R., Xi, Q. & Schneider, R. J. (2000). Adenovirus-specific translation by 
displacement of kinase Mnk1 from cap-initiation complex eIF4F. Embo J 19, 
3465-3474. 
 262
Cuesta, R., Xi, Q. & Schneider, R. J. (2004). Structural basis for competitive inhibition 
of eIF4G-Mnk1 interaction by the adenovirus 100-kilodalton protein. J Virol 78, 
7707-7716. 
Curiel, D. T. (1999). Strategies to adapt adenoviral vectors for targeted delivery. Ann N 
Y Acad Sci 886, 158-171. 
Dales, S. & Chardonnet, Y. (1973). Early events in the interaction of adenoviruses 
with HeLa cells. IV. Association with microtubules and the nuclear pore complex 
during vectorial movement of the inoculum. Virology 56, 465-483. 
Davis, D. A., Dorsey, K., Wingfield, P. T., Stahl, S. J., Kaufman, J., Fales, H. M. & 
Levine, R. L. (1996). Regulation of HIV-1 protease activity through cysteine 
modification. Biochemistry 35, 2482-2488. 
Davison, E., Diaz, R. M., Hart, I. R., Santis, G. & Marshall, J. F. (1997). Integrin 
alpha5beta1-mediated adenovirus infection is enhanced by the integrin-
activating antibody TS2/16. J Virol 71, 6204-6207. 
Davison, E., Kirby, I., Elliott, T. & Santis, G. (1999). The human HLA-A*0201 allele, 
expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 
fiber. J Virol 73, 4513-4517. 
Davison, E., Kirby, I., Whitehouse, J., Hart, I., Marshall, J. F. & Santis, G. (2001). 
Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates 
with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be 
modulated by changes in beta1 integrin function. J Gene Med 3, 550-559. 
De Geest, B., Snoeys, J., Van Linthout, S., Lievens, J. & Collen, D. (2005). 
Elimination of innate immune responses and liver inflammation by PEGylation 
of adenoviral vectors and methylprednisolone. Hum Gene Ther 16, 1439-1451. 
Debbas, M. & White, E. (1993). Wild-type p53 mediates apoptosis by E1A, which is 
inhibited by E1B. Genes Dev 7, 546-554. 
Dechecchi, M. C., Melotti, P., Bonizzato, A., Santacatterina, M., Chilosi, M. & 
Cabrini, G. (2001). Heparan sulfate glycosaminoglycans are receptors 
sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 75, 
8772-8780. 
Dechecchi, M. C., Tamanini, A., Bonizzato, A. & Cabrini, G. (2000). Heparan sulfate 
glycosaminoglycans are involved in adenovirus type 5 and 2-host cell 
interactions. Virology 268, 382-390. 
Denby, L., Work, L. M., Seggern, D. J., Wu, E., McVey, J. H., Nicklin, S. A. & Baker, 
A. H. (2007). Development of renal-targeted vectors through combined in vivo 
phage display and capsid engineering of adenoviral fibers from serotype 19p. 
Mol Ther 15, 1647-1654. 
 263
Derynck, R., Akhurst, R. J. & Balmain, A. (2001). TGF-beta signaling in tumor 
suppression and cancer progression. Nat Genet 29, 117-129. 
Dhar, D., Spencer, J. F., Toth, K. & Wold, W. S. (2009). Effect of preexisting 
immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in 
immunocompetent and immunosuppressed Syrian hamsters. J Virol 83, 2130-
2139. 
Dhawan, P., Singh, A. B., Deane, N. G., No, Y., Shiou, S. R., Schmidt, C., Neff, J., 
Washington, M. K. & Beauchamp, R. D. (2005). Claudin-1 regulates cellular 
transformation and metastatic behavior in colon cancer. J Clin Invest 115, 1765-
1776. 
Di Paolo, N. C., Kalyuzhniy, O. & Shayakhmetov, D. M. (2007). Fiber shaft-chimeric 
adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. J 
Virol 81, 12249-12259. 
Di Paolo, N. C., Miao, E. A., Iwakura, Y., Murali-Krishna, K., Aderem, A., Flavell, R. 
A., Papayannopoulou, T. & Shayakhmetov, D. M. (2009a). Virus Binding to a 
Plasma Membrane Receptor Triggers Interleukin-1alpha-Mediated 
Proinflammatory Macrophage Response In Vivo. Immunity. 
Di Paolo, N. C., van Rooijen, N. & Shayakhmetov, D. M. (2009b). Redundant and 
synergistic mechanisms control the sequestration of blood-born adenovirus in 
the liver. Mol Ther 17, 675-684. 
Diaconu, I., Denby, L., Pesonen, S., Cerullo, V., Bauerschmitz, G. J., Guse, K., 
Rajecki, M., Dias, J. D., Taari, K., Kanerva, A., Baker, A. H. & Hemminki, A. 
(2009). Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for 
targeting renal cancer and untargeting the liver. Hum Gene Ther 20, 611-620. 
DiCara, D., Burman, A., Clark, S., Berryman, S., Howard, M. J., Hart, I. R., 
Marshall, J. F. & Jackson, T. (2008). Foot-and-mouth disease virus forms a 
highly stable, EDTA-resistant complex with its principal receptor, integrin 
alphavbeta6: implications for infectiousness. J Virol 82, 1537-1546. 
DiCara, D., Rapisarda, C., Sutcliffe, J. L., Violette, S. M., Weinreb, P. H., Hart, I. R., 
Howard, M. J. & Marshall, J. F. (2007). Structure-function analysis of Arg-Gly-
Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem 282, 9657-9665. 
Ding, J., McGrath, W. J., Sweet, R. M. & Mangel, W. F. (1996). Crystal structure of 
the human adenovirus proteinase with its 11 amino acid cofactor. Embo J 15, 
1778-1783. 
Dixit, R. B., Chen, A., Chen, J. & Sheppard, D. (1996). Identification of a sequence 
within the integrin beta6 subunit cytoplasmic domain that is required to support 
the specific effect of alphavbeta6 on proliferation in three-dimensional culture. J 
Biol Chem 271, 25976-25980. 
 264
Dmitriev, I., Kashentseva, E., Rogers, B. E., Krasnykh, V. & Curiel, D. T. (2000). 
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to 
epidermal growth factor mediates adenovirus targeting to epidermal growth 
factor receptor-positive cells. J Virol 74, 6875-6884. 
Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., 
Belousova, N. & Curiel, D. T. (1998). An adenovirus vector with genetically 
modified fibers demonstrates expanded tropism via utilization of a 
coxsackievirus and adenovirus receptor-independent cell entry mechanism. J 
Virol 72, 9706-9713. 
Dorner, A. A., Wegmann, F., Butz, S., Wolburg-Buchholz, K., Wolburg, H., Mack, 
A., Nasdala, I., August, B., Westermann, J., Rathjen, F. G. & Vestweber, D. 
(2005). Coxsackievirus-adenovirus receptor (CAR) is essential for early 
embryonic cardiac development. J Cell Sci 118, 3509-3521. 
Doronin, K., Toth, K., Kuppuswamy, M., Krajcsi, P., Tollefson, A. E. & Wold, W. S. 
(2003). Overexpression of the ADP (E3-11.6K) protein increases cell lysis and 
spread of adenovirus. Virology 305, 378-387. 
Douglas, J. T., Kim, M., Sumerel, L. A., Carey, D. E. & Curiel, D. T. (2001). Efficient 
oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on 
tumor expression of primary ad receptors. Cancer Res 61, 813-817. 
Douglas, J. T., Miller, C. R., Kim, M., Dmitriev, I., Mikheeva, G., Krasnykh, V. & 
Curiel, D. T. (1999). A system for the propagation of adenoviral vectors with 
genetically modified receptor specificities. Nat Biotechnol 17, 470-475. 
Duncan, S. J., Gordon, F. C., Gregory, D. W., McPhie, J. L., Postlethwaite, R., 
White, R. & Willcox, H. N. (1978). Infection of mouse liver by human 
adenovirus type 5. J Gen Virol 40, 45-61. 
Eggerman, T. L., Mondoro, T. H., Lozier, J. N. & Vostal, J. G. (2002). Adenoviral 
vectors do not induce, inhibit, or potentiate human platelet aggregation. Hum 
Gene Ther 13, 125-128. 
Einfeld, D. A., Schroeder, R., Roelvink, P. W., Lizonova, A., King, C. R., Kovesdi, I. 
& Wickham, T. J. (2001). Reducing the native tropism of adenovirus vectors 
requires removal of both CAR and integrin interactions. J Virol 75, 11284-
11291. 
Elayadi, A. N., Samli, K. N., Prudkin, L., Liu, Y. H., Bian, A., Xie, X. J., Wistuba, II, 
Roth, J. A., McGuire, M. J. & Brown, K. C. (2007). A peptide selected by 
biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for 
nonsmall cell lung cancer. Cancer Res 67, 5889-5895. 
Elkon, K. B., Liu, C. C., Gall, J. G., Trevejo, J., Marino, M. W., Abrahamsen, K. A., 
Song, X., Zhou, J. L., Old, L. J., Crystal, R. G. & Falck-Pedersen, E. (1997). 
 265
Tumor necrosis factor alpha plays a central role in immune-mediated clearance 
of adenoviral vectors. Proc Natl Acad Sci U S A 94, 9814-9819. 
Engler, H., Machemer, T., Philopena, J., Wen, S. F., Quijano, E., Ramachandra, M., 
Tsai, V. & Ralston, R. (2004). Acute hepatotoxicity of oncolytic adenoviruses in 
mouse models is associated with expression of wild-type E1a and induction of 
TNF-alpha. Virology 328, 52-61. 
Eto, Y., Yoshioka, Y., Mukai, Y., Okada, N. & Nakagawa, S. (2008). Development of 
PEGylated adenovirus vector with targeting ligand. Int J Pharm 354, 3-8. 
Evans, J. D. & Hearing, P. (2003). Distinct roles of the Adenovirus E4 ORF3 protein in 
viral DNA replication and inhibition of genome concatenation. J Virol 77, 5295-
5304. 
Evans, J. D. & Hearing, P. (2005). Relocalization of the Mre11-Rad50-Nbs1 complex 
by the adenovirus E4 ORF3 protein is required for viral replication. J Virol 79, 
6207-6215. 
Everitt, E., Lutter, L. & Philipson, L. (1975). Structural proteins of adenoviruses. XII. 
Location and neighbor relationship among proteins of adenovirion type 2 as 
revealed by enzymatic iodination, immunoprecipitation and chemical cross-
linking. Virology 67, 197-208. 
Everitt, E., Sundquist, B., Pettersson, U. & Philipson, L. (1973). Structural proteins 
of adenoviruses. X. Isolation and topography of low molecular weight antigens 
from the virion of adenovirus type 2. Virology 52, 130-147. 
Ewing, S. G., Byrd, S. A., Christensen, J. B., Tyler, R. E. & Imperiale, M. J. (2007). 
Ternary complex formation on the adenovirus packaging sequence by the IVa2 
and L4 22-kilodalton proteins. J Virol 81, 12450-12457. 
Falanga, A. (2005). Thrombophilia in cancer. Semin Thromb Hemost 31, 104-110. 
Farmer, C., Morton, P. E., Snippe, M., Santis, G. & Parsons, M. (2009). Coxsackie 
adenovirus receptor (CAR) regulates integrin function through activation of 
p44/42 MAPK. Exp Cell Res. 
Fauquet, C. M., Mayo, M. A., Maniloff, J., Desselberger, U. & Ball, L. A. (2005). 
Virus Taxonomy; Seventh Report of the International Committee of Viruses. 
San Diego: Academic Press. 
Fechner, H., Haack, A., Wang, H., Wang, X., Eizema, K., Pauschinger, M., 
Schoemaker, R., Veghel, R., Houtsmuller, A., Schultheiss, H. P., Lamers, J. 
& Poller, W. (1999). Expression of coxsackie adenovirus receptor and alphav-
integrin does not correlate with adenovector targeting in vivo indicating 
anatomical vector barriers. Gene Ther 6, 1520-1535. 
Fejer, G., Drechsel, L., Liese, J., Schleicher, U., Ruzsics, Z., Imelli, N., Greber, U. 
F., Keck, S., Hildenbrand, B., Krug, A., Bogdan, C. & Freudenberg, M. A. 
 266
(2008). Key role of splenic myeloid DCs in the IFN-alphabeta response to 
adenoviruses in vivo. PLoS Pathog 4, e1000208. 
Feldman, A. L., Restifo, N. P., Alexander, H. R., Bartlett, D. L., Hwu, P., Seth, P. & 
Libutti, S. K. (2000). Antiangiogenic gene therapy of cancer utilizing a 
recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer 
Res 60, 1503-1506. 
Ferrigno, D., Buccheri, G. & Ricca, I. (2001). Prognostic significance of blood 
coagulation tests in lung cancer. Eur Respir J 17, 667-673. 
Fisher, K. D., Stallwood, Y., Green, N. K., Ulbrich, K., Mautner, V. & Seymour, L. 
W. (2001). Polymer-coated adenovirus permits efficient retargeting and evades 
neutralising antibodies. Gene Ther 8, 341-348. 
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 
1182-1186. 
Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. 
Nat Med 1, 27-31. 
Freimuth, P., Springer, K., Berard, C., Hainfeld, J., Bewley, M. & Flanagan, J. 
(1999). Coxsackievirus and adenovirus receptor amino-terminal 
immunoglobulin V-related domain binds adenovirus type 2 and fiber knob from 
adenovirus type 12. J Virol 73, 1392-1398. 
Fromm, J. R., Hileman, R. E., Caldwell, E. E., Weiler, J. M. & Linhardt, R. J. (1995). 
Differences in the interaction of heparin with arginine and lysine and the 
importance of these basic amino acids in the binding of heparin to acidic 
fibroblast growth factor. Arch Biochem Biophys 323, 279-287. 
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., 
Mitlianga, P., Shi, Y. X., Levin, V. A., Yung, W. K. & Kyritsis, A. P. (2000). A 
mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma 
effect in vivo. Oncogene 19, 2-12. 
Furumoto, K., Nagayama, S., Ogawara, K., Takakura, Y., Hashida, M., Higaki, K. & 
Kimura, T. (2004). Hepatic uptake of negatively charged particles in rats: 
possible involvement of serum proteins in recognition by scavenger receptor. J 
Control Release 97, 133-141. 
Gaggar, A., Shayakhmetov, D. & Lieber, A. (2007). Identifying functional adenovirus-
host interactions using tandem mass spectrometry. Methods Mol Med 131, 141-
155. 
Gaggar, A., Shayakhmetov, D. M. & Lieber, A. (2003). CD46 is a cellular receptor for 
group B adenoviruses. Nat Med 9, 1408-1412. 
Gahery-Segard, H., Farace, F., Godfrin, D., Gaston, J., Lengagne, R., Tursz, T., 
Boulanger, P. & Guillet, J. G. (1998). Immune response to recombinant capsid 
 267
proteins of adenovirus in humans: antifiber and anti-penton base antibodies 
have a synergistic effect on neutralizing activity. J Virol 72, 2388-2397. 
Gahery-Segard, H., Juillard, V., Gaston, J., Lengagne, R., Pavirani, A., Boulanger, 
P. & Guillet, J. G. (1997). Humoral immune response to the capsid 
components of recombinant adenoviruses: routes of immunization modulate 
virus-induced Ig subclass shifts. Eur J Immunol 27, 653-659. 
Galy, A. H. & Spits, H. (1992). CD40 is functionally expressed on human thymic 
epithelial cells. J Immunol 149, 775-782. 
Ganesh, S., Gonzalez-Edick, M., Gibbons, D., Van Roey, M. & Jooss, K. (2008). 
Intratumoral coadministration of hyaluronidase enzyme and oncolytic 
adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer 
Res 14, 3933-3941. 
Ganesh, S., Gonzalez Edick, M., Idamakanti, N., Abramova, M., Vanroey, M., 
Robinson, M., Yun, C. O. & Jooss, K. (2007). Relaxin-expressing, fiber 
chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer 
Res 67, 4399-4407. 
Ganly, I., Mautner, V. & Balmain, A. (2000). Productive replication of human 
adenoviruses in mouse epidermal cells. J Virol 74, 2895-2899. 
Ganter, M. T., Roux, J., Miyazawa, B., Howard, M., Frank, J. A., Su, G., Sheppard, 
D., Violette, S. M., Weinreb, P. H., Horan, G. S., Matthay, M. A. & Pittet, J. F. 
(2008). Interleukin-1beta causes acute lung injury via alphavbeta5 and 
alphavbeta6 integrin-dependent mechanisms. Circ Res 102, 804-812. 
Gimenez-Alejandre, M., Cascallo, M., Bayo-Puxan, N. & Alemany, R. (2008). 
Coagulation factors determine tumor transduction in vivo. Hum Gene Ther. 
Ginsberg, H. S., Moldawer, L. L., Sehgal, P. B., Redington, M., Kilian, P. L., 
Chanock, R. M. & Prince, G. A. (1991). A mouse model for investigating the 
molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A 
88, 1651-1655. 
Glasgow, J. N., Everts, M. & Curiel, D. T. (2006). Transductional targeting of 
adenovirus vectors for gene therapy. Cancer Gene Ther 13, 830-844. 
Gonzalez, R., Huang, W., Finnen, R., Bragg, C. & Flint, S. J. (2006). Adenovirus 
E1B 55-kilodalton protein is required for both regulation of mRNA export and 
efficient entry into the late phase of infection in normal human fibroblasts. J 
Virol 80, 964-974. 
Gonzalez, R., Vereecque, R., Wickham, T. J., Facon, T., Hetuin, D., Kovesdi, I., 
Bauters, F., Fenaux, P. & Quesnel, B. (1999). Transduction of bone marrow 
cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene 
transfer in myeloma cells. Hum Gene Ther 10, 2709-2717. 
 268
Grable, M. & Hearing, P. (1992). cis and trans requirements for the selective 
packaging of adenovirus type 5 DNA. J Virol 66, 723-731. 
Grandien, M., Pettersson, C. A., Svensson, L. & Uhnoo, I. (1987). Latex 
agglutination test for adenovirus diagnosis in diarrheal disease. J Med Virol 23, 
311-316. 
Greber, U. F. (1998). Virus assembly and disassembly: the adenovirus cysteine 
protease as a trigger factor. Rev Med Virol 8, 213-222. 
Greber, U. F., Suomalainen, M., Stidwill, R. P., Boucke, K., Ebersold, M. W. & 
Helenius, A. (1997). The role of the nuclear pore complex in adenovirus DNA 
entry. Embo J 16, 5998-6007. 
Greber, U. F., Willetts, M., Webster, P. & Helenius, A. (1993). Stepwise dismantling 
of adenovirus 2 during entry into cells. Cell 75, 477-486. 
Green, N. K., Morrison, J., Hale, S., Briggs, S. S., Stevenson, M., Subr, V., Ulbrich, 
K., Chandler, L., Mautner, V., Seymour, L. W. & Fisher, K. D. (2008). 
Retargeting polymer-coated adenovirus to the FGF receptor allows productive 
infection and mediates efficacy in a peritoneal model of human ovarian cancer. 
J Gene Med 10, 280-289. 
Greenberger, S., Shaish, A., Varda-Bloom, N., Levanon, K., Breitbart, E., 
Goldberg, I., Barshack, I., Hodish, I., Yaacov, N., Bangio, L., Goncharov, T., 
Wallach, D. & Harats, D. (2004). Transcription-controlled gene therapy against 
tumor angiogenesis. J Clin Invest 113, 1017-1024. 
Gros, A., Martinez-Quintanilla, J., Puig, C., Guedan, S., Mollevi, D. G., Alemany, R. 
& Cascallo, M. (2008). Bioselection of a gain of function mutation that 
enhances adenovirus 5 release and improves its antitumoral potency. Cancer 
Res 68, 8928-8937. 
Gu, X., Niu, J., Dorahy, D. J., Scott, R. & Agrez, M. V. (2002). Integrin alpha(v)beta6-
associated ERK2 mediates MMP-9 secretion in colon cancer cells. Br J Cancer 
87, 348-351. 
Guan, H., McGuire, M. J., Li, S. & Brown, K. C. (2008). Peptide-targeted polyglutamic 
acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive 
cancers. Bioconjug Chem 19, 1813-1821. 
Guedan, S., Gros, A., Cascallo, M., Vile, R., Mercade, E. & Alemany, R. (2008). 
Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing 
a fusogenic glycoprotein at a late stage of replication. Gene Ther 15, 1240-
1245. 
Guo, W. & Giancotti, F. G. (2004). Integrin signalling during tumour progression. Nat 
Rev Mol Cell Biol 5, 816-826. 
 269
Guo, W., Zhu, H., Zhang, L., Davis, J., Teraishi, F., Roth, J. A., Stephens, C., 
Fueyo, J., Jiang, H., Conrad, C. & Fang, B. (2006). Combination effect of 
oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast 
cancer models. Cancer Gene Ther 13, 82-90. 
Guse, K., Diaconu, I., Rajecki, M., Sloniecka, M., Hakkarainen, T., Ristimaki, A., 
Kanerva, A., Pesonen, S. & Hemminki, A. (2009). Ad5/3-9HIF-Delta24-
VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic 
oncolytic adenovirus for kidney cancer treatment. Gene Ther. 
Gustin, K. E. & Imperiale, M. J. (1998). Encapsidation of viral DNA requires the 
adenovirus L1 52/55-kilodalton protein. J Virol 72, 7860-7870. 
Haapasalmi, K., Zhang, K., Tonnesen, M., Olerud, J., Sheppard, D., Salo, T., 
Kramer, R., Clark, R. A., Uitto, V. J. & Larjava, H. (1996). Keratinocytes in 
human wounds express alpha v beta 6 integrin. J Invest Dermatol 106, 42-48. 
Haisma, H. J., Boesjes, M., Beerens, A. M., van der Strate, B. W., Curiel, D. T., 
Pluddemann, A., Gordon, S. & Bellu, A. R. (2009). Scavenger Receptor A: A 
New Route for Adenovirus 5. Mol Pharm 6, 366-374. 
Haisma, H. J., Kamps, J. A., Kamps, G. K., Plantinga, J. A., Rots, M. G. & Bellu, A. 
R. (2008). Polyinosinic acid enhances delivery of adenovirus vectors in vivo by 
preventing sequestration in liver macrophages. J Gen Virol 89, 1097-1105. 
Hakkarainen, T., Hemminki, A., Pereboev, A. V., Barker, S. D., Asiedu, C. K., 
Strong, T. V., Kanerva, A., Wahlfors, J. & Curiel, D. T. (2003). CD40 is 
expressed on ovarian cancer cells and can be utilized for targeting 
adenoviruses. Clin Cancer Res 9, 619-624. 
Hallden, G., Hill, R., Wang, Y., Anand, A., Liu, T. C., Lemoine, N. R., Francis, J., 
Hawkins, L. & Kirn, D. (2003). Novel immunocompetent murine tumor models 
for the assessment of replication-competent oncolytic adenovirus efficacy. Mol 
Ther 8, 412-424. 
Hamidi, S., Salo, T., Kainulainen, T., Epstein, J., Lerner, K. & Larjava, H. (2000). 
Expression of alpha(v)beta6 integrin in oral leukoplakia. Br J Cancer 82, 1433-
1440. 
Harada, J. N., Shevchenko, A., Shevchenko, A., Pallas, D. C. & Berk, A. J. (2002). 
Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to 
ubiquitination machinery. J Virol 76, 9194-9206. 
Harlow, E., Whyte, P., Franza, B. R., Jr. & Schley, C. (1986). Association of 
adenovirus early-region 1A proteins with cellular polypeptides. Mol Cell Biol 6, 
1579-1589. 
 270
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., 
Jain, R. K. & McDonald, D. M. (2000). Openings between defective endothelial 
cells explain tumor vessel leakiness. Am J Pathol 156, 1363-1380. 
Hasson, T. B., Ornelles, D. A. & Shenk, T. (1992). Adenovirus L1 52- and 55-
kilodalton proteins are present within assembling virions and colocalize with 
nuclear structures distinct from replication centers. J Virol 66, 6133-6142. 
Hasson, T. B., Soloway, P. D., Ornelles, D. A., Doerfler, W. & Shenk, T. (1989). 
Adenovirus L1 52- and 55-kilodalton proteins are required for assembly of 
virions. J Virol 63, 3612-3621. 
Hausner, S. H., Abbey, C. K., Bold, R. J., Gagnon, M. K., Marik, J., Marshall, J. F., 
Stanecki, C. E. & Sutcliffe, J. L. (2009a). Targeted In vivo Imaging of Integrin 
{alpha} v{beta}6 with an Improved Radiotracer and Its Relevance in a 
Pancreatic Tumor Model. Cancer Res. 
Hausner, S. H., DiCara, D., Marik, J., Marshall, J. F. & Sutcliffe, J. L. (2007). Use of 
a peptide derived from foot-and-mouth disease virus for the noninvasive 
imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl 
A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron 
emission tomography. Cancer Res 67, 7833-7840. 
Hausner, S. H., Kukis, D. L., Gagnon, M. K., Stanecki, C. E., Ferdani, R., Marshall, 
J. F., Anderson, C. J. & Sutcliffe, J. L. (2009b). Evaluation of [64Cu]Cu-
DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission 
tomography with an alphavbeta6-specific peptide. Mol Imaging 8, 111-121. 
Hawkins, L. K., Johnson, L., Bauzon, M., Nye, J. A., Castro, D., Kitzes, G. A., 
Young, M. D., Holt, J. K., Trown, P. & Hermiston, T. W. (2001). Gene delivery 
from the E3 region of replicating human adenovirus: evaluation of the 6.7 
K/gp19 K region. Gene Ther 8, 1123-1131. 
Hayes, B. W., Telling, G. C., Myat, M. M., Williams, J. F. & Flint, S. J. (1990). The 
adenovirus L4 100-kilodalton protein is necessary for efficient translation of viral 
late mRNA species. J Virol 64, 2732-2742. 
Hazelbag, S., Kenter, G. G., Gorter, A., Dreef, E. J., Koopman, L. A., Violette, S. 
M., Weinreb, P. H. & Fleuren, G. J. (2007). Overexpression of the alpha v beta 
6 integrin in cervical squamous cell carcinoma is a prognostic factor for 
decreased survival. J Pathol 212, 316-324. 
Hearing, P., Samulski, R. J., Wishart, W. L. & Shenk, T. (1987). Identification of a 
repeated sequence element required for efficient encapsidation of the 
adenovirus type 5 chromosome. J Virol 61, 2555-2558. 
Heikkila, O., Susi, P., Stanway, G. & Hyypia, T. (2009). Integrin alphaVbeta6 is a 
high-affinity receptor for coxsackievirus A9. J Gen Virol 90, 197-204. 
 271
Henning, P., Magnusson, M. K., Gunneriusson, E., Hong, S. S., Boulanger, P., 
Nygren, P. A. & Lindholm, L. (2002). Genetic modification of adenovirus 5 
tropism by a novel class of ligands based on a three-helix bundle scaffold 
derived from staphylococcal protein A. Hum Gene Ther 13, 1427-1439. 
Herman, J. R., Adler, H. L., Aguilar-Cordova, E., Rojas-Martinez, A., Woo, S., 
Timme, T. L., Wheeler, T. M., Thompson, T. C. & Scardino, P. T. (1999). In 
situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. 
Hum Gene Ther 10, 1239-1249. 
Hernandez-Alcoceba, R., Pihalja, M., Wicha, M. S. & Clarke, M. F. (2000). A novel, 
conditionally replicative adenovirus for the treatment of breast cancer that 
allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther 
11, 2009-2024. 
Hilleman, M. R. & Werner, J. H. (1954). Recovery of new agent from patients with 
acute respiratory illness. Proc Soc Exp Biol Med 85, 183-188. 
Honda, T., Saitoh, H., Masuko, M., Katagiri-Abe, T., Tominaga, K., Kozakai, I., 
Kobayashi, K., Kumanishi, T., Watanabe, Y. G., Odani, S. & Kuwano, R. 
(2000). The coxsackievirus-adenovirus receptor protein as a cell adhesion 
molecule in the developing mouse brain. Brain Res Mol Brain Res 77, 19-28. 
Hong, J. S. & Engler, J. A. (1996). Domains required for assembly of adenovirus type 
2 fiber trimers. J Virol 70, 7071-7078. 
Hong, S. S., Karayan, L., Tournier, J., Curiel, D. T. & Boulanger, P. A. (1997). 
Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface 
of human epithelial and B lymphoblastoid cells. Embo J 16, 2294-2306. 
Hong, S. S., Szolajska, E., Schoehn, G., Franqueville, L., Myhre, S., Lindholm, L., 
Ruigrok, R. W., Boulanger, P. & Chroboczek, J. (2005). The 100K-chaperone 
protein from adenovirus serotype 2 (Subgroup C) assists in trimerization and 
nuclear localization of hexons from subgroups C and B adenoviruses. J Mol Biol 
352, 125-138. 
Honkavuori, K. S., Pollard, B. D., Rodriguez, M. S., Hay, R. T. & Kemp, G. D. 
(2004). Dual role of the adenovirus pVI C terminus as a nuclear localization 
signal and activator of the viral protease. J Gen Virol 85, 3367-3376. 
Hoover, K. B., Liao, S. Y. & Bryant, P. J. (1998). Loss of the tight junction MAGUK 
ZO-1 in breast cancer: relationship to glandular differentiation and loss of 
heterozygosity. Am J Pathol 153, 1767-1773. 
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, 
K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., Goyal, J., Feghali-Bostwick, C. 
A., Matteson, E. L., O'Hara, C., Lafyatis, R., Davis, G. S., Huang, X., 
Sheppard, D. & Violette, S. M. (2008). Partial inhibition of integrin 
 272
alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. 
Am J Respir Crit Care Med 177, 56-65. 
Horton, R. M. (1995). PCR-mediated recombination and mutagenesis. SOEing 
together tailor-made genes. Mol Biotechnol 3, 93-99. 
Horton, R. M. (1997). In vitro recombination and mutagenesis of DNA. SOEing 
together tailor-made genes. Methods Mol Biol 67, 141-149. 
Horton, R. M., Cai, Z. L., Ho, S. N. & Pease, L. R. (1990). Gene splicing by overlap 
extension: tailor-made genes using the polymerase chain reaction. 
Biotechniques 8, 528-535. 
Horwitz, M. S., Scharff, M. D. & Maizel, J. V., Jr. (1969). Synthesis and assembly of 
adenovirus 2. I. Polypeptide synthesis, assembly of capsomeres, and 
morphogenesis of the virion. Virology 39, 682-694. 
Horwood, N. J., Smith, C., Andreakos, E., Quattrocchi, E., Brennan, F. M., 
Feldmann, M. & Foxwell, B. M. (2002). High-efficiency gene transfer into 
nontransformed cells: utility for studying gene regulation and analysis of 
potential therapeutic targets. Arthritis Res 4 Suppl 3, S215-225. 
Hotta, Y., Honda, T., Naito, M. & Kuwano, R. (2003). Developmental distribution of 
coxsackie virus and adenovirus receptor localized in the nervous system. Brain 
Res Dev Brain Res 143, 1-13. 
Hsu, C., Boysen, M., Gritton, L. D., Frosst, P. D., Nemerow, G. R. & Von Seggern, 
D. J. (2005). In vitro dendritic cell infection by pseudotyped adenoviral vectors 
does not correlate with their in vivo immunogenicity. Virology 332, 1-7. 
Hsu, Y. M., Lucci, J., Su, L., Ehrenfels, B., Garber, E. & Thomas, D. (1997). 
Heteromultimeric complexes of CD40 ligand are present on the cell surface of 
human T lymphocytes. J Biol Chem 272, 911-915. 
Huang, D., Desbois, A. & Hou, S. T. (2005). A novel adenoviral vector which 
mediates hypoxia-inducible gene expression selectively in neurons. Gene Ther 
12, 1369-1376. 
Huang, S., Kamata, T., Takada, Y., Ruggeri, Z. M. & Nemerow, G. R. (1996). 
Adenovirus interaction with distinct integrins mediates separate events in cell 
entry and gene delivery to hematopoietic cells. J Virol 70, 4502-4508. 
Huang, T. G., Savontaus, M. J., Shinozaki, K., Sauter, B. V. & Woo, S. L. (2003). 
Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 
10, 1241-1247. 
Huang, X., Wu, J., Spong, S. & Sheppard, D. (1998). The integrin alphavbeta6 is 
critical for keratinocyte migration on both its known ligand, fibronectin, and on 
vitronectin. J Cell Sci 111 ( Pt 15), 2189-2195. 
 273
Huebner, R. J., Rowe, W. P., Schatten, W. E., Smith, R. R. & Thomas, L. B. (1956). 
Studies on the use of viruses in the treatment of carcinoma of the cervix. 
Cancer 9, 1211-1218. 
Impola, U., Uitto, V. J., Hietanen, J., Hakkinen, L., Zhang, L., Larjava, H., Isaka, K. 
& Saarialho-Kere, U. (2004). Differential expression of matrilysin-1 (MMP-7), 
92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous 
and squamous cell cancer. J Pathol 202, 14-22. 
Ito, M., Kodama, M., Masuko, M., Yamaura, M., Fuse, K., Uesugi, Y., Hirono, S., 
Okura, Y., Kato, K., Hotta, Y., Honda, T., Kuwano, R. & Aizawa, Y. (2000). 
Expression of coxsackievirus and adenovirus receptor in hearts of rats with 
experimental autoimmune myocarditis. Circ Res 86, 275-280. 
Iversen, N., Lindahl, A. K. & Abildgaard, U. (2002). Elevated plasma levels of the 
factor Xa-TFPI complex in cancer patients. Thromb Res 105, 33-36. 
Jackson, T., Clark, S., Berryman, S., Burman, A., Cambier, S., Mu, D., Nishimura, 
S. & King, A. M. (2004). Integrin alphavbeta8 functions as a receptor for foot-
and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated 
infection. J Virol 78, 4533-4540. 
Jackson, T., Mould, A. P., Sheppard, D. & King, A. M. (2002). Integrin alphavbeta1 
is a receptor for foot-and-mouth disease virus. J Virol 76, 935-941. 
Jackson, T., Sharma, A., Ghazaleh, R. A., Blakemore, W. E., Ellard, F. M., 
Simmons, D. L., Newman, J. W., Stuart, D. I. & King, A. M. (1997). Arginine-
glycine-aspartic acid-specific binding by foot-and-mouth disease viruses to the 
purified integrin alpha(v)beta3 in vitro. J Virol 71, 8357-8361. 
Jackson, T., Sheppard, D., Denyer, M., Blakemore, W. & King, A. M. (2000). The 
epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J 
Virol 74, 4949-4956. 
Jakubczak, J. L., Rollence, M. L., Stewart, D. A., Jafari, J. D., Von Seggern, D. J., 
Nemerow, G. R., Stevenson, S. C. & Hallenbeck, P. L. (2001). Adenovirus 
type 5 viral particles pseudotyped with mutagenized fiber proteins show 
diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol 
75, 2972-2981. 
Janes, S. M. & Watt, F. M. (2004). Switch from alphavbeta5 to alphavbeta6 integrin 
expression protects squamous cell carcinomas from anoikis. J Cell Biol 166, 
419-431. 
Jee, Y. S., Lee, S. G., Lee, J. C., Kim, M. J., Lee, J. J., Kim, D. Y., Park, S. W., 
Sung, M. W. & Heo, D. S. (2002). Reduced expression of coxsackievirus and 
adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in 
 274
head and neck squamous cell carcinoma patients. Anticancer Res 22, 2629-
2634. 
Jelsma, T. N., Howe, J. A., Mymryk, J. S., Evelegh, C. M., Cunniff, N. F. & Bayley, 
S. T. (1989). Sequences in E1A proteins of human adenovirus 5 required for 
cell transformation, repression of a transcriptional enhancer, and induction of 
proliferating cell nuclear antigen. Virology 171, 120-130. 
Jenkins, R. G., Su, X., Su, G., Scotton, C. J., Camerer, E., Laurent, G. J., Davis, G. 
E., Chambers, R. C., Matthay, M. A. & Sheppard, D. (2006). Ligation of 
protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-
beta activation and promotes acute lung injury. J Clin Invest 116, 1606-1614. 
Jones, J., Watt, F. M. & Speight, P. M. (1997). Changes in the expression of alpha v 
integrins in oral squamous cell carcinomas. J Oral Pathol Med 26, 63-68. 
Jones, N. & Shenk, T. (1979). An adenovirus type 5 early gene function regulates 
expression of other early viral genes. Proc Natl Acad Sci U S A 76, 3665-3669. 
Jooss, K., Yang, Y. & Wilson, J. M. (1996). Cyclophosphamide diminishes 
inflammation and prolongs transgene expression following delivery of 
adenoviral vectors to mouse liver and lung. Hum Gene Ther 7, 1555-1566. 
Kajiji, S., Tamura, R. N. & Quaranta, V. (1989). A novel integrin (alpha E beta 4) from 
human epithelial cells suggests a fourth family of integrin adhesion receptors. 
Embo J 8, 673-680. 
Kallewaard, N. L., Zhang, L., Chen, J. W., Guttenberg, M., Sanchez, M. D. & 
Bergelson, J. M. (2009). Tissue-specific deletion of the coxsackievirus and 
adenovirus receptor protects mice from virus-induced pancreatitis and 
myocarditis. Cell Host Microbe 6, 91-98. 
Kalyuzhniy, O., Di Paolo, N. C., Silvestry, M., Hofherr, S. E., Barry, M. A., Stewart, 
P. L. & Shayakhmetov, D. M. (2008). Adenovirus serotype 5 hexon is critical 
for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A 105, 5483-
5488. 
Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. (2006). Type I 
interferons directly regulate lymphocyte recirculation and cause transient blood 
lymphopenia. Blood 108, 3253-3261. 
Kanerva, A., Mikheeva, G. V., Krasnykh, V., Coolidge, C. J., Lam, J. T., 
Mahasreshti, P. J., Barker, S. D., Straughn, M., Barnes, M. N., Alvarez, R. 
D., Hemminki, A. & Curiel, D. T. (2002a). Targeting adenovirus to the serotype 
3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin 
Cancer Res 8, 275-280. 
Kanerva, A., Wang, M., Bauerschmitz, G. J., Lam, J. T., Desmond, R. A., Bhoola, 
S. M., Barnes, M. N., Alvarez, R. D., Siegal, G. P., Curiel, D. T. & Hemminki, 
 275
A. (2002b). Gene transfer to ovarian cancer versus normal tissues with fiber-
modified adenoviruses. Mol Ther 5, 695-704. 
Kater, A. P., Peppelenbosch, M. P., Brandjes, D. P. & Lumbantobing, M. (2002). 
Dichotomal effect of the coumadin derivative warfarin on inflammatory signal 
transduction. Clin Diagn Lab Immunol 9, 1396-1397. 
Katze, M. G., DeCorato, D., Safer, B., Galabru, J. & Hovanessian, A. G. (1987). 
Adenovirus VAI RNA complexes with the 68 000 Mr protein kinase to regulate 
its autophosphorylation and activity. Embo J 6, 689-697. 
Kawashima, A., Tsugawa, S., Boku, A., Kobayashi, M., Minamoto, T., Nakanishi, I. 
& Oda, Y. (2003). Expression of alphav integrin family in gastric carcinomas: 
increased alphavbeta6 is associated with lymph node metastasis. Pathol Res 
Pract 199, 57-64. 
Kelkar, S. A., Pfister, K. K., Crystal, R. G. & Leopold, P. L. (2004). Cytoplasmic 
dynein mediates adenovirus binding to microtubules. J Virol 78, 10122-10132. 
Kiang, A., Hartman, Z. C., Everett, R. S., Serra, D., Jiang, H., Frank, M. M. & 
Amalfitano, A. (2006). Multiple innate inflammatory responses induced after 
systemic adenovirus vector delivery depend on a functional complement 
system. Mol Ther 14, 588-598. 
Kirby, I., Davison, E., Beavil, A. J., Soh, C. P., Wickham, T. J., Roelvink, P. W., 
Kovesdi, I., Sutton, B. J. & Santis, G. (1999). Mutations in the DG loop of 
adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular 
receptor CAR. J Virol 73, 9508-9514. 
Kirby, I., Davison, E., Beavil, A. J., Soh, C. P., Wickham, T. J., Roelvink, P. W., 
Kovesdi, I., Sutton, B. J. & Santis, G. (2000). Identification of contact residues 
and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol 
74, 2804-2813. 
Klinger, J. R., Sanchez, M. P., Curtin, L. A., Durkin, M. & Matyas, B. (1998). Multiple 
cases of life-threatening adenovirus pneumonia in a mental health care center. 
Am J Respir Crit Care Med 157, 645-649. 
Kogelberg, H., Tolner, B., Thomas, G. J., Di Cara, D., Minogue, S., Ramesh, B., 
Sodha, S., Marsh, D., Lowdell, M. W., Meyer, T., Begent, R. H., Hart, I., 
Marshall, J. F. & Chester, K. (2008). Engineering a single-chain Fv antibody to 
alpha v beta 6 integrin using the specificity-determining loop of a foot-and-
mouth disease virus. J Mol Biol 382, 385-401. 
Koizumi, N., Kawabata, K., Sakurai, F., Watanabe, Y., Hayakawa, T. & Mizuguchi, 
H. (2006). Modified adenoviral vectors ablated for coxsackievirus-adenovirus 
receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue 
transduction and toxicity. Hum Gene Ther 17, 264-279. 
 276
Koizumi, N., Mizuguchi, H., Utoguchi, N., Watanabe, Y. & Hayakawa, T. (2003). 
Generation of fiber-modified adenovirus vectors containing heterologous 
peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 5, 
267-276. 
Koizumi, N., Yamaguchi, T., Kawabata, K., Sakurai, F., Sasaki, T., Watanabe, Y., 
Hayakawa, T. & Mizuguchi, H. (2007). Fiber-modified adenovirus vectors 
decrease liver toxicity through reduced IL-6 production. J Immunol 178, 1767-
1773. 
Kontermann, R. E., Korn, T. & Jerome, V. (2003). Recombinant adenoviruses for in 
vivo expression of antibody fragments. Methods Mol Biol 207, 421-433. 
Koski, A., Rajecki, M., Guse, K., Kanerva, A., Ristimaki, A., Pesonen, S., 
Escutenaire, S. & Hemminki, A. (2009). Systemic adenoviral gene delivery to 
orthotopic murine breast tumors with ablation of coagulation factors, 
thrombocytes and Kupffer cells. J Gene Med. 
Kraft, S., Diefenbach, B., Mehta, R., Jonczyk, A., Luckenbach, G. A. & Goodman, 
S. L. (1999). Definition of an unexpected ligand recognition motif for alphav 
beta6 integrin. J Biol Chem 274, 1979-1985. 
Krasnykh, V., Belousova, N., Korokhov, N., Mikheeva, G. & Curiel, D. T. (2001). 
Genetic targeting of an adenovirus vector via replacement of the fiber protein 
with the phage T4 fibritin. J Virol 75, 4176-4183. 
Krasnykh, V., Dmitriev, I., Mikheeva, G., Miller, C. R., Belousova, N. & Curiel, D. T. 
(1998). Characterization of an adenovirus vector containing a heterologous 
peptide epitope in the HI loop of the fiber knob. J Virol 72, 1844-1852. 
Krasnykh, V. N., Mikheeva, G. V., Douglas, J. T. & Curiel, D. T. (1996). Generation 
of recombinant adenovirus vectors with modified fibers for altering viral tropism. 
J Virol 70, 6839-6846. 
Kreppel, F., Gackowski, J., Schmidt, E. & Kochanek, S. (2005). Combined genetic 
and chemical capsid modifications enable flexible and efficient de- and 
retargeting of adenovirus vectors. Mol Ther 12, 107-117. 
Kritz, A. B., Nicol, C. G., Dishart, K. L., Nelson, R., Holbeck, S., Von Seggern, D. 
J., Work, L. M., McVey, J. H., Nicklin, S. A. & Baker, A. H. (2007). Adenovirus 
5 fibers mutated at the putative HSPG-binding site show restricted retargeting 
with targeting peptides in the HI loop. Mol Ther 15, 741-749. 
Kurachi, S., Koizumi, N., Sakurai, F., Kawabata, K., Sakurai, H., Nakagawa, S., 
Hayakawa, T. & Mizuguchi, H. (2007a). Characterization of capsid-modified 
adenovirus vectors containing heterologous peptides in the fiber knob, protein 
IX, or hexon. Gene Ther 14, 266-274. 
 277
Kurachi, S., Tashiro, K., Sakurai, F., Sakurai, H., Kawabata, K., Yayama, K., 
Okamoto, H., Nakagawa, S. & Mizuguchi, H. (2007b). Fiber-modified 
adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber 
knob have efficient gene transfer activity. Gene Ther 14, 1160-1165. 
Kuzmin, A. I., Finegold, M. J. & Eisensmith, R. C. (1997). Macrophage depletion 
increases the safety, efficacy and persistence of adenovirus-mediated gene 
transfer in vivo. Gene Ther 4, 309-316. 
Le, L. P., Everts, M., Dmitriev, I. P., Davydova, J. G., Yamamoto, M. & Curiel, D. T. 
(2004). Fluorescently labeled adenovirus with pIX-EGFP for vector detection. 
Mol Imaging 3, 105-116. 
Le, L. P., Li, J., Ternovoi, V. V., Siegal, G. P. & Curiel, D. T. (2005). Fluorescently 
tagged canine adenovirus via modification with protein IX-enhanced green 
fluorescent protein. J Gen Virol 86, 3201-3208. 
Lechner, R. L. & Kelly, T. J., Jr. (1977). The structure of replicating adenovirus 2 DNA 
molecules. Cell 12, 1007-1020. 
Lei, N., Shen, F. B., Chang, J. H., Wang, L., Li, H., Yang, C., Li, J. & Yu, D. C. 
(2009). An oncolytic adenovirus expressing granulocyte macrophage colony-
stimulating factor shows improved specificity and efficacy for treating human 
solid tumors. Cancer Gene Ther 16, 33-43. 
Leissner, P., Legrand, V., Schlesinger, Y., Hadji, D. A., van Raaij, M., Cusack, S., 
Pavirani, A. & Mehtali, M. (2001). Influence of adenoviral fiber mutations on 
viral encapsidation, infectivity and in vivo tropism. Gene Ther 8, 49-57. 
Leopold, P. L. & Crystal, R. G. (2007). Intracellular trafficking of adenovirus: many 
means to many ends. Adv Drug Deliv Rev 59, 810-821. 
Leopold, P. L., Kreitzer, G., Miyazawa, N., Rempel, S., Pfister, K. K., Rodriguez-
Boulan, E. & Crystal, R. G. (2000). Dynein- and microtubule-mediated 
translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene 
Ther 11, 151-165. 
Li, D., Duan, L., Freimuth, P. & O'Malley, B. W., Jr. (1999a). Variability of adenovirus 
receptor density influences gene transfer efficiency and therapeutic response in 
head and neck cancer. Clin Cancer Res 5, 4175-4181. 
Li, E., Brown, S. L., Stupack, D. G., Puente, X. S., Cheresh, D. A. & Nemerow, G. 
R. (2001). Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol 75, 5405-
5409. 
Li, E., Stupack, D., Bokoch, G. M. & Nemerow, G. R. (1998a). Adenovirus 
endocytosis requires actin cytoskeleton reorganization mediated by Rho family 
GTPases. J Virol 72, 8806-8812. 
 278
Li, E., Stupack, D., Klemke, R., Cheresh, D. A. & Nemerow, G. R. (1998b). 
Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH 
kinase. J Virol 72, 2055-2061. 
Li, H. J., Everts, M., Pereboeva, L., Komarova, S., Idan, A., Curiel, D. T. & 
Herschman, H. R. (2007). Adenovirus tumor targeting and hepatic untargeting 
by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen 
bispecific adapter. Cancer Res 67, 5354-5361. 
Li, S., McGuire, M. J., Lin, M., Liu, Y. H., Oyama, T., Sun, X. & Brown, K. C. (2009). 
Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand 
for in vitro and in vivo applications. Mol Cancer Ther. 
Li, X., Yang, Y., Hu, Y., Dang, D., Regezi, J., Schmidt, B. L., Atakilit, A., Chen, B., 
Ellis, D. & Ramos, D. M. (2003). Alphavbeta6-Fyn signaling promotes oral 
cancer progression. J Biol Chem 278, 41646-41653. 
Li, Y., Pong, R. C., Bergelson, J. M., Hall, M. C., Sagalowsky, A. I., Tseng, C. P., 
Wang, Z. & Hsieh, J. T. (1999b). Loss of adenoviral receptor expression in 
human bladder cancer cells: a potential impact on the efficacy of gene therapy. 
Cancer Res 59, 325-330. 
Lichtenstein, D. L., Doronin, K., Toth, K., Kuppuswamy, M., Wold, W. S. & 
Tollefson, A. E. (2004). Adenovirus E3-6.7K protein is required in conjunction 
with the E3-RID protein complex for the internalization and degradation of 
TRAIL receptor 2. J Virol 78, 12297-12307. 
Lichtenstein, D. L., Spencer, J. F., Doronin, K., Patra, D., Meyer, J. M., Shashkova, 
E. V., Kuppuswamy, M., Dhar, D., Thomas, M. A., Tollefson, A. E., 
Zumstein, L. A., Wold, W. S. & Toth, K. (2009). An acute toxicology study with 
INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian 
hamsters; comparisons with wild-type Ad5 and a replication-defective 
adenovirus vector. Cancer Gene Ther. 
Lieber, A., He, C. Y., Meuse, L., Schowalter, D., Kirillova, I., Winther, B. & Kay, M. 
A. (1997). The role of Kupffer cell activation and viral gene expression in early 
liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71, 8798-
8807. 
Lievens, J., Snoeys, J., Vekemans, K., Van Linthout, S., de Zanger, R., Collen, D., 
Wisse, E. & De Geest, B. (2004). The size of sinusoidal fenestrae is a critical 
determinant of hepatocyte transduction after adenoviral gene transfer. Gene 
Ther 11, 1523-1531. 
Lim, B. K., Xiong, D., Dorner, A., Youn, T. J., Yung, A., Liu, T. I., Gu, Y., Dalton, N. 
D., Wright, A. T., Evans, S. M., Chen, J., Peterson, K. L., McCulloch, A. D., 
Yajima, T. & Knowlton, K. U. (2008). Coxsackievirus and adenovirus receptor 
 279
(CAR) mediates atrioventricular-node function and connexin 45 localization in 
the murine heart. J Clin Invest 118, 2758-2770. 
Lisewski, U., Shi, Y., Wrackmeyer, U., Fischer, R., Chen, C., Schirdewan, A., 
Juttner, R., Rathjen, F., Poller, W., Radke, M. H. & Gotthardt, M. (2008). The 
tight junction protein CAR regulates cardiac conduction and cell-cell 
communication. J Exp Med 205, 2369-2379. 
Liu, Q. & Muruve, D. A. (2003). Molecular basis of the inflammatory response to 
adenovirus vectors. Gene Ther 10, 935-940. 
Liu, Q., Zaiss, A. K., Colarusso, P., Patel, K., Haljan, G., Wickham, T. J. & Muruve, 
D. A. (2003). The role of capsid-endothelial interactions in the innate immune 
response to adenovirus vectors. Hum Gene Ther 14, 627-643. 
Liu, Y., Wang, H., Yumul, R., Gao, W., Gambotto, A., Morita, T., Baker, A., 
Shayakhmetov, D. & Lieber, A. (2009). Transduction of liver metastases after 
intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-
binding protein pretreatment. Hum Gene Ther 20, 621-629. 
Lord, R., Parsons, M., Kirby, I., Beavil, A., Hunt, J., Sutton, B. & Santis, G. (2006). 
Analysis of the interaction between RGD-expressing adenovirus type 5 fiber 
knob domains and alphavbeta3 integrin reveals distinct binding profiles and 
intracellular trafficking. J Gen Virol 87, 2497-2505. 
Louie, J. K., Kajon, A. E., Holodniy, M., Guardia-LaBar, L., Lee, B., Petru, A. M., 
Hacker, J. K. & Schnurr, D. P. (2008). Severe pneumonia due to adenovirus 
serotype 14: a new respiratory threat? Clin Infect Dis 46, 421-425. 
Lowe, S. W. & Ruley, H. E. (1993). Stabilization of the p53 tumor suppressor is 
induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7, 535-
545. 
Lozier, J. N., Csako, G., Mondoro, T. H., Krizek, D. M., Metzger, M. E., Costello, R., 
Vostal, J. G., Rick, M. E., Donahue, R. E. & Morgan, R. A. (2002). Toxicity of 
a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 13, 
113-124. 
Lutz, P. & Kedinger, C. (1996). Properties of the adenovirus IVa2 gene product, an 
effector of late-phase-dependent activation of the major late promoter. J Virol 
70, 1396-1405. 
Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T. & Gallagher, J. T. (1994). 
Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the 
major heparan sulfate structural determinants. J Biol Chem 269, 11216-11223. 
Lyons, M., Onion, D., Green, N. K., Aslan, K., Rajaratnam, R., Bazan-Peregrino, 
M., Phipps, S., Hale, S., Mautner, V., Seymour, L. W. & Fisher, K. D. (2006). 
 280
Adenovirus type 5 interactions with human blood cells may compromise 
systemic delivery. Mol Ther 14, 118-128. 
Ma, L. J., Yang, H., Gaspert, A., Carlesso, G., Barty, M. M., Davidson, J. M., 
Sheppard, D. & Fogo, A. B. (2003). Transforming growth factor-beta-
dependent and -independent pathways of induction of tubulointerstitial fibrosis 
in beta6(-/-) mice. Am J Pathol 163, 1261-1273. 
Magnusson, M. K., Henning, P., Myhre, S., Wikman, M., Uil, T. G., Friedman, M., 
Andersson, K. M., Hong, S. S., Hoeben, R. C., Habib, N. A., Stahl, S., 
Boulanger, P. & Lindholm, L. (2007). Adenovirus 5 vector genetically re-
targeted by an Affibody molecule with specificity for tumor antigen HER2/neu. 
Cancer Gene Ther 14, 468-479. 
Magnusson, M. K., Hong, S. S., Henning, P., Boulanger, P. & Lindholm, L. (2002). 
Genetic retargeting of adenovirus vectors: functionality of targeting ligands and 
their influence on virus viability. J Gene Med 4, 356-370. 
Maizel, J. V., Jr., White, D. O. & Scharff, M. D. (1968). The polypeptides of 
adenovirus. I. Evidence for multiple protein components in the virion and a 
comparison of types 2, 7A, and 12. Virology 36, 115-125. 
Majem, M., Cascallo, M., Bayo-Puxan, N., Mesia, R., Germa, J. R. & Alemany, R. 
(2006). Control of E1A under an E2F-1 promoter insulated with the myotonic 
dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-
Delta24RGD. Cancer Gene Ther 13, 696-705. 
Mal, A., Piotrkowski, A. & Harter, M. L. (1996). Cyclin-dependent kinases 
phosphorylate the adenovirus E1A protein, enhancing its ability to bind pRb and 
disrupt pRb-E2F complexes. J Virol 70, 2911-2921. 
Mangel, W. F., McGrath, W. J., Toledo, D. L. & Anderson, C. W. (1993). Viral DNA 
and a viral peptide can act as cofactors of adenovirus virion proteinase activity. 
Nature 361, 274-275. 
Manickan, E., Smith, J. S., Tian, J., Eggerman, T. L., Lozier, J. N., Muller, J. & 
Byrnes, A. P. (2006). Rapid Kupffer cell death after intravenous injection of 
adenovirus vectors. Mol Ther 13, 108-117. 
Maran, A. & Mathews, M. B. (1988). Characterization of the double-stranded RNA 
implicated in the inhibition of protein synthesis in cells infected with a mutant 
adenovirus defective for VA RNA. Virology 164, 106-113. 
Marsh, D., Dickinson, S., Neill, G. W., Marshall, J. F., Hart, I. R. & Thomas, G. J. 
(2008). alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell 
carcinoma through stromal modulation. Cancer Res 68, 3295-3303. 
 281
Martin, K., Brie, A., Saulnier, P., Perricaudet, M., Yeh, P. & Vigne, E. (2003). 
Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 
liver tropism. Mol Ther 8, 485-494. 
Massague, J., Cheifetz, S., Laiho, M., Ralph, D. A., Weis, F. M. & Zentella, A. 
(1992). Transforming growth factor-beta. Cancer Surv 12, 81-103. 
Mathis, J. M., Stoff-Khalili, M. A. & Curiel, D. T. (2005). Oncolytic adenoviruses - 
selective retargeting to tumor cells. Oncogene 24, 7775-7791. 
Matsumoto, K., Shariat, S. F., Ayala, G. E., Rauen, K. A. & Lerner, S. P. (2005). 
Loss of coxsackie and adenovirus receptor expression is associated with 
features of aggressive bladder cancer. Urology 66, 441-446. 
Mautner, V. & Pereira, H. G. (1971). Crystallization of a second adenovirus protein 
(the fibre). Nature 230, 456-457. 
McCartney-Francis, N. L. & Wahl, S. M. (1994). Transforming growth factor beta: a 
matter of life and death. J Leukoc Biol 55, 401-409. 
McCarty, J. H., Cook, A. A. & Hynes, R. O. (2005). An interaction between 
{alpha}v{beta}8 integrin and Band 4.1B via a highly conserved region of the 
Band 4.1 C-terminal domain. Proc Natl Acad Sci U S A 102, 13479-13483. 
McConnell, M. J., Danthinne, X. & Imperiale, M. J. (2006). Characterization of a 
permissive epitope insertion site in adenovirus hexon. J Virol 80, 5361-5370. 
McDonald, D., Stockwin, L., Matzow, T., Blair Zajdel, M. E. & Blair, G. E. (1999). 
Coxsackie and adenovirus receptor (CAR)-dependent and major 
histocompatibility complex (MHC) class I-independent uptake of recombinant 
adenoviruses into human tumour cells. Gene Ther 6, 1512-1519. 
McNeish, I. A., Tenev, T., Bell, S., Marani, M., Vassaux, G. & Lemoine, N. (2001). 
Herpes simplex virus thymidine kinase/ganciclovir-induced cell death is 
enhanced by co-expression of caspase-3 in ovarian carcinoma cells. Cancer 
Gene Ther 8, 308-319. 
Meier, O., Boucke, K., Hammer, S. V., Keller, S., Stidwill, R. P., Hemmi, S. & 
Greber, U. F. (2002). Adenovirus triggers macropinocytosis and endosomal 
leakage together with its clathrin-mediated uptake. J Cell Biol 158, 1119-1131. 
Meier, O. & Greber, U. F. (2003). Adenovirus endocytosis. J Gene Med 5, 451-462. 
Merron, A., Peerlinck, I., Martin-Duque, P., Burnet, J., Quintanilla, M., Mather, S., 
Hingorani, M., Harrington, K., Iggo, R. & Vassaux, G. (2007). SPECT/CT 
imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I 
symporter as a reporter gene. Gene Ther 14, 1731-1738. 
Meulenbroek, R. A., Sargent, K. L., Lunde, J., Jasmin, B. J. & Parks, R. J. (2004). 
Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--
 282
generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 
9, 617-624. 
Michael, S. I., Hong, J. S., Curiel, D. T. & Engler, J. A. (1995). Addition of a short 
peptide ligand to the adenovirus fiber protein. Gene Ther 2, 660-668. 
Mikami, T., Ookawa, K., Shimoyama, T., Fukuda, S., Saito, H. & Munakata, A. 
(2001). KAI1, CAR, and Smad4 expression in the progression of colorectal 
tumor. J Gastroenterol 36, 465-469. 
Miller, C. R., Buchsbaum, D. J., Reynolds, P. N., Douglas, J. T., Gillespie, G. Y., 
Mayo, M. S., Raben, D. & Curiel, D. T. (1998). Differential susceptibility of 
primary and established human glioma cells to adenovirus infection: targeting 
via the epidermal growth factor receptor achieves fiber receptor-independent 
gene transfer. Cancer Res 58, 5738-5748. 
Mistchenko, A. S., Diez, R. A., Mariani, A. L., Robaldo, J., Maffey, A. F., Bayley-
Bustamante, G. & Grinstein, S. (1994). Cytokines in adenoviral disease in 
children: association of interleukin-6, interleukin-8, and tumor necrosis factor 
alpha levels with clinical outcome. J Pediatr 124, 714-720. 
Mittal, S. K., McDermott, M. R., Johnson, D. C., Prevec, L. & Graham, F. L. (1993). 
Monitoring foreign gene expression by a human adenovirus-based vector using 
the firefly luciferase gene as a reporter. Virus Res 28, 67-90. 
Miyazawa, N., Crystal, R. G. & Leopold, P. L. (2001). Adenovirus serotype 7 
retention in a late endosomal compartment prior to cytosol escape is modulated 
by fiber protein. J Virol 75, 1387-1400. 
Miyazawa, N., Leopold, P. L., Hackett, N. R., Ferris, B., Worgall, S., Falck-
Pedersen, E. & Crystal, R. G. (1999). Fiber swap between adenovirus 
subgroups B and C alters intracellular trafficking of adenovirus gene transfer 
vectors. J Virol 73, 6056-6065. 
Mizuguchi, H., Koizumi, N., Hosono, T., Ishii-Watabe, A., Uchida, E., Utoguchi, N., 
Watanabe, Y. & Hayakawa, T. (2002). CAR- or alphav integrin-binding ablated 
adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do 
not change the systemic gene transfer properties in mice. Gene Ther 9, 769-
776. 
Moran, E., Zerler, B., Harrison, T. M. & Mathews, M. B. (1986). Identification of 
separate domains in the adenovirus E1A gene for immortalization activity and 
the activation of virus early genes. Mol Cell Biol 6, 3470-3480. 
Morgan, M. R., Thomas, G. J., Russell, A., Hart, I. R. & Marshall, J. F. (2004). The 
integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor 
cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol 
Chem 279, 26533-26539. 
 283
Morgenstern, J. P. & Land, H. (1990). Advanced mammalian gene transfer: high titre 
retroviral vectors with multiple drug selection markers and a complementary 
helper-free packaging cell line. Nucleic Acids Res 18, 3587-3596. 
Morris, D. G., Huang, X., Kaminski, N., Wang, Y., Shapiro, S. D., Dolganov, G., 
Glick, A. & Sheppard, D. (2003). Loss of integrin alpha(v)beta6-mediated 
TGF-beta activation causes Mmp12-dependent emphysema. Nature 422, 169-
173. 
Morrison, J., Briggs, S. S., Green, N., Fisher, K., Subr, V., Ulbrich, K., Kehoe, S. & 
Seymour, L. W. (2008). Virotherapy of ovarian cancer with polymer-cloaked 
adenovirus retargeted to the epidermal growth factor receptor. Mol Ther 16, 
244-251. 
Mu, D., Cambier, S., Fjellbirkeland, L., Baron, J. L., Munger, J. S., Kawakatsu, H., 
Sheppard, D., Broaddus, V. C. & Nishimura, S. L. (2002). The integrin 
alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent 
activation of TGF-beta1. J Cell Biol 157, 493-507. 
Mul, Y. M., Verrijzer, C. P. & van der Vliet, P. C. (1990). Transcription factors NFI and 
NFIII/oct-1 function independently, employing different mechanisms to enhance 
adenovirus DNA replication. J Virol 64, 5510-5518. 
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J., Dalton, S. L., Wu, J., 
Pittet, J. F., Kaminski, N., Garat, C., Matthay, M. A., Rifkin, D. B. & 
Sheppard, D. (1999). The integrin alpha v beta 6 binds and activates latent 
TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. 
Cell 96, 319-328. 
Munoz, V. & Serrano, L. (1997). Development of the multiple sequence approximation 
within the AGADIR model of alpha-helix formation: comparison with Zimm-
Bragg and Lifson-Roig formalisms. Biopolymers 41, 495-509. 
Murata, K. & Sakamoto, A. (2008). Impairment of clathrin-mediated endocytosis via 
cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a 
possible mechanism of des-gamma-carboxy prothrombin production in 
hepatocellular carcinoma. Int J Oncol 33, 1149-1155. 
Muruve, D. A., Barnes, M. J., Stillman, I. E. & Libermann, T. A. (1999). Adenoviral 
gene therapy leads to rapid induction of multiple chemokines and acute 
neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10, 965-976. 
Muruve, D. A., Cotter, M. J., Zaiss, A. K., White, L. R., Liu, Q., Chan, T., Clark, S. 
A., Ross, P. J., Meulenbroek, R. A., Maelandsmo, G. M. & Parks, R. J. 
(2004). Helper-dependent adenovirus vectors elicit intact innate but attenuated 
adaptive host immune responses in vivo. J Virol 78, 5966-5972. 
 284
Muruve, D. A., Petrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., Parks, 
R. J. & Tschopp, J. (2008). The inflammasome recognizes cytosolic microbial 
and host DNA and triggers an innate immune response. Nature 452, 103-107. 
Myhre, S., Henning, P., Friedman, M., Stahl, S., Lindholm, L. & Magnusson, M. K. 
(2009). Re-targeted adenovirus vectors with dual specificity; binding 
specificities conferred by two different Affibody molecules in the fiber. Gene 
Ther 16, 252-261. 
Nagai, K., Arai, H., Yanagita, M., Matsubara, T., Kanamori, H., Nakano, T., Iehara, 
N., Fukatsu, A., Kita, T. & Doi, T. (2003). Growth arrest-specific gene 6 is 
involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J 
Biol Chem 278, 18229-18234. 
Nagata, K., Guggenheimer, R. A. & Hurwitz, J. (1983). Specific binding of a cellular 
DNA replication protein to the origin of replication of adenovirus DNA. Proc Natl 
Acad Sci U S A 80, 6177-6181. 
Nagel, H., Maag, S., Tassis, A., Nestle, F. O., Greber, U. F. & Hemmi, S. (2003). The 
alphavbeta5 integrin of hematopoietic and nonhematopoietic cells is a 
transduction receptor of RGD-4C fiber-modified adenoviruses. Gene Ther 10, 
1643-1653. 
Nakamura, T., Sato, K. & Hamada, H. (2003). Reduction of natural adenovirus 
tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus 
receptor interaction and use of replaceable short fiber. J Virol 77, 2512-2521. 
Nakayama, M., Both, G. W., Banizs, B., Tsuruta, Y., Yamamoto, S., Kawakami, Y., 
Douglas, J. T., Tani, K., Curiel, D. T. & Glasgow, J. N. (2006). An adenovirus 
serotype 5 vector with fibers derived from ovine atadenovirus demonstrates 
CAR-independent tropism and unique biodistribution in mice. Virology 350, 103-
115. 
Nettelbeck, D. M., Miller, D. W., Jerome, V., Zuzarte, M., Watkins, S. J., Hawkins, 
R. E., Muller, R. & Kontermann, R. E. (2001). Targeting of adenovirus to 
endothelial cells by a bispecific single-chain diabody directed against the 
adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 3, 882-
891. 
Ni, S., Bernt, K., Gaggar, A., Li, Z. Y., Kiem, H. P. & Lieber, A. (2005). Evaluation of 
biodistribution and safety of adenovirus vectors containing group B fibers after 
intravenous injection into baboons. Hum Gene Ther 16, 664-677. 
Nicklin, S. A. & Baker, A. H. (2008). Efficient vascular endothelial gene transfer 
following intravenous adenovirus delivery. Mol Ther 16, 1904-1905. 
Nicklin, S. A., Von Seggern, D. J., Work, L. M., Pek, D. C., Dominiczak, A. F., 
Nemerow, G. R. & Baker, A. H. (2001). Ablating adenovirus type 5 fiber-CAR 
 285
binding and HI loop insertion of the SIGYPLP peptide generate an endothelial 
cell-selective adenovirus. Mol Ther 4, 534-542. 
Nicklin, S. A., White, S. J., Nicol, C. G., Von Seggern, D. J. & Baker, A. H. (2004). 
In vitro and in vivo characterisation of endothelial cell selective adenoviral 
vectors. J Gene Med 6, 300-308. 
Nicklin, S. A., White, S. J., Watkins, S. J., Hawkins, R. E. & Baker, A. H. (2000). 
Selective targeting of gene transfer to vascular endothelial cells by use of 
peptides isolated by phage display. Circulation 102, 231-237. 
Nicklin, S. A., Wu, E., Nemerow, G. R. & Baker, A. H. (2005). The influence of 
adenovirus fiber structure and function on vector development for gene therapy. 
Mol Ther 12, 384-393. 
Nicol, C. G., Graham, D., Miller, W. H., White, S. J., Smith, T. A., Nicklin, S. A., 
Stevenson, S. C. & Baker, A. H. (2004). Effect of adenovirus serotype 5 fiber 
and penton modifications on in vivo tropism in rats. Mol Ther 10, 344-354. 
Nishimura, S. L., Boylen, K. P., Einheber, S., Milner, T. A., Ramos, D. M. & Pytela, 
R. (1998). Synaptic and glial localization of the integrin alphavbeta8 in mouse 
and rat brain. Brain Res 791, 271-282. 
Niu, J., Dorahy, D. J., Gu, X., Scott, R. J., Draganic, B., Ahmed, N. & Agrez, M. V. 
(2002). Integrin expression in colon cancer cells is regulated by the cytoplasmic 
domain of the beta6 integrin subunit. Int J Cancer 99, 529-537. 
Novelli, A. & Boulanger, P. A. (1991). Deletion analysis of functional domains in 
baculovirus-expressed adenovirus type 2 fiber. Virology 185, 365-376. 
Nystrom, M. L., McCulloch, D., Weinreb, P. H., Violette, S. M., Speight, P. M., 
Marshall, J. F., Hart, I. R. & Thomas, G. J. (2006). Cyclooxygenase-2 
inhibition suppresses alphavbeta6 integrin-dependent oral squamous 
carcinoma invasion. Cancer Res 66, 10833-10842. 
O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, 
A. E. & Francis, G. E. (1999). PEGylation of adenovirus with retention of 
infectivity and protection from neutralizing antibody in vitro and in vivo. Hum 
Gene Ther 10, 1349-1358. 
O'Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., 
Pandey, K., Soria, C., Kunich, J., Shen, Y., Habets, G., Ginzinger, D. & 
McCormick, F. (2004). Late viral RNA export, rather than p53 inactivation, 
determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623. 
Onion, D., Crompton, L. J., Milligan, D. W., Moss, P. A., Lee, S. P. & Mautner, V. 
(2007). The CD4+ T-cell response to adenovirus is focused against conserved 
residues within the hexon protein. J Gen Virol 88, 2417-2425. 
 286
Ono, H. A., Le, L. P., Davydova, J. G., Gavrikova, T. & Yamamoto, M. (2005). 
Noninvasive visualization of adenovirus replication with a fluorescent reporter in 
the E3 region. Cancer Res 65, 10154-10158. 
Othman, M., Labelle, A., Mazzetti, I., Elbatarny, H. S. & Lillicrap, D. (2007). 
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-
selectin in mediating accelerated platelet clearance. Blood 109, 2832-2839. 
Pameijer, C. R., Navanjo, A., Meechoovet, B., Wagner, J. R., Aguilar, B., Wright, C. 
L., Chang, W. C., Brown, C. E. & Jensen, M. C. (2007). Conversion of a 
tumor-binding peptide identified by phage display to a functional chimeric T cell 
antigen receptor. Cancer Gene Ther 14, 91-97. 
Pang, S., Dannull, J., Kaboo, R., Xie, Y., Tso, C. L., Michel, K., deKernion, J. B. & 
Belldegrun, A. S. (1997). Identification of a positive regulatory element 
responsible for tissue-specific expression of prostate-specific antigen. Cancer 
Res 57, 495-499. 
Parker, A. L., McVey, J. H., Doctor, J. H., Lopez-Franco, O., Waddington, S. N., 
Havenga, M. J., Nicklin, S. A. & Baker, A. H. (2007). Influence of coagulation 
factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from 
subgroup D. J Virol 81, 3627-3631. 
Parker, A. L., Waddington, S. N., Buckley, S. M., Custers, J., Havenga, M. J., van 
Rooijen, N., Goudsmit, J., McVey, J. H., Nicklin, S. A. & Baker, A. H. (2009). 
Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene 
transfer. J Virol 83, 479-483. 
Parker, A. L., Waddington, S. N., Nicol, C. G., Shayakhmetov, D. M., Buckley, S. 
M., Denby, L., Kemball-Cook, G., Ni, S., Lieber, A., McVey, J. H., Nicklin, S. 
A. & Baker, A. H. (2006). Multiple vitamin K-dependent coagulation zymogens 
promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-
2561. 
Parks, C. L. & Shenk, T. (1997). Activation of the adenovirus major late promoter by 
transcription factors MAZ and Sp1. J Virol 71, 9600-9607. 
Pasquinucci, G. (1971). Possible effect of measles on leukaemia. Lancet 1, 136. 
Peerlinck, I., Amini-Nik, S., Phillips, R. K., Iggo, R., Lemoine, N. R., Tejpar, S. & 
Vassaux, G. (2008). Therapeutic potential of replication-selective oncolytic 
adenoviruses on cells from familial and sporadic desmoid tumors. Clin Cancer 
Res 14, 6187-6192. 
Pelner, L., Fowler, G. A. & Nauts, H. C. (1958). Effects of concurrent infections and 
their toxins on the course of leukemia. Acta Med Scand Suppl 338, 1-47. 
Peng, Z. (2005). Current status of gendicine in China: recombinant human Ad-p53 
agent for treatment of cancers. Hum Gene Ther 16, 1016-1027. 
 287
Pereboev, A. V., Asiedu, C. K., Kawakami, Y., Dong, S. S., Blackwell, J. L., 
Kashentseva, E. A., Triozzi, P. L., Aldrich, W. A., Curiel, D. T., Thomas, J. 
M. & Dmitriev, I. P. (2002). Coxsackievirus-adenovirus receptor genetically 
fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic 
cells. Gene Ther 9, 1189-1193. 
Perez-Romero, P., Gustin, K. E. & Imperiale, M. J. (2006). Dependence of the 
encapsidation function of the adenovirus L1 52/55-kilodalton protein on its 
ability to bind the packaging sequence. J Virol 80, 1965-1971. 
Post, D. E., Sandberg, E. M., Kyle, M. M., Devi, N. S., Brat, D. J., Xu, Z., Tighiouart, 
M. & Van Meir, E. G. (2007). Targeted cancer gene therapy using a hypoxia 
inducible factor dependent oncolytic adenovirus armed with interleukin-4. 
Cancer Res 67, 6872-6881. 
Post, D. E. & Van Meir, E. G. (2003). A novel hypoxia-inducible factor (HIF) activated 
oncolytic adenovirus for cancer therapy. Oncogene 22, 2065-2072. 
Pouyssegur, J., Dayan, F. & Mazure, N. M. (2006). Hypoxia signalling in cancer and 
approaches to enforce tumour regression. Nature 441, 437-443. 
Prime, S. S., Davies, M., Pring, M. & Paterson, I. C. (2004a). The role of TGF-beta in 
epithelial malignancy and its relevance to the pathogenesis of oral cancer (part 
II). Crit Rev Oral Biol Med 15, 337-347. 
Prime, S. S., Pring, M., Davies, M. & Paterson, I. C. (2004b). TGF-beta signal 
transduction in oro-facial health and non-malignant disease (part I). Crit Rev 
Oral Biol Med 15, 324-336. 
Prudencio, M., Rodriguez, A. & Mota, M. M. (2006). The silent path to thousands of 
merozoites: the Plasmodium liver stage. Nat Rev Microbiol 4, 849-856. 
Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., 
Devitt, M. L., Horan, G. S., Weinreb, P. H., Lukashev, M. E., Violette, S. M., 
Grant, K. S., Colarossi, C., Formenti, S. C. & Munger, J. S. (2008). Inhibition 
of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, 
prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 177, 82-90. 
Querido, E., Blanchette, P., Yan, Q., Kamura, T., Morrison, M., Boivin, D., Kaelin, 
W. G., Conaway, R. C., Conaway, J. W. & Branton, P. E. (2001a). 
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a 
novel mechanism involving a Cullin-containing complex. Genes Dev 15, 3104-
3117. 
Querido, E., Marcellus, R. C., Lai, A., Charbonneau, R., Teodoro, J. G., Ketner, G. 
& Branton, P. E. (1997). Regulation of p53 levels by the E1B 55-kilodalton 
protein and E4orf6 in adenovirus-infected cells. J Virol 71, 3788-3798. 
 288
Querido, E., Morrison, M. R., Chu-Pham-Dang, H., Thirlwell, S. W., Boivin, D. & 
Branton, P. E. (2001b). Identification of three functions of the adenovirus 
e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J 
Virol 75, 699-709. 
Ramos, D. M., But, M., Regezi, J., Schmidt, B. L., Atakilit, A., Dang, D., Ellis, D., 
Jordan, R. & Li, X. (2002). Expression of integrin beta 6 enhances invasive 
behavior in oral squamous cell carcinoma. Matrix Biol 21, 297-307. 
Ramsay, A. G., Keppler, M. D., Jazayeri, M., Thomas, G. J., Parsons, M., Violette, 
S., Weinreb, P., Hart, I. R. & Marshall, J. F. (2007). HS1-associated protein X-
1 regulates carcinoma cell migration and invasion via clathrin-mediated 
endocytosis of integrin alphavbeta6. Cancer Res 67, 5275-5284. 
Rancourt, C., Tihanyi, K., Bourbonniere, M. & Weber, J. M. (1994). Identification of 
active-site residues of the adenovirus endopeptidase. Proc Natl Acad Sci U S A 
91, 844-847. 
Ranki, T., Kanerva, A., Ristimaki, A., Hakkarainen, T., Sarkioja, M., Kangasniemi, 
L., Raki, M., Laakkonen, P., Goodison, S. & Hemminki, A. (2007). A heparan 
sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the 
treatment of advanced breast cancer. Gene Ther 14, 58-67. 
Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S. & White, E. 
(1992). The adenovirus E1A proteins induce apoptosis, which is inhibited by the 
E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci U S A 89, 7742-7746. 
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G. P., Wilson, J. 
M. & Batshaw, M. L. (2003). Fatal systemic inflammatory response syndrome 
in a ornithine transcarbamylase deficient patient following adenoviral gene 
transfer. Mol Genet Metab 80, 148-158. 
Raper, S. E., Yudkoff, M., Chirmule, N., Gao, G. P., Nunes, F., Haskal, Z. J., Furth, 
E. E., Propert, K. J., Robinson, M. B., Magosin, S., Simoes, H., Speicher, L., 
Hughes, J., Tazelaar, J., Wivel, N. A., Wilson, J. M. & Batshaw, M. L. (2002). 
A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in 
partial ornithine transcarbamylase deficiency. Hum Gene Ther 13, 163-175. 
Rauen, K. A., Sudilovsky, D., Le, J. L., Chew, K. L., Hann, B., Weinberg, V., 
Schmitt, L. D. & McCormick, F. (2002). Expression of the coxsackie 
adenovirus receptor in normal prostate and in primary and metastatic prostate 
carcinoma: potential relevance to gene therapy. Cancer Res 62, 3812-3818. 
Rea, D., Havenga, M. J., van Den Assem, M., Sutmuller, R. P., Lemckert, A., 
Hoeben, R. C., Bout, A., Melief, C. J. & Offringa, R. (2001). Highly efficient 
transduction of human monocyte-derived dendritic cells with subgroup B fiber-
 289
modified adenovirus vectors enhances transgene-encoded antigen presentation 
to cytotoxic T cells. J Immunol 166, 5236-5244. 
Regezi, J. A., Ramos, D. M., Pytela, R., Dekker, N. P. & Jordan, R. C. (2002). 
Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ 
carcinomas and invasive squamous cell carcinomas. Oral Oncol 38, 332-336. 
Regulier, E., Paul, S., Marigliano, M., Kintz, J., Poitevin, Y., Ledoux, C., Roecklin, 
D., Cauet, G., Calenda, V. & Homann, H. E. (2001). Adenovirus-mediated 
delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther 
8, 45-54. 
Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., 
Rubin, J. & Kirn, D. (2001). Intra-arterial administration of a replication-
selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to 
the liver: a phase I trial. Gene Ther 8, 1618-1626. 
Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L. M., Andrews, J., Randlev, 
B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J. & Kirn, D. 
(2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus 
(dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62, 
6070-6079. 
Rein, D. T., Breidenbach, M., Wu, H., Han, T., Haviv, Y. S., Wang, M., Kirby, T. O., 
Kawakami, Y., Dall, P., Alvarez, R. D. & Curiel, D. T. (2004). Gene transfer to 
cervical cancer with fiber-modified adenoviruses. Int J Cancer 111, 698-704. 
Rekosh, D. M., Russell, W. C., Bellet, A. J. & Robinson, A. J. (1977). Identification 
of a protein linked to the ends of adenovirus DNA. Cell 11, 283-295. 
Reynolds, P., Dmitriev, I. & Curiel, D. (1999). Insertion of an RGD motif into the HI 
loop of adenovirus fiber protein alters the distribution of transgene expression of 
the systemically administered vector. Gene Ther 6, 1336-1339. 
Reynolds, P. N., Zinn, K. R., Gavrilyuk, V. D., Balyasnikova, I. V., Rogers, B. E., 
Buchsbaum, D. J., Wang, M. H., Miletich, D. J., Grizzle, W. E., Douglas, J. 
T., Danilov, S. M. & Curiel, D. T. (2000). A targetable, injectable adenoviral 
vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2, 
562-578. 
Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., 
Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., Lifton, M. A., 
Lemckert, A. A., Holterman, L., Chen, B., Dilraj, A., Carville, A., Mansfield, 
K. G., Goudsmit, J. & Barouch, D. H. (2006). Hexon-chimaeric adenovirus 
serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 
239-243. 
 290
Robinson, A. J., Younghusband, H. B. & Bellett, A. J. (1973). A circula DNA-protein 
complex from adenoviruses. Virology 56, 54-69. 
Roelvink, P. W., Lizonova, A., Lee, J. G., Li, Y., Bergelson, J. M., Finberg, R. W., 
Brough, D. E., Kovesdi, I. & Wickham, T. J. (1998). The coxsackievirus-
adenovirus receptor protein can function as a cellular attachment protein for 
adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72, 7909-7915. 
Roelvink, P. W., Mi Lee, G., Einfeld, D. A., Kovesdi, I. & Wickham, T. J. (1999). 
Identification of a conserved receptor-binding site on the fiber proteins of CAR-
recognizing adenoviridae. Science 286, 1568-1571. 
Rosen, L. (1960). A hemagglutination-inhibition technique for typing adenoviruses. Am 
J Hyg 71, 120-128. 
Rowe, W. P., Huebner, R. J., Gilmore, L. K., Parrott, R. H. & Ward, T. G. (1953). 
Isolation of a cytopathogenic agent from human adenoids undergoing 
spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84, 570-
573. 
Rudin, C. M., Cohen, E. E., Papadimitrakopoulou, V. A., Silverman, S., Jr., Recant, 
W., El-Naggar, A. K., Stenson, K., Lippman, S. M., Hong, W. K. & Vokes, E. 
E. (2003). An attenuated adenovirus, ONYX-015, as mouthwash therapy for 
premalignant oral dysplasia. J Clin Oncol 21, 4546-4552. 
Russell, W. C. (2000). Update on adenovirus and its vectors. J Gen Virol 81, 2573-
2604. 
Russell, W. C. (2009). Adenoviruses: update on structure and function. J Gen Virol 90, 
1-20. 
Ruzindana-Umunyana, A., Imbeault, L. & Weber, J. M. (2002). Substrate specificity 
of adenovirus protease. Virus Res 89, 41-52. 
Sachs, M. D., Rauen, K. A., Ramamurthy, M., Dodson, J. L., De Marzo, A. M., 
Putzi, M. J., Schoenberg, M. P. & Rodriguez, R. (2002). Integrin alpha(v) and 
coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 
60, 531-536. 
Sakurai, F., Mizuguchi, H., Yamaguchi, T. & Hayakawa, T. (2003). Characterization 
of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. 
Mol Ther 8, 813-821. 
Sakurai, F., Nakamura, S., Akitomo, K., Shibata, H., Terao, K., Kawabata, K., 
Hayakawa, T. & Mizuguchi, H. (2008). Transduction properties of adenovirus 
serotype 35 vectors after intravenous administration into nonhuman primates. 
Mol Ther 16, 726-733. 
 291
Salone, B., Martina, Y., Piersanti, S., Cundari, E., Cherubini, G., Franqueville, L., 
Failla, C. M., Boulanger, P. & Saggio, I. (2003). Integrin alpha3beta1 is an 
alternative cellular receptor for adenovirus serotype 5. J Virol 77, 13448-13454. 
Santis, G., Legrand, V., Hong, S. S., Davison, E., Kirby, I., Imler, J. L., Finberg, R. 
W., Bergelson, J. M., Mehtali, M. & Boulanger, P. (1999). Molecular 
determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. 
J Gen Virol 80 ( Pt 6), 1519-1527. 
Sarnow, P., Hearing, P., Anderson, C. W., Halbert, D. N., Shenk, T. & Levine, A. J. 
(1984). Adenovirus early region 1B 58,000-dalton tumor antigen is physically 
associated with an early region 4 25,000-dalton protein in productively infected 
cells. J Virol 49, 692-700. 
Sasisekharan, R., Shriver, Z., Venkataraman, G. & Narayanasami, U. (2002). Roles 
of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2, 521-
528. 
Schiedner, G., Bloch, W., Hertel, S., Johnston, M., Molojavyi, A., Dries, V., Varga, 
G., Van Rooijen, N. & Kochanek, S. (2003a). A hemodynamic response to 
intravenous adenovirus vector particles is caused by systemic Kupffer cell-
mediated activation of endothelial cells. Hum Gene Ther 14, 1631-1641. 
Schiedner, G., Hertel, S., Johnston, M., Dries, V., van Rooijen, N. & Kochanek, S. 
(2003b). Selective depletion or blockade of Kupffer cells leads to enhanced and 
prolonged hepatic transgene expression using high-capacity adenoviral vectors. 
Mol Ther 7, 35-43. 
Schnell, M. A., Zhang, Y., Tazelaar, J., Gao, G. P., Yu, Q. C., Qian, R., Chen, S. J., 
Varnavski, A. N., LeClair, C., Raper, S. E. & Wilson, J. M. (2001). Activation 
of innate immunity in nonhuman primates following intraportal administration of 
adenoviral vectors. Mol Ther 3, 708-722. 
Schoggins, J. W., Nociari, M., Philpott, N. & Falck-Pedersen, E. (2005). Influence of 
fiber detargeting on adenovirus-mediated innate and adaptive immune 
activation. J Virol 79, 11627-11637. 
Schultz-Cherry, S. & Hinshaw, V. S. (1996). Influenza virus neuraminidase activates 
latent transforming growth factor beta. J Virol 70, 8624-8629. 
Scott, K. A., Arnott, C. H., Robinson, S. C., Moore, R. J., Thompson, R. G., 
Marshall, J. F. & Balkwill, F. R. (2004). TNF-alpha regulates epithelial 
expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role 
for TNF-alpha in keratinocyte migration? Oncogene 23, 6954-6966. 
Segerman, A., Atkinson, J. P., Marttila, M., Dennerquist, V., Wadell, G. & Arnberg, 
N. (2003). Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77, 
9183-9191. 
 292
Seiradake, E., Henaff, D., Wodrich, H., Billet, O., Perreau, M., Hippert, C., 
Mennechet, F., Schoehn, G., Lortat-Jacob, H., Dreja, H., Ibanes, S., 
Kalatzis, V., Wang, J. P., Finberg, R. W., Cusack, S. & Kremer, E. J. (2009). 
The cell adhesion molecule "CAR" and sialic acid on human erythrocytes 
influence adenovirus in vivo biodistribution. PLoS Pathog 5, e1000277. 
Seshidhar Reddy, P., Ganesh, S., Limbach, M. P., Brann, T., Pinkstaff, A., Kaloss, 
M., Kaleko, M. & Connelly, S. (2003). Development of adenovirus serotype 35 
as a gene transfer vector. Virology 311, 384-393. 
Sharma, K. & Ziyadeh, F. N. (1994). The emerging role of transforming growth factor-
beta in kidney diseases. Am J Physiol 266, F829-842. 
Shashkova, E. V., Doronin, K., Senac, J. S. & Barry, M. A. (2008). Macrophage 
depletion combined with anticoagulant therapy increases therapeutic window of 
systemic treatment with oncolytic adenovirus. Cancer Res 68, 5896-5904. 
Shashkova, E. V., May, S. M., Doronin, K. & Barry, M. A. (2009). Expanded 
Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus. Mol 
Ther. 
Shaw, C. A., Holland, P. C., Sinnreich, M., Allen, C., Sollerbrant, K., Karpati, G. & 
Nalbantoglu, J. (2004). Isoform-specific expression of the Coxsackie and 
adenovirus receptor (CAR) in neuromuscular junction and cardiac intercalated 
discs. BMC Cell Biol 5, 42. 
Shayakhmetov, D. M., Carlson, C. A., Stecher, H., Li, Q., Stamatoyannopoulos, G. 
& Lieber, A. (2002). A high-capacity, capsid-modified hybrid adenovirus/adeno-
associated virus vector for stable transduction of human hematopoietic cells. J 
Virol 76, 1135-1143. 
Shayakhmetov, D. M., Eberly, A. M., Li, Z. Y. & Lieber, A. (2005a). Deletion of 
penton RGD motifs affects the efficiency of both the internalization and the 
endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber 
knobs. J Virol 79, 1053-1061. 
Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z. Y. & Lieber, A. (2005b). Adenovirus 
binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 
79, 7478-7491. 
Shayakhmetov, D. M., Li, Z. Y., Gaggar, A., Gharwan, H., Ternovoi, V., Sandig, V. 
& Lieber, A. (2004a). Genome size and structure determine efficiency of 
postinternalization steps and gene transfer of capsid-modified adenovirus 
vectors in a cell-type-specific manner. J Virol 78, 10009-10022. 
Shayakhmetov, D. M., Li, Z. Y., Ni, S. & Lieber, A. (2004b). Analysis of adenovirus 
sequestration in the liver, transduction of hepatic cells, and innate toxicity after 
injection of fiber-modified vectors. J Virol 78, 5368-5381. 
 293
Shayakhmetov, D. M., Li, Z. Y., Ni, S. & Lieber, A. (2005c). Interference with the IL-
1-signaling pathway improves the toxicity profile of systemically applied 
adenovirus vectors. J Immunol 174, 7310-7319. 
Shayakhmetov, D. M., Li, Z. Y., Ternovoi, V., Gaggar, A., Gharwan, H. & Lieber, A. 
(2003). The interaction between the fiber knob domain and the cellular 
attachment receptor determines the intracellular trafficking route of 
adenoviruses. J Virol 77, 3712-3723. 
Sherr, C. J. & McCormick, F. (2002). The RB and p53 pathways in cancer. Cancer 
Cell 2, 103-112. 
Shinozaki, K., Suominen, E., Carrick, F., Sauter, B., Kahari, V. M., Lieber, A., Woo, 
S. L. & Savontaus, M. (2006). Efficient infection of tumor endothelial cells by a 
capsid-modified adenovirus. Gene Ther 13, 52-59. 
Silvestry, M., Lindert, S., Smith, J. G., Maier, O., Wiethoff, C. M., Nemerow, G. R. & 
Stewart, P. L. (2009). Cryo-electron microscopy structure of adenovirus type 2 
temperature-sensitive mutant 1 reveals insight into the cell entry defect. J Virol 
83, 7375-7383. 
Sipos, B., Hahn, D., Carceller, A., Piulats, J., Hedderich, J., Kalthoff, H., 
Goodman, S. L., Kosmahl, M. & Kloppel, G. (2004). Immunohistochemical 
screening for beta6-integrin subunit expression in adenocarcinomas using a 
novel monoclonal antibody reveals strong up-regulation in pancreatic ductal 
adenocarcinomas in vivo and in vitro. Histopathology 45, 226-236. 
Smith, T., Idamakanti, N., Kylefjord, H., Rollence, M., King, L., Kaloss, M., Kaleko, 
M. & Stevenson, S. C. (2002). In vivo hepatic adenoviral gene delivery occurs 
independently of the coxsackievirus-adenovirus receptor. Mol Ther 5, 770-779. 
Smith, T. A., Idamakanti, N., Marshall-Neff, J., Rollence, M. L., Wright, P., Kaloss, 
M., King, L., Mech, C., Dinges, L., Iverson, W. O., Sherer, A. D., Markovits, 
J. E., Lyons, R. M., Kaleko, M. & Stevenson, S. C. (2003a). Receptor 
interactions involved in adenoviral-mediated gene delivery after systemic 
administration in non-human primates. Hum Gene Ther 14, 1595-1604. 
Smith, T. A., Idamakanti, N., Rollence, M. L., Marshall-Neff, J., Kim, J., Mulgrew, 
K., Nemerow, G. R., Kaleko, M. & Stevenson, S. C. (2003b). Adenovirus 
serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 
14, 777-787. 
Smith, T. A., White, B. D., Gardner, J. M., Kaleko, M. & McClelland, A. (1996). 
Transient immunosuppression permits successful repetitive intravenous 
administration of an adenovirus vector. Gene Ther 3, 496-502. 
 294
Smythe, W. R., LeBel, E., Bavaria, J. E., Kaiser, L. R. & Albelda, S. M. (1995). 
Integrin expression in non-small cell carcinoma of the lung. Cancer Metastasis 
Rev 14, 229-239. 
Song, W., Sun, Q., Dong, Z., Spencer, D. M., Nunez, G. & Nor, J. E. (2005). 
Antiangiogenic gene therapy: disruption of neovascular networks mediated by 
inducible caspase-9 delivered with a transcriptionally targeted adenoviral 
vector. Gene Ther 12, 320-329. 
Spencer, J. F., Sagartz, J. E., Wold, W. S. & Toth, K. (2009). New pancreatic 
carcinoma model for studying oncolytic adenoviruses in the permissive Syrian 
hamster. Cancer Gene Ther. 
Sprangers, M. C., Lakhai, W., Koudstaal, W., Verhoeven, M., Koel, B. F., Vogels, 
R., Goudsmit, J., Havenga, M. J. & Kostense, S. (2003). Quantifying 
adenovirus-neutralizing antibodies by luciferase transgene detection: 
addressing preexisting immunity to vaccine and gene therapy vectors. J Clin 
Microbiol 41, 5046-5052. 
Staba, M. J., Wickham, T. J., Kovesdi, I. & Hallahan, D. E. (2000). Modifications of 
the fiber in adenovirus vectors increase tropism for malignant glioma models. 
Cancer Gene Ther 7, 13-19. 
Stallwood, Y., Fisher, K. D., Gallimore, P. H. & Mautner, V. (2000). Neutralisation of 
adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther 7, 
637-643. 
Starnes, H. F., Pearce, M., Yim, J., Abrams, J., Tewari, A. & Zou, J. (1992). Anti-IL-6 
monoclonal antibodies protect against lethal Escherichia coli infection and lethal 
tumor necrosis factor-alpha challenge in mice. J Immunol 148, 1968. 
Stevenson, M., Hale, A. B., Hale, S. J., Green, N. K., Black, G., Fisher, K. D., 
Ulbrich, K., Fabra, A. & Seymour, L. W. (2007). Incorporation of a laminin-
derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-
specific targeting via alpha6-integrins. Cancer Gene Ther 14, 335-345. 
Stoff-Khalili, M. A., Rivera, A. A., Glasgow, J. N., Le, L. P., Stoff, A., Everts, M., 
Tsuruta, Y., Kawakami, Y., Bauerschmitz, G. J., Mathis, J. M., Pereboeva, 
L., Seigal, G. P., Dall, P. & Curiel, D. T. (2005). A human adenoviral vector 
with a chimeric fiber from canine adenovirus type 1 results in novel expanded 
tropism for cancer gene therapy. Gene Ther 12, 1696-1706. 
Stone, D., Liu, Y., Li, Z. Y., Tuve, S., Strauss, R. & Lieber, A. (2007a). Comparison 
of adenoviruses from species B, C, E, and F after intravenous delivery. Mol 
Ther 15, 2146-2153. 
 295
Stone, D., Liu, Y., Shayakhmetov, D., Li, Z. Y., Ni, S. & Lieber, A. (2007b). 
Adenovirus-platelet interaction in blood causes virus sequestration to the 
reticuloendothelial system of the liver. J Virol 81, 4866-4871. 
Stone, D., Ni, S., Li, Z. Y., Gaggar, A., DiPaolo, N., Feng, Q., Sandig, V. & Lieber, 
A. (2005). Development and assessment of human adenovirus type 11 as a 
gene transfer vector. J Virol 79, 5090-5104. 
Stracker, T. H., Carson, C. T. & Weitzman, M. D. (2002). Adenovirus oncoproteins 
inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418, 348-352. 
Sumida, S. M., Truitt, D. M., Lemckert, A. A., Vogels, R., Custers, J. H., Addo, M. 
M., Lockman, S., Peter, T., Peyerl, F. W., Kishko, M. G., Jackson, S. S., 
Gorgone, D. A., Lifton, M. A., Essex, M., Walker, B. D., Goudsmit, J., 
Havenga, M. J. & Barouch, D. H. (2005). Neutralizing antibodies to adenovirus 
serotype 5 vaccine vectors are directed primarily against the adenovirus hexon 
protein. J Immunol 174, 7179-7185. 
Sundquist, B., Everitt, E., Philipson, L. & Hoglund, S. (1973). Assembly of 
adenoviruses. J Virol 11, 449-459. 
Suomalainen, M., Nakano, M. Y., Boucke, K., Keller, S. & Greber, U. F. (2001). 
Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-
mediated nuclear targeting of virus. Embo J 20, 1310-1319. 
Suomalainen, M., Nakano, M. Y., Keller, S., Boucke, K., Stidwill, R. P. & Greber, U. 
F. (1999). Microtubule-dependent plus- and minus end-directed motilities are 
competing processes for nuclear targeting of adenovirus. J Cell Biol 144, 657-
672. 
Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T. & Alemany, R. 
(2001). A conditionally replicative adenovirus with enhanced infectivity shows 
improved oncolytic potency. Clin Cancer Res 7, 120-126. 
Taipale, J., Saharinen, J. & Keski-Oja, J. (1998). Extracellular matrix-associated 
transforming growth factor-beta: role in cancer cell growth and invasion. Adv 
Cancer Res 75, 87-134. 
Tamanini, A., Nicolis, E., Bonizzato, A., Bezzerri, V., Melotti, P., Assael, B. M. & 
Cabrini, G. (2006). Interaction of adenovirus type 5 fiber with the 
coxsackievirus and adenovirus receptor activates inflammatory response in 
human respiratory cells. J Virol 80, 11241-11254. 
Tao, N., Gao, G. P., Parr, M., Johnston, J., Baradet, T., Wilson, J. M., Barsoum, J. 
& Fawell, S. E. (2001). Sequestration of adenoviral vector by Kupffer cells 
leads to a nonlinear dose response of transduction in liver. Mol Ther 3, 28-35. 
Taqi, A. M., Abdurrahman, M. B., Yakubu, A. M. & Fleming, A. F. (1981). 
Regression of Hodgkin's disease after measles. Lancet 1, 1112. 
 296
Tarassishin, L., Szawlowski, P., Kidd, A. H. & Russell, W. C. (2000). An epitope on 
the adenovirus fibre tail is common to all human subgroups. Arch Virol 145, 
805-811. 
Taylor, A. W. (1953). Effects of glandular fever infection in acute leukaemia. Br Med J 
1, 589-593. 
Thomas, G. J., Hart, I. R., Speight, P. M. & Marshall, J. F. (2002). Binding of TGF-
beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates 
behaviour of squamous carcinoma cells. Br J Cancer 87, 859-867. 
Thomas, G. J., Lewis, M. P., Hart, I. R., Marshall, J. F. & Speight, P. M. (2001a). 
AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through 
up-regulation of matrix metalloproteinase-9. Int J Cancer 92, 641-650. 
Thomas, G. J., Lewis, M. P., Whawell, S. A., Russell, A., Sheppard, D., Hart, I. R., 
Speight, P. M. & Marshall, J. F. (2001b). Expression of the alphavbeta6 
integrin promotes migration and invasion in squamous carcinoma cells. J Invest 
Dermatol 117, 67-73. 
Thomas, G. J., Nystrom, M. L. & Marshall, J. F. (2006a). Alphavbeta6 integrin in 
wound healing and cancer of the oral cavity. J Oral Pathol Med 35, 1-10. 
Thomas, G. J., Poomsawat, S., Lewis, M. P., Hart, I. R., Speight, P. M. & Marshall, 
J. F. (2001c). alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 
and promotes migration of normal oral keratinocytes. J Invest Dermatol 116, 
898-904. 
Thomas, M. A., Spencer, J. F., La Regina, M. C., Dhar, D., Tollefson, A. E., Toth, K. 
& Wold, W. S. (2006b). Syrian hamster as a permissive immunocompetent 
animal model for the study of oncolytic adenovirus vectors. Cancer Res 66, 
1270-1276. 
Thomas, M. A., Spencer, J. F., Toth, K., Sagartz, J. E., Phillips, N. J. & Wold, W. S. 
(2008). Immunosuppression enhances oncolytic adenovirus replication and 
antitumor efficacy in the Syrian hamster model. Mol Ther 16, 1665-1673. 
Tian, J., Xu, Z., Smith, J. S., Hofherr, S. E., Barry, M. A. & Byrnes, A. P. (2009). 
Adenovirus activates complement by distinctly different mechanisms in vitro and 
in vivo: indirect complement activation by virions in vivo. J Virol 83, 5648-5658. 
Tibbles, L. A., Spurrell, J. C., Bowen, G. P., Liu, Q., Lam, M., Zaiss, A. K., Robbins, 
S. M., Hollenberg, M. D., Wickham, T. J. & Muruve, D. A. (2002). Activation 
of p38 and ERK signaling during adenovirus vector cell entry lead to expression 
of the C-X-C chemokine IP-10. J Virol 76, 1559-1568. 
Tollefson, A. E., Scaria, A., Hermiston, T. W., Ryerse, J. S., Wold, L. J. & Wold, W. 
S. (1996). The adenovirus death protein (E3-11.6K) is required at very late 
 297
stages of infection for efficient cell lysis and release of adenovirus from infected 
cells. J Virol 70, 2296-2306. 
Tollefson, A. E., Toth, K., Doronin, K., Kuppuswamy, M., Doronina, O. A., 
Lichtenstein, D. L., Hermiston, T. W., Smith, C. A. & Wold, W. S. (2001). 
Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL 
receptor 1 by adenovirus proteins. J Virol 75, 8875-8887. 
Tollefson, A. E., Ying, B., Doronin, K., Sidor, P. D. & Wold, W. S. (2007). 
Identification of a new human adenovirus protein encoded by a novel late l-
strand transcription unit. J Virol 81, 12918-12926. 
Tomko, R. P., Xu, R. & Philipson, L. (1997). HCAR and MCAR: the human and 
mouse cellular receptors for subgroup C adenoviruses and group B 
coxsackieviruses. Proc Natl Acad Sci U S A 94, 3352-3356. 
Toth, K., Spencer, J. F. & Wold, W. S. (2007). Immunocompetent, semi-permissive 
cotton rat tumor model for the evaluation of oncolytic adenoviruses. Methods 
Mol Med 130, 157-168. 
Travis, M. A., Reizis, B., Melton, A. C., Masteller, E., Tang, Q., Proctor, J. M., 
Wang, Y., Bernstein, X., Huang, X., Reichardt, L. F., Bluestone, J. A. & 
Sheppard, D. (2007). Loss of integrin alpha(v)beta8 on dendritic cells causes 
autoimmunity and colitis in mice. Nature 449, 361-365. 
Trepel, M., Grifman, M., Weitzman, M. D. & Pasqualini, R. (2000). Molecular 
adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther 11, 
1971-1981. 
Trevillian, P., Paul, H., Millar, E., Hibberd, A. & Agrez, M. V. (2004). alpha(v)beta(6) 
Integrin expression in diseased and transplanted kidneys. Kidney Int 66, 1423-
1433. 
Tsujimura, A., Shida, K., Kitamura, M., Nomura, M., Takeda, J., Tanaka, H., 
Matsumoto, M., Matsumiya, K., Okuyama, A., Nishimune, Y., Okabe, M. & 
Seya, T. (1998). Molecular cloning of a murine homologue of membrane 
cofactor protein (CD46): preferential expression in testicular germ cells. 
Biochem J 330 ( Pt 1), 163-168. 
Tsukuda, K., Wiewrodt, R., Molnar-Kimber, K., Jovanovic, V. P. & Amin, K. M. 
(2002). An E2F-responsive replication-selective adenovirus targeted to the 
defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to 
normal cell. Cancer Res 62, 3438-3447. 
Tsuruta, Y., Pereboeva, L., Glasgow, J. N., Luongo, C. L., Komarova, S., 
Kawakami, Y. & Curiel, D. T. (2005). Reovirus sigma1 fiber incorporated into 
adenovirus serotype 5 enhances infectivity via a CAR-independent pathway. 
Biochem Biophys Res Commun 335, 205-214. 
 298
Tummino, P. J., Ferguson, D. & Hupe, D. (1994). Competitive inhibition of HIV-1 
protease by warfarin derivatives. Biochem Biophys Res Commun 201, 290-294. 
Tyler, R. E., Ewing, S. G. & Imperiale, M. J. (2007). Formation of a multiple protein 
complex on the adenovirus packaging sequence by the IVa2 protein. J Virol 81, 
3447-3454. 
Ulasov, I. V., Rivera, A. A., Han, Y., Curiel, D. T., Zhu, Z. B. & Lesniak, M. S. (2007). 
Targeting adenovirus to CD80 and CD86 receptors increases gene transfer 
efficiency to malignant glioma cells. J Neurosurg 107, 617-627. 
Van Aarsen, L. A., Leone, D. R., Ho, S., Dolinski, B. M., McCoon, P. E., LePage, D. 
J., Kelly, R., Heaney, G., Rayhorn, P., Reid, C., Simon, K. J., Horan, G. S., 
Tao, N., Gardner, H. A., Skelly, M. M., Gown, A. M., Thomas, G. J., Weinreb, 
P. H., Fawell, S. E. & Violette, S. M. (2008). Antibody-mediated blockade of 
integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming 
growth factor-beta-regulated mechanism. Cancer Res 68, 561-570. 
van Oostrum, J. & Burnett, R. M. (1985). Molecular composition of the adenovirus 
type 2 virion. J Virol 56, 439-448. 
van Raaij, M. J., Chouin, E., van der Zandt, H., Bergelson, J. M. & Cusack, S. 
(2000). Dimeric structure of the coxsackievirus and adenovirus receptor D1 
domain at 1.7 A resolution. Structure 8, 1147-1155. 
van Raaij, M. J., Mitraki, A., Lavigne, G. & Cusack, S. (1999). A triple beta-spiral in 
the adenovirus fibre shaft reveals a new structural motif for a fibrous protein. 
Nature 401, 935-938. 
Varda-Bloom, N., Shaish, A., Gonen, A., Levanon, K., Greenbereger, S., Ferber, 
S., Levkovitz, H., Castel, D., Goldberg, I., Afek, A., Kopolovitc, Y. & Harats, 
D. (2001). Tissue-specific gene therapy directed to tumor angiogenesis. Gene 
Ther 8, 819-827. 
Varnavski, A. N., Calcedo, R., Bove, M., Gao, G. & Wilson, J. M. (2005). Evaluation 
of toxicity from high-dose systemic administration of recombinant adenovirus 
vector in vector-naive and pre-immunized mice. Gene Ther 12, 427-436. 
Vassaux, G., Manson, A. L. & Huxley, C. (1997). Copy number-dependent 
expression of a YAC-cloned human CFTR gene in a human epithelial cell line. 
Gene Ther 4, 618-623. 
Vattemi, E. & Claudio, P. P. (2009). The feasibility of gene therapy in the treatment of 
head and neck cancer. Head Neck Oncol 1, 3. 
Vigant, F., Descamps, D., Jullienne, B., Esselin, S., Connault, E., Opolon, P., 
Tordjmann, T., Vigne, E., Perricaudet, M. & Benihoud, K. (2008). 
Substitution of hexon hypervariable region 5 of adenovirus serotype 5 
 299
abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16, 
1474-1480. 
Vincent, T., Neve, E. P., Johnson, J. R., Kukalev, A., Rojo, F., Albanell, J., Pietras, 
K., Virtanen, I., Philipson, L., Leopold, P. L., Crystal, R. G., de Herreros, A. 
G., Moustakas, A., Pettersson, R. F. & Fuxe, J. (2009). A SNAIL1-SMAD3/4 
transcriptional repressor complex promotes TGF-beta mediated epithelial-
mesenchymal transition. Nat Cell Biol 11, 943-950. 
Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de 
Bethune, M. P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., 
Cecchini, M., Wetterwald, A., Sprangers, M., Lemckert, A., Ophorst, O., 
Koel, B., van Meerendonk, M., Quax, P., Panitti, L., Grimbergen, J., Bout, 
A., Goudsmit, J. & Havenga, M. (2003). Replication-deficient human 
adenovirus type 35 vectors for gene transfer and vaccination: efficient human 
cell infection and bypass of preexisting adenovirus immunity. J Virol 77, 8263-
8271. 
Von Seggern, D. J., Huang, S., Fleck, S. K., Stevenson, S. C. & Nemerow, G. R. 
(2000). Adenovirus vector pseudotyping in fiber-expressing cell lines: improved 
transduction of Epstein-Barr virus-transformed B cells. J Virol 74, 354-362. 
Waddington, S. N., McVey, J. H., Bhella, D., Parker, A. L., Barker, K., Atoda, H., 
Pink, R., Buckley, S. M., Greig, J. A., Denby, L., Custers, J., Morita, T., 
Francischetti, I. M., Monteiro, R. Q., Barouch, D. H., van Rooijen, N., 
Napoli, C., Havenga, M. J., Nicklin, S. A. & Baker, A. H. (2008). Adenovirus 
serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409. 
Waddington, S. N., Parker, A. L., Havenga, M., Nicklin, S. A., Buckley, S. M., 
McVey, J. H. & Baker, A. H. (2007). Targeting of adenovirus serotype 5 (Ad5) 
and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation 
factors and redundancy of CAR binding by Ad5. J Virol 81, 9568-9571. 
Wahl, S. M. (1992). Transforming growth factor beta (TGF-beta) in inflammation: a 
cause and a cure. J Clin Immunol 12, 61-74. 
Walters, R. W., Freimuth, P., Moninger, T. O., Ganske, I., Zabner, J. & Welsh, M. J. 
(2002). Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing 
virus escape. Cell 110, 789-799. 
Wang, B., Dolinski, B. M., Kikuchi, N., Leone, D. R., Peters, M. G., Weinreb, P. H., 
Violette, S. M. & Bissell, D. M. (2007). Role of alphavbeta6 integrin in acute 
biliary fibrosis. Hepatology 46, 1404-1412. 
Wang, H., Liu, Y., Li, Z., Tuve, S., Stone, D., Kalyushniy, O., Shayakhmetov, D., 
Verlinde, C. L., Stehle, T., McVey, J., Baker, A., Peng, K. W., Roffler, S. & 
 300
Lieber, A. (2008). In vitro and in vivo properties of adenovirus vectors with 
increased affinity to CD46. J Virol 82, 10567-10579. 
Wang, K., Huang, S., Kapoor-Munshi, A. & Nemerow, G. (1998). Adenovirus 
internalization and infection require dynamin. J Virol 72, 3455-3458. 
Wang, Y., Hallden, G., Hill, R., Anand, A., Liu, T. C., Francis, J., Brooks, G., 
Lemoine, N. & Kirn, D. (2003). E3 gene manipulations affect oncolytic 
adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21, 
1328-1335. 
Watkins, S. J., Mesyanzhinov, V. V., Kurochkina, L. P. & Hawkins, R. E. (1997). 
The 'adenobody' approach to viral targeting: specific and enhanced adenoviral 
gene delivery. Gene Ther 4, 1004-1012. 
Weinacker, A., Chen, A., Agrez, M., Cone, R. I., Nishimura, S., Wayner, E., Pytela, 
R. & Sheppard, D. (1994). Role of the integrin alpha v beta 6 in cell attachment 
to fibronectin. Heterologous expression of intact and secreted forms of the 
receptor. J Biol Chem 269, 6940-6948. 
Weinreb, P. H., Simon, K. J., Rayhorn, P., Yang, W. J., Leone, D. R., Dolinski, B. 
M., Pearse, B. R., Yokota, Y., Kawakatsu, H., Atakilit, A., Sheppard, D. & 
Violette, S. M. (2004). Function-blocking integrin alphavbeta6 monoclonal 
antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem 
279, 17875-17887. 
Wernert, N. (1997). The multiple roles of tumour stroma. Virchows Arch 430, 433-443. 
Whalen, S. G., Marcellus, R. C., Whalen, A., Ahn, N. G., Ricciardi, R. P. & Branton, 
P. E. (1997). Phosphorylation within the transactivation domain of adenovirus 
E1A protein by mitogen-activated protein kinase regulates expression of early 
region 4. J Virol 71, 3545-3553. 
White, E., Cipriani, R., Sabbatini, P. & Denton, A. (1991). Adenovirus E1B 19-
kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol 65, 2968-
2978. 
White, E., Sabbatini, P., Debbas, M., Wold, W. S., Kusher, D. I. & Gooding, L. R. 
(1992). The 19-kilodalton adenovirus E1B transforming protein inhibits 
programmed cell death and prevents cytolysis by tumor necrosis factor alpha. 
Mol Cell Biol 12, 2570-2580. 
Whyte, P., Williamson, N. M. & Harlow, E. (1989). Cellular targets for transformation 
by the adenovirus E1A proteins. Cell 56, 67-75. 
Wickham, T. J., Mathias, P., Cheresh, D. A. & Nemerow, G. R. (1993). Integrins 
alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not 
virus attachment. Cell 73, 309-319. 
 301
Wickham, T. J., Roelvink, P. W., Brough, D. E. & Kovesdi, I. (1996). Adenovirus 
targeted to heparan-containing receptors increases its gene delivery efficiency 
to multiple cell types. Nat Biotechnol 14, 1570-1573. 
Wickham, T. J., Tzeng, E., Shears, L. L., 2nd, Roelvink, P. W., Li, Y., Lee, G. M., 
Brough, D. E., Lizonova, A. & Kovesdi, I. (1997). Increased in vitro and in 
vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J 
Virol 71, 8221-8229. 
Wiethoff, C. M., Wodrich, H., Gerace, L. & Nemerow, G. R. (2005). Adenovirus 
protein VI mediates membrane disruption following capsid disassembly. J Virol 
79, 1992-2000. 
Willcox, N. & Mautner, V. (1976). Antigenic determinants of adenovirus capsids. I. 
Measurement of antibody cross-reactivity. J Immunol 116, 19-24. 
Williams, C. H., Kajander, T., Hyypia, T., Jackson, T., Sheppard, D. & Stanway, G. 
(2004). Integrin alpha v beta 6 is an RGD-dependent receptor for 
coxsackievirus A9. J Virol 78, 6967-6973. 
Wisse, E., Jacobs, F., Topal, B., Frederik, P. & De Geest, B. (2008). The size of 
endothelial fenestrae in human liver sinusoids: implications for hepatocyte-
directed gene transfer. Gene Ther 15, 1193-1199. 
Wold, W. S. & Gooding, L. R. (1991). Region E3 of adenovirus: a cassette of genes 
involved in host immunosurveillance and virus-cell interactions. Virology 184, 1-
8. 
Wolff, G., Worgall, S., van Rooijen, N., Song, W. R., Harvey, B. G. & Crystal, R. G. 
(1997). Enhancement of in vivo adenovirus-mediated gene transfer and 
expression by prior depletion of tissue macrophages in the target organ. J Virol 
71, 624-629. 
Wolins, N., Lozier, J., Eggerman, T. L., Jones, E., Aguilar-Cordova, E. & Vostal, J. 
G. (2003). Intravenous administration of replication-incompetent adenovirus to 
rhesus monkeys induces thrombocytopenia by increasing in vivo platelet 
clearance. Br J Haematol 123, 903-905. 
Worgall, S., Wolff, G., Falck-Pedersen, E. & Crystal, R. G. (1997). Innate immune 
mechanisms dominate elimination of adenoviral vectors following in vivo 
administration. Hum Gene Ther 8, 37-44. 
Worgall, S., Worgall, T. S., Kostarelos, K., Singh, R., Leopold, P. L., Hackett, N. R. 
& Crystal, R. G. (2000). Free cholesterol enhances adenoviral vector gene 
transfer and expression in CAR-deficient cells. Mol Ther 1, 39-48. 
Work, L. M., Nicklin, S. A., Brain, N. J., Dishart, K. L., Von Seggern, D. J., Hallek, 
M., Buning, H. & Baker, A. H. (2004a). Development of efficient viral vectors 
selective for vascular smooth muscle cells. Mol Ther 9, 198-208. 
 302
Work, L. M., Reynolds, P. N. & Baker, A. H. (2004b). Improved gene delivery to 
human saphenous vein cells and tissue using a peptide-modified adenoviral 
vector. Genet Vaccines Ther 2, 14. 
Wortmann, A., Vohringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., 
Kochanek, S. & Kreppel, F. (2008). Fully detargeted polyethylene glycol-
coated adenovirus vectors are potent genetic vaccines and escape from pre-
existing anti-adenovirus antibodies. Mol Ther 16, 154-162. 
Wu, E., Pache, L., Von Seggern, D. J., Mullen, T. M., Mikyas, Y., Stewart, P. L. & 
Nemerow, G. R. (2003). Flexibility of the adenovirus fiber is required for 
efficient receptor interaction. J Virol 77, 7225-7235. 
Wu, H. & Curiel, D. T. (2008). Fiber-modified adenoviruses for targeted gene therapy. 
Methods Mol Biol 434, 113-132. 
Wu, H., Seki, T., Dmitriev, I., Uil, T., Kashentseva, E., Han, T. & Curiel, D. T. (2002). 
Double modification of adenovirus fiber with RGD and polylysine motifs 
improves coxsackievirus-adenovirus receptor-independent gene transfer 
efficiency. Hum Gene Ther 13, 1647-1653. 
Wysocka, M., Kubin, M., Vieira, L. Q., Ozmen, L., Garotta, G., Scott, P. & 
Trinchieri, G. (1995). Interleukin-12 is required for interferon-gamma 
production and lethality in lipopolysaccharide-induced shock in mice. Eur J 
Immunol 25, 672-676. 
Xi, Q., Cuesta, R. & Schneider, R. J. (2004). Tethering of eIF4G to adenoviral mRNAs 
by viral 100k protein drives ribosome shunting. Genes Dev 18, 1997-2009. 
Xia, D., Henry, L. J., Gerard, R. D. & Deisenhofer, J. (1994). Crystal structure of the 
receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. 
Structure 2, 1259-1270. 
Xia, H., Anderson, B., Mao, Q. & Davidson, B. L. (2000). Recombinant human 
adenovirus: targeting to the human transferrin receptor improves gene transfer 
to brain microcapillary endothelium. J Virol 74, 11359-11366. 
Xu, Z., Tian, J., Smith, J. S. & Byrnes, A. P. (2008). Clearance of adenovirus by 
Kupffer cells is mediated by scavenger receptors, natural antibodies, and 
complement. J Virol 82, 11705-11713. 
Xue, H., Atakilit, A., Zhu, W., Li, X., Ramos, D. M. & Pytela, R. (2001). Role of the 
alpha(v)beta6 integrin in human oral squamous cell carcinoma growth in vivo 
and in vitro. Biochem Biophys Res Commun 288, 610-618. 
Yang, G. Y., Xu, K. S., Pan, Z. Q., Zhang, Z. Y., Mi, Y. T., Wang, J. S., Chen, R. & 
Niu, J. (2008). Integrin alpha v beta 6 mediates the potential for colon cancer 
cells to colonize in and metastasize to the liver. Cancer Sci 99, 879-887. 
 303
Yee, S. P. & Branton, P. E. (1985). Detection of cellular proteins associated with 
human adenovirus type 5 early region 1A polypeptides. Virology 147, 142-153. 
Ying, B., Toth, K., Spencer, J. F., Meyer, J., Tollefson, A. E., Patra, D., Dhar, D., 
Shashkova, E. V., Kuppuswamy, M., Doronin, K., Thomas, M. A., Zumstein, 
L. A., Wold, W. S. & Lichtenstein, D. L. (2009). INGN 007, an oncolytic 
adenovirus vector, replicates in Syrian hamsters but not mice: comparison of 
biodistribution studies. Cancer Gene Ther. 
Ying, B. & Wold, W. S. (2003). Adenovirus ADP protein (E3-11.6K), which is required 
for efficient cell lysis and virus release, interacts with human MAD2B. Virology 
313, 224-234. 
Yolken, R. H., Lawrence, F., Leister, F., Takiff, H. E. & Strauss, S. E. (1982). 
Gastroenteritis associated with enteric type adenovirus in hospitalized infants. J 
Pediatr 101, 21-26. 
Yoshioka, Y., Asavatanabodee, R., Eto, Y., Watanabe, H., Morishige, T., Yao, X., 
Kida, S., Maeda, M., Mukai, Y., Mizuguchi, H., Kawasaki, K., Okada, N. & 
Nakagawa, S. (2008). Tat conjugation of adenovirus vector broadens tropism 
and enhances transduction efficiency. Life Sci 83, 747-755. 
Youil, R., Toner, T. J., Su, Q., Chen, M., Tang, A., Bett, A. J. & Casimiro, D. (2002). 
Hexon gene switch strategy for the generation of chimeric recombinant 
adenovirus. Hum Gene Ther 13, 311-320. 
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P. & Jain, 
R. K. (1995). Vascular permeability in a human tumor xenograft: molecular size 
dependence and cutoff size. Cancer Res 55, 3752-3756. 
Yun, C. O., Kim, E., Koo, T., Kim, H., Lee, Y. S. & Kim, J. H. (2005). ADP-
overexpressing adenovirus elicits enhanced cytopathic effect by induction of 
apoptosis. Cancer Gene Ther 12, 61-71. 
Yurchenco, P. D., Amenta, P. S. & Patton, B. L. (2004). Basement membrane 
assembly, stability and activities observed through a developmental lens. Matrix 
Biol 22, 521-538. 
Zambruno, G., Marchisio, P. C., Marconi, A., Vaschieri, C., Melchiori, A., 
Giannetti, A. & De Luca, M. (1995). Transforming growth factor-beta 1 
modulates beta 1 and beta 5 integrin receptors and induces the de novo 
expression of the alpha v beta 6 heterodimer in normal human keratinocytes: 
implications for wound healing. J Cell Biol 129, 853-865. 
Zhang, Y. & Bergelson, J. M. (2005). Adenovirus receptors. J Virol 79, 12125-12131. 
Zhang, Y., Chirmule, N., Gao, G. P., Qian, R., Croyle, M., Joshi, B., Tazelaar, J. & 
Wilson, J. M. (2001). Acute cytokine response to systemic adenoviral vectors 
in mice is mediated by dendritic cells and macrophages. Mol Ther 3, 697-707. 
 304
Zhao, C., Crews, C. J., Derdeyn, C. A. & Blackwell, J. L. (2009). Lac-regulated 
system for generating adenovirus 5 vaccine vectors expressing cytolytic human 
immunodeficiency virus 1 genes. J Virol Methods 160, 101-110. 
Zhu, J., Huang, X. & Yang, Y. (2007). Innate immune response to adenoviral vectors 
is mediated by both Toll-like receptor-dependent and -independent pathways. J 
Virol 81, 3170-3180. 
Zinn, K. R., Douglas, J. T., Smyth, C. A., Liu, H. G., Wu, Q., Krasnykh, V. N., 
Mountz, J. D., Curiel, D. T. & Mountz, J. M. (1998). Imaging and tissue 
biodistribution of 99mTc-labeled adenovirus knob (serotype 5). Gene Ther 5, 
798-808. 
Zygiert, Z. (1971). Hodgkin's disease: remissions after measles. Lancet 1, 593. 
 
 
